other	G-A609//Other//SNMI	2.16.840.1.113883.1.11.10616//Other//HL7V3.0	NHIS//Adult//NCI	CES-D//Other//NCI	C17649//Other//NCI_NICHD	TCGA//Enterovirus//NCI	LA46-8//Other//LNC	74964007//Other//SNOMEDCT_US	U003446//Other//MTH	U000265//OTHER//CCPSS	SDTM-NSYSPCID//OTHER//NCI_CDISC	SDTM-ACSPCAT//OTHER//NCI_CDISC	SDTM-INTTYPE//OTHER//NCI_CDISC	SDTM-NCOMPLT//OTHER//NCI_CDISC	SDTM-SDTHSDTP//OTHER//NCI_CDISC	U000081//Other//AIR	C53289//Other Health Care Professional//NCI	C38290//OTHER//NCI_FDA	135//OTHER//NCI_FDA	O//In Process//HL7V2.5	ORH//Other//HL7V2.5	OT//Occupational Therapy//HL7V2.5	5//Conservator//HL7V2.5	99//Other//HL7V2.5	4//2nd Operative//HL7V2.5	OTH//Other manufacturer//HL7V2.5	MTHU000080//Other//OMIM	LP21049-9//Other//LNC	MTHU029809//Other//LNC	52483-5//Other:-:Pt:^Patient:-//LNC	349//Other//SOP	C118472//Other//NCI_FDA	C123269//OTHER//NCI_FDA
the following are appropriate:	
seizures	SEIZ//Seizures//AIR	D012640//Seizures//MSH	673//Seizures//MTH	U000217//Seizures//SNM	060315//Seizures//NOC	070819//Seizures//NOC	MTHU000242//Seizures//OMIM	N0000002713//Seizures [Disease/Finding]//NDFRT	396//Seizures//MEDLINEPLUS	LA15899-0//Seizures//LNC	2063//Seizures//NCI_FDA	HP:0001250//Seizures//HPO	10039910//Seizures//MDR	46145//Seizures//PSY	NOCODE//Developmental arithmetic disorder//MTH	BI00559//seizure disorder//BI	0000011162//seizure//CHV
hearing loss	0000003627//deafness//CHV	0000005856//partial hearing loss//CHV	N0000011013//Hearing Loss [Disease/Finding]//NDFRT	D034381//Hearing Loss//MSH	XE0s9//Hearing loss//RCD	F-X6000//Deafness//SNM	LP56780-7//Hearing loss//LNC	204//Hearing Disorders and Deafness//MEDLINEPLUS	MTHU036353//Hearing loss//OMIM	MTHU021608//Hearing loss//LNC	HP:0000365//Hearing impairment//HPO	10019246//Hearing loss//MDR	389//Hearing loss//ICD9CM	15188001//Hearing loss//SNOMEDCT_US	0041617//HEARING LOSS//CCPSS	345//HEARING LOSS//COSTAR	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	141//loss of hearing//MEDCIN	BI00650//hearing loss//BI	0977-5687//hearing disorder//CSP	34076//hearing loss//MEDCIN	6676//hearing loss by exam//MEDCIN	C35731//Hearing Loss//NCI_NICHD	1882//Hearing Loss//NCI_FDA	LA24366-9//Hearing loss//LNC
skeletal	CDR0000044350//skeletal//NCI_NCI-GLOSS	T-11000//Skeletal system, NOS//SNMI	NOCODE//Developmental arithmetic disorder//MTH	0000037923//skeletal//CHV	MTHU000029//SKELETAL//OMIM
cardiovascular	T-30000//Cardiovascular system, NOS//SNMI	C12686//Cardiovascular System//NCI	BI00027//cardiovascular//BI	0060472//CARDIOVASCULAR//CCPSS	LP31409-3//Cardiovascular//LNC	LA18277-6//Cardiovascular//LNC	C25292//Cardiovascular//NCI	NOCODE//Developmental arithmetic disorder//MTH	CDR0000044005//cardiovascular//NCI_NCI-GLOSS	MTHU000109//CARDIOVASCULAR//OMIM
respiratory	D012122//Respiratory//MSHPOL	BI00201//respiratory//BI	NOCODE//Developmental arithmetic disorder//MTH	0041936//RESPIRATORY//CCPSS	R//RESPIRATORY//ICPC	MTHU000104//RESPIRATORY//OMIM	T-20000//Respiratory system, NOS//SNMI	LA16975-7//Respiratory//LNC	MTHU052973//Respiratory//LNC	LP208442-6//Respiratory//LNC	C25656//Respiratory//NCI	RES//Respiratory//HL7V2.5
dental	DNTL//Dental//HL7V3.0	T-54010//Tooth, NOS//SNMI	LP89803-8//Dental//LNC	MTHU031898//Dental//LNC	MTHU000053//Dental//LNC	C41136//Dental//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000022081//dental//CHV	LP31759-1//DENTAL//LNC	C69059//Dental//NCI_NCPDP	C38197//Dental//NCI_FDA	DT//Dental//HL7V2.5	038//DENTAL//NCI_FDA	D//Significant change down//HL7V2.5	DENTA//Dental//HL7V2.5	54571-5//Dental:-:Pt:^Patient:-//LNC	561//Dental//SOP
treatment includes the following:	
gastrointestinal	BI00029//gastrointestinal//BI	0000037933//gastrointestinal (GI)//CHV	CDR0000045692//gastrointestinal//NCI_NCI-GLOSS	NOCODE//Developmental arithmetic disorder//MTH	T-50100//Digestive tract, NOS//SNMI	LP89777-4//Gastrointestinal//LNC	MTHU031867//Gastrointestinal//LNC	TCGA//Enterovirus//NCI	LA16968-2//Gastrointestinal//LNC	C13359//Gastrointestinal//NCI	MTHU000224//Gastrointestinal//OMIM	C53802//GASTROINTESTINAL//NCI_CTCAE	54534-3//Gastrointestinal:-:Pt:^Patient:-//LNC
hearing	U002101//Hearing//LCH	D006309//Hearing//MSH	X75pr//Perception of sound//RCD	19//Hearing//OMS	LP30518-2//Hearing//LNC	MTHU015042//Hearing//LNC	sh85059612//Hearing//LCH_NW	LA22109-5//Hearing//LNC	MTHU051593//Hearing//LNC	47078008//Hearing//SNOMEDCT_US	C16670//Hearing//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000006094//hearing//AOD	0973-7729//hearing//CSP	GO:0007605//sensory perception of sound//GO	0000005854//hearing//CHV	6674//examination of hearing//MEDCIN	091305//Hearing//NOC	0000042156//audiological observations//CHV	133083//outcomes otolaryngology hearing//MEDCIN
the following are indicated:	
neurologic	G-B119//Neurologic//SNMI	LA16973-2//Neurologic//LNC	C25262//Neurologic//NCI	1199008//Neurologic//SNOMEDCT_US	BI00565//neurologic//BI	0000020628//neurological//CHV	CDR0000044117//neurologic//NCI_NCI-GLOSS	0045754//NEUROLOGIC//CCPSS	MTHU000057//NEUROLOGIC//OMIM
treatment is symptomatic	
motor dysfunction	MTHU024651//Motor dysfunction//OMIM	10061296//Motor dysfunction//MDR	52559000//Motor dysfunction//SNOMEDCT_US	0000023247//motor dysfunction//CHV
gross motor dysfunction	
consider use of durable medical equipment as needed (e	
fine motor dysfunction	
oral motor dysfunction	
eyes	D005123//Eye//MSH	LP7222-5//Eyes//LNC	MTHU001409//Eyes//LNC	MTHU000020//Eyes//OMIM	0000004810//eye//CHV
skin	SKN//Skin//HL7V3.0	U004333//Skin//LCH	D012867//Skin//MSH	NOCODE//Developmental arithmetic disorder//MTH	7N7..//Skin//RCD	T-01000//Skin//SNM	7163//Skin//UWDA	MTHU000083//Skin//OMIM	26//Skin//OMS	LP76007-1//Skin//LNC	LP36760-4//Skin//LNC	LP130014-6//Skin//LNC	MTHU001414//Skin//LNC	sh85123164//Skin//LCH_NW	TCGA//Enterovirus//NCI	C12470//SKIN//NCI_CDISC	LA4332-8//Skin//LNC	39937001//Skin structure//SNOMEDCT_US	0000002281//skin//AOD	2716-0373//skin//CSP	0000054821//skin//CHV	0012516//SKIN//CCPSS	S//SKIN//ICPC
developmental pediatricians can provide assistance with transition to adulthood	
some issues to consider:	
renal disease	X30Hc//Disorder of kidney//RCD	D-6502//Kidney disease//SNM	91//Kidney Diseases//MEDLINEPLUS	MTHU047531//Renal disease//OMIM	10051051//Renal disease//MDR	90708001//Kidney disease//SNOMEDCT_US	0000023503//renal disease//AOD	BI00465//renal disease//BI	0000007090//kidney disease//CHV	236575//renal disease//MEDCIN	0013357//RENAL DISEASE//CCPSS	C3149//Kidney Disorder//NCI
eye	NOCODE//Sepsis//COSTAR	U001714//Eye//LCH	D005123//Eye//MSH	X74in//Eye//RCD	T-XX000//Eye//SNM	54448//Eye//UWDA	LP7218-3//Eye//LNC	LP117007-7//Eye//LNC	MTHU001430//Eye//LNC	MTHU000064//Eye//LNC	MTHU038905//Eye//LNC	sh85046642//Eye//LCH_NW	TCGA//Enterovirus//NCI	LP207778-4//Eye//LNC	81745001//Eye structure//SNOMEDCT_US	C12401//Eye//NCI	EYE//Eye//HL7V2.5	U003284//Eye//MTH	0000002468//eye//AOD	1107-6922//eye//CSP	0000004810//eye//CHV	0057369//EYE//CCPSS	F//EYE//ICPC	LP7797-6//EYE//LNC
sensorineural hearing loss	XE17N//Sensorineural hearing loss//RCD	MTHU001056//Sensorineural hearing loss//OMIM	10040016//Sensorineural hearing loss//MDR	389.1//Sensorineural hearing loss//ICD9CM	60700002//Sensorineural hearing loss//SNOMEDCT_US	BI00649//sensorineural hearing loss//BI	0977-6000//sensorineural hearing loss//CSP	34075//sensorineural hearing loss//MEDCIN	0000005863//sensorineural hearing loss//CHV	HP:0000407//Sensorineural hearing impairment//HPO	NOCODE//Sepsis//COSTAR	N0000001427//Hearing Loss, Sensorineural [Disease/Finding]//NDFRT	C26739//Sensorineural Hearing Loss//NCI	46555//Sensorineural Hearing Loss//PSY	D006319//Hearing Loss, Sensorineural//MSH
nutrition	C16927//Nutritional Science//NCI	2116-4900//nutrition//CSP	0000032037//nutritional status//CHV	K//Nutrition//NOC	2//Nutrition//NANDA-I	36//Nutrition//MEDLINEPLUS	1006812//NUTRITION//CCPSS	Xa97T//Feeding and dietary regimes//RCD	U003305//Nutrition//LCH	35//Nutrition//OMS	LP172860-1//Nutrition//LNC	MTHU047298//Nutrition//LNC	sh85093451//Nutrition//LCH_NW	C28294//Nutrition//NCI_NICHD	34720//Nutrition//PSY	384759009//Nutrition//SNOMEDCT_US	0000001786//nutrition//AOD	CDR0000044698//nutrition//NCI_NCI-GLOSS	C15820//Nutritional Study//NCI
growth	U002048//Growth//LCH	D006128//Growth//MSH	0110//Growth//NOC	C18825//Generalized Growth//NCI	sh85057525//Growth//LCH_NW	13_1//Growth//NANDA-I	21910//Growth//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000005714//physical growth process//CHV	GO:0040007//growth//GO	1003950//GROWTH//CCPSS	MTHU000046//GROWTH//OMIM	Q000254//growth & development//MSH	C16648//Tissue Growth//NCI	C64379//Growth//NCI
ophthalmologic	C16939//Ophthalmology//NCI	G-B106//Ophthalmologic//SNMI	239005//Ophthalmologic//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	BI00642//ophthalmologic//BI	0000020617//ophthalmologic//CHV
manifestation	0000020498//manifestation of//CHV	0000057112//manifestation of//CHV
treatment	Q000628//therapy//MSH	C49236//Therapeutic Procedure//NCI	LP94823-9//Treatment//LNC	LP100632-1//Treatment//LNC	TCGA//Enterovirus//NCI	54190//Treatment//PSY	0373//Treatment//HL7V2.5	D013812//Therapeutics//MSH	0000016079//treatment//CHV	C70742//Treat//NCI	C25409//Administration//NCI	C43442//Biomaterial Treatment//NCI	SDTM-TTYPE//TREATMENT//NCI_CDISC	SDTM-TINDTP//TREATMENT//NCI_CDISC	C101526//TREATMENT//NCI_CDISC	TREAT//treatment//HL7V3.0
communication issues	0000012476//communication issues//AOD
and	C16289//Andorra//NCI	TCGA//Enterovirus//NCI	C37912//And//NCI	NOCODE//Developmental arithmetic disorder//MTH	AND//and//HL7V3.0	421829000//And//SNOMEDCT_US
craniofacial	4006-0029//craniofacial//CSP	0000041543//craniofacial//CHV
hypothyroidism	HYPOT//Hypothyroidism//AIR	T86009//hypothyroidism//ICPC2P	U002348//Hypothyroidism//LCH	10021114//Hypothyroidism//MDR	D007037//Hypothyroidism//MSH	X40IQ//Hypothyroidism//RCD	D-2200//Hypothyroidism//SNM	MTHU002670//Hypothyroidism//OMIM	N0000001654//Hypothyroidism [Disease/Finding]//NDFRT	MTHU020783//Hypothyroidism//LNC	sh85063828//Hypothyroidism//LCH_NW	C26800//Hypothyroidism//NCI_NICHD	E10334//Hypothyroidism//NCI_CTCAE	LA14303-4//Hypothyroidism//LNC	6175//Hypothyroidism//MEDLINEPLUS	HP:0000821//Hypothyroidism//HPO	02495//Hypothyroidism//NANDA-I	40930008//Hypothyroidism//SNOMEDCT_US	24120//Hypothyroidism//PSY	NOCODE//Developmental arithmetic disorder//MTH	1017778//HYPOTHYROIDISM//CCPSS	404//HYPOTHYROIDISM//COSTAR	HYPOTHYR//HYPOTHYROIDISM//CST	U002059//HYPOTHYROIDISM//DXP	0417//HYPOTHYROIDISM//WHO	0000005992//hypothyroidism//AOD	BI00015//hypothyroidism//BI	2928-6836//hypothyroidism//CSP	CDR0000489292//hypothyroidism//PDQ	0000006501//hypothyroidism//CHV	CDR0000044547//hypothyroidism//NCI_NCI-GLOSS	MTHU037239//hypothyroidism//ICPC2ICD10ENG	30524//hypothyroidism//MEDCIN
treatment is supportive	
forearm crutches or canes for gait stability	
special shoes, including those with good ankle support	
5 g/m2	
table 3	
considerations/other	
standard recommendations may vary from country to country	
ages 0-3 years	
ages 3-5 years	
ages 5-21 years	
all ages	
liver transplantation	311//Liver Transplantation//MEDLINEPLUS	C15271//Liver Transplantation//NCI	D016031//Liver Transplantation//MSH	1756-4994//liver transplantation//CSP	0000007508//liver transplantation//CHV	CDR0000474023//liver transplantation//PDQ	10024716//Liver transplantation//MDR
canes and walkers help prevent falls	
no specific therapy is available	
renal	T-71000//Kidney, NOS//SNMI	LP34712-7//Renal//LNC	LA18284-2//Renal//LNC	RENL//Renal//HL7V2.5	C25225//Renal//NCI	0000001845//renal//AOD	0000007085//kidney//CHV	1679-5191//kidney//CSP	0022293//RENAL//CCPSS
cardiomyopathy	7.2.2.1//Cardiomyopathy//CCS	I42//Cardiomyopathy//ICD10	K84041//cardiomyopathy//ICPC2P	G55..//Cardiomyopathy//RCD	D-7100//Cardiomyopathy//SNM	LP128708-7//Cardiomyopathy//LNC	3754//Cardiomyopathy//MEDLINEPLUS	MTHU036362//Cardiomyopathy//OMIM	MTHU040649//Cardiomyopathy//LNC	C34830//Cardiomyopathy//NCI_NICHD	1764//Cardiomyopathy//NCI_FDA	HP:0001638//Cardiomyopathy//HPO	10007636//Cardiomyopathy//MDR	D009202//Cardiomyopathies//MSH	425//Cardiomyopathy//ICD9CM	85898001//Cardiomyopathy//SNOMEDCT_US	1002024//CARDIOMYOPATHY//CCPSS	156//CARDIOMYOPATHY//COSTAR	CARDIOMYOPATHY//CARDIOMYOPATHY//CST	U000553//ENDOMETRIOSIS//DXP	0425//CARDIOMYOPATHY//WHO	0000005390//cardiomyopathy//AOD	BI00081//cardiomyopathy//BI	1393-3627//myocardium disorder//CSP	1393-3642//hypertrophic myocardiopathy//CSP	0000008422//heart muscle disease//CHV	MTHU014927//cardiomyopathy//ICPC2ICD10ENG	33263//cardiomyopathy//MEDCIN
intellectual disability	D008607//Intellectual Disability//MSH	N0000001995//Intellectual Disability [Disease/Finding]//NDFRT	C97250//Intellectual Disability//NCI	NOCODE//Developmental arithmetic disorder//MTH	MTHU035437//Intellectual disability//OMIM	HP:0001249//Intellectual disability//HPO	10067989//Intellectual disability//MDR	228156007//Intellectual functioning disability//SNOMEDCT_US	P28005//intellectual disability//ICPC2P	0000036317//intellectual disability//CHV
ataxia	N29011//ataxia//ICPC2P	U000411//Ataxia//LCH	10003591//Ataxia//MDR	D001259//Ataxia//MSH	X76q7//Ataxia//RCD	F-84580//Ataxia//SNM	N0000000502//Ataxia [Disease/Finding]//NDFRT	4359//Friedreich's Ataxia//MEDLINEPLUS	5919//Cerebellar Disorders//MEDLINEPLUS	619//Degenerative Nerve Diseases//MEDLINEPLUS	520//Movement Disorders//MEDLINEPLUS	MTHU036349//Ataxia//OMIM	sh85009080//Ataxia//LCH_NW	E12597//Ataxia//NCI_CTCAE	C26702//Ataxia//NCI_NICHD	20262006//Ataxia//SNOMEDCT_US	04250//Ataxia//PSY	NOCODE//Developmental arithmetic disorder//MTH	1014485//ATAXIA//CCPSS	U000053//ATAXIA//COSTAR	ATAXIA//ATAXIA//CST	0088//ATAXIA//WHO	0000005037//ataxia//AOD	2057-3228//ataxia//CSP	734//walk is wobbly or unsteady//MEDCIN	0000001550//ataxia//CHV	CDR0000043999//ataxia//NCI_NCI-GLOSS	MTHU008913//ataxia//ICPC2ICD10ENG	278526//ataxia//MEDCIN	HP:0001251//Ataxia//HPO
special education	D004519//Education, Special//MSH	48930//Special Education//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000012600//special education//AOD	0988-7567//remedial/special education//CSP	0000004285//special education//CHV	193301//special education//MEDCIN	sh85046212//Special education//LCH_NW
failure to thrive	D005183//Failure to Thrive//MSH	N0000001205//Failure to Thrive [Disease/Finding]//NDFRT	G17.1//Failure to Thrive//CCC	265//Growth Disorders//MEDLINEPLUS	C107587//Failure to Thrive//NCI	19105//Failure to Thrive//PSY	NOCODE//Developmental arithmetic disorder//MTH	1015628//FAILURE TO THRIVE//CCPSS	U000276//FAILURE TO THRIVE//COSTAR	1626//FAILURE TO THRIVE//WHO	T10//Failure to thrive//ICPC	T10002//failure to thrive//ICPC2P	10016165//Failure to thrive//MDR	XM07a//Failure to thrive//RCD	MTHU000081//Failure to thrive//OMIM	LP36298-5//Failure to thrive//LNC	MTHU019355//Failure to thrive//LNC	00736//Failure to thrive//NANDA-I	783.41//Failure to thrive//ICD9CM	54840006//Failure to thrive//SNOMEDCT_US	10022898//Failure To Thrive//ICNP	1354-8678//postnatal growth disorder//CSP	2403-8925//prenatal growth disorder//CSP	38610//failure to thrive//MEDCIN	0000004874//growth failure//CHV	3587//failure to thrive//MEDCIN	HP:0001508//Failure to thrive//HPO	C113099//Failure to Thrive//NCI_GAIA	C85038//Infant Failure to Thrive//NCI_NICHD
developmental delay	X76B7//Developmental delay//RCD	MTHU000185//Developmental delay//OMIM	10012559//Developmental delay//MDR	00382//Developmental delay//NANDA-I	248290002//Developmental delay//SNOMEDCT_US	0058649//DEVELOPMENTAL DELAY//CCPSS	1577//DEVELOPMENTAL DELAY//WHO	0000006238//developmental delay//AOD	0000033357//child developmental delay//CHV	C116942//Developmental Delay//NCI_NICHD	HP:0001263//Global developmental delay//HPO
1-0	
treatment is symptomatic and may include the following:	
dystonia	N08007//dystonia//ICPC2P	10013983//Dystonia//MDR	D004421//Dystonia//MSH	X76qI//Dystonia//RCD	F-81330//Dystonia//SNM	F-A0950//Dystonia//SNMI	HP:0001332//Dystonia//HPO	15695//Dystonia//PSY	NOCODE//Developmental arithmetic disorder//MTH	DYSTONIA//DYSTONIA//CST	730//involuntary twisting movements//MEDCIN	0000004220//abnormal muscle twitching or contraction//CHV	MTHU024557//dystonia//ICPC2ICD10ENG	8993//dystonia//MEDCIN	G24//Dystonia//ICD10	U001488//Dystonia//LCH	N0000001033//Dystonia [Disease/Finding]//NDFRT	1252//Dystonia//MEDLINEPLUS	MTHU036384//Dystonia//OMIM	sh85040348//Dystonia//LCH_NW	C34563//Dystonia//NCI_NICHD	15802004//Dystonia//SNOMEDCT_US	0057274//DYSTONIA//CCPSS	U001018//LARYNX, HERPES//DXP	0068//DYSTONIA//WHO	2057-3370//dystonia//CSP	0000032219//dystonic disorder//CHV	335098//dystonia//MEDCIN
in the united states:	
consider evaluation for alternative means of communication (e	
yes	HGNC:12841//YES proto-oncogene 1, Src family tyrosine kinase//HGNC	373066001//Yes//SNOMEDCT_US	Y//Evaluation completed//HL7V2.5	TCGA//Enterovirus//NCI	C49488//Y//NCI_CDISC	LA33-6//Yes//LNC
short stature	237836003//Short stature disorder//SNOMEDCT_US	0000004192//short stature//CHV	Xa0MN//Short stature//RCD	MTHU000145//Short stature//OMIM	HP:0004322//Short stature//HPO	10040600//Short stature//MDR	783.43//Short stature//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	0037420//SHORT STATURE//CCPSS	GROWTH RETARD//GROWTH RETARDED//CST	C118686//Short Stature//NCI_NICHD	0000031268//short stature//CHV	T10009//short stature//ICPC2P	6077//short stature//MEDCIN	320653//SHOX gene with short stature//MEDCIN	C55745//Short stature//NCI_CTCAE
endocrine	LP31396-2//Endocrine//LNC	T-B0000//Endocrine gland, NOS//SNMI	C41064//Endocrine//NCI	NOCODE//Developmental arithmetic disorder//MTH	CDR0000458098//endocrine//NCI_NCI-GLOSS	0000037951//endocrine//CHV	0057755//ENDOCRINE//CCPSS	SKINENDO//ENDOCRINE//CST	C53801//ENDOCRINE//NCI_CTCAE
neurologic manifestations	N0000002173//Neurologic Manifestations [Disease/Finding]//NDFRT	D009461//Neurologic Manifestations//MSH	0000008643//neurologic manifestations//CHV
pulmonary	0000007565//lung//CHV	2612-7088//lung//CSP	54542-6//Pulmonary:-:Pt:^Patient:-//LNC	MFLUN//Pulmonary//AIR	XC0L5//Pulmonary//RCD	T-28000//Lung, NOS//SNMI	LP89785-7//Pulmonary//LNC	LP32264-1//Pulmonary//LNC	MTHU031874//Pulmonary//LNC	OMFAQ//Anemia//NCI	LA18283-4//Pulmonary//LNC	C13304//Pulmonary//NCI	264164005//Pulmonary//SNOMEDCT_US	CDR0000045852//pulmonary//NCI_NCI-GLOSS	0042932//PULMONARY//CCPSS
cancer	A79001//cancer//ICPC2P	U006339//Cancer//LCH	X78ef//Malignant tumour//RCD	M-8000/3//Neoplasm, malignant//SNM	M-80003//Neoplasm, malignant//SNMI	LP100805-3//Cancer//LNC	LP7106-0//Cancer//LNC	25//Cancer//MEDLINEPLUS	MTHU010328//Cancer//LNC	sh85019492//Cancer//LCH_NW	LA10524-9//Cancer//LNC	3262//Cancer//NCI_FDA	C9305//Cancer//NCI_NICHD	HP:0002664//Neoplasm//HPO	10007050//Cancer//MDR	01968//Cancer//NANDA-I	MTHU051589//Cancer//LNC	363346000//Malignant neoplastic disease//SNOMEDCT_US	D009369//Neoplasms//MSH	1001968//CANCER//CCPSS	CARCINOMA//CARCINOMA//CST	U000537//ENCEPHALITIS, SAINT LOUIS//DXP	0000004520//cancer//AOD	0000002337//cancer//CHV	CDR0000045333//cancer//NCI_NCI-GLOSS	CDR0000041060//cancer//PDQ	2000-0173//neoplasm/cancer//CSP	31465//cancer//MEDCIN	4103//reported family history of cancer//MEDCIN	6754//Cancer//NCBI	86049000//Neoplasm, malignant (primary)//SNOMEDCT_US	CAN//Cancel. Used to cancel a query//HL7V2.5	54532-7//Cancer:-:Pt:^Patient:-//LNC
physical therapy	MTHU030048//physical therapy//ICPC2ICD10ENG	722138006//Physiotherapy//SNOMEDCT_US	0000044521//physical therapy//CHV	16.26//Physical therapy//CCS	U003663//Physical therapy//LCH	LP6449-5//Physical therapy//LNC	LP98456-4//Physical therapy//LNC	MTHU035236//Physical therapy//LNC	sh85101568//Physical therapy//LCH_NW	10050334//Physical therapy//MDR	NOCODE//Developmental arithmetic disorder//MTH	522//Rehabilitation//MEDLINEPLUS	C15302//Physical Therapy//NCI_NICHD	38590//Physical Therapy//PSY	0000007923//physical therapy//AOD	1385-4813//physical therapy//CSP	CDR0000044708//physical therapy//NCI_NCI-GLOSS	A57003//physical therapy//ICPC2P	0000053447//physical therapy//CHV	0044460//PHYSICAL THERAPY//CCPSS	PT//Patient external identifier//HL7V2.5
renal anomalies	MTHU010000//Renal anomalies//OMIM	HP:0000077//Abnormality of the kidney//HPO
deafness	NOCODE//Sepsis//COSTAR	H86003//deafness//ICPC2P	U001277//Deafness//LCH	D003638//Deafness//MSH	XE0s9//Hearing loss//RCD	F-X6000//Deafness//SNM	MTHU002823//Deafness//OMIM	N0000000901//Deafness [Disease/Finding]//NDFRT	204//Hearing Disorders and Deafness//MEDLINEPLUS	3693//Hearing Problems in Children//MEDLINEPLUS	15188001//Deafness//SNOMEDCT_VET	sh85036068//Deafness//LCH_NW	C27644//Deafness//NCI_NICHD	1801//Deafness//NCI_FDA	HP:0000365//Hearing impairment//HPO	10011878//Deafness//MDR	H86//Deafness//ICPC2EENG	1003290//DEAFNESS//CCPSS	DEAF//DEAFNESS//CST	DA-95000//Deafness, NOS//SNMI	0258//DEAFNESS//WHO	0000006099//deafness//AOD	BI00646//deafness//BI	0977-5812//deafness//CSP	345//Hearing Loss, Partial//MTH	0000040635//complete hearing loss//CHV	0000003627//deafness//CHV	MTHU023796//deafness//ICPC2ICD10ENG	314703//deafness//MEDCIN	0000005856//partial hearing loss//CHV
5-1	
treatment follows routine practices	
speech therapy	NBC//Speech therapy//ALT	D013070//Speech Therapy//MSH	49190//Speech Therapy//PSY	NOCODE//Developmental arithmetic disorder//MTH	U004412//Speech therapy//LCH	8E21.//Speech and language therapy//RCD	P-8840//Speech therapy//SNM	LP6526-0//Speech therapy//LNC	sh85126455//Speech therapy//LCH_NW	10051217//Speech therapy//MDR	5154007//Speech therapy//SNOMEDCT_US	1579-3394//speech therapy//CSP	0000011578//speech and language therapy//CHV	48848//speech therapy//MEDCIN	Z50.5//Speech therapy//ICD10AM	MTHU069178//speech therapy//ICPC2ICD10ENG
some individuals require forearm crutches or canes for gait stability	
cardiac	T-32000//Heart, NOS//SNMI	C12727//Heart//NCI	0000002500//cardiac//AOD	BI00027//cardiovascular//BI	0000005865//heart//CHV	1390-0233//heart//CSP	0002824//CARDIAC//CCPSS	LA27421-9//Cardiac//LNC	C13306//Cardiac//NCI	CDR0000045634//cardiac//NCI_NCI-GLOSS
caregivers	610//Caregivers//MEDLINEPLUS	sh88007577//Caregivers//LCH_NW	07715//Caregivers//PSY	D017028//Caregivers//MSH	0000015637//caregiver//CHV
heart defects	198//Congenital Heart Defects//MEDLINEPLUS
psychotropic medication may also be indicated	
constipation	9.12.1//Constipation//CCS	K59.0//Constipation//ICD10	D12//Constipation//ICPC	D12001//constipation//ICPC2P	U001143//Constipation//LCH	10010774//Constipation//MDR	D003248//Constipation//MSH	020402//Constipation//NOC	PRB_01000.06//Constipation//PCDS	Q0200081//Constipation//QMR	XE0rD//Constipation//RCD	F-62350//Constipation//SNM	D5-44010//Constipation//SNMI	040416//Constipation//NOC	050110//Constipation//NOC	050005//Constipation//NOC	MTHU001907//Constipation//OMIM	10000567//Constipation//ICNP	N0000000841//Constipation [Disease/Finding]//NDFRT	B03.6//Constipation//CCC	200//Constipation//MEDLINEPLUS	MTHU020768//Constipation//LNC	sh85031314//Constipation//LCH_NW	E10562//Constipation//NCI_CTCAE	C37930//Constipation//NCI_NICHD	3274//Constipation//NCI_FDA	HP:0002019//Constipation//HPO	00011//Constipation//NANDA-I	00249//Risk for pressure ulcer//NANDA-I	LA22282-0//Constipation//LNC	14760008//Constipation//SNOMEDCT_US	11440//Constipation//PSY	564.0//Constipation//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	1015408//CONSTIPATION//CCPSS	CONSTIP//CONSTIPATION//CST	U000845//HIRSCHSPRUNG DISEASE//DXP	0204//CONSTIPATION//WHO	0000005514//constipation//AOD	BI00230//constipation//BI	1248-3977//constipation//CSP	444//constipation//MEDCIN	0000003300//constipation//CHV	CDR0000407757//constipation//NCI_NCI-GLOSS	MTHU018925//constipation//ICPC2ICD10ENG	230057//constipation//MEDCIN	C57141//Constipation//NCI_CTCAE	MSAS-SF//Almost Constantly//NCI	MSAS//Dry mouth//NCI
antiepileptic drugs	03150//Antiepileptic Drugs//PSY	D000927//Anticonvulsants//MSH	0000001284//antiepileptics//CHV
musculoskeletal	LP89781-6//Musculoskeletal//LNC	MTHU031870//Musculoskeletal//LNC	LA16972-4//Musculoskeletal//LNC	C25348//Musculoskeletal//NCI	NOCODE//Developmental arithmetic disorder//MTH	0047159//MUSCULOSKELETAL//CCPSS	L//MUSCULOSKELETAL//ICPC	BI00516//musculoskeletal//BI	CDR0000044938//musculoskeletal//NCI_NCI-GLOSS	0000037430//musculoskeletal//CHV	54538-4//Musculoskeletal:-:Pt:^Patient:-//LNC
spasticity	PRB_17010.05//Spasticity//PCDS	X76qL//Spasticity//RCD	091107//Spasticity//NOC	MTHU000300//Spasticity//OMIM	C79750//Spasticity//NCI	1518//Neuromuscular Disorders//MEDLINEPLUS	sh85126342//Spasticity//LCH_NW	E12820//Spasticity//NCI_CTCAE	HP:0001257//Spasticity//HPO	10041416//Spasticity//MDR	397790002//Spasticity//SNOMEDCT_US	221360009//Spasticity//SNOMEDCT_US	U003757//SPASTICITY//DXP	0000008355//spasticity//CHV	8943//spasticity//MEDCIN
global developmental disability / intellectual disability educational issues	
private supportive therapies based on the affected individual’s needs	
medications	0000004159//drug//CHV	31//Medicines//MEDLINEPLUS	LA20271-5//Medications//LNC	MTHU008870//Medications//LNC	19789-7//Medications:Prid:Stdy:^Patient:Nom//LNC	52471-0//Medications:-:Pt:^Patient:-//LNC	MTHU854705//Medications//LNC	NOCODE//Developmental arithmetic disorder//MTH
0-3	
developmental	Xa0ts//Developmental//RCD	278923009//Developmental//SNOMEDCT_US	0000036759//developmental//CHV	C17770//Maturation//NCI
8-2	
gerd = gastroesophageal reflux disease	
hydrocephalus	G91//Hydrocephalus//ICD10	U002272//Hydrocephalus//LCH	10020508//Hydrocephalus//MDR	D006849//Hydrocephalus//MSH	X00EG//Hydrocephalus//RCD	M-33320//Hydrocephalus//SNM	MTHU002499//Hydrocephalus//OMIM	N0000001566//Hydrocephalus [Disease/Finding]//NDFRT	607//Hydrocephalus//MEDLINEPLUS	sh85063378//Hydrocephalus//LCH_NW	C3111//Hydrocephalus//NCI_NICHD	E12682//Hydrocephalus//NCI_CTCAE	3272//Hydrocephalus//NCI_FDA	HP:0000238//Hydrocephalus//HPO	230745008//Hydrocephalus//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0045789//HYDROCEPHALUS//CCPSS	U000361//HYDROCEPHALUS//COSTAR	HYDROCEPHALUS//HYDROCEPHALUS//CST	U002006//VIRAL MYOSITIS//DXP	0692//HYDROCEPHALUS//WHO	0000006135//hydrocephalus//AOD	0485-8483//hydrocephalus//CSP	0000006343//hydrocephalus//CHV	CDR0000045498//hydrocephalus//NCI_NCI-GLOSS	MTHU035873//hydrocephalus//ICPC2ICD10ENG	31969//hydrocephalus//MEDCIN	C55401//Hydrocephalus//NCI_CTCAE
adrenal insufficiency	C26691//Adrenocortical Insufficiency//NCI	N0000000326//Adrenal Insufficiency [Disease/Finding]//NDFRT	1233//Addison Disease//MEDLINEPLUS	D000309//Adrenal Insufficiency//MSH	1000462//ADRENAL INSUFFICIENCY//CCPSS	030//ADRENAL INSUFFICIENCY//COSTAR	ADREN INSUFFIC//ADRENAL CORTEX INSUFFIENCY//CST	U000092//ANEMIA, HEMOLYTIC, G6PD DEFICIENCY//DXP	0410//ADRENAL INSUFFICIENCY//WHO	C154.//Corticoadrenal insufficiency//RCD	MTHU008542//Adrenal insufficiency//OMIM	E10298//Adrenal insufficiency//NCI_CTCAE	HP:0000846//Adrenal insufficiency//HPO	10001367//Adrenal insufficiency//MDR	386584007//Adrenal cortical hypofunction//SNOMEDCT_US	BI00331//adrenal insufficiency//BI	0060-4666//hypoadrenalism//CSP	0000000766//adrenal insufficiency//CHV	T99003//adrenal insufficiency//ICPC2P	312629//adrenal insufficiency//MEDCIN	0000032628//adrenal insufficiency//CHV	C55748//Adrenal insufficiency//NCI_CTCAE
hypertension	7.1//Hypertension//CCS	K86005//hypertension//ICPC2P	U002317//Hypertension//LCH	005//Hypotension//MTH	PRB_11000.06//Hypertension//PCDS	XE0Ub//Hypertension//RCD	F-70700//Hypertension//SNM	050419//Hypertension//NOC	070808//Hypertension//NOC	MTHU002068//Hypertension//OMIM	N0000001616//Hypertension [Disease/Finding]//NDFRT	997.91//Hypertension//MTHICD9	34//High Blood Pressure//MEDLINEPLUS	MTHU020789//Hypertension//LNC	sh85063723//Hypertension//LCH_NW	E13785//Hypertension//NCI_CTCAE	LA7444-8//Hypertension//LNC	1908//Hypertension//NCI_FDA	C3117//Hypertension//NCI_NICHD	HP:0000822//Hypertension//HPO	10020772//Hypertension//MDR	00905//Hypertension//NANDA-I	38341003//Hypertensive disorder//SNOMEDCT_US	23830//Hypertension//PSY	D006973//Hypertension//MSH	1017493//HYPERTENSION//CCPSS	397//HYPERTENSION//COSTAR	CVHYPERT//HYPERTENSION//CST	HYPERTENS//HYPERTENSION//CST	U002034//YAWS//DXP	0210//HYPERTENSION//WHO	0000005280//hypertension//AOD	BI00001//hypertension//BI	0571-5243//hypertension//CSP	0000006443//high blood pressure disorder//CHV	MTHU036479//hypertension//ICPC2ICD10ENG	CDR0000044038//hypertension//NCI_NCI-GLOSS	C55060//Hypertension//NCI_CTCAE
liver disease	0025497//LIVER DISEASE//CCPSS	U000418//MOBITZ TYPE 2 SECOND DEGREE HEART BLOCK//COSTAR	U002405//LIVER DISEASE//DXP	D008107//Liver Diseases//MSH	C3196//Liver and Intrahepatic Bile Duct Disorder//NCI	9.8//Liver disease//CCS	X306R//Disorder of liver//RCD	OMFAQ//Anemia//NCI	HP:0001392//Abnormality of the liver//HPO	LA25810-5//Liver disease//LNC	235856003//Disease of liver//SNOMEDCT_US	D97002//liver disease//ICPC2P	0000007501//liver disease//CHV	3493//reported prior liver disease//MEDCIN
hepatic disease	310//Liver Diseases//MEDLINEPLUS	10019650//Hepatic disease//MDR	235856003//Hepatic disease//SNOMEDCT_VET	0353//HEPATOCELLULAR DAMAGE//WHO	0000007501//liver disease//CHV
pulmonary disease	N0000001879//Lung Diseases [Disease/Finding]//NDFRT	C3198//Lung Disorder//NCI	D008171//Lung Diseases//MSH	628//PULMONARY DISEASE//COSTAR	U003269//PULMONARY DISEASE//DXP	0000007568//lung disease//CHV	236576//pulmonary disease//MEDCIN	LP97125-6//Pulmonary disease//LNC	19829001//Disorder of lung//SNOMEDCT_US	3497//reported previous pulmonary disease//MEDCIN
renal manifestations	
hyperlipidemia	U002308//Hyperlipidemia//LCH	X40Wy//Hyperlipidemia//RCDAE	MTHU002043//Hyperlipidemia//OMIM	N0000001592//Hyperlipidemias [Disease/Finding]//NDFRT	4277//Triglycerides//MEDLINEPLUS	26//Cholesterol//MEDLINEPLUS	sh85063704//Hyperlipidemia//LCH_NW	HP:0003077//Hyperlipidemia//HPO	10020667//Hyperlipidemia//MDR	02489//Hyperlipidemia//NANDA-I	D006949//Hyperlipidemias//MSH	10062060//Hyperlipidaemia//MDR	55822004//Hyperlipidemia//SNOMEDCT_US	C34707//Hyperlipidemia//NCI	NOCODE//Developmental arithmetic disorder//MTH	1006712//HYPERLIPIDEMIA//CCPSS	395//HYPERLIPIDEMIA//COSTAR	HYPERLIPEM//HYPERLIPEMIA//CST	U002027//WISKOTT-ALDRICH SYNDROME//DXP	0000005732//hyperlipidemia//AOD	BI00109//hyperlipidemia//BI	1744-2444//hyperlipidemia//CSP	0000006419//excessive fat in the blood//CHV	T93008//hyperlipidaemia//ICPC2P	MTHU036253//hyperlipidemia//ICPC2ICD10ENG	214032//hyperlipidemia//MEDCIN	166816003//Hyperlipemia//SNOMEDCT_VET
bleeding	A10001//bleeding//ICPC2P	Xa9I7//Bleeding//RCD	M-37000//Hemorrhage//SNM	C26791//Hemorrhage//NCI	110018//Bleeding//NOC	040902//Bleeding//NOC	N0000001481//Hemorrhage [Disease/Finding]//NDFRT	6039//Bleeding//MEDLINEPLUS	LA7418-2//Bleeding//LNC	1888//Hemorrhage//NCI_FDA	10005103//Bleeding//MDR	00152//Risk for powerlessness//NANDA-I	MTHU053652//Bleeding//OMIM	131148009//Bleeding//SNOMEDCT_US	50960005//Hemorrhage//SNOMEDCT_US	D006470//Hemorrhage//MSH	110//BLEEDING//COSTAR	U000382//COLON, DIVERTICULOSIS//DXP	0000006008//bleeding//CHV	0571-4198//hemorrhage//CSP	MTHU034211//bleeding//ICPC2ICD10ENG	282941//bleeding//MEDCIN
dialysis	U001377//Dialysis//LCH	LP32538-8//Dialysis//LNC	LP20688-5//Dialysis//LNC	LP6226-7//Dialysis//LNC	MTHU026059//Dialysis//LNC	sh85037540//Dialysis//LCH_NW	D003956//Dialysis//MSH	0000001524//dialysis//AOD	2323-1315//dialysis//CSP	3789//Dialysis//MEDLINEPLUS	LA7216-0//Dialysis//LNC	10061105//Dialysis//MDR	14020//Dialysis//PSY	C15221//Dialysis//NCI	0000052369//dialysis//CHV	0000003858//dialysis//CHV	CDR0000045485//dialysis//NCI_NCI-GLOSS	CDR0000042471//dialysis//PDQ	MTHU022883//dialysis//ICPC2ICD10ENG	41810//dialysis//MEDCIN	1015724//DIALYSIS//CCPSS	124307//Dialysis//NCBI	NOCODE//administration devices//MMSL
surgical stabilization of the spine may be required	
pectus excavatum can be severe	
optic atrophy	NOCODE//Sepsis//COSTAR	D009896//Optic Atrophy//MSH	N0000002226//Optic Atrophy [Disease/Finding]//NDFRT	C34863//Optic Atrophy//NCI	0047751//OPTIC ATROPHY//CCPSS	ATROPHY OPTIC//OPTIC ATROPHY//CST	0135//OPTIC ATROPHY//WHO	H47.2//Optic atrophy//ICD10	10030910//Optic atrophy//MDR	F4H1.//Optic atrophy//RCD	M-58000//Atrophy//SNM	MTHU036360//Optic atrophy//OMIM	HP:0000648//Optic atrophy//HPO	377.1//Optic atrophy//ICD9CM	76976005//Optic atrophy//SNOMEDCT_US	2042-6601//optic nerve disorder//CSP	0000008978//optic atrophy//CHV	36835//optic atrophy//MEDCIN
appropriate treatment includes the following:	
diabetes mellitus	D003920//diabetes mellitus//MSHCZE	10012601//Diabetes mellitus//MDRCZE	T90//Diabetes mellitus//ICPCDAN	U000263//Brassica napus//MTH	N0000000950//Diabetes Mellitus [Disease/Finding]//NDFRT	4//Diabetes//MEDLINEPLUS	45//Diabetes Mellitus//MEDLINEPLUS	TCGA//Enterovirus//NCI	C2985//Diabetes Mellitus//NCI_NICHD	13970//Diabetes Mellitus//PSY	NOCODE//Developmental arithmetic disorder//MTH	1018264//DIABETES MELLITUS//CCPSS	230//DIABETES MELLITUS//COSTAR	DIABETES MELL//DIABETES MELLITUS//CST	U000960//JAUNDICE, OBSTRUCTIVE//DXP	R0121582//DIABETES MELLITUS//QMR	0371//DIABETES MELLITUS//WHO	DIABT//Diabetes mellitus//AIR	E10-E14.9//Diabetes mellitus//ICD10	T90002//diabetes mellitus//ICPC2P	C10..//Diabetes mellitus//RCD	D-2381//Diabetes mellitus//SNM	MTHU036798//Diabetes mellitus//OMIM	MTHU020781//Diabetes mellitus//LNC	LA14291-1//Diabetes mellitus//LNC	HP:0000819//Diabetes mellitus//HPO	00385//Diabetes mellitus//NANDA-I	250//Diabetes mellitus//ICD9CM	73211009//Diabetes mellitus//SNOMEDCT_US	0000005999//diabetes mellitus//AOD	BI00008//diabetes mellitus//BI	0862-6160//diabetes mellitus//CSP	0000003834//diabetes//CHV	CDR0000044129//diabetes mellitus//NCI_NCI-GLOSS	30479//diabetes mellitus//MEDCIN
for ages 0-3 years	
for ages 3-5 years	
for ages 5-21 years	
for all ages	
social/behavioral difficulties	
05-0	
weight control to avoid obesity	
feeding difficulties	MTHU001721//Feeding difficulties//OMIM	R63.3//Feeding difficulties//ICD10CM	338368//Feeding difficulties//MEDCIN	HP:0011968//Feeding difficulties//HPO	NOCODE//Developmental arithmetic disorder//MTH	0000022945//feeding problems//CHV
osteopenia	D001851//Choroby kości metaboliczne//MSHPOL	L95002//osteopenia//ICPC2P	10049088//Osteopenia//MDR	XaE5D//Osteopenia//RCD	M-59180//Osteopenia//SNM	M-59070//Osteopenia//SNMI	C50910//Osteopenia//NCI	MTHU000031//Osteopenia//OMIM	5935//Bone Density//MEDLINEPLUS	sh85095982//Osteopenia//LCH_NW	2651//Osteopenia//NCI_FDA	HP:0000938//Osteopenia//HPO	312894000//Osteopenia//SNOMEDCT_US	78441005//Osteopenia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0045116//OSTEOPENIA//CCPSS	0000005166//osteopenia//AOD	4001-0098//osteopenia//CSP	0000009092//bone loss//CHV	CDR0000538637//osteopenia//NCI_NCI-GLOSS	32589//osteopenia//MEDCIN
management is supportive	
development	13_2//Development//NANDA-I	Q000254//growth & development//MSH	C17770//Maturation//NCI	C18732//Development//NCI	GO:0032502//developmental process//GO	C84377//Development//NCI	13830//Development//PSY	NOCODE//Developmental arithmetic disorder//MTH	C96110//Development//NCI_FDA
exocrine pancreatic insufficiency	D5-90550//Exocrine pancreatic insufficiency//SNMI	MTHU010290//Exocrine pancreatic insufficiency//OMIM	HP:0001738//Exocrine pancreatic insufficiency//HPO	K86.81//Exocrine pancreatic insufficiency//ICD10CM	363695//Exocrine pancreatic insufficiency//MEDCIN	47367009//Exocrine pancreatic insufficiency//SNOMEDCT_US	U000150//Exocrine pancreatic insufficiency//MTH	C84316//Pancreatic Insufficiency//NCI	N0000011093//Exocrine Pancreatic Insufficiency [Disease/Finding]//NDFRT	D010188//Exocrine Pancreatic Insufficiency//MSH
anemia	4.1//Anemia//CCS	U000235//Anemia//LCH	D000740//Anemia//MSH	U000161//Anemia//MTH	U000164//Poisoning by antiviral drug//MTH	XM05A//Anemia//RCDAE	D-4010//Anemia//SNM	050423//Anemia//NOC	MTHU002606//Anemia//OMIM	N0000000384//Anemia [Disease/Finding]//NDFRT	139//Anemia//MEDLINEPLUS	MTHU020823//Anemia//LNC	sh85004940//Anemia//LCH_NW	OMFAQ//Anemia//NCI	E10010//Anemia//NCI_CTCAE	C2869//Anemia//NCI_NICHD	LA18969-8//Anemia//LNC	1706//Anemia//NCI_FDA	HP:0001903//Anemia//HPO	10002272//Anemia//MDR	01904//Anemia//NANDA-I	10002034//Anaemia//MDR	271737000//Anemia//SNOMEDCT_US	02450//Anemia//PSY	NOCODE//Developmental arithmetic disorder//MTH	1017210//ANEMIA//CCPSS	051//ANEMIA//COSTAR	ANEMIA//ANEMIA//CST	U000172//ATAXIA, CEREBELLAR, ACUTE//DXP	0000005870//anemia//AOD	BI00026//anemia//BI	0427-0313//anemia//CSP	30.06//anemia//OMS	0000001118//anemia//CHV	CDR0000045360//anemia//NCI_NCI-GLOSS	CDR0000041382//anemia//PDQ	MTHU005706//anemia//ICPC2ICD10ENG	B82005//anaemia//ICPC2P	30320//anemia//MEDCIN	0544//ANEMIA//WHOPOR	12939//Anemia//NCBI
malignancy	MALIG//Malignancy//AIR	M-8000/3//Neoplasm, malignant//SNM	M-80003//Neoplasm, malignant//SNMI	LP20701-6//Malignancy//LNC	LP128794-7//Malignancy//LNC	25//Cancer//MEDLINEPLUS	MTHU040703//Malignancy//LNC	C9305//Cancer//NCI_NICHD	02867//Malignancy//NANDA-I	D009369//Neoplasms//MSH	1017904//MALIGNANCY//CCPSS	RETICMALIG//MALIGNANCY//CST	465//MALIGNANCY//COSTAR	CDR0000045771//malignancy//NCI_NCI-GLOSS	BB02.//Malignant tumour morphology//RCD	86049000//Neoplasm, malignant (primary)//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH
exercise within the individual's capability	
fewer than 5% need wheelchairs	
symptomatic treatment	
5-0	
0 g/m2	
audiologic	
fitting with appropriate hearing aids	
enrollment in an appropriate educational program for the hearing impaired	
growth hormone deficiency	10056438//Growth hormone deficiency//MDR	Xa9Ap//Growth hormone deficiency//RCD	MTHU004822//Growth hormone deficiency//OMIM	397827003//Growth hormone deficiency//SNOMEDCT_US	2715-1517//pituitary dwarfism//CSP	0000026643//growth hormone deficiency//CHV	HP:0000824//Growth hormone deficiency//HPO	C112835//Growth Hormone Deficiency//NCI_NICHD	34030//growth hormone deficiency//MEDCIN
tolerance to different primary layers varies	
nonstick products (e	
silicone-based products without adhesive (e	
rolls of gauze (e	
cleft palate	NOCODE//Sepsis//COSTAR	D002972//Cleft Palate//MSH	C87069//Cleft Palate//NCI	N0000000793//Cleft Palate [Disease/Finding]//NDFRT	191//Cleft Lip and Palate//MEDLINEPLUS	09480//Cleft Palate//PSY	CLEFT PALATE//CLEFT PALATE//CST	U000774//HEART FAILURE, HIGH OUTPUT//DXP	0680//CLEFT PALATE//WHO	Q35//Cleft palate//ICD10	U001048//Cleft palate//LCH	10009269//Cleft palate//MDR	P90..//Cleft palate//RCD	MTHU000511//Cleft palate//OMIM	sh85026926//Cleft palate//LCH_NW	LA14412-3//Cleft palate//LNC	02033//Cleft palate//NANDA-I	749.0//Cleft palate//ICD9CM	87979003//Cleft palate//SNOMEDCT_US	0000004973//cleft palate//AOD	0725-9049//cleft palate//CSP	0000003027//cleft palate//CHV	30403//cleft palate//MEDCIN	119540//CLEFT PALATE, ISOLATED//OMIM	6826//cleft palate on exam//MEDCIN	M-21510//Congenital fissure//SNM	HP:0000175//Cleft palate//HPO
table 5	
neutropenia	LEUKOPENIA//LEUKOPENIA//CST	NOCODE//Sepsis//COSTAR	B84008//neutropenia//ICPC2P	10029354//Neutropenia//MDR	D009503//Neutropenia//MSH	M-59100//Cytopenia//SNM	288.0//Neutropenia//ICD9CM	D70//Neutropenia//ICD10CM	N0000002182//Neutropenia [Disease/Finding]//NDFRT	0045739//NEUTROPENIA//CCPSS	U002790//NEUTROPENIA//DXP	0572//GRANULOCYTOPENIA//WHO	BI00317//neutropenia//BI	5000-0035//neutropenia//CSP	0000008679//neutropenia//CHV	CDR0000041387//neutropenia//PDQ	MTHU052896//neutropenia//ICPC2ICD10ENG	30301//neutropenia//MEDCIN	42J2.//Neutropenia//RCD	MTHU001686//Neutropenia//OMIM	C80520//Neutropenia//NCI	HP:0001875//Neutropenia//HPO	165517008//Neutropenia//SNOMEDCT_US	CDR0000045361//neutropenia//NCI_NCI-GLOSS
physical therapy is recommended to maximize mobility	
no specific treatment is available	
prevention of secondary manifestations	
ketogenic diet	D055423//Diet, Ketogenic//MSH	NOCODE//Developmental arithmetic disorder//MTH	U005709//Ketogenic diet//LCH	Ub02Z//Ketogenic diet//RCD	C-F2730//Ketogenic diet//SNMI	10073855//Ketogenic diet//MDR	sh85072093//Ketogenic diet//LCH_NW	226108007//Ketogenic diet//SNOMEDCT_US	0000025270//ketogenic diet//CHV
7-2	
pediatric issues	
liver	U002724//Liver//LCH	D008099//Liver//MSH	U000466//Liver//SNM	T-56000//Liver//SNM	7197//Liver//UWDA	MTHU000220//Liver//OMIM	LP29289-3//Liver//LNC	LP7400-7//Liver//LNC	MTHU002039//Liver//LNC	sh85077748//Liver//LCH_NW	TCGA//Enterovirus//NCI	LA4584-4//Liver//LNC	LP199933-5//Liver//LNC	10200004//Liver structure//SNOMEDCT_US	28620//Liver//PSY	C12392//Liver//NCI	LIVER//Liver//HL7V2.5	U002051//Liver//MTH	0050526//LIVER//CCPSS	T-62000//Liver, NOS//SNMI	0000002569//liver//AOD	1754-0095//liver//CSP	CDR0000046312//liver//NCI_NCI-GLOSS	0000007494//liver//CHV	N0000145839//LIVER//NDFRT	4017451//LIVER//VANDF	NOCODE//administration devices//MMSL	0000045892//Liver brand//CHV	14013//Liver//MMSL	7N330//Liver//RCD	C73399//LIVER//NCI_FDA
sodium benzoate	C66541//Sodium Benzoate//NCI	5206//LVP solution Ringers Injection intravenous solution//MMSL	56455//Sodium Benzoate//RXNORM	N0000006712//Sodium Benzoate [Chemical/Ingredient]//NDFRT	OJ245FE5EU//Sodium Benzoate//MTHSPL	D020160//Sodium Benzoate//MSH	d03096//sodium benzoate//MMSL	5472//beta-carotene 25000 units oral capsule//MMSL	0000016501//sodium benzoate//CHV	001243//POTASSIUM ACETATE MISCELL GRANULES (GRAM)//NDDF	003194//ESTRADIOL CYPIONATE 1 mg/mL INTRAMUSC VIAL (ML)//NDDF	A16AX11//sodium benzoate//ATC	U005211//Sodium benzoate//LCH	X79Ed//Sodium benzoate//RCD	LP62281-8//Sodium benzoate//LNC	sh85124256//Sodium benzoate//LCH_NW	398718007//Sodium benzoate//SNOMEDCT_US	125706008//Sodium benzoate//SNOMEDCT_US	N0000146158//SODIUM BENZOATE//NDFRT	4017797//SODIUM BENZOATE//VANDF
table 4	
orthopedic	D009985//Orthopedics//MSH	LP100610-7//Orthopedic//LNC	C16942//Orthopedics//NCI	0000009051//orthopedic surgery//CHV
supportive therapy includes the following:	
use of respiratory aids when indicated	
genitourinary abnormalities	N0000003083//Urogenital Abnormalities [Disease/Finding]//NDFRT	D014564//Urogenital Abnormalities//MSH
epilepsy	6.4.1//Epilepsy//CCS	G40//Epilepsy//ICD10	N88006//epilepsy//ICPC2P	U001630//Epilepsy//LCH	D004827//Epilepsy//MSH	F25..//Epilepsy//RCD	F-87000//Seizure//SNM	MTHU022799//Epilepsy//OMIM	N0000001126//Epilepsy [Disease/Finding]//NDFRT	244//Epilepsy//MEDLINEPLUS	MTHU020586//Epilepsy//LNC	sh85044401//Epilepsy//LCH_NW	C3020//Epilepsy//NCI_NICHD	OMFAQ//Anemia//NCI	LA16985-6//Epilepsy//LNC	HP:0001250//Seizures//HPO	10015037//Epilepsy//MDR	LP248725-6//Epilepsy//LNC	84757009//Epilepsy//SNOMEDCT_US	N88//Epilepsy//ICPC2EENG	17680//Epilepsy//PSY	NOCODE//Developmental arithmetic disorder//MTH	283//EPILEPSY//COSTAR	CONVULS//CONVULSION//CST	U001142//MEASLES//DXP	0093//CONVULSIONS//WHO	0000006149//epilepsy//AOD	BI00559//seizure disorder//BI	0485-6986//epilepsy//CSP	0000004556//epilepsy//CHV	CDR0000044028//epilepsy//NCI_NCI-GLOSS	MTHU026633//epilepsy//ICPC2ICD10ENG	313582//epilepsy//MEDCIN
see hereditary hearing loss and deafness	
supportive and symptomatic management is indicated	
9-2	
2(1	
0(1	
5-2	
7-4	
surgery	sh85130766//Surgery//LCH_NW	TCGA//Enterovirus//NCI	C17173//Surgery//NCI	SUR//Summary product experience report//HL7V2.5	426//Surgery//MEDLINEPLUS	Q000601//surgery//MSH	U004538//Surgery//LCH	X79q6//Surgery//RCD	LP97910-1//Surgery//LNC	LP32925-7//Surgery//LNC	LP173473-2//Surgery//LNC	MTHU007597//Surgery//LNC	1003143//Surgery//CPT	LA14620-1//Surgery//LNC	10042609//Surgery//MDR	MTHU051579//Surgery//LNC	MTHU854701//Surgery//LNC	50790//Surgery//PSY	C15329//Surgical Procedure//NCI	257556004//Surgery//SNOMEDCT_US	2846-3981//surgery//CSP	0000038661//surgery//CHV	CDR0000045570//surgery//NCI_NCI-GLOSS	CDR0000042869//surgery//PDQ	41559//surgery//MEDCIN	0038373//SURGERY//CCPSS	D013502//General Surgery//MSH	MTHU055642//surgery//ICPC2ICD10ENG	S//Stat (do immediately)//HL7V2.5	C49611//SG//NCI_CDISC
dysphagia	D003680//Slikaandoening//MSHDUT	9.12.2//Dysphagia//CCS	R13//Dysphagia//ICD10	D21004//dysphagia//ICPC2P	10013950//Dysphagia//MDR	MT160004//Dysphagia//MTHMST	XM08J//Dysphagia//RCD	F-61020//Dysphagia//SNM	787.2//Dysphagia//ICD9CM	R13.1//Dysphagia//ICD10CM	N0000000910//Deglutition Disorders [Disease/Finding]//NDFRT	1309//Swallowing Disorders//MEDLINEPLUS	MTHU036443//Dysphagia//OMIM	E10621//Dysphagia//NCI_CTCAE	C2980//Dysphagia//NCI_NICHD	1815//Dysphagia//NCI_FDA	HP:0002015//Dysphagia//HPO	40739000//Dysphagia//SNOMEDCT_US	15654//Dysphagia//PSY	1014574//DYSPHAGIA//CCPSS	265//DYSPHAGIA//COSTAR	DYSPHAGIA//DYSPHAGIA//CST	U001012//LARYNX, CARCINOMA, INTRINSIC//DXP	0280//DYSPHAGIA//WHO	0000005507//dysphagia//AOD	BI00239//dysphagia//BI	5000-0052//dysphagia//CSP	CDR0000524080//dysphagia//PDQ	399//difficulty swallowing//MEDCIN	0000003662//swallowing difficulty//CHV	CDR0000044666//dysphagia//NCI_NCI-GLOSS	MTHU024378//dysphagia//ICPC2ICD10ENG	312702//dysphagia//MEDCIN
vision	U004965//Vision//LCH	091302//Vision//NOC	F-X0000//Visual function//SNM	20//Vision//OMS	C38533//Sight//NCI	LP30560-4//Vision//LNC	MTHU014733//Vision//LNC	sh85143872//Vision//LCH_NW	D014785//Vision, Ocular//MSH	MTHU051591//Vision//LNC	55820//Vision//PSY	NOCODE//Developmental arithmetic disorder//MTH	0034996//VISION//CCPSS	F-F0000//Vision, NOS//SNMI	0000002747//vision//AOD	1113-5071//vision//CSP	GO:0007601//visual perception//GO	0000013030//vision//CHV	54543-4//Vision:-:Pt:^Patient:-//LNC	562//Vision//SOP
hypogonadism	T99032//hypogonadism//ICPC2P	U002330//Hypogonadism//LCH	10058359//Hypogonadism//MDR	D007006//Hypogonadism//MSH	X40Ov//Hypogonadism//RCD	C9227//Hypogonadism//NCI	MTHU000132//Hypogonadism//OMIM	N0000001636//Hypogonadism [Disease/Finding]//NDFRT	sh85063790//Hypogonadism//LCH_NW	HP:0000135//Hypogonadism//HPO	48130008//Hypogonadism//SNOMEDCT_US	24000//Hypogonadism//PSY	NOCODE//Developmental arithmetic disorder//MTH	1013140//HYPOGONADISM//CCPSS	U000373//HYPOGONADISM//COSTAR	U002049//HYPOGONADISM//DXP	0000005865//hypogonadism//AOD	2586-8835//hypogonadism//CSP	0000006477//hypogonadism//CHV	30700//hypogonadism//MEDCIN
care by a pediatric endocrinologist is recommended	
standard management	
craniosynostosis	Q75.0//Craniosynostosis//ICD10	10049889//Craniosynostosis//MDR	XE1Lz//Craniosynostosis//RCD	M-22650//Congenital ossification of sutures//SNM	D4-00C00//Craniosynostosis syndrome//SNMI	MTHU002205//Craniosynostosis//OMIM	C84655//Craniosynostosis//NCI	N0000000870//Craniosynostoses [Disease/Finding]//NDFRT	5757//Craniofacial Abnormalities//MEDLINEPLUS	HP:0001363//Craniosynostosis//HPO	D003398//Craniosynostoses//MSH	57219006//Craniosynostosis syndrome//SNOMEDCT_US	756.0//Craniosynostosis//MTHICD9	N85006//craniosynostosis//ICPC2P	NOCODE//Developmental arithmetic disorder//MTH	U000901//HYPOGLYCEMIA, REACTIVE FUNCTIONAL//DXP	0726-0275//craniosynostosis//CSP	0000003432//craniosynostosis//CHV	MTHU019901//craniosynostosis//ICPC2ICD10ENG	37675//craniosynostosis//MEDCIN
org)	
obesity	3.11.2//Obesity//CCS	E66//Obesity//ICD10	U003312//Obesity//LCH	10029883//Obesity//MDR	D009765//Obesity//MSH	545//Obesity//MTH	C380.//Obesity//RCD	M-71800//Obesity//SNM	MTHU000250//Obesity//OMIM	N0000002200//Obesity [Disease/Finding]//NDFRT	61//Obesity//MEDLINEPLUS	sh85093646//Obesity//LCH_NW	E12361//Obesity//NCI_CTCAE	LA6301-1//Obesity//LNC	HP:0001513//Obesity//HPO	00232//Obesity//NANDA-I	02972//Obesity//NANDA-I	T82//Obesity//ICPC2EENG	34780//Obesity//PSY	C3283//Obesity//NCI	414916001//Obesity//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	1003545//OBESITY//CCPSS	529//OBESITY//COSTAR	OBESITY//OBESITY//CST	U002906//OBESITY//DXP	R0121694//OBESITY//QMR	0397//OBESITY//WHO	155541//MELANOCORTIN 4 RECEPTOR//OMIM	601665//OBESITY//OMIM	0000004374//obesity//AOD	BI00002//obesity//BI	0467-3154//obesity//CSP	CDR0000467910//obesity//PDQ	0000008861//obesity//CHV	CDR0000527371//obesity//NCI_NCI-GLOSS	MTHU053527//obesity//ICPC2ICD10ENG	33649//obesity//MEDCIN	C55334//Obesity//NCI_CTCAE
obstructive sleep apnea	X0084//Obstructive sleep apnea//RCDAE	MTHU001467//Obstructive sleep apnea//OMIM	HP:0002870//Obstructive sleep apnea//HPO	78275009//Obstructive sleep apnea syndrome//SNOMEDCT_US	0000037771//obstructive sleep apnea//CHV	4003-0054//sleep apnea//CSP	270273//obstructive sleep apnea//MEDCIN	N0000004021//Sleep Apnea, Obstructive [Disease/Finding]//NDFRT	C116337//Obstructive Sleep Apnea//NCI	D020181//Sleep Apnea, Obstructive//MSH
ocular	C12401//Eye//NCI	0000004810//eye//CHV	C38533//Sight//NCI	371398005//Ocular//SNOMEDCT_VET	T-AA000//Eye, NOS//SNMI	C87163//Ocular//NCI	0045304//OCULAR//CCPSS
cleft lip/palate	D81005//cleft lip/palate//ICPC2P	MTHU015010//Cleft lip/palate//OMIM	HP:0000202//Oral cleft//HPO
chronic treatment	
hypogonadotropic hypogonadism	C34752//Klinefelter Syndrome//NCI	226//chromosome XXY syndrome//JABL	0000007121//klinefelter's syndrome//CHV	DB-12710//Hypogonadotropic hypogonadism//SNMI	MTHU004823//Hypogonadotropic hypogonadism//OMIM	E23.0//Hypopituitarism//ICD10CM	33927004//Hypogonadotropic hypogonadism//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000026650//hypogonadotropic hypogonadism//CHV	C113347//Hypogonadotropic Hypogonadism//NCI	D007006//Hypogonadism//MSH
other treatments	
movement disorder	0042860//MOVEMENT DISORDER//CCPSS	MOVEMENT DIS//MOVEMENT DISORDER//CST	NOCODE//Sepsis//COSTAR	D009069//Movement Disorders//MSH	C116757//Movement Disorder//NCI	2057-3596//neuromuscular disorder//CSP	2057-3603//degenerative motor system disease//CSP	0000008293//movement disorders//CHV	276423//movement disorder//MEDCIN	MTHU044333//Movement disorder//OMIM	HP:0100022//Abnormality of movement//HPO	10028035//Movement disorder//MDR	60342002//Movement disorder//SNOMEDCT_US
lung disease	D008171//Lung Diseases//MSH	LA10531-4//Lung Disease//LNC	0027432//LUNG DISEASE//CCPSS	10051054//Lung disease//MDR	HP:0002088//Abnormality of lung morphology//HPO	0000007568//lung disease//CHV	R99024//lung disease//ICPC2P	236576//pulmonary disease//MEDCIN
no definitive treatments for the limb-girdle muscular dystrophies exist	
thrombocytopenia	4.2.2//Thrombocytopenia//CCS	U004668//Thrombocytopenia//LCH	10043554//Thrombocytopenia//MDR	D013921//Thrombocytopenia//MSH	XE24o//Thrombocytopenia//RCD	M-59100//Cytopenia//SNM	MTHU000212//Thrombocytopenia//OMIM	N0000002932//Thrombocytopenia [Disease/Finding]//NDFRT	5218//Platelet Disorders//MEDLINEPLUS	sh85135069//Thrombocytopenia//LCH_NW	C3408//Thrombocytopenia//NCI_NICHD	HP:0001873//Thrombocytopenia//HPO	302215000//Thrombocytopenic disorder//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	1015045//THROMBOCYTOPENIA//CCPSS	731//THROMBOCYTOPENIA//COSTAR	THROMBOCYTOPENIA//THROMBOCYTOPENIA//CST	U004003//THROMBOCYTOPENIA//DXP	0594//THROMBOCYTOPENIA//WHO	0000005934//thrombocytopenia//AOD	BI00327//thrombocytopenia//BI	0446-5652//thrombocytopenia//CSP	U000208//Musculosketally mobile//MTH	0000012221//reduced platelet count//CHV	CDR0000045365//thrombocytopenia//NCI_NCI-GLOSS	CDR0000041408//thrombocytopenia//PDQ	MTHU075511//thrombocytopenia//ICPC2ICD10ENG	B83012//thrombocytopaenia//ICPC2P	30298//thrombocytopenia//MEDCIN
reducing the risk of neurologic damage	
see deafness and hereditary hearing loss overview, management	
immunodeficiency	MTHU007447//Immunodeficiency//OMIM	HP:0002721//Immunodeficiency//HPO	10061598//Immunodeficiency//MDR	C39725//Immunodeficiency//NCI_NICHD	02515//Immunodeficiency//NANDA-I	MTHU054768//Immunodeficiency//LNC	LP231628-1//Immunodeficiency//LNC	234532001//Immunodeficiency disorder//SNOMEDCT_US	0000004832//immunodeficiency//AOD	1560-5885//immunodeficiency//CSP	0000006602//immunodeficiency syndrome//CHV	CDR0000046357//immunodeficiency//NCI_NCI-GLOSS	MTHU037620//immunodeficiency//ICPC2ICD10ENG	C3131//Immunodeficiency Syndrome//NCI	1007151//IMMUNODEFICIENCY//CCPSS	82757-6//Immunodeficiency:Type:Pt:^Patient:Nom//LNC
some symptoms (e	
bone marrow transplantation	D016026//Bone Marrow Transplantation//MSH	1457//Bone Marrow Transplantation//MEDLINEPLUS	TCGA//Enterovirus//NCI	C15194//Bone Marrow Transplantation//NCI_NICHD	NOCODE//Developmental arithmetic disorder//MTH	P-1429//Transplantation, allogeneic//SNM	0432-1339//bone marrow transplantation//CSP	0000002077//bone marrow transplant (BMT)//CHV	CDR0000045263//bone marrow transplantation//NCI_NCI-GLOSS	CDR0000039793//bone marrow transplantation//PDQ
symptoms typically resolve within days	
bone marrow transplantation (bmt)	
education of parents regarding common seizure presentations is appropriate	
, contractures, scoliosis, hip dislocation)	
parkinsonism	N87//Parkinsonism//ICPC	N87003//parkinsonism//ICPC2P	10034010//Parkinsonism//MDR	X003Z//Disorders presenting primarily with parkinsonism//RCD	D-8450//Paralysis agitans//SNM	MTHU000764//Parkinsonism//OMIM	N0000004168//Parkinsonian Disorders [Disease/Finding]//NDFRT	C116922//Parkinsonism//NCI	HP:0001300//Parkinsonism//HPO	32798002//Parkinsonism//SNOMEDCT_US	36715//Parkinsonism//PSY	D020734//Parkinsonian Disorders//MSH	U000510//PARKINSONISM//COSTAR	EXTRAPYR SYND//EXTRAPYRAMIDAL SYNDROME//CST	U003023//PARKINSONISM//DXP	0106//EXTRAPYRAMIDAL DISORDER//WHO	BI00554//parkinson's disease//BI	0000024819//parkinsonism//CHV	MTHU057914//parkinsonism//ICPC2ICD10ENG	312997//parkinsonism//MEDCIN
other features	
ovarian insufficiency	C113351//Ovarian Failure//NCI	5804//Ovarian Disorders//MEDLINEPLUS	3684//Premature Ovarian Failure//MEDLINEPLUS	NOCODE//Developmental arithmetic disorder//MTH
infertility	U002427//Infertility//LCH	D007246//Infertility//MSH	Q0200152//Infertility//QMR	X76Lv//Infertility//RCD	F-30710//Infertility//SNM	MTHU006969//Infertility//OMIM	N0000001684//Infertility [Disease/Finding]//NDFRT	250//Infertility//MEDLINEPLUS	8619003//Infertility//SNOMEDCT_VET	sh85066087//Infertility//LCH_NW	HP:0000789//Infertility//HPO	10021926//Infertility//MDR	25210//Infertility//PSY	C3836//Infertility//NCI	NOCODE//Developmental arithmetic disorder//MTH	1007691//INFERTILITY//CCPSS	416//INFERTILITY//COSTAR	U002093//INFERTILITY//DXP	0000005861//infertility//AOD	BI00389//infertility//BI	1138-0208//fertility//CSP	47.06//infertility//OMS	1085//inability to conceive//MEDCIN	0000006699//infertility//CHV	CDR0000046348//infertility//NCI_NCI-GLOSS	CDR0000040782//fertility assessment/management//PDQ	283389//infertility//MEDCIN
cardiac defects are managed in a routine manner	
the following are recommended:	
precocious puberty	C79704//Precocious Puberty//NCI	N0000002535//Puberty, Precocious [Disease/Finding]//NDFRT	D011629//Puberty, Precocious//MSH	NOCODE//Developmental arithmetic disorder//MTH	E30.1//Precocious puberty//ICD10	10058084//Precocious puberty//MDR	XE10t//Precocious puberty//RCD	F-96410//Precocious puberty//SNM	MTHU037101//Precocious puberty//OMIM	sh89003319//Precocious puberty//LCH_NW	E10340//Precocious puberty//NCI_CTCAE	HP:0000826//Precocious puberty//HPO	400179000//Precocious puberty//SNOMEDCT_US	0000005969//precocious puberty//AOD	2586-8869//precocious puberty//CSP	0000010360//precocious puberty//CHV	T99051//precocious puberty//ICPC2P	30589//precocious puberty//MEDCIN
physical therapy and rehabilitation to improve motor function	
they can tolerate carbohydrates, fats, and protein	
oral motor dysfunction with persistent vomiting	
consultation with a gastroenterologist and nutritionist is often necessary	
"infantile catastrophic phase	
strabismus	D013285//strabismus//MSHCZE	10042159//Strabismus//MDRCZE	F95//Strabismus//ICPCDUT	F95002//strabismus//ICPC2P	U004482//Strabismus//LCH	X75dL//Ocular dissociation//RCD	Xa9Bh//Disorder of binocular eye movements//RCD	F-X1320//Strabismus//SNM	MTHU000389//Strabismus//OMIM	N0000002836//Strabismus [Disease/Finding]//NDFRT	5873//Eye Movement Disorders//MEDLINEPLUS	sh85128443//Strabismus//LCH_NW	C35040//Strabismus//NCI_NICHD	HP:0000486//Strabismus//HPO	MTHU051221//Strabismus//LNC	LP200651-0//Strabismus//LNC	22066006//Strabismus//SNOMEDCT_US	50140//Strabismus//PSY	NOCODE//Developmental arithmetic disorder//MTH	1004827//STRABISMUS//CCPSS	704//STRABISMUS//COSTAR	STRABISMUS//STRABISMUS//CST	U003832//STRABISMUS//DXP	0256//STRABISMUS//WHO	BI00859//strabismus//BI	1115-2310//eye coordination disorder//CSP	0000011750//crossed eye//CHV	MTHU070561//strabismus//ICPC2ICD10ENG	30753//strabismus//MEDCIN	HGNC:15511//VANGL planar cell polarity protein 2//HGNC	6547//strabismus on exam//MEDCIN	LA16300-8//Strabismus//LNC
stroke-like episodes	MTHU013464//Stroke-like episodes//OMIM	HP:0002401//Stroke-like episode//HPO
coagulopathy	10009802//Coagulopathy//MDR	D30..//Coagulation disorder//RCD	D-4400//Blood coagulation disorder, disease or syndrome//SNM	MTHU008649//Coagulopathy//OMIM	1779//Coagulopathy//NCI_FDA	HP:0003256//Abnormality of the coagulation cascade//HPO	C2902//Coagulation Disorder//NCI_NICHD	64779008//Blood coagulation disorder//SNOMEDCT_US	0027739//COAGULOPATHY//CCPSS	U000185//DEVIATED NASAL SEPTUM//COSTAR	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	0000005929//coagulopathy//AOD	0000001990//bleeding tendency//CHV	MTHU017004//coagulopathy//ICPC2ICD10ENG
deep venous thrombosis (dvt)	
independent living issues	
0-2	
ocular manifestations	
aeruginosa in airway cultures	
bronchodilator	2599-2967//bronchodilator//CSP	CDR0000476099//bronchodilator//NCI_NCI-GLOSS	0000002190//bronchodilator//CHV	Xa7kI//Bronchodilator//RCD	LP31460-6//Bronchodilator//LNC	TCGA//Enterovirus//NCI	C319//Bronchodilator//NCI	372580007//Bronchodilator//SNOMEDCT_US
hypertonic saline	E-8727//Sodium chloride//SNM	C-70880//Hypertonic saline//SNMI	51103004//Hypertonic saline//SNOMEDCT_US	373766008//Hypertonic saline//SNOMEDCT_US	0000011003//hypertonic saline//CHV	CDR0000467928//hypertonic saline//PDQ	C60814//Hypertonic Saline//NCI
dornase alfa	337623//Dornase Alfa//RXNORM	C81664//Dornase Alfa//NCI	NOCODE//Developmental arithmetic disorder//MTH	d03173//dornase alfa//MMSL	4633//magnesium lactate 84 mg oral tablet, extended release//MMSL	45935//dornase alfa//MEDCIN	0000054886//dornase alpha//CHV	004413//SALICYLAMIDE/ATROPINE/SCOPOLAMINE/HYOSCYAMINE/BUTABARBITAL ORAL TABLET//NDDF	C568813//dornase alfa//MSH	cd2..//Dornase alfa//RCD	DB00003//Dornase alfa//DRUGBANK	386882003//Dornase alfa//SNOMEDCT_US	108630006//Dornase alfa//SNOMEDCT_US	953A26OA1Y//DORNASE ALFA//NCI_FDA
airway clearance	
fertility	U001764//Fertility//LCH	D005298//Fertility//MSH	X76Lt//Fertility//RCD	F-30700//Fertility//SNM	C94191//Fertile//NCI	4455//Preconception Care//MEDLINEPLUS	250//Infertility//MEDLINEPLUS	sh85047895//Fertility//LCH_NW	19618//Fertility//PSY	C16578//Fertility//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000002589//fertility//AOD	1138-0208//fertility//CSP	CDR0000046399//fertility//NCI_NCI-GLOSS	0000004977//fertility//CHV	MTHU000074//Fertility//LNC	C95089//FE//NCI_CDISC
refractive errors may be managed with spectacles or contact lenses	
to improve alignment in primary gaze position	
colitis	D003092//Colitis//MSHDUT	10009887//colitis//MDRDUT	D99045//colitis//ICPC2P	U001091//Colitis//LCH	X303f//Colitis//RCD	M-40000//Inflammation//SNM	N0000000806//Colitis [Disease/Finding]//NDFRT	MTHU036324//Colitis//OMIM	446//Ulcerative Colitis//MEDLINEPLUS	sh85027957//Colitis//LCH_NW	E10521//Colitis//NCI_CTCAE	C26723//Colitis//NCI_NICHD	HP:0002583//Colitis//HPO	64226004//Colitis//SNOMEDCT_US	10220//Colitis//PSY	009.0//Colitis//MTHICD9	NOCODE//Developmental arithmetic disorder//MTH	0059526//COLITIS//CCPSS	190//COLITIS//COSTAR	COLITIS//COLITIS//CST	U000794//HEMOGLOBIN E DISEASE//DXP	0271//COLITIS//WHO	0000005557//colitis//AOD	BI00225//colitis//BI	1248-5200//colitis//CSP	0000003154//colitis//CHV	CDR0000044318//colitis//NCI_NCI-GLOSS	MTHU017132//colitis//ICPC2ICD10ENG	313223//colitis//MEDCIN	C57134//Colitis//NCI_CTCAE
antidepressants are often required to treat concurrent depression	
ocular abnormalities	
services provided vary based on age and needs	
physical and occupational therapy	
ventilatory support	
daily heel cord stretching exercises to prevent achilles tendon shortening	
orthopedic surgery	0000009051//orthopedic surgery//CHV	C16942//Orthopedics//NCI	D009985//Orthopedics//MSH	0000017846//orthopedic surgery//CHV	41730//orthopedic surgical procedures//MEDCIN	02985//Orthopedic surgery//NANDA-I	LP97123-1//Orthopedic surgery//LNC	0054510//ORTHOPEDIC SURGERY//CCPSS
fewer than 5% of individuals need wheelchairs	
respiratory dysfunction	0000056356//abnormal breathing//CHV
odontoid hypoplasia	MTHU003440//Odontoid hypoplasia//OMIM	HP:0003311//Hypoplasia of the odontoid process//HPO	C86969//Odontoid Hypoplasia//NCI	613628//ODONTOID HYPOPLASIA//OMIM
exercise within the individual's capability to remain physically active	
hearing aids as needed	
management includes the following:	
0 mm in diameter	
pharmacologic treatment	
central nervous system	V09A//CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS//ATC	NER/CNS//Central Nervous System//CST	D002490//Central Nervous System//MSH	TCGA//Enterovirus//NCI	LA4174-4//Central Nervous System//LNC	08100//Central Nervous System//PSY	C12438//Central Nervous System//NCI	NOCODE//Developmental arithmetic disorder//MTH	U000879//Central nervous system//LCH	Xa0eL//Central nervous system//RCD	T-X0090//Central nervous system//SNM	T-A0090//Central nervous system//SNMI	MTHU000058//Central nervous system//OMIM	55675//Neuraxis//FMA	sh85021906//Central nervous system//LCH_NW	21483005//Structure of central nervous system//SNOMEDCT_US	0000017844//central nervous system//AOD	2049-9515//central nervous system//CSP	CDR0000046481//central nervous system//NCI_NCI-GLOSS	854//central nervous system//NEU
cognitive	C37926//Cognitive//NCI
endocrinopathies	0000004447//hormonal disorder//CHV	D004700//Maladies endocriniennes//MSHFRE
spine	U004435//Spine//LCH	X74Xc//Spine//RCD	T-10500//Vertebral column//SNM	13478//Vertebral column//UWDA	MTHU000142//Spine//AOT	MTHU000034//Spine//OMIM	LP7596-2//Spine//LNC	MTHU003055//Spine//LNC	sh85126694//Spine//LCH_NW	LA4340-1//Spine//LNC	LP200016-6//Spine//LNC	C12998//Vertebral Column//NCI	D013131//Spine//MSH	0000017079//spine//AOD	2715-6251//spine//CSP	CDR0000415914//spine//NCI_NCI-GLOSS	0000011627//spine//CHV	0045295//SPINE//CCPSS	GO:0044309//neuron spine//GO
sodium benzoate: 250 mg/kg or 5	
sodium phenylacetate: 250 mg/kg or 5	
10% arginine hcl: 600 mg/kg or 12	
reversal of catabolism	
gastroesophageal reflux should be addressed in a standard manner	
ophthalmologic abnormalities are treated in the standard manner	
skeletal abnormalities (e	
hearing loss is treated with a trial of hearing aids	
infants benefit from enrollment in an early-intervention program	
pulmonary fibrosis	D011658//Pulmonary Fibrosis//MSH	N0000002544//Pulmonary Fibrosis [Disease/Finding]//NDFRT	378//Pulmonary Fibrosis//MEDLINEPLUS	C26869//Pulmonary Fibrosis//NCI_NICHD	NOCODE//Developmental arithmetic disorder//MTH	0042976//PULMONARY FIBROSIS//CCPSS	U000569//PULMONARY FIBROSIS//COSTAR	FIBRO LUNG//LUNG FIBROSIS//CST	0532//PULMONARY FIBROSIS//WHO	U003945//Pulmonary fibrosis//LCH	10037383//Pulmonary fibrosis//MDR	X102u//Pulmonary fibrosis//RCD	D2-61310//Fibrosis of lung, NOS//SNMI	MTHU007791//Pulmonary fibrosis//OMIM	LP128703-8//Pulmonary fibrosis//LNC	MTHU040644//Pulmonary fibrosis//LNC	sh85109004//Pulmonary fibrosis//LCH_NW	E13527//Pulmonary fibrosis//NCI_CTCAE	HP:0002206//Pulmonary fibrosis//HPO	51615001//Fibrosis of lung//SNOMEDCT_US	0000005464//pulmonary fibrosis//AOD	2596-8265//pulmonary fibrosis/granuloma//CSP	0000010390//pulmonary fibrosis//CHV	R99010//pulmonary fibrosis//ICPC2P	33019//pulmonary fibrosis//MEDCIN
thiamine	D013831//Thiamine//MSH	X80RQ//Vitamin B1//RCD	F-16210//Thiamine//SNM	F-BB310//Thiamine//SNMI	10454//Thiamine//RXNORM	N0000007147//Thiamine [Chemical/Ingredient]//NDFRT	X66NSO3N35//Thiamine//MTHSPL	LP15886-2//Thiamine//LNC	5376//B Vitamins//MEDLINEPLUS	MTHU008943//Thiamine//LNC	C874//Thiamin//NCI_CRCH	05001//Thiamine//NCI_DCP	DB00152//Thiamine//DRUGBANK	30866//Thiamine//CPM	259659006//Vitamin B1//SNOMEDCT_US	U002296//Thiamine//MTH	0000004766//thiamine//AOD	3147-2928//thiamine//CSP	41296//thiamine//MEDCIN	0000012172//thiamine//CHV	A11DA01//thiamine//ATC	CDR0000556404//thiamine//NCI_NCI-GLOSS	CDR0000037856//thiamine//PDQ	d03130//thiamine//MMSL	N0000145862//THIAMINE//NDFRT	4017474//THIAMINE//VANDF	10058787//thiamine//MDRDUT	U002824//Radiolabelled sucralfate scan//MTH	C74896//Thiamine//NCI_CDISC	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC	N0000029453//[VT105] THIAMINE//NDFRT	4021900//THIAMINE//VANDF
riboflavin	D012256//riboflavin//MSHCZE	5062//morphine 100 mg/24 hours oral capsule, extended release//MMSL	X80RU//Vitamin B2//RCD	F-16220//Riboflavin//SNM	F-BB320//Riboflavin//SNMI	9346//Riboflavin//RXNORM	N0000005897//Riboflavin [Chemical/Ingredient]//NDFRT	TLM2976OFR//Riboflavin//MTHSPL	LP15853-2//Riboflavin//LNC	5376//B Vitamins//MEDLINEPLUS	MTHU007595//Riboflavin//LNC	C74898//Riboflavin//NCI_CDISC	C808//Riboflavin//NCI_CRCH	02185//Riboflavin//NCI_DCP	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC	DB00140//Riboflavin//DRUGBANK	13235001//Riboflavin//SNOMEDCT_US	U002226//Riboflavin//MTH	0000018237//riboflavin//AOD	3147-2745//riboflavin//CSP	d00409//riboflavin//MMSL	5422//levoFLOXacin 500 mg/100 mL intravenous solution//MMSL	41298//riboflavin//MEDCIN	0000010877//riboflavin//CHV	A11HA04//riboflavin//ATC	CDR0000556406//riboflavin//NCI_NCI-GLOSS	CDR0000038330//riboflavin//PDQ	N0000146013//RIBOFLAVIN//NDFRT	NSC0033298//RIBOFLAVIN//NCI_DTP	4017633//RIBOFLAVIN//VANDF	10058790//Riboflavin//MDRCZE	U002823//Histology Procedure//MTH	0000031661//riboflavin//CHV	N0000029454//[VT106] RIBOFLAVIN//NDFRT	4021901//RIBOFLAVIN//VANDF
initial treatment	
long-term medical management	
levodopa	D007980//levodopa//MSHCZE	1804//lidocaine 5%-0.8% injectable solution//MMSL	dq1..//Levodopa//RCD	E-7741//Dihydroxyphenylalanine//SNM	C-B70E0//Levodopa//SNMI	6375//Levodopa//RXNORM	46627O600J//Levodopa//MTHSPL	N0000006700//Levodopa [Chemical/Ingredient]//NDFRT	LP16328-4//Levodopa//LNC	MTHU015998//Levodopa//LNC	DB01235//Levodopa//DRUGBANK	15383004//Levodopa//SNOMEDCT_US	387086006//Levodopa//SNOMEDCT_US	28290//Levodopa//PSY	C611//Levodopa//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000020119//levodopa//AOD	5000-0053//levodopa//CSP	d00277//levodopa//MMSL	4971//naphazoline-zinc ophthalmic 0.02%-0.25% ophthalmic solution//MMSL	0000007378//levodopa//CHV	001639//FERROUS SULFATE 220 mg/5 mL ORAL ELIXIR//NDDF	N04BA01//levodopa//ATC	CDR0000042622//levodopa//PDQ	N0000146151//LEVODOPA//NDFRT	4017790//LEVODOPA//VANDF
treatment of psychiatric problems with appropriate psychotropic medications	
adaptation of environment and care to the level of dementia	
individuals with severe heart block may require pacemaker implantation	
growth retardation	GRDST//Growth retardation//AIR	U006451//Growth retardation//LCH	10053759//Growth retardation//MDR	M-70110//Growth retardation//SNM	MTHU000166//Growth retardation//OMIM	444896005//Growth retardation//SNOMEDCT_US	HP:0001510//Growth delay//HPO	59576002//Growth retardation//SNOMEDCT_US	783.43//Growth retardation//MTHICD9	NOCODE//Developmental arithmetic disorder//MTH	0055830//GROWTH RETARDATION//CCPSS	U001751//SJOGREN SYNDROME//DXP	Q0200129//Growth Retardation//QMR	C78328//Growth Retardation//NCI	0000005009//growth retardation//AOD	T10010//growth retardation//ICPC2P	0000017034//growth retardation//CHV
feeding therapy	
oral medications are usually tried first:	
baclofen (lioresal®)	
benzodiazepines	U000538//Benzodiazepines//LCH	D001569//Benzodiazepines//MSH	N0000007542//Benzodiazepines [Chemical/Ingredient]//NDFRT	LP15014-1//Benzodiazepines//LNC	MTHU001123//Benzodiazepines//LNC	sh85013239//Benzodiazepines//LCH_NW	MTHU002730//Benzodiazepines//USPMG	32097//Benzodiazepines//CPM	05824//Benzodiazepines//PSY	U001735//Benzodiazepines//MTH	0000018905//benzodiazepines//AOD	41395//benzodiazepines//MEDCIN	1022254//Benzodiazepines//CPT	C-64500//Benzodiazepine, NOS//SNMI	0000001794//benzodiazepine//CHV
primary layers include the following:	
, telfa®, n-terface®)	
, mepitel®, mepilex®)	
, kerlix®) are commonly used	
hypotrichosis	D007039//Hypotrichosis//MSHDUT	10021126//Hypotrichosis//MDR	X509L//Hypotrichosis//RCD	MTHU002744//Hypotrichosis//OMIM	N0000001655//Hypotrichosis [Disease/Finding]//NDFRT	HP:0001006//Hypotrichosis//HPO	53602002//Hypotrichosis//SNOMEDCT_US	C34720//Hypotrichosis//NCI	U001999//Hypotrichosis//MTH	ALOPECIA//ALOPECIA//CST	0828//HYPOTRICHOSIS//WHO	MTHU037279//hypotrichosis//ICPC2ICD10ENG	0000006503//hypotrichosis//CHV
see prevention of primary manifestations	
hematologic	C16673//Hematology//NCI	G-B113//Hematologic//SNMI	C62780//Hematologic//NCI	TCGA//Enterovirus//NCI	57407000//Hematologic//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000020623//hematologic//CHV	0053403//HEMATOLOGIC//CCPSS
treatment of manifestations in individuals with ethylmalonic encephalopathy	
gorman et al [2016]	
enrollment in developmental disabilities administration (dda) is recommended	
hernia	D006547//hernie//MSHCZE	10019909//hernia//MDRDUT	K40-K46.9//Hernia//ICD10	D91001//hernia//ICPC2P	U002183//Hernia//LCH	J3...//Hernia of abdominal cavity//RCD	M-31600//Hernia//SNM	MTHU012924//Hernia//OMIM	N0000001516//Hernia [Disease/Finding]//NDFRT	283//Hernia//MEDLINEPLUS	sh85060424//Hernia//LCH_NW	C34685//Hernia//NCI_NICHD	2240//Hernia//NCI_FDA	HP:0100790//Hernia//HPO	52515009//Hernia of abdominal cavity//SNOMEDCT_US	414403008//Hernia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	1006190//HERNIA//CCPSS	360//HERNIA//COSTAR	HERNIA//HERNIA//CST	0000004460//hernia//AOD	BI00271//hernia//BI	0944-5779//hernia//CSP	0000006079//hernia//CHV	CDR0000630906//hernia//NCI_NCI-GLOSS	MTHU034462//hernia//ICPC2ICD10ENG	96160//hernia//MEDCIN
arterial abnormalities	HP:0011004//Abnormality of the systemic arterial tree//HPO
acute photosensitivity	
grey or smoke-colored filters provide only partial protection	
topical sunscreens are typically not useful	
close monitoring is warranted	
treatment of thrombosis in children	
antoun et al [2016]	
huemer et al [2015]	
the following measures are appropriate:	
referral of the family to support groups and other resources	
cryptorchidism	D003456//Cryptorchidism//MSH	PC50.//Cryptorchism//RCD	D4-85110//Undescended testis//SNMI	MTHU000066//Cryptorchidism//OMIM	N0000000881//Cryptorchidism [Disease/Finding]//NDFRT	HP:0000028//Cryptorchidism//HPO	10056600//Cryptorchidism//MDR	C12326//Cryptorchidism//NCI_NICHD	204878001//Undescended testicle//SNOMEDCT_US	U001835//Cryptorchidism//MTH	0059144//CRYPTORCHIDISM//CCPSS	U000019//CRYPTORCHIDISM//COSTAR	U000914//HYPOVITAMINOSIS A//DXP	146738//INSULIN-LIKE 3//OMIM	2586-8788//cryptorchidism//CSP	0000003493//cryptorchidism//CHV	CDR0000046458//cryptorchidism//NCI_NCI-GLOSS	7506//cryptorchidism//MEDCIN
dental problems	HP:0000164//Abnormality of the dentition//HPO	0000040304//dental problem//CHV
pain	D001939//Pain//MSHFRE	A29020//pain//ICPC2P	U003436//Pain//LCH	D010146//Pain//MSH	306//Abdominal Pain//MTH	120324//Pain//NOC	Xa07F//Pain//RCD	F-82600//Pain//SNM	200714//Pain//NOC	110407//Pain//NOC	110021//Pain//NOC	230324//Pain//NOC	24//Pain//OMS	10023130//Pain//ICNP	N0000002278//Pain [Disease/Finding]//NDFRT	Q63.0//Pain//CCC	MTHU033713//Pain//OMIM	351//Pain//MEDLINEPLUS	MTHU029813//Pain//LNC	sh85096617//Pain//LCH_NW	C3303//Pain//NCI_NICHD	E11167//Pain//NCI_CTCAE	ESAS//Pain//NCI	LASA//Pain//NCI	LA7460-4//Pain//LNC	1994//Pain//NCI_FDA	HP:0012531//Pain//HPO	10033371//Pain//MDR	01394//Pain//NANDA-I	22253000//Pain//SNOMEDCT_US	36150//Pain//PSY	NOCODE//Developmental arithmetic disorder//MTH	0035760//PAIN//CCPSS	548//PAIN//COSTAR	PAIN//PAIN//CST	0730//PAIN//WHO	338-338.99//PAIN//ICD9CM	0000002779//pain//AOD	BI00754//pain//BI	2683-4824//pain//CSP	0000009185//pain//CHV	CDR0000041399//pain//PDQ	MTHU059479//pain//ICPC2ICD10ENG	283263//pain//MEDCIN	MSAS//Dry mouth//NCI	SDS//Bowel//NCI	PT//Patient external identifier//HL7V2.5	C53794//PAIN//NCI_CTCAE	C53837//Pain//NCI_CTCAE	52500-6//Pain:-:Pt:^Patient:-//LNC	MSAS-SF//Almost Constantly//NCI
thus, good sleep hygiene should be encouraged	
corticosteroids	x002V//Corticosteroids//RCD	N0000011309//Adrenal Cortex Hormones [Chemical/Ingredient]//NDFRT	LP20687-7//Corticosteroids//LNC	4557//Steroids//MEDLINEPLUS	79440004//Corticoid preparation//SNOMEDCT_US	12000//Corticosteroids//PSY	C211//Therapeutic Corticosteroid//NCI	D000305//Adrenal Cortex Hormones//MSH	0000028357//corticosteroids//AOD	0000000762//corticosteroid//CHV	R01AD//Corticosteroid nasal preparations for topical use//ATC	S02BA//Corticosteroids//ATC	S02B//Corticosteroid otologicals//ATC	S03BA//Corticosteroids//ATC	S03B//Corticosteroid ophthalmologic and otologic preparations//ATC	C05AA//Corticosteroids, topical for treatment of hemorrhoids and anal fissures//ATC
immunoglobulins	U002384//Immunoglobulins//LCH	D007136//Immunoglobulins//MSH	U000207//Immunoglobulins//SNM	N0000007920//Immunoglobulins [Chemical/Ingredient]//NDFRT	LP31769-0//Immunoglobulins//LNC	sh85064568//Immunoglobulins//LCH_NW	24580//Immunoglobulins//PSY	C572//Immunoglobulin//NCI	U002003//Immunoglobulins//MTH	F-C8000//Immunoglobulin, NOS//SNMI	4021646//IMMUNOGLOBULINS//VANDF	N0000029199//[IM500] IMMUNOGLOBULINS//NDFRT	J06B//IMMUNOGLOBULINS//ATC	0000020386//immunoglobulins//AOD	0000006598//immunoglobulin//CHV	10021496//Immunoglobulins//MDR
educational programming directed to the specific disabilities identified	
cardiac manifestations	
intramuscular injections should be avoided unless under factor coverage	
dermatologic	G-B114//Dermatologic//SNMI	C41128//Dermatologic//NCI	64947008//Dermatologic//SNOMEDCT_US	BI00622//dermatologic//BI	0000020624//dermatologic//CHV	0017118//DERMATOLOGIC//CCPSS
cataract	F92//Cataract//ICPCDUT	D002386//Cataract//MSHDUT	10007739//cataract//MDRDUT	6.7.1//Cataract//CCS	86//Cataract//CCS	F92001//cataract//ICPC2P	U000841//Cataract//LCH	622//Cataract//MTH	F46..//Cataract//RCD	M-51100//Cataract//SNM	MTHU004637//Cataract//OMIM	N0000000698//Cataract [Disease/Finding]//NDFRT	LP128693-1//Cataract//LNC	116//Cataract//MEDLINEPLUS	MTHU040525//Cataract//LNC	sh85020947//Cataract//LCH_NW	E10350//Cataract//NCI_CTCAE	C26713//Cataract//NCI_NICHD	1766//Cataract//NCI_FDA	HP:0000518//Cataract//HPO	128306009//Cataract//SNOMEDCT_US	193570009//Cataract//SNOMEDCT_US	366//Cataract//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	1017415//CATARACT//CCPSS	162//CATARACT//COSTAR	CATARACT//CATARACT SPECIFIED//CST	0235//CATARACT//WHO	0000006040//cataract//AOD	BI00628//cataract//BI	1114-9096//cataract//CSP	30745//cataract//MEDCIN	0000015953//cataract//CHV	CDR0000440102//cataract//NCI_NCI-GLOSS	MTHU015169//cataract//ICPC2ICD10ENG	MTHU007394//cataract//OMIM	6620//cataract on exam//MEDCIN	C55830//Cataract//NCI_CTCAE
250 mg/kg/day	
sodium phenylacetate	48N6U1781G//sodium phenylacetate//MTHSPL	56510//sodium phenylacetate//RXNORM	C025136//phenylacetic acid//MSH	001244//POTASSIUM BICARBONATE 100 % MISCELL POWDER (GRAM)//NDDF	d05460//sodium phenylacetate//MMSL	19292//sodium phenylacetate//MMSL	NOCODE//Developmental arithmetic disorder//MTH	N0000147675//SODIUM PHENYLACETATE//NDFRT	4019576//SODIUM PHENYLACETATE//VANDF	NSC0003039//Sodium phenylacetate//NCI_DTP	398818001//Sodium phenylacetate//SNOMEDCT_US	125705007//Sodium phenylacetate//SNOMEDCT_US	31742//Sodium Phenylacetate//NCI_DCP	C66723//Sodium Phenylacetate//NCI
mechanisms of drug action in treatment of hyperammonemia	
raises insulin levels	
induces anabolic state	
causes protein sparing effect from skeletal muscle amino acids	
stimulates secretion of insulin	
eliminates one amino group in the urine	
eliminates two amino groups in the urine	
a non-essential amino acid in humans	
surgical management	C16080//Surgical Management//NCI
renal and liver function	
full blood count	424..//Full blood count//RCD	10017411//Full blood count//MDR	0000003246//complete blood count test (CBC)//CHV	A34011//full blood count//ICPC2P	C28133//Blood Cell Count//NCI
psychological support	Ua1Nf//Emotional support//RCD	342386//Psychological support//MEDCIN	133921002//Emotional support//SNOMEDCT_US	0000042145//emotional support//CHV
table 7	
principles of treatment for individuals with hokpp	
add 0	
3 meq/kg/h	
(2) in the work setting	
myopathy	L99023//myopathy//ICPC2P	10028641//Myopathy//MDR	D009135//Muscular Diseases//MSH	X708s//Myopathy//RCD	D-8004//Muscle disease or syndrome//SNM	MTHU003653//Myopathy//OMIM	510//Muscle Disorders//MEDLINEPLUS	C101216//Myopathy//NCI	HP:0003198//Myopathy//HPO	129565002//Disorder of muscle//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0045912//MYOPATHY//CCPSS	U000457//MYOPATHY//COSTAR	MYOPATHY//MYOPATHY//CST	U002703//MYOPATHY//DXP	0074//MYOPATHY//WHO	590075//TRANSFER RNA, MITOCHONDRIAL, PROLINE//OMIM	590030//TRANSFER RNA, MITOCHONDRIAL, GLUTAMINE//OMIM	0000005066//myopathy//AOD	BI00507//myopathy//BI	0000008361//muscle disease//CHV	MTHU051138//myopathy//ICPC2ICD10ENG
behavior	D001519//Behavior//MSH	U000232//Behavior//SNM	F-94000//Behavior//SNM	LP89757-6//Behavior//LNC	LP28433-8//Behavior//LNC	MTHU031771//Behavior//LNC	MTHU013956//Behavior//LNC	C16326//Behavior//NCI_NICHD	05670//Behavior//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000000085//behavior//AOD	2483-0090//behavior//CSP	GO:0007610//behavior//GO	0000001751//behavior//CHV	MTHU000008//BEHAVIOR//OMS	54511-1//Behavior:-:Pt:^Patient:-//LNC
drugs to reduce muscle spasticity (e	
, oxybutynin)	
cd46	1556-6810//CD antigen//CSP	F-C7A10//Membrane cofactor protein//SNMI	LP20089-6//CD46//LNC	MTHU022288//CD46//LNC	D051916//Antigènes CD46//MSHFRE	HGNC:6953//CD46 molecule//HGNC	C126977//CD46 Gene//NCI	120920//CD46 ANTIGEN//OMIM
cfh	C97209//CFH Gene//NCI	HGNC:4883//complement factor H//HGNC	134370//COMPLEMENT FACTOR H//OMIM
dgke	HGNC:2852//diacylglycerol kinase epsilon//HGNC	601440//DIACYLGLYCEROL KINASE, EPSILON, 64-KD//OMIM
thbd	HGNC:11784//thrombomodulin//HGNC	C101378//THBD Gene//NCI	188040//THROMBOMODULIN//OMIM
hyperuricemia/gout	
lifelong therapy with allopurinol may be required	
the transplanted kidney does not develop the disease	
current recommended drug therapies for adults with fh	
15% 1, 3	
50% 5	
often ineffective in hofh	
kastelein et al [2008]	
rader et al [2003]	
approved only for adults with hofh	
cuchel et al [2014]	
raal & santos [2012]	
physical therapy to improve motor function	
pharmacologic treatment of spasticity and seizures	
maintenance therapy	314122007//Maintenance therapy//SNOMEDCT_US	CDR0000045768//maintenance therapy//NCI_NCI-GLOSS	0000042690//maintenance therapy//CHV	TCGA//Enterovirus//NCI	29142//Maintenance Therapy//PSY	C15688//Maintenance Therapy//NCI
genital anomalies	MTHU053771//Genital anomalies//OMIM	HP:0000078//Abnormality of the genital system//HPO
surgery as required	
routine management	
thyroid hormone replacement as needed	
treatment of manifestations in individuals with kcnk9 imprinting syndrome	
standard treatment for scoliosis	
developmental disabilities administration (dda) enrollment is recommended	
social/behavioral issues	
therapeutic management of the sleep disorder	
management of seizures in accordance with standard practice	
auditory amplification if hearing loss is identified	
gonadotropin therapy	
spastic paraplegia	NOCODE//Sepsis//COSTAR	D010264//Paraplegia//MSH	U003756//SPASTIC PARAPLEGIA//DXP	605//spastic paraplegia//JABL	0000011557//spastic paraplegia//CHV	G82.1//Spastic paraplegia//ICD10	MTHU000470//Spastic paraplegia//OMIM	HP:0001258//Spastic paraplegia//HPO	10048792//Spastic paraplegia//MDR	364126//Spastic paraplegia//MEDCIN	192967009//Spastic paraplegia//SNOMEDCT_US
general guidelines can be followed	
antiepileptic drugs (aed) if epileptic seizures are present	
acidosis	NOCODE//Sepsis//COSTAR	E87.2//Acidosis//ICD10	U000036//Acidosis//LCH	D000138//Acidosis//MSH	U000118//Compensation as a Defense Mechanism//MTH	C362.//Acidosis//RCD	C83504//Acidosis//NCI	N0000000283//Acidosis [Disease/Finding]//NDFRT	338589//Acidosis//MEDCIN	sh85000531//Acidosis//LCH_NW	HP:0001941//Acidosis//HPO	10000486//Acidosis//MDR	51387008//Acidosis//SNOMEDCT_US	276.2//Acidosis//ICD9CM	0063443//ACIDOSIS//CCPSS	METACIDOSIS//ACIDOSIS//CST	ACIDOSIS//ACIDOSIS//CST	U000077//AMNESTIC SYNDROME//DXP	0363//ACIDOSIS//WHO	0000005821//acidosis//AOD	0465-0952//acidosis//CSP	MTHU002955//acidosis//ICPC2ICD10ENG	0000000634//acidosis//CHV	E12237//Acidosis//NCI_CTCAE
psychological support for the affected individual and family is essential	
feeding	Xa4Hu//Feeding//RCD	1050//Feeding//NIC	75118006//Feeding patient//SNOMEDCT_US	0000001801//feeding//AOD	133435//feeding of newborn//MEDCIN	LA19832-7//Feeding//LNC	C88198//Feeding//NCI	129007004//Feeding//SNOMEDCT_US	309102//feeding//MEDCIN	Barthel//Bladder//NCI
psychomotor development	65401001//Psychomotor development//SNOMEDCT_US	41780//Psychomotor Development//PSY
gerd	D005764//gastroezofageální reflux//MSHCZE	N0000001319//Gastroesophageal Reflux [Disease/Finding]//NDFRT	109350//GASTROESOPHAGEAL REFLUX//OMIM	512//GERD//MEDLINEPLUS	10018203//GERD//MDR	C26781//Gastroesophageal Reflux Disease//NCI_NICHD	HP:0002020//Gastroesophageal reflux//HPO	BI00251//gastroesophageal reflux//BI	0000005382//gastroesophageal reflux disease (GERD)//CHV
neurobehavioral symptoms	
the choice should be left to personal preference	
dural ectasia is usually asymptomatic	
no effective therapies for symptomatic dural ectasia currently exist	
hernias tend to recur after surgical intervention	
long-term treatment	0000024957//long-term treatment//AOD	0000007534//long term care//CHV
genitourinary	T-70200//Genitourinary system, NOS//SNMI	BI00472//genitourinary//BI	0000035689//genitourinary system//CHV	54535-0//Genitourinary:-:Pt:^Patient:-//LNC	C38214//Genitourinary Route of Administration//NCI	LP89778-2//Genitourinary//LNC	MTHU031868//Genitourinary//LNC	TCGA//Enterovirus//NCI	LA16969-0//Genitourinary//LNC	C25350//Genitourinary//NCI	NOCODE//Developmental arithmetic disorder//MTH	MTHU000003//GENITOURINARY//OMIM
joint contractures	MTHU000680//Joint contractures//OMIM	HP:0001371//Flexion contracture//HPO
developmental delay/cognitive impairment	
specialized learning programs to meet individual needs	
no specific antiepileptic or antipsychotic medications are indicated	
cardiac malformations	MTHU052238//Cardiac malformations//OMIM
treatment should follow standard practice	
see hereditary hearing loss and deafness overview	
congenital heart defects	N0000001431//Heart Defects, Congenital [Disease/Finding]//NDFRT	198//Congenital Heart Defects//MEDLINEPLUS	D006330//Heart Defects, Congenital//MSH	NOCODE//Developmental arithmetic disorder//MTH	0000005874//congenital heart defect//CHV	MTHU013668//Congenital heart defects//OMIM	HP:0001627//Abnormal heart morphology//HPO
stretching exercises are ineffective and painful	
the following treatment is appropriate:	
joints	U002546//Joints//LCH	D007596//Joints//MSH	NOCODE//Developmental arithmetic disorder//MTH	73023//Set of joints//FMA	sh85070658//Joints//LCH_NW	C13044//Joint//NCI	0000007022//joint//CHV	s7701//Joints//ICF	81087007//Articular system structure//SNOMEDCT_US	0000032186//joint//CHV
reasons for 28 hospitalizations in 15 infants with msud	
strauss et al [2010]	
4(2	
3(1	
1(1	
5-6	LA14354-7//5-6//LNC
3-9	
3-1	
0(3	
7(3	
7-7	
2(5	
50(0	
43-0	
58)	
from strauss et al [2010]	
with permission from elsevier	
acute pancreatitis	K85//Acute pancreatitis//ICD10DUT	10000971//acute pancreatitis//MDRDUT	9.9.1//Acute pancreatitis//CCS	MT180012//Acute pancreatitis//MTHMST	J670.//Acute pancreatitis//RCD	D5-90110//Acute pancreatitis//SNMI	HP:0001735//Acute pancreatitis//HPO	577.0//Acute pancreatitis//ICD9CM	197456007//Acute pancreatitis//SNOMEDCT_US	NOCODE//Sepsis//COSTAR	5876//Pancreatitis//MEDLINEPLUS	C95437//Acute Pancreatitis//NCI	0000005654//acute pancreatitis//AOD	BI00281//acute pancreatitis//BI	0000000688//acute pancreatitis//CHV	30029//acute pancreatitis//MEDCIN
infection	N0000001681//Infection [Disease/Finding]//NDFRT	1930//Infection//NCI_FDA	02120//Infection//NANDA-I	C26726//Infectious Disorder//NCI	40733004//Disorder due to infection//SNOMEDCT_US	4000-0216//infection//CSP	C53791//INFECTION//NCI_CTCAE	U002423//Infection//LCH	D007239//Infection//MSH	PRB_07010.00//Infection//PCDS	X79pw//Infection//RCD	D-0070//Infection//SNM	031102//Infection//NOC	251113//Infection//NOC	10023032//Infection//ICNP	K25.6//Infection//CCC	LP130385-0//Infection//LNC	MTHU041099//Infection//LNC	sh85066076//Infection//LCH_NW	LA7446-3//Infection//LNC	10021789//Infection//MDR	11_1//Infection//NANDA-I	C128320//Infection//NCI_NICHD	A78051//infection//ICPC2P	NOCODE//Developmental arithmetic disorder//MTH	1018029//INFECTION//CCPSS	413//INFECTION//COSTAR	PATHINFECT//INFECTION//CST	PULMINFECT//INFECTION//CST	INFECT//INFECTION//CST	U002090//INFECTION//DXP	0736//INFECTION//WHO	0000004491//infection//AOD	50.01//infection//OMS	0000006691//infection//CHV	CDR0000045364//infection//NCI_NCI-GLOSS	CDR0000041393//infection//PDQ	MTHU038002//infection//ICPC2ICD10ENG	363071//infection//MEDCIN
see hirschsprung disease overview	
cataracts	NOCODE//Sepsis//COSTAR	D002386//Cataract//MSH	U000341//Cataracts//SNM	MTHU000155//Cataracts//OMIM	MTHU020817//Cataracts//LNC	10007771//Cataracts//MDR	07890//Cataracts//PSY	HP:0000518//Cataract//HPO	DA-73500//Cataract, NOS//SNMI	0000015953//cataract//CHV	LA16306-5//Cataracts//LNC	95722004//Bilateral cataracts//SNOMEDCT_US
deep brain stimulation (dbs)	
cataracts can be removed if they impair vision	
other tumors	
photodysphoria (discomfort in bright light	
orthopedic treatment	
dental treatment	10061813//Dental treatment//MDR	0000003709//dental care//CHV	13550//Dental Treatment//PSY
treatment of decreased visual acuity is symptomatic (e	
, low-vision aids)	
250 mg/kg	
5,500 mg/m2	
batshaw et al [2001]	
loading dose given over 90 to 120 minutes	
maintenance dose given over 24 hours	
the typical dilution is 1:10	
arginine infusion not to exceed 150mg/kg/h	
surgery has been reported to be helpful by many patients	
fecal elastase-1 analysis (schebo® biotech ag	
, cck-8) or receptor agonists (e	
their nature (e	
blocking of pancreatic lipase (e	
diseases of the intestinal mucosa	
diffusion-weighted mri	C111116//Diffusion Weighted Imaging//NCI
monitoring for glucose intolerance	
hypoventilation	NOCODE//Sepsis//COSTAR	10021133//Hypoventilation//MDR	D007040//Hypoventilation//MSH	U000115//Mental tolerance//MTH	F-76570//Hypoventilation//SNM	C50594//Hypoventilation//NCI	N0000001656//Hypoventilation [Disease/Finding]//NDFRT	MTHU041452//Hypoventilation//OMIM	1916//Hypoventilation//NCI_FDA	HP:0002791//Hypoventilation//HPO	31515003//Hypoventilation//SNOMEDCT_US	0003592//HYPOVENTILATION//CCPSS	HYPOVENTIL//HYPOVENTILATION//CST	U002061//HYPOVENTILATION//DXP	0518//HYPOVENTILATION//WHO	0000005443//hypoventilation//AOD	2602-3621//hypoventilation//CSP	MTHU037284//hypoventilation//ICPC2ICD10ENG	0000032373//hypoventilation//CHV
consider aspirin treatment	
severe atp8b1 deficiency	
mild atp8b1 deficiency	
reduction of calcium oxalate supersaturation	
organ transplantation	D016377//Organ Transplantation//MSH	1462//Organ Transplantation//MEDLINEPLUS	35660//Organ Transplantation//PSY	C15289//Organ Transplantation//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000008151//organ transplantation//AOD	0000009013//organ transplantation//CHV	CDR0000474022//organ transplantation//PDQ
only if affected person is known to be b6 responsive	
from cochat et al [2012]	
recommendations assume the availability of facilities	
pox= plasma oxalate	
see note	
visual impairment	HP:0000505//Visual impairment//HPO	D014786//Vision Disorders//MSH	55964//Visual Impairment//PSY	NOCODE//Developmental arithmetic disorder//MTH	VISION ABNORM//ABNORMAL VISION//CST	0257//VISION ABNORMAL//WHO	XE16L//Impaired vision//RCD	MTHU002513//Visual impairment//OMIM	10047571//Visual impairment//MDR	397540003//Visual impairment//SNOMEDCT_US	BI00637//impaired vision//BI	0000013036//cannot see properly//CHV	0000025347//vision problem//CHV	F28006//visual impairment//ICPC2P	36646//visual impairment//MEDCIN
cys282tyr / p	
treatment of medical manifestations in individuals with ptls	
standard treatment as recommended by dentist/orthodontist	
poor weight gain / failure to thrive	
global developmental delay / intellectual disability educational issues	
, orthotics, adaptive strollers)	
chemotherapy	D004358//Drug Therapy//MSH	Q000188//drug therapy//MSH	02005//Chemotherapy//NANDA-I	0000032192//cancer chemotherapy//CHV	2.15.2//Chemotherapy//CCS	A50009//chemotherapy//ICPC2P	U005481//Chemotherapy//LCH	X71bL//Chemotherapy//RCD	P-5110//Chemotherapy//SNM	464//Cancer Chemotherapy//MEDLINEPLUS	MTHU010425//Chemotherapy//LNC	sh85023041//Chemotherapy//LCH_NW	TCGA//Enterovirus//NCI	LA6172-6//Chemotherapy//LNC	10044583//Chemotherapy//ICNP	10061758//Chemotherapy//MDR	367336001//Chemotherapy//SNOMEDCT_US	08580//Chemotherapy//PSY	C15632//Chemotherapy//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000024419//chemotherapy//AOD	0962-5748//chemotherapy//CSP	0000004154//drug therapy//CHV	CDR0000045214//chemotherapy//NCI_NCI-GLOSS	CDR0000039455//chemotherapy//PDQ	MTHU016113//chemotherapy//ICPC2ICD10ENG	342594//chemotherapy//MEDCIN	1017439//CHEMOTHERAPY//CCPSS
5 years	
joint pain	N0000003851//Arthralgia [Disease/Finding]//NDFRT	2355//Arthralgia//NCI_FDA	C50464//Arthralgia//NCI_NICHD	D018771//Arthralgia//MSH	U000033//ANISOCORIA//COSTAR	ARTHRALGIA//ARTHRALGIA//CST	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	0063//ARTHRALGIA//WHO	XE1EY//Joint pain//RCD	F-13100//Joint pain//SNMI	070629//Joint pain//NOC	MTHU002712//Joint pain//OMIM	MTHU020863//Joint pain//LNC	HP:0002829//Arthralgia//HPO	10023222//Joint pain//MDR	57676002//Joint pain//SNOMEDCT_US	BI00473//arthralgia//BI	L20005//joint pain//ICPC2P	0000001465//joint pain//CHV	C56095//Joint pain//NCI_CTCAE	C125623//Level of Joint Pain//NCI
see published guidelines/consensus statements	
treatment of manifestations in individuals with pura-related neurodevelopmental disorders	
scoliosis	M41//Scoliosis//ICD10	U004240//Scoliosis//LCH	10039722//Scoliosis//MDR	Xa6vS//Scoliosis deformity of spine//RCD	M-31510//Scoliosis//SNM	MTHU000036//Scoliosis//OMIM	C78603//Scoliosis//NCI	N0000002703//Scoliosis [Disease/Finding]//NDFRT	395//Scoliosis//MEDLINEPLUS	sh85118750//Scoliosis//LCH_NW	E12521//Scoliosis//NCI_CTCAE	76631//Scoliosis//UWDA	298382003//Scoliosis deformity of spine//SNOMEDCT_US	D012600//Scoliosis//MSH	668//SCOLIOSIS//COSTAR	U003455//SCOLIOSIS//DXP	1684//SCOLIOSIS//WHO	BI00512//scoliosis//BI	2715-3059//scoliosis//CSP	0000011122//scoliosis//CHV	MTHU066716//scoliosis//ICPC2ICD10ENG	34520//scoliosis//MEDCIN	X789G//Congenital scoliosis//RCD	L85002//scoliosis//ICPC2P	X70D3//Acquired scoliosis//RCD	HP:0002650//Scoliosis//HPO
sleep	U004339//Sleep//LCH	D012890//Sleep//MSH	0004//Sleep//NOC	X7A2s//Sleep//RCD	F-85800//Sleep//SNM	C73425//Sleep//NCI	sh85123396//Sleep//LCH_NW	HFRDIS//Leisure Activities//NCI	LA18125-7//Sleep//LNC	258158006//Sleep//SNOMEDCT_US	47820//Sleep//PSY	U002247//Sleep//MTH	0000003419//sleep//AOD	2482-1824//sleep//CSP	GO:0030431//sleep//GO	0000011413//sleep//CHV	7461//Sleep//MMSL
skeletal abnormalities	HP:0000924//Abnormality of the skeletal system//HPO
treatments include the following:	
standard treatment with antiepileptic drugs for seizures	
physical, occupational, and speech therapies, if necessary	
standard treatment is indicated	
treatment of manifestations in individuals with trio-related intellectual disability	
treatment of manifestations in individuals with unc80 deficiency	
see retinitis pigmentosa overview, management	
educational support	
hearing impairment	0000005856//partial hearing loss//CHV	H28002//hearing impairment//ICPC2P	NOCODE//Developmental arithmetic disorder//MTH	HEARL//Hearing impairment//AIR	XE0s9//Hearing loss//RCD	MTHU038541//Hearing impairment//OMIM	LA16989-8//Hearing impairment//LNC	HP:0000365//Hearing impairment//HPO	02421//Hearing impairment//NANDA-I	15188001//Hearing loss//SNOMEDCT_US	U001869//THYROID, ECTOPIC//DXP	C50576//Hearing Impairment//NCI	N0000011013//Hearing Loss [Disease/Finding]//NDFRT	1881//Hearing Impairment//NCI_FDA	D034381//Hearing Loss//MSH	0000023586//hearing impairment//AOD
medical measures	
early use of antibiotics for bacterial infections	
insertion	P-1270//Implantation//SNM	X79w8//Insertion//RCD	_Insertion//Insertion//HL7V3.0	C48685//Insertion//NCI	71861002//Implantation//SNOMEDCT_US	0000034855//insertion procedure//CHV	C19295//Insertion Mutation//NCI	2.16.840.1.113883.1.11.14687//Insertion//HL7V3.0	LA6687-3//Insertion//LNC	C45518//Insert//NCI	LP111537-9//insertion//LNC
physiotherapy including hydrotherapy to avoid strain on the joints	
use of a wheelchair if necessary	
orthopedic intervention if necessary	
special shoes may help with ankle and foot support	
therefore, ventriculocaval shunts are preferred	
educational opportunities/social considerations	
use of sign language in individuals with significant hearing loss	
early educational intervention for development of social skills	
speech therapy to improve speech	
special education to maximize learning	
planning housing for possible future wheelchair use	
hbh disease	
cortisol deficiency	10078563//Cortisol deficiency//MDR
genital abnormalities	HP:0000078//Abnormality of the genital system//HPO
hypospadias and cryptorchidism may be corrected with surgery	
vaginal reconstruction may be performed in females with vaginal hypoplasia	
ovarian cysts	D010048//Ovarian Cysts//MSH	N0000002272//Ovarian Cysts [Disease/Finding]//NDFRT	349//Ovarian Cysts//MEDLINEPLUS	NOCODE//Developmental arithmetic disorder//MTH	BI00396//ovarian cysts//BI	0000009119//ovarian cyst//CHV	MTHU016093//Ovarian cysts//OMIM
nasal stints or tracheotomy may be required	
joint contractures and elbow synostosis	
early developmental/educational intervention is appropriate for cognitive delays	
low-dose neuroleptics may be useful for psychiatric manifestations	
referral for psychiatric evaluation is appropriate	
low vision aids include high-powered magnifiers for reading	
achromat	
provide palliative care for viable newborns	
only modest effects on adult stature seem to accrue	
measures to avoid obesity should start in early childhood	
craniocervical junction constriction	
the best predictors of need for suboccipital decompression include:	
lower-limb hyperreflexia or clonus	
central hypopnea demonstrated by polysomnography	
treatment may include the following:	
adenotonsillectomy	10001256//Adenotonsillectomy//MDR	75306//Tonsillectomy and adenoidectomy//RCD	28913000//Tonsillectomy and adenoidectomy//SNOMEDCT_US	0000019518//adenotonsillectomy//CHV
weight reduction	N0000010968//Weight Loss [Disease/Finding]//NDFRT	D015431//Weight Loss//MSH	0000013130//weight loss//CHV
continuous positive airway pressure	D045422//Airway Pressure Release Ventilation//MSHDUT	C124040//Continuous Positive Airway Pressure//NCI	NOCODE//Developmental arithmetic disorder//MTH	2592-7337//positive pressure breathing//CSP	LA6176-7//Continuous positive airway pressure//LNC	10052934//Continuous positive airway pressure//MDR
tracheostomy for extreme cases	
middle ear dysfunction	
varus deformity	M-31570//Varus deformity//SNM	257756001//Varus deformity//SNOMEDCT_VET	127562007//Varus deformity//SNOMEDCT_US	0000038713//varus deformity//CHV	0000035336//varus deformity//CHV
various interventions may be elected (e	
kyphosis	L85004//kyphosis//ICPC2P	U002597//Kyphosis//LCH	10023509//Kyphosis//MDR	Xa6vT//Kyphosis deformity of spine//RCD	M-31530//Kyphosis//SNM	MTHU000681//Kyphosis//OMIM	N0000001768//Kyphosis [Disease/Finding]//NDFRT	414564002//Kyphosis deformity of spine//SNOMEDCT_US	1505//Spine Injuries and Disorders//MEDLINEPLUS	sh85073583//Kyphosis//LCH_NW	E12447//Kyphosis//NCI_CTCAE	HP:0002808//Kyphosis//HPO	C34754//Kyphosis//NCI_NICHD	737.1//Acquired kyphosis//MTHICD9	D007738//Kyphosis//MSH	U002296//KYPHOSIS//DXP	0000007144//hunchback//CHV	MTHU042267//kyphosis//ICPC2ICD10ENG	335709//kyphosis//MEDCIN	N371.//Acquired kyphosis//RCD	XE1M4//Congenital kyphosis//RCD	0000025940//inborn hunchback//CHV	7992//kyphosis//MEDCIN	NOCODE//Developmental arithmetic disorder//MTH
spinal stenosis	SPI//Spinal Stenosis//AIR	DXSPI//Spinal Stenosis//AIR	D013130//Spinal Stenosis//MSH	N0000002801//Spinal Stenosis [Disease/Finding]//NDFRT	412//Spinal Stenosis//MEDLINEPLUS	NOCODE//Developmental arithmetic disorder//MTH	1003773//SPINAL STENOSIS//CCPSS	696//SPINAL STENOSIS//COSTAR	M48.0//Spinal stenosis//ICD10	X70Co//Spinal stenosis//RCD	MTHU038291//Spinal stenosis//OMIM	76107001//Spinal stenosis//SNOMEDCT_US	BI00513//spinal stenosis//BI	0000011626//spinal narrowing//CHV	L86011//spinal stenosis//ICPC2P	35861//spinal stenosis//MEDCIN	HP:0003416//Spinal canal stenosis//HPO
socialization	U004371//Socialization//LCH	C88512//Socialization//NCI	sh85124152//Socialization//LCH_NW	48470//Socialization//PSY	D012951//Socialization//MSH	0000009691//socialization//AOD	2727-6778//socialization//CSP	0000011471//socialization//CHV
desferrioxamine	x01GJ//Desferrioxamine//RCD	N0000007065//Deferoxamine [Chemical/Ingredient]//NDFRT	NSC0527604//Desferal//NCI_DTP	DB00746//Deferoxamine//DRUGBANK	372825006//Deferoxamine//SNOMEDCT_US	70702006//Deferoxamine//SNOMEDCT_US	C416//Deferoxamine//NCI	D003676//Deferoxamine//MSH	0000003658//deferoxamine//CHV	1629-5423//deferoxamine//CSP
treatment with iron chelating agents (i	
deferasirox	614373//deferasirox//RXNORM	CDR0000435986//deferasirox//PDQ	302332//deferasirox//MEDCIN	N0000171608//deferasirox [Chemical/Ingredient]//NDFRT	011097//deferasirox//NDDF	V03AC03//deferasirox//ATC	CDR0000514444//deferasirox//NCI_NCI-GLOSS	d05659//deferasirox//MMSL	20643//deferasirox//MMSL	C415250//deferasirox//MSH	4024936//DEFERASIROX//VANDF	N0000023118//DEFERASIROX//NDFRT	V8G4MOF2V9//DEFERASIROX//NCI_FDA	C48384//Deferasirox//NCI	50595//Deferasirox//NCI_DCP	MTHU003565//Deferasirox//USPMG	DB01609//Deferasirox//DRUGBANK	419985007//Deferasirox//SNOMEDCT_US	417910004//Deferasirox//SNOMEDCT_US
deferiprone	11645//deferiprone//RXNORM	0000013302//deferiprone//CHV	007561//BETAMETHASONE DIPROPIONATE/PROPYLENE GLYCOL 0.05 % TOPICAL CREAM (GRAM)//NDDF	d04976//deferiprone//MMSL	18035//deferiprone//MMSL	V03AC02//deferiprone//ATC	C044919//deferiprone//MSH	NOCODE//Developmental arithmetic disorder//MTH	N0000183921//DEFERIPRONE//NDFRT	4031179//DEFERIPRONE//VANDF	2BTY8KH53L//DEFERIPRONE//NCI_FDA	C73030//Deferiprone//NCI	MTHU003566//Deferiprone//USPMG	DB08826//Deferiprone//DRUGBANK	396011004//Deferiprone//SNOMEDCT_US	329482000//Deferiprone//SNOMEDCT_US
fresh-frozen human plasma	
if the serum potassium concentration is low (<3	
treatment for actg2-related disorders remains supportive	
urologic manifestations	
management of bladder dysfunction by an urologist is recommended	
gastrointestinal manifestations	
however, bladder catheterization was still required	
prophylaxis for pneumocystis jiroveci	
intravenous immunoglobulin (ivig)	
cutaneous/cranial	
wounds without calvarial involvement	
plastic wrap (e	
, duoderm®)	
other less preferred, less costly dressings are:	
wounds with calvarial defects: acute care	
wounds with calvarial defects: late calvarial reconstruction	
limb	D005121//Extremities//MSH	X74Yt//Limb//RCD	T-Y1800//Extremity//SNM	7182//Limb//UWDA	TCGA//Enterovirus//NCI	C12429//Limb//NCI	66019005//Limb structure//SNOMEDCT_US	0000004703//limb//AOD	0000004807//arms and legs//CHV	2715-5305//limb//CSP
early physiotherapy can maximize motor function and range of motion	
management of seizures is per routine	
if typical signs (e	
medication has been variably effective in suppressing debilitating symptoms	
j friedman, personal observation]	
fm hisama, personal observation]	
stress management	Ub014//Stress management//RCD	441151000124104//Stress management//SNOMEDCT_US	sh88004681//Stress management//LCH_NW	226060000//Stress management//SNOMEDCT_US	4006-0088//stress management//CSP	56//stress management//OMS	0000016930//stress management//CHV	79650//stress management//MEDCIN	50175//Stress Management//PSY
intrafamilial variation in pharmaco-responsiveness occurs	
therefore, all appropriate aeds should be tried	
speech, occupational, and physical therapy	
specialized learning programs depending on individual needs	
nutritional support if necessary	
routine treatment of cardiac and ophthalmologic findings	
ankyloblepharon filiforme adnatum	MTHU019531//Ankyloblepharon filiforme adnatum//OMIM	HP:0009755//Ankyloblepharon//HPO	C536373//Ankyloblepharon filiforme adnatum//MSH	400952003//Ankyloblepharon filiforme adnatum//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	HGNC:310//ankyloblepharon filiforme adnatum//HGNC
larger ones may require surgical separation by an ophthalmologist	
ectodermal defects	
skin erosions	MTHU009028//Skin erosions//OMIM
empiric treatment (i	
clefting should be addressed as soon as developmentally possible	
chest physiotherapy and vigorous treatment of respiratory complications	
management of seizures using standard protocols	
acute episodes	
correction of hyperkalemia may be needed	
, solu-cortef®)	
adequate sodium must be provided	
treatment during stress	
, intercurrent illness, surgery, trauma)	
glucose and sodium may be needed	
parents should have access to rapid medical advice	
guidelines for hospital admission should be clear	
acth levels should normalize when replacement therapy is adequate	
acute neurovisceral attack	
clinical assessment should include a full neurologic evaluation	
investigations should include:	
full blood count (fbc)	
serum and urine osmolality	
urine sodium concentration if hyponatremic	
, crp, blood cultures, ck, magnesium	
mri should be considered if cns symptoms are present	
general measures	
see agents/circumstances to avoid	
restore energy balance using an enteral route if possible	
treat intercurrent infections and other diseases promptly	
supportive treatment	
pain relief	10033487//Pain relief//MDR	182970005//Pain relief//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000036051//pain relief//CHV	BPI-Short Form//Pain at its Worst//NCI	C112216//Pain Relief//NCI	0000046073//Pain Relief brand//CHV	6725//candesartan 8 mg oral tablet//MMSL
nausea and vomiting	17.1.6//Nausea and vomiting//CCS	250//Nausea and vomiting//CCS	R11//Nausea and vomiting//ICD10	Xa1pJ//Nausea and vomiting//RCD	F-61640//Nausea and vomiting//SNM	F-52840//Nausea and vomiting//SNMI	HP:0002017//Nausea and vomiting//HPO	16932000//Nausea and vomiting//SNOMEDCT_US	787.0//Nausea and vomiting//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	NAUSEA VOMIT//NAUSEA AND VOMITING//CST	CDR0000041395//nausea and vomiting//PDQ	C3259//Nausea and Vomiting//NCI	489//Nausea and Vomiting//MEDLINEPLUS
prochloperazine, promazine or ondansetron are considered safe	
beta blockers are considered safe	
fluid balance and electrolytes	
dextrose saline is preferred	
specific treatment	
it is infused over at least 30 minutes	
recurrent acute attacks	
gynecological review and bone density monitoring are recommended	
prophylactic hemin infusion	
however, evidence for clinical efficacy remains elusive	
, medicalert® or similar)	
see resources	
liver transplantation for end-stage liver disease has an 80	
cardiac involvement is treated in a standard manner	
renal anomalies are treated in a standard manner	
vascular accidents should be treated in a standard manner	
head injuries and neurologic symptoms should be evaluated aggressively	
ophthalmologic abnormalities rarely need intervention	
vertebral anomalies are rarely symptomatic	
no specific therapy is currently available for alexander disease	
neuroblastoma and ganglioneuroblastoma	
aortic stenosis may necessitate valve replacement	
treatment is limited to symptom management and supportive care	
alpers-huttenlocher syndrome	D002549//Diffuse Cerebral Sclerosis of Schilder//MSH	203700//MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE)//OMIM
family education is critical	
supportive therapies	
hepatic	T-62000//Liver, NOS//SNMI	LP92703-5//Hepatic//LNC	TCGA//Enterovirus//NCI	C13308//Hepatic//NCI	U000508//Hepatic//MTH	1754-0095//liver//CSP	CDR0000045709//hepatic//NCI_NCI-GLOSS
treatment with cpap or bipap as indicated is appropriate	
seizure control is a goal of treatment	
other phenotypes	
gastrostomy may be required to provide adequate nutrition	
surgery for ptosis may provide symptomatic relief for some	
, influenza and pneumococcal)	
controls	
recommend intravenous aat augmentation therapy for individuals with established emphysema	
, fev1 35%-60% predicted)	
2 months post-liver transplant and not achieving statistical significance	
panniculitis	D015434//panniculitis//MSHCZE	10033675//panniculitis//MDRDUT	10033674//panniculitis//MDRDUT	NOCODE//Sepsis//COSTAR	L99083//panniculitis//ICPC2P	X707z//Panniculitis//RCD	M-40000//Inflammation//SNM	N0000003238//Panniculitis [Disease/Finding]//NDFRT	MTHU032395//Panniculitis//OMIM	C112112//Panniculitis//NCI	HP:0012490//Panniculitis//HPO	22125009//Panniculitis//SNOMEDCT_US	0039159//PANNICULITIS//CCPSS	CELLULITIS//CELLULITIS//CST	1416//PANNICULITIS//WHO	0000005146//panniculitis//AOD	0000009236//panniculitis//CHV	MTHU057236//panniculitis//ICPC2ICD10ENG	211130//panniculitis//MEDCIN
hypertensive individuals should receive appropriate management	
male relative without hematuria	
male relative with hematuria	
female relative without hematuria	
female relative with hematuria (i	
, heterozygous female)	
cochlear	C12395//Cochlea//NCI
hearing aids should be prescribed when appropriate	
some individuals develop cataracts that interfere with vision	
these should be extracted when necessary	
diffuse leiomyomatosis	HP:0006756//Diffuse leiomyomatosis//HPO
symptomatic leiomyomas may require surgical intervention	
monitoring for and treatment of lymphoproliferation and hypersplenism	
however, sirolimus is not without side effects	
treatment of lymphoma is according to conventional protocols	
treatment of cytopenias and other autoimmune diseases	
caregiver and patient support groups are valuable	
options include:	
ssris	4146//Antidepressants//MEDLINEPLUS	D000068760//СЕРОТОНИНА И НОРАДРЕНАЛИНА ОБРАТНОГО ЗАХВАТА ИНГИБИТОРЫ//MSHRUS
venlafaxine	5002-0025//venlafaxine//CSP	d03181//venlafaxine//MMSL	39786//venlafaxine//RXNORM	0000015055//venlafaxine//CHV	004428//MAGNESIUM SALICYLATE/PHENYLTOLOXAMINE CITRATE 325 mg-30 mg ORAL TABLET//NDDF	340497//venlafaxine//MEDCIN	N06AX16//venlafaxine//ATC	CDR0000046117//venlafaxine//NCI_NCI-GLOSS	GRZ5RCB1QG//venlafaxine//MTHSPL	CDR0000043238//venlafaxine//PDQ	NOCODE//Developmental arithmetic disorder//MTH	da7..//Venlafaxine//RCD	LP17950-4//Venlafaxine//LNC	MTHU004272//Venlafaxine//LNC	N0000006524//Venlafaxine [Chemical/Ingredient]//NDFRT	DB00285//Venlafaxine//DRUGBANK	108432009//Venlafaxine//SNOMEDCT_US	372490001//Venlafaxine//SNOMEDCT_US	55450//Venlafaxine//PSY	C1278//Venlafaxine//NCI	MTHU000317//Venlafaxine//USPMG	D000069470//Venlafaxine Hydrochloride//MSH	4023901//VENLAFAXINE//VANDF	N0000021906//VENLAFAXINE//NDFRT
however, weakness and lethargy are common side effects	
low-tech (e	
, alphabet board) and high-tech (i	
no therapy exists to prevent the progressive organ involvement	
rod-cone dystrophy	N0000002614//Retinitis Pigmentosa [Disease/Finding]//NDFRT	D012174//Retinitis Pigmentosa//MSH	0000010812//Retinitis pigmentosa (RP)//CHV	MTHU030127//Rod-cone dystrophy//OMIM	HP:0000510//Rod-cone dystrophy//HPO
progressive sensorineural hearing loss	
hearing can be maximized with bilateral digital hearing aids	
exercise	D015444//Exercise//MSH	X79ON//Exercise//RCD	LP61581-2//Exercise//LNC	sh85046328//Exercise//LCH_NW	LA22651-6//Exercise//LNC	LP207667-9//Exercise//LNC	256235009//Exercise//SNOMEDCT_US	18390//Exercise//PSY	C16567//Exercise//NCI	NOCODE//Developmental arithmetic disorder//MTH	1101-5144//exercise//CSP	0000004762//exercise//CHV	C26387//Exercise Pain Management//NCI
and metformin	
hypertriglyceridemia	D015228//Hypertriglyceridemia//MSH	U000352//Ammonia measurement//MTH	Xa9At//Hypertriglyceridemia//RCDAE	N0000003210//Hypertriglyceridemia [Disease/Finding]//NDFRT	4277//Triglycerides//MEDLINEPLUS	sh91000712//Hypertriglyceridemia//LCH_NW	10020870//Hypertriglyceridemia//MDR	10020869//Hypertriglyceridaemia//MDR	302870006//Hypertriglyceridemia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	1006866//HYPERTRIGLYCERIDEMIA//CCPSS	399//HYPERTRIGLYCERIDEMIA//COSTAR	HYPERLIPEM//HYPERLIPEMIA//CST	U002037//ZINC CHLORIDE POISONING//DXP	0000005733//hypertriglyceridemia//AOD	BI00121//hypertriglyceridemia//BI	1744-2731//hypertriglyceridemia//CSP	0000006455//high triglycerides//CHV	T93005//hypertriglyceridaemia//ICPC2P	166848004//Hypertriglyceridemia//SNOMEDCT_VET	MTHU002090//Hypertriglyceridemia//OMIM	E12299//Hypertriglyceridemia//NCI_CTCAE	C37971//Hypertriglyceridemia//NCI_NICHD	HP:0002155//Hypertriglyceridemia//HPO
pancreatitis should be treated as in the general population	
urologic	G-B104//Urologic//SNMI	C17243//Urology//NCI	77926000//Urologic//SNOMEDCT_US	0000020615//urologic//CHV
prevention of primary complications	
depression and seizures should be treated with appropriate medications	
the first such drug was tacrine	
however, this agent is also hepatotoxic	
antidepressant medication may improve associated depression	
seizures have occurred in some affected infants	
assignment of sex of rearing	
even in cais this may not always be easy	
cais	C120191//Complete Androgen Insensitivity Syndrome//NCI
however, the issue of gonadectomy is controversial	
pais with predominantly female genitalia (incomplete ais)	
pais with ambiguous genitalia or predominantly male genitalia	
gynecomastia that develops in puberty eventually requires reduction mammoplasty	
mais	D003313//КУКУРУЗА//MSHRUS
the customary medical treatment (i	
sometimes fundoplication as required	
no one drug has proven superior	
medications used for minor motor seizures (e	
hypermotoric behaviors are typically resistant to behavioral therapies	
unstable or nonambulatory children may benefit from physical therapy	
individualization and flexibility in the school are important educational strategies	
administration of 0	
strabismus may require surgical correction	
aniridia	10002532//Aniridia//MDR	D015783//Aniridia//MSH	P343.//Aniridia//RCD	M-21000//Absence, congenital//SNM	D4-A0310//Aniridia//SNMI	MTHU007655//Aniridia//OMIM	C84563//Aniridia//NCI	Q13.1//Absence of iris//ICD10CM	N0000003313//Aniridia [Disease/Finding]//NDFRT	HP:0000526//Aniridia//HPO	743.45//Aniridia//ICD9CM	69278003//Congenital aniridia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	U000184//BACILLUS CEREUS DIARRHEA//DXP	0689//EYE MALFORMATION//WHO	607108//PAIRED BOX GENE 6//OMIM	0000001211//aniridia//CHV	297655//aniridia//MEDCIN	MTHU006498//aniridia//ICPC2ICD10ENG	38547//aniridia//MEDCIN
simple measures are often the most important:	
regular eye examinations and correction of refractive errors	
occlusion therapy for anisometropic amblyopia or strabismic amblyopia in childhood	
advice and help with schooling	
social support	220307//Social support//NOC	U002253//Social support//MTH	1504//Social Support//NOC	48416//Social Support//PSY	D012944//Social Support//MSH	0000009753//social support//AOD	0000011465//social support//CHV	CDR0000440116//social support//NCI_NCI-GLOSS	315042007//Social support//SNOMEDCT_US	250805//Social support//NOC	441141000124101//Social support//SNOMEDCT_US
lens	NOCODE//Developmental arithmetic disorder//MTH	7N160//Lens//RCD	T-XX700//Crystalline lens//SNM	58241//Lens//UWDA	LA25447-6//Lens//LNC	C12743//Lens//NCI	LENS//Lens//HL7V2.5	78076003//Lens clear//SNOMEDCT_US	1110-6890//lens//CSP	CDR0000572035//lens//NCI_NCI-GLOSS	SDTM-LOC//PERIPANCREATIC LYMPH NODE//NCI_CDISC	D007908//Øyets linse//MSHNOR	D007909//Lens//MSHDUT	0000007303//lens//CHV	3863//Lens//NCBI	D027806//Lens//MSHCZE	YF//LENS//NDDF	6619//examination of lens//MEDCIN	C50030//Lens Device Component//NCI
children rarely require surgery (lens aspiration or lensectomy)	
in adults, phacoemulsification can be successful	
intraocular pressure	D007429//Intraocular Pressure//MSH	U002489//Intraocular pressure//LCH	X77Nd//Intraocular pressure//RCD	F-X3290//Intraocular pressure//SNM	LP96294-1//Intraocular pressure//LNC	MTHU034775//Intraocular pressure//LNC	sh85067624//Intraocular pressure//LCH_NW	41633001//Intraocular pressure//SNOMEDCT_US	0000006874//pressure in eye//CHV	1110-3144//intraocular pressure//CSP	10022801//Intraocular pressure//MDR	0000057830//pressure in eye//CHV	6670//intraocular pressure//MEDCIN	C87143//Intraocular Pressure//NCI_CDISC	SDTM-OETEST//Color//NCI_CDISC	SS/EYE/IOP//intraocular pressure//CST	0000041433//pressure in eye//CHV	OPHIOP//INTRAOCULAR PRESSURE//CST
glaucoma is usually initially treated with topical anti-glaucoma medication	
trabeculectomy with or without antimetabolites (e	
medical treatment is generally ineffective and surgery is required	
cornea	D003315//rohovka//MSHCZE	U001163//Cornea//LCH	7N151//Cornea//RCD	T-XX200//Cornea//SNM	58238//Cornea//UWDA	s2201//Cornea//ICF	LP32986-9//Cornea//LNC	MTHU010519//Cornea//LNC	sh85032796//Cornea//LCH_NW	28726007//Corneal structure//SNOMEDCT_US	11830//Cornea//PSY	C12342//Cornea//NCI	CORN//Cornea//HL7V2.5	U001828//Cornea//MTH	SDTM-LOC//PERIPANCREATIC LYMPH NODE//NCI_CDISC	0000017573//cornea//AOD	1109-3779//cornea//CSP	LP91416-5//cornea//LNC	0000003354//outer coat of the eyeball//CHV	CDR0000044199//cornea//NCI_NCI-GLOSS	90095//corneal disorder//MEDCIN	CRN//Cornea//HL7V3.0
aniridic fibrosis syndrome	
wilms tumor	10047985//Wilms tumor//MDRDUT	C3267//Wilms Tumor//NCI	N0000171666//Wilms Tumor [Disease/Finding]//NDFRT	3075//Wilms Tumor//MEDLINEPLUS	D009396//Wilms Tumor//MSH	0048278//WILMS TUMOR//CCPSS	CARCINOMA//CARCINOMA//CST	U002025//WILMS TUMOR//DXP	600185//BRCA2 GENE//OMIM	0000023021//Wilms tumor//AOD	MTHU006873//Wilms tumor//OMIM	HP:0002667//Nephroblastoma//HPO	CDR0000042957//Wilms' tumor and other childhood kidney tumors//PDQ	302849000//Nephroblastoma//SNOMEDCT_US	0000008581//wilms tumor//CHV	D030321//Denys-Drash' syndrom//MSHNOR	C103086//Wilms Tumor//NCI_CTEP-SDC
see wilms tumor overview	
the need for orthoses or other assistive devices varies individually	
most patients remain ambulatory without assistance for decades	
provide palliative care for the viable newborn	
educational support (e	
, behavioralists) who can provide the following:	
gait safety devices including canes and wheel chairs	
behavioral modification and cognitive aids as needed	
there are no formal management guidelines for apoe p	
leu167del-related lipid disorders	
in patients with fasting triglyceride levels:	
splenomegaly	SPLEN//Splenomegaly//AIR	B87//Splenomegaly//ICPC	B87003//splenomegaly//ICPC2P	10041660//Splenomegaly//MDR	XM096//Splenomegaly//RCD	M-71000//Hypertrophy//SNM	MTHU001744//Splenomegaly//OMIM	N0000002808//Splenomegaly [Disease/Finding]//NDFRT	414//Spleen Diseases//MEDLINEPLUS	HP:0001744//Splenomegaly//HPO	16294009//Splenomegaly//SNOMEDCT_US	C3384//Splenomegaly//NCI	789.2//Splenomegaly//ICD9CM	D013163//Splenomegaly//MSH	1012345//SPLENOMEGALY//CCPSS	U000635//SPLENOMEGALY//COSTAR	SPLENOMEGALY//SPLENOMEGALY//CST	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	0569//SPLENOMEGALY//WHO	0000005960//splenomegaly//AOD	0427-9482//splenomegaly//CSP	0000011648//enlarged spleen//CHV	CDR0000373017//splenomegaly//NCI_NCI-GLOSS	360329//splenomegaly//MEDCIN	MTHU068980//splenomegaly//ICPC2ICD10ENG	7434//splenomegaly//MEDCIN
splenectomy should be avoided as it may worsen hyperlipidemia	
liver function abnormalities	
persistent nausea	03039//Persistent nausea//NANDA-I
vomiting	D10//Vomiting//ICPC	D10004//vomiting//ICPC2P	U004996//Vomiting//LCH	D014839//Vomiting//MSH	XE0rA//Vomiting//RCD	F-61570//Vomiting//SNM	070813//Vomiting//NOC	250928//Vomiting//NOC	040609//Vomiting//NOC	040507//Vomiting//NOC	230322//Vomiting//NOC	230204//Vomiting//NOC	070622//Vomiting//NOC	210519//Vomiting//NOC	040410//Vomiting//NOC	251025//Vomiting//NOC	422400008//Vomiting//SNOMEDCT_US	MTHU000225//Vomiting//OMIM	b5106//Vomiting//ICF-CY	10025981//Vomiting//ICNP	R11.1//Vomiting//ICD10CM	N0000003141//Vomiting [Disease/Finding]//NDFRT	B04.2//Vomiting//CCC	489//Nausea and Vomiting//MEDLINEPLUS	MTHU013530//Vomiting//LNC	sh85144382//Vomiting//LCH_NW	E11068//Vomiting//NCI_CTCAE	C3442//Vomiting//NCI_NICHD	LA15099-7//Vomiting//LNC	2144//Vomiting//NCI_FDA	HP:0002013//Vomiting//HPO	10047700//Vomiting//MDR	01771//Vomiting//NANDA-I	56340//Vomiting//PSY	NOCODE//Developmental arithmetic disorder//MTH	793//VOMITING//COSTAR	VOMIT//VOMITING//CST	U004425//VOMITING//DXP	0228//VOMITING//WHO	0000005506//vomiting//AOD	BI00287//vomiting//BI	415//vomiting//MEDCIN	0000013085//vomiting//CHV	MTHU012494//vomiting//ICPC2ICD10ENG	1248-4787//emesis//CSP	293335//vomiting//MEDCIN	C57896//Vomiting//NCI_CTCAE	MSAS-SF//Almost Constantly//NCI	MSAS//Dry mouth//NCI	BCPTSS//Night sweats//NCI
abdominal pain	D015746//Abdominal Pain//MSH	306//Abdominal Pain//MTH	N0000003309//Abdominal Pain [Disease/Finding]//NDFRT	3061//Abdominal Pain//MEDLINEPLUS	1685//Pain, Abdominal//NCI_FDA	C26682//Abdominal Pain//NCI_NICHD	MPN-SAF//Problem//NCI	10043953//Abdominal Pain//ICNP	NOCODE//Developmental arithmetic disorder//MTH	004//ABDOMINAL PAIN//COSTAR	PAIN ABDO//ABDOMINAL PAIN//CST	U000023//ACID PHOSPHATASE, LYSOSOMAL, DEFICIENCY//DXP	0268//ABDOMINAL PAIN//WHO	17.1.7//Abdominal pain//CCS	251//Abdominal pain//CCS	1969.//Abdominal pain//RCD	F-50860//Abdominal pain//SNMI	250912//Abdominal pain//NOC	040408//Abdominal pain//NOC	MTHU036407//Abdominal pain//OMIM	MTHU013636//Abdominal pain//LNC	sh85000111//Abdominal pain//LCH_NW	E10460//Abdominal pain//NCI_CTCAE	LA15468-4//Abdominal pain//LNC	HP:0002027//Abdominal pain//HPO	10000081//Abdominal pain//MDR	00005//Risk for imbalanced body temperature//NANDA-I	789.0//Abdominal pain//ICD9CM	21522001//Abdominal pain//SNOMEDCT_US	0000005516//abdominal pain//AOD	BI00206//abdominal pain//BI	0000000535//abdominal pain//CHV	D01006//abdominal pain//ICPC2P	475//abdominal pain//MEDCIN
yellow discoloration of the skin	
bruising	XM0AW//Bruise//RCD	M-14200//Contusion, NOS//SNMI	C37921//Bruise//NCI	040903//Bruising//NOC	E11666//Bruising//NCI_CTCAE	10006504//Bruising//MDR	125667009//Contusion//SNOMEDCT_US	308492005//Contusion - lesion//SNOMEDCT_US	0032910//BRUISING//CCPSS	0000003331//bruise//CHV	26.08//bruising//OMS	124703//reported bruising//MEDCIN
any new petechial rash	
allopurinol	1816//heparin 20000 units/mL injectable solution//MMSL	j61..//Allopurinol//RCD	E-8987//Allopurinol//SNM	C-B7020//Allopurinol//SNMI	519//Allopurinol//RXNORM	63CZ7GJN5I//Allopurinol//MTHSPL	N0000005830//Allopurinol [Chemical/Ingredient]//NDFRT	LP17988-4//Allopurinol//LNC	MTHU024809//Allopurinol//LNC	DB00437//Allopurinol//DRUGBANK	25246002//Allopurinol//SNOMEDCT_US	387135004//Allopurinol//SNOMEDCT_US	C224//Allopurinol//NCI	MTHU000412//Allopurinol//USPMG	D000493//Allopurinol//MSH	0875-2372//allopurinol//CSP	d00023//allopurinol//MMSL	4150//calcium carbonate-magnesium carbonate 520 mg-400 mg oral tablet//MMSL	0000000917//allopurinol//CHV	001084//CHLORPHENIRAMINE MALEATE/PHENYLPROPANOLAMINE HCL 8 mg-75 mg ORAL TABLET, EXTENDED RELEASE//NDDF	M04AA01//allopurinol//ATC	CDR0000045052//allopurinol//NCI_NCI-GLOSS	CDR0000038452//allopurinol//PDQ	0062165//ALLOPURINOL//CCPSS	N0000146247//ALLOPURINOL//NDFRT	4017895//ALLOPURINOL//VANDF
febuxostat	D000069465//febuxostat//MSHCZE	73689//febuxostat//RXNORM	101V0R1N2E//febuxostat//MTHSPL	26212//febuxostat//MMSL	d07397//febuxostat//MMSL	M04AA03//febuxostat//ATC	012966//febuxostat//NDDF	NOCODE//Developmental arithmetic disorder//MTH	N0000171777//FEBUXOSTAT//NDFRT	4025245//FEBUXOSTAT//VANDF	C65629//Febuxostat//NCI	441610003//Febuxostat//SNOMEDCT_US	441743008//Febuxostat//SNOMEDCT_US	304534//Febuxostat//MEDCIN	MTHU002406//Febuxostat//USPMG	N0000179385//Febuxostat [Chemical/Ingredient]//NDFRT	DB04854//Febuxostat//DRUGBANK
treatment of esrd	
kidney transplantation	D016030//Kidney Transplantation//MSH	1299//Kidney Transplantation//MEDLINEPLUS	C15265//Kidney Transplantation//NCI	NOCODE//Developmental arithmetic disorder//MTH	P-1429//Transplantation, allogeneic//SNM	70536003//Transplant of kidney//SNOMEDCT_US	1683-2651//kidney transplantation//CSP	0000007098//kidney transplant//CHV	CDR0000354477//kidney transplantation//PDQ
arginine supplementation is obviously contraindicated	
rapidly reducing plasma ammonia concentration	
pharmacologic management to allow alternative pathway excretion of excess nitrogen	
in early treatment, feeding 1	
0 to 1	
older children require and tolerate lower protein intake	
seizures are easily treated by phenobarbital or carbamazepine	
discontinuing oral protein intake	
intravenous nitrogen scavenging therapy	
ammonia levels usually normalize with therapy	
nitrogen scavenging therapy needs to be continued during hemodialysis	
curative therapy is not available	
clinical history studies are limited	
aneurysms and focal stenoses are amenable to surgical intervention	
hernias may recur after surgical repair	
emphysema is treated symptomatically	
, swimming) performed in moderation	
no treatment is available	
see hereditary ataxias, management	
beta blockers are considered first line therapy	
however, individual responses to specific medications (e	
(see also therapies under investigation	
speech therapy may benefit persons with dysarthria	
one of the following vitamin e preparations is used:	
the naturally occurring form, rrr-α-tocopherol	
thalassemia major	D017086//beta-Thalassemia//MSH	0046795//THALASSEMIA MAJOR//CCPSS	730//THALASSEMIA MAJOR//COSTAR	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	D-4181//beta Thalassemia, homozygous//SNM	282.44//Cooley's anemia//MTHICD9	314996//Thalassemia major//MEDCIN	D56.1//Beta thalassemia//ICD10CM	10054661//Thalassemia major//MDR	75451007//Thalassemia major//SNOMEDCT_US	0000001121//cooley's anemia//CHV	1418-5761//thalassemia//CSP
transfusions are usually given every two to three weeks	
thalassemia intermedia	10062923//thalassemia intermedia//MDRDUT	10062921//thalassemia intermedia//MDRDUT	D017086//beta-Thalassemia//MSH	0000026688//thalassemia intermedia//CHV	141900//HEMOGLOBIN--BETA LOCUS//OMIM	D56.1//Beta thalassemia//ICD10CM	282.44//Cooley's anemia//MTHICD9	934007//Thalassemia intermedia//SNOMEDCT_US
cord blood transplantation	CDR0000042637//umbilical cord blood transplantation//PDQ	C15640//Cord Blood Transplantation//NCI_NICHD
uveal melanoma	MTHU035642//Uveal melanoma//OMIM	309341000009105//Melanoma of uvea//SNOMEDCT_VET	HP:0007716//Intraocular melanoma//HPO	C536494//Uveal melanoma//MSH	0000021169//intraocular melanoma//CHV	CDR0000038817//intraocular melanoma//PDQ	C7712//Uveal Melanoma//NCI
malignant mesothelioma	BBP1.//Malignant mesothelioma//RCD	4014//Mesothelioma//MEDLINEPLUS	HP:0100001//Malignant mesothelioma//HPO	109378008//Mesothelioma (malignant, clinical disorder)//SNOMEDCT_US	62064005//Mesothelioma, malignant//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000031033//malignant mesothelioma//CHV	CDR0000044992//malignant mesothelioma//NCI_NCI-GLOSS	CDR0000038142//malignant mesothelioma//PDQ	C4456//Malignant Mesothelioma//NCI
thus, a cure is unlikely	
there is no specific treatment of bwcff syndrome	
symptomatic management involves the following	
ptosis may require surgical treatment	
hearing loss may require routine care including hearing aids	
epilepsy is treated using standard protocols	
management of heart failure	
management of neutropenia	
78 ± 0	
45-12	
8 years, with an average exposure of 7	
3 years	
educational support in school	
, renal or hepatic dysfunction)	
indicators are functional interference and poorly fitting footwear	
dental extractions are appropriate as required for dental crowding	
insertion of grommets is commonplace	
manifestations should be treated by specialists (e	
keratocysts usually require surgical excision	
systemic treatment with retinoids (e	
bethlem myopathy	718572004//Bethlem myopathy//SNOMEDCT_US	C535436//Bethlem myopathy//MSH	158810//BETHLEM MYOPATHY 1//OMIM
ullrich cmd	
contractures tend to be aggressive and may require surgery	
kcnq2-bfne	
refractory seizures are uncommon in kcnq2-related bfne	
kcnq2-nee	
augmentative communication techniques can be valuable for many patients	
antiepileptic treatment for seizures	
symptomatic treatment for headaches	
biotin and thiamine therapy	
biotin and thiamine need to be given lifelong	
in the acute stage empiric treatment with antimicrobial/antiviral agents	
fever control	
antiepileptic drugs for effective control of seizures	
symptomatic treatment of dystonia, including administration of l-dopa	
rehabilitation, physiotherapy, occupational therapy, and speech therapy	
educational programs adapted to individual needs	
therefore, renal tumors greater than 3	
no treatment for bcd currently exists	
psychosocial	NOCODE//Developmental arithmetic disorder//MTH	BI00025//psychosocial//BI	0000038590//psychosocial//CHV	0043148//PSYCHOSOCIAL//CCPSS	CDR0000648685//psychosocial//NCI_NCI-GLOSS
milunsky et al [2011] provided management guidelines	
see table iii)	
they should not be cauterized	
most larger skin defects require surgical excision	
recommended treatment:	
second branchial arch anomalies	
excise branchial cleft cysts/fistulae	
otologic anomalies	
fit with appropriate aural habilitation as indicated	
enroll in an appropriate educational program for the hearing impaired	
consider canaloplasty to correct an atretic canal	
treat urologic and renal abnormalities in the standard manner	
if renal anomalies (e	
if esrd develops, consider renal transplantation	
global developmental disability/intellectual disability	
disordered sleep	
ophthalmologic findings	
eye findings are treated in a routine manner	
regular pulmonary hygiene to manage risk for pulmonary complications	
tracheostomy as indicated when secretions are difficult to manage	
eyelid surgery	
timing of eyelid surgery is controversial	
however, it remains controversial	
hormone replacement therapy (hrt)	0000027580//hormone replacement therapy (HRT)//CHV
it is important to:	
controversy exists regarding the treatment of asymptomatic individuals	
treatment of craniofacial manifestations (e	
there are no reports on the use of aflibercept	
the cnv regressed and the subretinal hemorrhage resolved	
genetic counseling and occupational counseling should be offered	
abdominal wall repair for omphalocele soon after birth	
generally, this surgery is well tolerated	
management of difficulties arising from macroglossia:	
some children benefit from tongue reduction surgery	
orthodontic intervention as needed in later childhood/adolescence	
assessment of speech difficulties	
management of cleft palate following standard protocols	
referral to a craniofacial surgeon if facial hemihyperplasia is significant	
treatment of neoplasias following standard pediatric oncology protocols	
, nephrocalcinosis)	
management of cardiac problems following standard protocols	
during acute episodes	
restrict protein intake if plasma ammonia is elevated	
without carglumic acid, hyperammonemia persisted longer (i	
, an additional 1-2 days)	
there is no treatment of proven efficacy for cadasil	
classic 21-ohd cah	
glucocorticoid replacement therapy	
the use of oral hydrocortisone suspension is discouraged	
during periods of stress (e	
affected individuals should carry medical information regarding emergency steroid dosing	
mineralocorticoid replacement therapy	
sodium chloride supplementation may not be necessary after infancy	
feminizing genitoplasty	
the systematic evidence for this belief is lacking	
testicular adrenal rest tumors	
transition from adolescence to adulthood	
women with classic cah had increased diastolic blood pressure	
subjective health status was significantly impaired and fertility compromised	
adrenalectomy	119//Adrenalectomy//ICD10AM	U000086//Adrenalectomy//LCH	7122.//Adrenalectomy//RCD	P-1100//Excision, NOS (-ectomy)//SNM	sh85001006//Adrenalectomy//LCH_NW	10061622//Adrenalectomy//MDR	31904001//Adrenalectomy//SNOMEDCT_US	01050//Adrenalectomy//PSY	C15177//Adrenalectomy//NCI	D000315//Adrenalectomy//MSH	0038762//ADRENALECTOMY//CCPSS	U000094//ANEMIA, HEMOLYTIC, MICROANGIOPATHIC//DXP	0000008376//adrenalectomy//AOD	0062-1836//adrenalectomy//CSP	0000000772//adrenalectomy//CHV	CDR0000458096//adrenalectomy//NCI_NCI-GLOSS	CDR0000038849//adrenalectomy//PDQ	41691//adrenalectomy//MEDCIN
non-classic 21-ohd cah	
most survivors with cd require orthopedic care	
club feet require surgical correction	
the hips should be checked for luxation	
bracing is usually not helpful	
neonatal/infantile canavan disease	
seizures may be treated with antiepileptic drugs (aeds)	
diamox® seems to reduce intracranial pressure	
botox® injections may be used to relieve spasticity	
mild/juvenile canavan disease	
scoliosis may require bracing or surgical correction	
personality change may require antipsychotic medication	
a wig or hairpiece may be helpful for alopecia	
the following interventions are routine:	
cardiac myxoma	10061005//Cardiac myxoma//MDR	C7748//Cardiac Myxoma//NCI	0000056522//cardiac myxoma//CHV	HP:0011672//Cardiac myxoma//HPO	35888//myxoma of heart//MEDCIN
open-heart surgery	
cutaneous and mammary myxoma	
surgical excision	X79vD//Surgical excision//RCD	0000046660//removal//CHV
cushing syndrome	D003480//Cushing Syndrome//MSH	C2969//Cushing Syndrome//NCI	N0000000883//Cushing Syndrome [Disease/Finding]//NDFRT	NOCODE//Developmental arithmetic disorder//MTH	0059645//CUSHING SYNDROME//CCPSS	U000916//HYPOVOLEMIC SHOCK//DXP	U000424//CUSHING SYNDROME//DXP	0000003509//cushing's syndrome//CHV	CDR0000626500//Cushing syndrome//NCI_NCI-GLOSS	MTHU016145//Cushing syndrome//OMIM	237735008//Adrenal Cushing's syndrome//SNOMEDCT_US	HP:0003118//Increased circulating cortisol level//HPO
bilateral adrenalectomy	Xa8OV//Bilateral adrenalectomy//RCD	P1-60342//Total adrenalectomy, NOS//SNMI	07.3//Bilateral adrenalectomy//ICD9CM	302340005//Bilateral adrenalectomy//SNOMEDCT_US	41693//bilateral adrenalectomy//MEDCIN
pituitary adenoma	C3329//ADENOMA, ANTERIOR LOBE PITUITARY GLAND, BENIGN//NCI_CDISC	D010911//Pituitary Neoplasms//MSH	NOCODE//Developmental arithmetic disorder//MTH	0039068//PITUITARY ADENOMA//CCPSS	584//PITUITARY ADENOMA//COSTAR	X78aD//Pituitary adenoma//RCD	MTHU016150//Pituitary adenoma//OMIM	354687//Pituitary adenoma//MEDCIN	HP:0002893//Pituitary adenoma//HPO	10035079//Pituitary adenoma//MDR	254956000//Pituitary adenoma//SNOMEDCT_US	128664001//Pituitary adenoma//SNOMEDCT_US	T73010//pituitary adenoma//ICPC2P	0000009757//pituitary adenoma//CHV
transsphenoidal surgery	C93344//Transsphenoidal Surgery//NCI	CDR0000476651//transsphenoidal surgery//NCI_NCI-GLOSS
thyroid adenomas	D013964//Thyroid Neoplasms//MSH
surgery if cancerous	
lccsct	
pms	D006064//ГОНАДОТРОПИНЫ СЫВОРОТКИ ЖЕРЕБЫХ КОБЫЛ//MSHRUS	D011293//premenstruační syndrom//MSHCZE	1138-6312//premenstrual syndrome//CSP	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	D7-76000//Premenstrual tension syndrome, NOS//SNMI	1504//PREMENSTRUAL TENSION//WHO	0000010085//premenstrual syndrome (PMS)//CHV	3793//Premenstrual Syndrome//MEDLINEPLUS	39185//PMS//PSY	82639001//Premenstrual tension syndrome//SNOMEDCT_US	BI00402//premenstrual syndrome//BI	180989//PROLINE-RICH PROTEIN, BstNI SUBFAMILY, 1//OMIM	HGNC:9337//proline rich protein BstNI subfamily 1//HGNC	174310//POLYDACTYLY, POSTAXIAL, WITH PROGRESSIVE MYOPIA//OMIM
surgery to remove primary and/or metastatic lesions	
no specific treatment is currently available for caveolinopathies	
management should include the following:	
infants are started with daily 1	
0 mg intramuscular or subcutaneous injections	
acute metabolic decompensation	MTHU023740//Acute metabolic decompensation//OMIM
long-term management	
these are accomplished by:	
parenteral ohcbl	
0 mg (~0	
betaine	E-8709//Betaine//SNM	C-85310//Betaine//SNMI	1512//Betaine//RXNORM	413645006//Betaine preparation//SNOMEDCT_US	N0000006734//Betaine [Chemical/Ingredient]//NDFRT	3SCV180C9W//Betaine//MTHSPL	C81038//Betaine//NCI	sh2005007337//Betaine//LCH_NW	DB06756//Glycine betaine//DRUGBANK	43356007//Betaine//SNOMEDCT_US	MTHU001174//Betaine//USPMG	D001622//Betaine//MSH	N0000147725//BETAINE//NDFRT	4019632//BETAINE//VANDF	258267//betaine//MEDCIN	0000001833//betaine//CHV	006281//betaine//NDDF	A16AA06//betaine//ATC	004543//PRIMIDONE 250 mg ORAL TABLET//NDDF	d04875//betaine//MMSL	11810//betaine//MMSL
optimal dosing and monitoring have not been adequately established	
folate and folinic acid	
the adult dose of folate is 1	
5 mg for maintenance	
dietary management	67//dietary management//OMS	Q000178//diet therapy//MSH
other therapeutic considerations that have not been fully validated:	
methionine supplementation	
pyridoxine	0000018236//pyridoxine//AOD	3147-5673//pyridoxine//CSP	d00412//pyridoxine//MMSL	684879//pyridoxine//RXNORM	41299//vitamin B6//MEDCIN	0000010456//pyridoxine//CHV	004538//DIVALPROEX SODIUM 125 mg ORAL TABLET, DELAYED RELEASE (ENTERIC COATED)//NDDF	KV2JZ1BI6Z//pyridoxine//MTHSPL	A11HA02//pyridoxine//ATC	CDR0000468776//pyridoxine//NCI_NCI-GLOSS	NOCODE//Developmental arithmetic disorder//MTH	6601//sildenafil 50 mg oral tablet//MMSL	X80RV//Vitamin B6//RCD	F-16250//Vitamin B6//SNM	F-BB350//Vitamin B6//SNMI	C62619//Pyridoxine//NCI	430469009//Pyridoxine//SNOMEDCT_US	N0000006060//Pyridoxine [Chemical/Ingredient]//NDFRT	LP32568-5//Pyridoxine//LNC	LP15842-5//Pyridoxine//LNC	MTHU012245//Pyridoxine//LNC	DB00165//Pyridoxine//DRUGBANK	D011736//Pyridoxine//MSH	N0000148007//PYRIDOXINE//NDFRT	4019922//PYRIDOXINE//VANDF	C74901//Pyridoxine//NCI_CDISC	N0000029452//[VT104] PYRIDOXINE//NDFRT	4021899//PYRIDOXINE//VANDF
levocarnitine	42955//Levocarnitine//RXNORM	0G389FZZ9M//Levocarnitine//MTHSPL	D002331//Carnitine//MSH	DB00583//L-Carnitine//DRUGBANK	C26657//Levocarnitine//NCI	372601001//L-Carnitine//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	d00491//levOCARNitine//MMSL	10540//LevOCARNitine//MMSL	48737//levocarnitine//MEDCIN	4970//naphazoline-zinc ophthalmic 0.12%-0.25% ophthalmic solution//MMSL	0000016097//l-carnitine//CHV	003576//PHENOBARBITAL SODIUM 30 mg/mL INJECTION SYRINGE (ML)//NDDF	A16AA01//levocarnitine//ATC	CDR0000321378//levocarnitine//NCI_NCI-GLOSS	CDR0000301896//levocarnitine//PDQ	N0000147225//LEVOCARNITINE//NDFRT	4018934//LEVOCARNITINE//VANDF
indicated for low plasma carnitine levels	
supportive therapy includes the following as needed:	
treatment of headache	
guidance for visual impairment	
classic cca	
this type of therapy is best instituted in childhood	
surgical release of contractures may be necessary	
consultation with an orthopedist is encouraged	
severe/lethal cca	
no general recommendations exist	
speech therapy may be required during periods of dental treatment	
sinus and middle ear infections require aggressive and timely treatment	
helmets may be advised for high-risk activities	
the treatment of cataracts is surgical	
regular rehabilitation can prevent or postpone osteoporosis	
recurrent hemorrhage or mass effect	
neuropsychological testing may be considered prior to any neurosurgical procedure	
microsurgical techniques rely on intraoperative examination for precise localization	
headaches	NOCODE//Sepsis//COSTAR	10019231//Headaches//MDR	D006261//Headache//MSH	120321//Headaches//NOC	091022//Headaches//NOC	210513//Headaches//NOC	121303//Headaches//NOC	090915//Headaches//NOC	240417//Headaches//NOC	MTHU036635//Headaches//OMIM	MTHU053651//Headaches//LNC	LP217220-5//Headaches//LNC	HP:0002315//Headache//HPO	BI00020//headache//BI	0000005820//headache//CHV
neurologic deficits	D009461//Neurologic Manifestations//MSH	0000038008//neurological deficit//CHV
hypotonia and weakness	
patients may benefit from physical therapy	
scoliosis and joint contractures	
patients with more severe symptoms may require respiratory support	
peginterferon-α2b has also been given once a week	
the mechanism behind this response is unknown	
splenectomy is of unproved value	
orthopedic issues—thorax shortening, scoliosis/kyphosis	
occasionally, surgical treatment of spinal curvature is warranted	
others may have a more refractory course	
renal issues	
immunologic status	
most individuals affected with cdgs have functional immune systems	
additional management issues of adults with cdg	
orthopedic issues — thorax shortening, scoliosis/kyphosis	
recently, therapy may start in the prenatal period	
postnatal treatment	
emphasis must be on preventing secondary lung injury	
it is unclear whether ecmo improves survival in cdh	
prenatal treatment	
surgical correction of intestinal malrotation if present	
alternative communicative methods (e	
standard treatment for hearing loss	
standard interventions for cardiac defects	
appropriate treatment for seizures	
antibiotic prophylaxis and follow up for vesicoureteral reflux	
orchiopexy if cryptorchidism is present	
standard intervention for bicornuate uterus, if present	
cervical spine stenosis may require decompression	
thoracic and lumbar spine (for scoliosis)	
l-carnitine supplementation	
l-carnitine supplementation has relatively few side effects:	
hypoglycemic episodes are treated with intravenous dextrose infusion	
cardiomyopathy requires management by specialists in cardiology	
correction of polydactyly (optional)	
orthopedic care as required (e	
, for hip dysplasia)	
dental care	223//Dental Care//MTH	D003729//Dental Care//MSH	U001306//Dental care//LCH	10056723//Dental care//MDR	sh85036869//Dental care//LCH_NW	108306002//Dental-oral procedure AND/OR service//SNOMEDCT_US	225362009//Dental care//SNOMEDCT_US	0000003709//dental care//CHV	0000032401//dental care//CHV
standard treatment for renal and liver abnormalities	
pneumonia should be treated with antibiotics	
asthma can be treated with steroids	
standard treatment for cardiac abnormalities	
no consensus management guidelines have been developed to date	
improving gait, exercise tolerance, and flexion contractures	
unsuccessful steroid therapy was reported in one adult	
less symptomatic individuals can be started on 0	
0 mg/kg every other day	
higher-dose steroids may help with acute pain crises	
calcitonin	U000739//Calcitonin//LCH	D002116//Calcitonin//MSH	XM0lH//Calcitonin//RCD	F-26960//Calcitonin//SNM	F-B3140//Calcitonin//SNMI	83348//Calcitonin//FMA	N0000006509//Calcitonin [Chemical/Ingredient]//NDFRT	LP14649-5//Calcitonin//LNC	DF35I47HCM//Calcitonin//MTHSPL	1311287//Calcitonin//RXNORM	MTHU003443//Calcitonin//LNC	sh85018767//Calcitonin//LCH_NW	30451//Calcitonin//CPM	63730009//Calcitonin//SNOMEDCT_US	U001773//Calcitonin//MTH	0000018771//calcitonin//AOD	2929-0286//calcitonin//CSP	0000002289//calcitonin//CHV	005019//METHOXYPHENAMINE HCL 100 mg ORAL TABLET//NDDF	CDR0000039292//calcitonin//PDQ	d00598//calcitonin//MMSL	N0000022460//CALCITONIN//NDFRT	4018749//CALCITONIN//VANDF	82308//Calcitonin//CPT	C74848//Calcitonin//NCI_CDISC	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC	10006940//Calcitonin//MDR	CDR0000045207//calcitonin//NCI_NCI-GLOSS	114130//CALCITONIN/CALCITONIN-RELATED POLYPEPTIDE, ALPHA//OMIM	HGNC:1437//calcitonin related polypeptide alpha//HGNC	C2281//Calcitonin Gene-Related Peptide 1//NCI	00630//Calcitonin//NCI_DCP	C329//Calcitonin Salmon//NCI	N0000175942//Calcitonin [EPC]//NDFRT	22657006//Calcitonin preparation//SNOMEDCT_US	41026//calcitonin//MEDCIN
losartan	D019808//losartan//MSHCZE	bk3..//Losartan//RCD	C-81310//Losartan//SNMI	52175//Losartan//RXNORM	C66869//Losartan//NCI	N0000005774//Losartan [Chemical/Ingredient]//NDFRT	LP171619-2//Losartan//LNC	JMS50MPO89//Losartan//MTHSPL	DB00678//Losartan//DRUGBANK	373567002//Losartan//SNOMEDCT_US	96309000//Losartan//SNOMEDCT_US	MTHU001043//Losartan//USPMG	0000018751//losartan//AOD	4009-0050//losartan//CSP	d03821//losartan//MMSL	0000016349//losartan//CHV	C09CA01//losartan//ATC	CDR0000560966//losartan//NCI_NCI-GLOSS	004991//AMPHETAMINE SULFATE/DEXTROAMPHETAMINE 20 mg ORAL CAPSULE//NDDF	N0000148401//LOSARTAN//NDFRT	4020913//LOSARTAN//VANDF
pain in the tibia resolved completely following the surgery	
corticosteroids may delay skull hyperostosis and cranial nerve impingement	
three underwent internal auditory canal decompression with mixed results	
celiac disease	D002446//Celiac Disease//MSH	N0000000704//Celiac Disease [Disease/Finding]//NDFRT	897//Celiac Disease//MEDLINEPLUS	LA15156-5//Celiac Disease//LNC	C26714//Celiac Disease//NCI	NOCODE//Developmental arithmetic disorder//MTH	0032735//CELIAC DISEASE//CCPSS	U000111//CELIAC DISEASE//COSTAR	U000577//EPIDIDYMOORCHITIS//DXP	K90.0//Celiac disease//ICD10AE	U000862//Celiac disease//LCH	MT210023//Celiac disease//MTHMST	XE0bK//Celiac disease//RCDAE	D-6218//Celiac disease//SNM	D5-47100//Celiac disease//SNMI	MTHU018114//Celiac disease//OMIM	sh85021632//Celiac disease//LCH_NW	HP:0002608//Celiac disease//HPO	10007864//Celiac disease//MDR	10009839//Coeliac disease//MDR	579.0//Celiac disease//ICD9CM	396331005//Celiac disease//SNOMEDCT_US	0000005573//celiac disease//AOD	1248-3893//celiac disease//CSP	0000002574//celiac disease//CHV	CDR0000377726//celiac disease//NCI_NCI-GLOSS	D99003//coeliac disease//ICPC2P	30192//celiac disease//MEDCIN
a dietitian experienced in treating celiac disease should be involved	
, 100 mg) can damage the small intestine	
note that a slice of bread contains approximately 2	
5 grams of gluten	
some hidden sources of gluten:	
non-starchy foods such as soy sauce and beer	
, lipstick)	
refractory sprue or celiac disease	
cutaneous photosensitivity	MTHU035822//Cutaneous photosensitivity//OMIM	HP:0000992//Cutaneous photosensitivity//HPO
reflectant sunscreens containing zinc oxide or titanium dioxide	
skin trauma should be avoided	
wound care is essential to prevent infection of opened blisters	
laser hair removal can be used to treat facial hypertrichosis	
topical antibiotics for corneal ulcers, scleritis, and blepharitis	
bone manifestations	
hemolytic anemia	U002151//Hemolytic anemia//LCH	D1...//Hemolytic anemia//RCDAE	D-4020//Hemolytic anemia//SNM	MTHU006276//Hemolytic anemia//OMIM	sh85060210//Hemolytic anemia//LCH_NW	HP:0001878//Hemolytic anemia//HPO	10019493//Hemolytic anemia//MDR	10018916//Haemolytic anaemia//MDR	61261009//Hemolytic anemia//SNOMEDCT_US	U000342//HEMOLYTIC ANEMIA//COSTAR	ANEMIA HEMOL//HEMOLYTIC ANEMIA//CST	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	0000005908//hemolytic anemia//AOD	0427-1005//hemolytic anemia//CSP	0000001123//hemolytic anemia//CHV	B82008//haemolytic anaemia//ICPC2P	30339//hemolytic anemia//MEDCIN	N0000000387//Anemia, Hemolytic [Disease/Finding]//NDFRT	C34376//Hemolytic Anemia//NCI_NICHD	2279//Hemolytic Anemia//NCI_FDA	D000743//Anemia, Hemolytic//MSH
consider blood transfusions when hemolysis is significant	
cystic fibrosis (cf)	0000003553//cystic fibrosis//CHV
inhaled dornase alfa in all individuals age ≥6 years	
inhaled hypertonic saline in all individuals age ≥6 years	
recommended sequence for inhaled medications:	
an aerosolized antibiotic	
gly551asp and other specific pathogenic variants	
phe508del	
lung or heart/lung transplantation	
an option for some individuals with severe disease	
oral pancreatic enzyme replacement with meals	
congenital absence of the vas deferens (cavd)	
prevention of primary manifestations – cystic fibrosis	
aerosolized antibiotic	
all routine immunizations should be given at the recommended times	
pancreatic enzyme replacement and supplementation of fat-soluble vitamins	
high-calorie, high-fat nutritional supplements	
consultation with a nutritionist specializing in cf	
surveillance – cystic fibrosis	
culture respiratory tract secretions at least four times yearly	
75 g/kg, or 75 g maximum	
evaluate bone mineral density in adolescence	
agents/circumstances to avoid – cystic fibrosis	
avoid the following:	
respiratory irritants (e	
, smoke, dust)	
individuals with respiratory infections	
dehydration	T11//Dehydration//ICPC	T11001//dehydration//ICPC2P	10012174//Dehydration//MDR	D003681//Dehydration//MSH	Q0200088//Dehydration//QMR	XM00s//Dehydration//RCD	F-01790//Dehydration//SNM	D6-20650//Dehydration//SNMI	251229//Dehydration//NOC	080111//Dehydration//NOC	080014//Dehydration//NOC	MTHU000177//Dehydration//OMIM	E86.0//Dehydration//ICD10CM	N0000000911//Dehydration [Disease/Finding]//NDFRT	6051//Dehydration//MEDLINEPLUS	C26740//Dehydration//NCI_NICHD	E12258//Dehydration//NCI_CTCAE	HP:0001944//Dehydration//HPO	10041882//Dehydration//ICNP	02151//Dehydration//NANDA-I	34095006//Dehydration//SNOMEDCT_US	13285//Dehydration//PSY	276.51//Dehydration//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	1015105//DEHYDRATION//CCPSS	220//DEHYDRATION//COSTAR	DEHYDRAT//DEHYDRATION//CST	U000936//INNOMINATE ARTERY, ANOMALOUS ORIGIN//DXP	0370//DEHYDRATION//WHO	0000005833//dehydration//AOD	0000003663//loss of body water//CHV	MTHU022122//dehydration//ICPC2ICD10ENG	CDR0000044659//dehydration//NCI_NCI-GLOSS	C57787//Dehydration//NCI_CTCAE	GTEx-BPV//Brevital//NCI	C126369//Dehydration//NCI
increasing caloric intake may be of benefit	
constipation affects the majority of individuals	
seizures are treated as in the general population	
recurrent otitis media may require placement of pe tubes	
hyperkeratoses are treated as in the general population	
nonsurgical treatment of ophthalmologic findings:	
correction of ptosis	7218.//Correction of ptosis//RCD	69769008//Repair of blepharoptosis//SNOMEDCT_US
eye muscle surgery	0000019684//eye muscle surgery//CHV	0059250//EYE MUSCLE SURGERY//CCPSS	LA14709-2//Eye muscle surgery//LNC	420419008//Strabismus surgery//SNOMEDCT_US
to correct or improve a compensatory head posture	
to improve ambulation and gross motor development in young children	
principles of surgical approach:	
profound weakening procedures (e	
orthodontic evaluation and appropriate intervention may be necessary	
treatment of colitis in cgd can be difficult	
corticosteroid treatment of heightened inflammatory response	
granulocyte infusions	
granulocyte infusions are generally well tolerated	
males with x-linked cgd	
, they are kell negative)	
kell-negative blood products are rarely available	
splints can be tried for foot drop	
choanal atresia	NOCODE//Sepsis//COSTAR	N0000000756//Choanal Atresia [Disease/Finding]//NDFRT	D002754//Choanal Atresia//MSH	Q30.0//Choanal atresia//ICD10	10008587//Choanal atresia//MDR	P80..//Choanal atresia//RCD	D4-21110//Choanal atresia//SNMI	MTHU036653//Choanal atresia//OMIM	HP:0000453//Choanal atresia//HPO	748.0//Choanal atresia//ICD9CM	204508009//Choanal atresia//SNOMEDCT_US	0000002848//choanal atresia//CHV	297932//choanal atresia//MEDCIN	99010//choanal atresia//MEDCIN
feeding/swallowing dysfunction	
renal evaluation	
renal ultrasound examination is recommended in all children	
endocrine evaluation	
coloboma	10009934//Coloboma//MDR	M-20190//Coloboma//SNM	MTHU012405//Coloboma//OMIM	N0000000810//Coloboma [Disease/Finding]//NDFRT	HP:0000589//Coloboma//HPO	D003103//Coloboma//MSH	0000003167//coloboma//CHV	MTHU017234//coloboma//ICPC2ICD10ENG	11534//coloboma//MEDCIN	1017416//COLOBOMA//CCPSS
hearing loss should be assumed until proven otherwise	
communication	U001112//Communication//LCH	D003142//Communication//MSH	U000079//Communication//PCDS	XC01S//Communication//RCD	0902//Communication//NOC	sh85029027//Communication//LCH_NW	5_5//Communication//NANDA-I	263536004//Communication//SNOMEDCT_US	10570//Communication//PSY	C16452//Communication//NCI	NOCODE//Developmental arithmetic disorder//MTH	U000149//COMMUNICATION//COSTAR	10//Spirituality//OMS	0000003920//communication//AOD	4009-0069//communication//CSP	0000003204//communication//CHV
deaf-blind service referral	
referral to deafblind education services (e	
frequent rest breaks may be needed	
myofacial release can improve posture and flexibility	
occasionally, sleep studies show obstructive apnea	
gi consultation is often indicated	
obsessive-compulsive disorder	D009771//Obsessive-Compulsive Disorder//MSH	N0000002203//Obsessive-Compulsive Disorder [Disease/Finding]//NDFRT	471//Obsessive-Compulsive Disorder//MEDLINEPLUS	C88411//Obsessive Compulsive Disorder//NCI_NICHD	NOCODE//Developmental arithmetic disorder//MTH	F42//Obsessive-compulsive disorder//ICD10	10029898//Obsessive-compulsive disorder//MDR	E203.//Obsessive-compulsive disorder//RCD	MTHU000246//Obsessive-compulsive disorder//OMIM	sh85093751//Obsessive-compulsive disorder//LCH_NW	HP:0000722//Obsessive-compulsive behavior//HPO	300.3//Other specified obsessive-compulsive and related disorder//DSM-5	191736004//Obsessive-compulsive disorder//SNOMEDCT_US	164230//OBSESSIVE-COMPULSIVE DISORDER//OMIM	0000006616//obsessive-compulsive disorder//AOD	0000008866//obsessive compulsive disorder (OCD)//CHV	P79003//obsessive-compulsive disorder//ICPC2P	CDR0000454805//obsessive-compulsive disorder//NCI_NCI-GLOSS
pervasive developmental disorder	X00TM//Autistic spectrum disorder//RCD	MTHU012301//Pervasive developmental disorder//OMIM	10061345//Pervasive developmental disorder//MDR	35919005//Autism spectrum disorder//SNOMEDCT_US	153//Autism Spectrum Disorder//MEDLINEPLUS	C97179//Pervasive Developmental Disorder//NCI_NICHD	0000006540//pervasive developmental disorder//AOD	5006-0029//pervasive developmental disorder//CSP	0000038288//pervasive developmental disorder//CHV	HP:0000729//Autistic behavior//HPO
sensory processing issues are likely implicated	
attention-deficit hyperactivity disorder	32643//attention-deficit hyperactivity disorder//MEDCIN	sh85063661//Attention-deficit hyperactivity disorder//LCH_NW	MTHU045734//Attention-deficit hyperactivity disorder//OMIM
understanding this is critical to devising appropriate interventional strategies	
general	G-A366//Generalized//SNMI	C63764//Generalized//NCI	LA17571-3//General//LNC	MPN-SAF//Problem//NCI	60132005//Generalized//SNOMEDCT_US	0000020435//general//CHV	0056036//GENERAL//CCPSS	GENRL//General//HL7V3.0	C115727//Safety Reporting Communications and Tracking Subcategory//NCI_CareLex
adequate nutrition and weight maintenance are essential	
appropriate bracing and stretching can minimize contractures	
mitochondrial myopathy	590000//TRANSFER RNA, MITOCHONDRIAL, ALANINE//OMIM	251900//MITOCHONDRIAL MYOPATHY//OMIM	N0000003559//Mitochondrial Myopathies [Disease/Finding]//NDFRT	C101328//Mitochondrial Myopathy//NCI	D017240//Mitochondrial Myopathies//MSH	10027710//Mitochondrial myopathy//MDR	X709I//Mitochondrial cytopathy//RCD	DA-51600//Mitochondrial myopathy//SNMI	MTHU005171//Mitochondrial myopathy//OMIM	HP:0003737//Mitochondrial myopathy//HPO	16851005//Mitochondrial myopathy//SNOMEDCT_US	0000017938//mitochondrial myopathy//CHV	5000-0048//mitochondrial disease/disorder//CSP	337551//mitochondrial myopathy//MEDCIN
assistance with ambulation and posture	
surgical correction of ptosis as needed	
amyotrophic lateral sclerosis	NOCODE//Sepsis//COSTAR	D000690//Amyotrophic Lateral Sclerosis//MSH	N0000000376//Amyotrophic Lateral Sclerosis [Disease/Finding]//NDFRT	135//Amyotrophic Lateral Sclerosis//MEDLINEPLUS	C34373//Amyotrophic Lateral Sclerosis//NCI	0062056//AMYOTROPHIC LATERAL SCLEROSIS//CCPSS	U000220//Amyotrophic lateral sclerosis//LCH	10002026//Amyotrophic lateral sclerosis//MDR	F152.//Motor neurone disease//RCD	D-8141//Amyotrophic lateral sclerosis//SNM	DA-23010//Amyotrophic lateral sclerosis//SNMI	G12.21//Amyotrophic lateral sclerosis//ICD10CM	MTHU038375//Amyotrophic lateral sclerosis//OMIM	sh85004728//Amyotrophic lateral sclerosis//LCH_NW	HP:0007354//Amyotrophic lateral sclerosis//HPO	LA27534-9//Amyotrophic lateral sclerosis//LNC	335.20//Amyotrophic lateral sclerosis//ICD9CM	86044005//Amyotrophic lateral sclerosis//SNOMEDCT_US	0000006207//amyotrophic lateral sclerosis//AOD	4000-0117//amyotrophic lateral sclerosis//CSP	0000001073//Lou Gehrig's disease (ALS)//CHV	32257//amyotrophic lateral sclerosis//MEDCIN
(als)	
frontotemporal dementia (ftd)	
spinal motor neuronopathy	
seizures should be managed by an experienced pediatric neurologist	
hematologic and immunologic defects	
select individuals may also receive intrathecal methotrexate and prednisilone	
once remission occurs, prompt hsct is recommended	
correction of refractive errors may improve visual acuity	
skin hypopigmentation	C78610//Skin Hypopigmentation//NCI	MTHU003037//Skin hypopigmentation//OMIM	10040868//Skin hypopigmentation//MDR	E13721//Skin hypopigmentation//NCI_CTCAE	HP:0001010//Hypopigmentation of the skin//HPO	0000017999//hypopigmentation//CHV	11442//skin hypopigmentation//MEDCIN
skin protection varies depending on the degree of hypopigmentation	
neurologic abnormalities	HP:0000707//Abnormality of the nervous system//HPO
skeletal dysplasia	HP:0002652//Skeletal dysplasia//HPO	C84978//Osteochondrodysplasia//NCI_NICHD	X70BZ//Skeletal dysplasia//RCD	10072610//Skeletal dysplasia//MDR	MTHU042509//Skeletal dysplasia//OMIM	105986008//Skeletal dysplasia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000032821//skeletal dysplasia//CHV
orthopedic surgery may be complicated by low bone density	
immunodeficiency and infection	
nutrition and ocular health have become increasingly topical:	
preparedness for appropriate countermeasures (e	
an apnea monitor is recommended	
anticonvulsants may be required	
surgical instrumentation or prolonged	
bracing may be required to correct a progressive thoracolumbar scoliosis	
paradoxical sweating	MTHU057598//Paradoxical sweating//OMIM
treatment should be reserved for adults and older children	
clonidine	U001056//Clonidine//LCH	x01Cz//Clonidine//RCD	E-7657//Clonidine//SNM	C-81130//Clonidine//SNMI	2599//Clonidine//RXNORM	MN3L5RMN02//Clonidine//MTHSPL	N0000006505//Clonidine [Chemical/Ingredient]//NDFRT	LP32548-7//Clonidine//LNC	LP14987-9//Clonidine//LNC	MTHU002290//Clonidine//LNC	sh85027121//Clonidine//LCH_NW	DB00575//Clonidine//DRUGBANK	372805007//Clonidine//SNOMEDCT_US	62782004//Clonidine//SNOMEDCT_US	09740//Clonidine//PSY	C380//Clonidine//NCI	MTHU000775//Clonidine//USPMG	D003000//Clonidine//MSH	0000020738//clonidine//AOD	1549-3722//clonidine//CSP	4478//Touro DM//MMSL	257582//clonidine//MEDCIN	0000003057//clonidine//CHV	004495//ACETAMINOPHEN 120 mg ORAL WAFER//NDDF	N02CX02//clonidine//ATC	C02AC01//clonidine//ATC	S01EA04//clonidine//ATC	CDR0000630972//clonidine//NCI_NCI-GLOSS	CDR0000041228//clonidine//PDQ	N0000146207//CLONIDINE//NDFRT	4017850//CLONIDINE//VANDF	d00044//cloNIDine//MMSL
oral clonidine, at starting doses of 0	
05 mg to 0	
1 mg four times daily may be required	
abrupt cessation of clonidine can lead to prominent hypertension	
moxonidine was well tolerated in the short term	
however, long-term observations are not yet available	
niccd	605814//CITRULLINEMIA, TYPE II, NEONATAL-ONSET//OMIM	C536398//Neonatal-onset citrullinemia type 2//MSH
the treatment with therapeutic formulas is not lifelong	
fttdcd	
ctln2	603471//CITRULLINEMIA, TYPE II, ADULT-ONSET//OMIM
other treatments include the following:	
saheki et al 2010	
yazaki et al 2010	
ohura et al, personal communication	
okano et al, personal communication]	
aro	D000761//anesteziologické oddělení nemocnice//MSHCZE	HGNC:2594//cytochrome P450 family 19 subfamily A member 1//HGNC	107910//CYTOCHROME P450, FAMILY 19, SUBFAMILY A, POLYPEPTIDE 1//OMIM	C52322//CYP19A1 wt Allele//NCI
adoii	
orthopedic treatment is often required for fractures and arthritis	
no specific dietary or other metabolic treatment is available	
a trial of antiepileptic drugs (aeds) (e	
treatment of behavioral problems is standard and requires periodic reassessment	
no definitive treatments exist for the congenital muscular dystrophies	
speech therapy may be indicated	
close attention to oral hygiene is indicated	
medical treatment	
acetylcholineesterase (ache) inhibitors (pyridostigmine)	
3,4-diaminopyridine (3,4-dap)	
quinidine, fluoxetine	
however, it may induce suicidal ideation	
non-medical treatment	
orthotics or a wheelchair	
a percutaneous gastric tube	
exercise within the affected individual's capability	
note: (1) fatigue may improve with exercise	
wheelchair for mobility because of gait instability	
lower urinary tract involvement [krhut et al 2014]	
vocal cord paresis	D014826//Vocal Cord Paralysis//MSH	10049234//Vocal cord paresis//MDR	Xa9Bv//Vocal cord palsy//RCD	MTHU002849//Vocal cord paresis//OMIM	HP:0001604//Vocal cord paresis//HPO
treatment may include:	
ankle/foot orthoses	
forearm crutches or canes	
rarely, wheelchairs	
career and employment counseling	
anticipatory counseling is appropriate	
forearm crutches or canes for gait stability for some individuals	
many remain physically active	
the following may be indicated:	
wheelchairs for mobility because of gait instability	
for treatment of findings common to all	
trpv4-associated disorders	
pain and depression	
neuropathy	N94010//neuropathy//ICPC2P	U005825//Neuropathy//LCH	XC0eJ//Neuropathy//RCD	D-8X30//Peripheral nervous system disease or syndrome//SNM	MTHU016030//Neuropathy//OMIM	1095//Peripheral Nerve Disorders//MEDLINEPLUS	338712//Neuropathy//MEDCIN	C4731//Neuropathy//NCI_NICHD	1465//Diabetic Nerve Problems//MEDLINEPLUS	1983//Neuropathy//NCI_FDA	HP:0009830//Peripheral neuropathy//HPO	10029328//Neuropathy//MDR	02957//Neuropathy//NANDA-I	386033004//Neuropathy//SNOMEDCT_US	33800//Neuropathy//PSY	NOCODE//Developmental arithmetic disorder//MTH	1009040//NEUROPATHY//CCPSS	516//NEUROPATHY//COSTAR	NEUROPATHY//NEUROPATHY//CST	0130//NEUROPATHY//WHO	0000006110//neuropathy//AOD	BI00553//neuropathy//BI	CDR0000046041//neuropathy//NCI_NCI-GLOSS	MTHU052562//neuropathy//ICPC2ICD10ENG	0000035183//neuropathy//CHV
vocal cord involvement	
respiratory therapy/support (e	
, bipap)	
physical therapy/exercise to maintain as much function as possible	
orthopedic evaluation with consideration of surgical intervention (i	
patients undergoing surgical fusion typically do well	
appropriate treatment includes:	
prosthetic and adaptive devices for weak hands	
ankle/foot orthoses to correct foot drop and aid walking	
fewer than 5% of affected individuals need wheelchairs	
treatment of spinal deformities	
physiotherapy helps to preserve flexibility	
treatment of foot deformities	
physiotherapy to preserve flexibility	
treatment of pain and cramps	
, pregabalin, gabapentin)	
cramps can be controlled with quinine	
some need wheelchairs	
surgery to correct spine deformities	
wheelchairs as needed because of gait instability	
no specific treatment reverses the manifestations of cmt4j	
severely affected individuals need wheelchairs	
bipap for those with respiratory muscle weakness	
peripheral neuropathy	D010523//Peripheral Nervous System Diseases//MSH	CDR0000044705//Peripheral Neuropathy//NCI_NCI-GLOSS	C119734//Peripheral Neuropathy//NCI	NOCODE//Developmental arithmetic disorder//MTH	XC0eJ//Neuropathy//RCD	D-8X30//Peripheral nervous system disease or syndrome//SNM	MTHU000700//Peripheral neuropathy//OMIM	1095//Peripheral Nerve Disorders//MEDLINEPLUS	HP:0009830//Peripheral neuropathy//HPO	03038//Peripheral neuropathy//NANDA-I	302226006//Peripheral nerve disease//SNOMEDCT_US	575//PERIPHERAL NEUROPATHY//COSTAR	R0121713//PERIPHERAL NEUROPATHY//QMR	U003097//PERIPHERAL NEUROPATHY//DXP	0000006111//peripheral neuropathy//AOD	BI00555//peripheral neuropathy//BI	2042-6617//polyneuritis//CSP	9438//peripheral neuropathy//MEDCIN	0000009515//peripheral neuropathy//CHV	N94011//peripheral neuropathy//ICPC2P	311304//peripheral neuropathy//MEDCIN
see charcot-marie-tooth hereditary neuropathy overview, management	
individualized educational program for developmental delay	
feeding gastrostomy tube placement for failure to thrive	
management of hearing loss	
management of cataracts and other ophthalmologic complications	
use of sunscreens for cutaneous photosensitivity	
use of sunglasses for lens and retina protection	
spectacle correction of refractive errors	
psychosocial support for affected individuals and their families	
recurrent infections should be treated per standard therapy	
no specific support exists for individuals with col4a1-related disorders	
seizures are managed using standard protocols	
glaucoma is initially treated with topical anti-glaucoma medication	
coenzyme q10 supplementation	
coq4-related coenzyme q10 deficiency	
coq6-related coenzyme q10 deficiency	
homozygotes for the pathogenic variants p	
gly255arg or p	
ala353asp responded [heeringa et al 2011]	
coq8b-related coenzyme q10 deficiency	
pdss2-related coenzyme q10 deficiency	
coq8a-related coenzyme q10 deficiency	
coq9-related coenzyme q10 deficiency	
most infants require nasogastric or gastrostomy feeding	
pyloric stenosis is treated surgically	
anecdotally, affected children have very high caloric needs	
kyphoscoliosis may require surgical correction	
dental abnormalities should be addressed by a pediatric dentist	
papillomata	10033725//papillomata//MDRDUT	0000009247//non cancerous skin tumor//CHV
thus, cortisol deficiency may also be considered	
malignant tumors	0000002337//cancer//CHV
treatment of malignant tumors follows standard protocols	
info and ghr	
nlm	C82620//National Library of Medicine//NCI	D009317//National Library of Medicine, USA//MSHNOR
nih	LA17113-4//NIH//LNC	C16895//National Institutes of Health//NCI	CDR0000044269//NIH//NCI_NCI-GLOSS	D009316//National Institutes of Health, USA//MSHNOR	C14476//NIH Mouse//NCI
gov	604350//RAS-ASSOCIATED PROTEIN RAB3D//OMIM
current treatment for long-chain fatty-acid oxidation disorders:	
avoid known triggers	
treatment consists primarily of surgical intervention	
cytokine administration may shorten the consolidation period	
timing of subsequent craniofacial surgeries influences their success	
limbs	MTHU000040//Limbs//OMIM	C12429//Limb//NCI	LP7395-9//Limbs//LNC	MTHU002838//Limbs//LNC	D005121//Extremities//MSH	0000004807//arms and legs//CHV
behavior therapy for behavior problems by developmental pediatrician	
seizure management with antiepileptic drugs by epilepsy specialist	
treatment of movement disorder by movement disorder specialist	
gamt deficiency	C537622//Guanidinoacetate methyltransferase deficiency//MSH	612736//CEREBRAL CREATINE DEFICIENCY SYNDROME 2//OMIM
treatment is as follows:	
4-0	
8g/kg/day)	
available databases (e	
treatment outcome of symptomatic individuals with gamt deficiency	
in 18% of individuals seizures were eliminated	
in 49% seizure frequency decreased	
improvement was seen in 60% of individuals	
treatment outcome of asymptomatic individuals with gamt deficiency	
agat deficiency	C567192//Arginine:Glycine Amidinotransferase Deficiency//MSH	612718//CEREBRAL CREATINE DEFICIENCY SYNDROME 3//OMIM
treatment outcome of symptomatic individuals with agat deficiency	
treatment outcome of asymptomatic individuals with agat deficiency	
crtr deficiency	
the goal of treatment is to replenish cerebral creatine levels	
treatment has included:	
glycine 150 mg/kg bw/day in 3 doses	
treatment outcome of individuals with crtr deficiency	
spectacles or contact lenses for correction of refractive errors	
management of strabismus	
penetrating keratoplasty	72452//Penetrating keratoplasty//RCD	42101009//Penetrating keratoplasty//SNOMEDCT_US	0000007063//penetrating keratoplasty//CHV	D015948//Keratoplasty, Penetrating//MSH
most grafts remain clear after penetrating keratoplasty	
see acmg-act sheet, acmg algorithm	
acute management of hyperammonemia	
rapidly decreasing plasma ammonia concentration	
scavenger therapy should be continued while dialysis is being performed	
note: exchange transfusions have no place in hyperammonemic treatment	
0-1	
control of intracranial pressure	
cerebral edema and ischemia may be documented by mri	
chronic management	
protein restriction	
nitrogen scavenger therapy	
as children grow, doses change to 9	
9-13 g/m2/day of sodium phenylbutyrate and 8	
8-15	
4 g/m2/day of arginine	
the initial dosage for phenylbutyrate-naïve patients is 4	
5-11	
2 ml/m2/day (5-12	
4 g/m2/day)	
living related-donor liver transplantation	
renal fanconi syndrome	D005198//Fanconi Syndrome//MSH	134600//FANCONI RENOTUBULAR SYNDROME 1//OMIM	MTHU007375//Renal Fanconi syndrome//OMIM	HP:0001994//Renal Fanconi syndrome//HPO
phosphate replacement to prevent and treat rickets	
renal glomerular disease	NOCODE//Developmental arithmetic disorder//MTH	0000026347//glomerular disease//CHV
renal transplantation	0000007098//kidney transplant//CHV	1683-2651//kidney transplantation//CSP	1057//Renal transplantation//ICD10AM	1299//Kidney Transplantation//MEDLINEPLUS	36503-00//Renal transplantation//ICD10AM	C15265//Kidney Transplantation//NCI	43927//Renal Transplantation//PSY	D016030//Kidney Transplantation//MSH
73 m2 and azotemia and hypertension rapidly progress	
symptoms often determine the exact time of transplantation	
retinal involvement is irreversible	
nutrition must be adequate for growth	
oral l-thyroxine replacement for hypothyroidism	
insulin for diabetes mellitus	
speech therapy and physical therapy	
standard treatment for benign intracranial hypertension	
other central nervous system complications are irreversible	
chenodeoxycholic acid (cdca)	
normalization of nerve conduction velocities and subsequent stabilization	
cdca treatment may be more useful when started early	
luyckx et al 2014]	
coenzyme q10 (coq10) treatment may improve muscle weakness	
repair of inguinal hernia(s)	
routine management of hip dislocation	
routine management of refractive errors	
antiepileptic drugs (aeds): valproate	
or a combination of aeds can be used	
psychological help as needed for self-image issues	
recommended drugs are nadolol (1-2	
flecainide	x01QJ//Flecainide//RCD	C-803F0//Flecainide//SNMI	4441//Flecainide//RXNORM	C62029//Flecainide//NCI	N0000006966//Flecainide [Chemical/Ingredient]//NDFRT	LP16148-6//Flecainide//LNC	MTHU004259//Flecainide//LNC	NSC0719273//Flecainide//NCI_DTP	DB01195//Flecainide//DRUGBANK	31980//Flecainide//CPM	372751001//Flecainide//SNOMEDCT_US	46576005//Flecainide//SNOMEDCT_US	MTHU000899//Flecainide//USPMG	D005424//Flecainide//MSH	d00234//flecainide//MMSL	42125//flecainide//MEDCIN	0000005089//flecainide//CHV	C01BC04//flecainide//ATC	CDR0000045381//flecainide//NCI_NCI-GLOSS	004483//ACETAMINOPHEN 80 mg/5 mL ORAL ELIXIR//NDDF	K94FTS1806//flecainide//MTHSPL	N0000147848//FLECAINIDE//NDFRT	4019757//FLECAINIDE//VANDF
however, urinary ne excretion exceeds normal levels	
fludrocortisone, at dosages of 0	
ptosis can be corrected by surgery	
sinus problems should be treated as needed	
dilated cardiomyopathy	I42.0//Dilated cardiomyopathy//ICD10	XE0Uz//Congestive cardiomyopathy//RCD	MTHU001652//Dilated cardiomyopathy//OMIM	3754//Cardiomyopathy//MEDLINEPLUS	HP:0001644//Dilated cardiomyopathy//HPO	10056419//Dilated cardiomyopathy//MDR	02196//Dilated cardiomyopathy//NANDA-I	399020009//Dilated cardiomyopathy//SNOMEDCT_US	0000005394//dilated cardiomyopathy//AOD	BI00079//dilated cardiomyopathy//BI	0000002450//dilated cardiomyopathy//CHV	35909//dilated cardiomyopathy//MEDCIN	C84673//Dilated Cardiomyopathy//NCI	N0000000686//Cardiomyopathy, Dilated [Disease/Finding]//NDFRT	D002311//Cardiomyopathy, Dilated//MSH	C91470//Dilated cardiomyopathy//NCI_KEGG
mean lvef increased from 36% to 53%	
measurement of reduced sphericity indicated improved ventricular geometry	
scoliosis treatment as needed is appropriate	
corticosteroid therapy	0000016698//steroid treatment//CHV	CDR0000038714//steroid therapy//PDQ
prednisone	U003802//Prednisone//LCH	D011241//Prednisone//MSH	fe7..//Prednisone//RCD	E-8536//Prednisone//SNM	8640//Prednisone//RXNORM	VB0R961HZT//Prednisone//MTHSPL	N0000006687//Prednisone [Chemical/Ingredient]//NDFRT	LP18109-6//Prednisone//LNC	4557//Steroids//MEDLINEPLUS	MTHU003245//Prednisone//LNC	sh85106259//Prednisone//LCH_NW	00934//Prednisone//NCI_DCP	DB00635//Prednisone//DRUGBANK	116602009//Prednisone//SNOMEDCT_US	C770//Prednisone//NCI	MTHU001276//Prednisone//USPMG	NOCODE//Developmental arithmetic disorder//MTH	0000021014//prednisone//AOD	0059-8338//prednisone//CSP	5351//povidone iodine ophthalmic 5% ophthalmic solution//MMSL	40982//prednisone//MEDCIN	0000010044//prednisone//CHV	002164//ASCORBIC ACID 750 mg ORAL TABLET, EXTENDED RELEASE//NDDF	H02AB07//prednisone//ATC	A07EA03//prednisone//ATC	CDR0000045492//prednisone//NCI_NCI-GLOSS	CDR0000042487//prednisone//PDQ	0054339//PREDNISONE//CCPSS	N0000146229//PREDNISONE//NDFRT	4017876//PREDNISONE//VANDF	d00350//predniSONE//MMSL	287//PredniSONE//MMSL
75 mg/kg/day or 1	
5 and 0	
6 mg/kg/day [fenichel et al 1991]	
follow-up studies showed that a dose of 0	
3 mg/kg/day [fenichel et al 1991]	
35 mg/kg/day) in both dmd and bmd	
4 mg/kg/day	
at lower doses of 0	
alternate-day dosing and intermittent dosing (e	
side effects did not negatively affect quality of life	
initiation and length of treatment	
75 mg/kg/day, prednisone 0	
published guidelines	
the optimal maintenance dose of prednisone (0	
3 mg/kg/day	
5 mg/kg/day	
3 mg/kg/day after three to four months	
deflazacort (0	
bmd	CDR0000415882//BMD//NCI_NCI-GLOSS	C61545//Bone Mineral Density Test//NCI	153700//MACULAR DYSTROPHY, VITELLIFORM, 2//OMIM	300376//MUSCULAR DYSTROPHY, BECKER TYPE//OMIM	HGNC:2928//dystrophin//HGNC	HGNC:12703//bestrophin 1//HGNC	C75321//DMD wt Allele//NCI
elements of the guidelines include the following:	
consider therapy based on cardiac phenotype (i	
, dcm or arrhythmia)	
cardiac conduction system disease and arrhythmias	
, atrial or atrioventricular node ablations)	
lmna-related dcm	
symptomatic dcm represents late disease	
individuals with idiopathic or familial dilated cardiomyopathy should:	
epileptic seizures require antiepileptic drugs (aeds)	
special adaptive chairs or positioners may be required	
educational	
spectacle correction is appropriate where indicated	
manifestations of the 16p11	
early diagnosis and provision of therapies facilitate the best outcome	
referral to other appropriate medical specialists (sue	
neurodevelopmental disabilities including asd	
obesity and overweight	
maintain an active lifestyle	
chiari i malformation or syringomyelia	
the spasms are responsive to acth	
special feeding techniques or devices, e	
structural anomalies (e	
hypothyroidism is treated in a standard manner	
no guidelines have been established for treatment of dent disease	
thiazide diuretics in doses greater than 0	
however, their effectiveness has not been clear	
the response to antiepileptic drugs (aeds) is variable	
routine ophthalmologic management of strabismus, if present	
routine correction of refractive error	
see hereditary deafness and hearing loss overview for details	
hearing habilitation	
for those with nonsyndromic bilateral congenital hearing loss	
hearing aids should be fitted as soon as possible	
educational programs designed for individuals with hearing impairment are appropriate	
see deafness and hereditary hearing loss overview	
management of neurologic manifestations in neonatal multisystem disease	
hypotonia may be significant	
the one-year survival rate was 64%	
five of the 14 survived longer than five years	
corticosteroid administration	
corticosteroids may be slowly tapered to the minimal effective dose	
the recommended maximum maintenance dose is ≤0	
red blood cell transfusion	D017707//Erythrocyte Transfusion//MSH	NOCODE//Developmental arithmetic disorder//MTH	0000015877//red blood cell transfusion//CHV
7% ±10	
1% ±11	
survival was the best (92	
cancer treatment	304181//cancer treatment//MEDCIN	LP114959-2//Cancer treatment//LNC	MTHU038130//Cancer treatment//LNC	C16212//Cancer Therapeutic Procedure//NCI
treatment of malignancies should be coordinated by an oncologist	
, for clubfeet)	
comprehensive coordinated care among specialties is required	
bone marrow failure (bmf)	
, aggression, mood swings)	
the suggested starting dose of oxymetholone is 0	
hematopoietic growth factors may be useful in bmf	
this risk has not been quantitated	
studies are ongoing	
dld pathogenic variants cause variable deficiency in three enzymatic pathways	
branched chain alpha-ketoacid dehydrogenase (bckdh) complex	
α-ketoglutarate dehydrogenase (αkgdh) complex	
pyruvate dehydrogenase (pdh) complex	
early-onset neurologic presentation	
review of treatment strategies	
protein/bcaa-restriction	
ketogenic/high-fat diet	
five had no clinical or biochemical benefit	
two improved clinically	
carbohydrate tolerance	
dichloroacetate (dca)	
additional therapies used with limited success include:	
coenzyme q10	C024989//coenzyme Q10//MSH	21406//coenzyme Q10//RXNORM	199475//coenzyme Q10//MEDCIN	N0000010094//coenzyme Q10 [Chemical/Ingredient]//NDFRT	CDR0000346488//coenzyme Q10//NCI_NCI-GLOSS	CDR0000039187//coenzyme Q10//PDQ	NOCODE//Developmental arithmetic disorder//MTH	0000013780//coenzyme q10//CHV	N0000148739//COENZYME Q10//NDFRT	4021303//COENZYME Q10//VANDF	C916//Coenzyme Q10//NCI	NSC0140865//Coenzyme Q10//NCI_DTP	46285//Coenzyme Q10//MMSL	412130008//Coenzyme Q10//SNOMEDCT_US	412129003//Coenzyme Q10//SNOMEDCT_US
lipoic acid	C61595//Alpha-Lipoic Acid//NCI	N0000010560//Thioctic Acid [Chemical/Ingredient]//NDFRT	DB00166//Lipoic Acid//DRUGBANK	NOCODE//administration devices//MMSL	D008063//Thioctic Acid//MSH	0000018231//lipoic acid//AOD	0000007460//alpha lipoic acid//CHV	F-630A0//Lipoic acid//SNMI	sh96009518//Lipoic acid//LCH_NW	70496003//Lipoic acid//SNOMEDCT_US
biotin	D001710//biotin//MSHCZE	U000584//Biotin//LCH	X80LX//Biotin//RCD	F-16280//Biotin//SNM	F-BB380//Biotin//SNMI	1588//Biotin//RXNORM	118935//Biotin//MMSL	13813003//Biotin preparation//SNOMEDCT_US	6SO6U10H04//Biotin//MTHSPL	N0000005852//Biotin [Chemical/Ingredient]//NDFRT	LP15451-5//Biotin//LNC	5376//B Vitamins//MEDLINEPLUS	MTHU008664//Biotin//LNC	sh85014267//Biotin//LCH_NW	C309//Biotin//NCI_CRCH	DB00121//Biotin//DRUGBANK	8919000//Biotin//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000018225//biotin//AOD	3147-0366//biotin//CSP	d06867//biotin//MMSL	11819//Hyalgan//MMSL	191869//biotin//MEDCIN	0000001914//biotin//CHV	001035//PHENYLPROPANOLAMINE/ACETAMINOPHEN/CHLORPHENIRAMINE/CAFFEINE ORAL TABLET//NDDF	A11HA05//biotin//ATC	CDR0000556403//biotin//NCI_NCI-GLOSS	N0000146018//BIOTIN//NDFRT	NSC0063865//BIOTIN//NCI_DTP	4017638//BIOTIN//VANDF	C74902//Biotin//NCI_CDISC
empiric recommendations	
for acute management (based on the above review)	
this is typically achieved by the following:	
promotion of an anabolic state:	
maintain serum glucose concentration in the normal range	
protein should then be reintroduced gradually	
hepatic presentation	
correction of metabolic acidosis with sodium bicarbonate	
correction of any coagulopathy with fresh frozen plasma	
avoidance of liver-toxic medications	
episodes of catabolic stress (e	
caution:	
high doses are usually required (0	
4-1	
0 mg/kg/day of glibenclamide)	
transfer protocols are available at www	
diabetesgenes	
org	C19711//Professional Organization or Group//NCI
high caloric intake should be maintained to achieve weight gain	
insulin can be discontinued when blood glucose concentrations stabilize	
, some residual endogenous insulin remains)	
note: macroglossia could potentially cause airway obstruction	
currently no effective treatment exists for any type of hsan	
provision of corrective lenses for myopia	
treatment of retinal detachments or glaucoma	
antiepileptic drugs for seizures	
children	U005340//Children//LCH	sh85023418//Children//LCH_NW	C16423//Child//NCI	D002648//Child//MSH	0000007008//children//AOD	0000002765//child//CHV	5002-0012//children//CSP	0060058//CHILDREN//CCPSS	C42708//Offspring//NCI
adults	D000328//Adult//MSH	0000000783//adult//CHV
gradual increase to higher doses is recommended	
for affected children, adaptation of educational programming to abilities	
duane anomaly	N0000001002//Duane Retraction Syndrome [Disease/Finding]//NDFRT	D004370//Duane Retraction Syndrome//MSH	126800//DUANE RETRACTION SYNDROME 1//OMIM	MTHU019421//Duane anomaly//OMIM	HP:0009921//Duane anomaly//HPO
severe strabismus may require eye surgery	
radial ray malformations	
hearing deficits	
hearing aids may be required	
nonsurgical treatment of ophthalmologic findings	
surgical treatment of ophthalmologic findings (extraocular muscle surgery)	
to correct or improve compensatory head posture	
to improve upshoot or downshoot	
principles of surgical approach as reviewed in	
kekunnaya et al [2015]	
type 1 and type 3	
type 2	X7A5V//Type 2//RCD	258195006//Type 2//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000034899//type 2//CHV	C125395//Bristol Stool Type 2//NCI	BSF//Bristol Stool Scale//NCI
approach for non-treatment	
approach for treatment	
the galactose challenge	
for example:	
, after the introduction of solid foods)	
supportive care may include the following:	
occupational and physical therapy	
alternative and augmentative communication	
behavioral therapy (e	
, applied behavioral analysis therapy)	
psychotropic medications for behavioral manifestations	
many of these are preventable	
seizures should be managed by a neurologist using standard practice	
childhood apraxia of speech	602081//SPEECH-LANGUAGE DISORDER 1//OMIM
anxiety/selective mutism	
autism spectrum disorder (asd)	
attention deficit hyperactivity disorder (adhd)	0000056595//attention deficit hyperactivity disorder (ADHD)//CHV	MTHU018058//Attention deficit hyperactivity disorder (ADHD)//OMIM	MTHU000353//Attention Deficit Hyperactivity Disorder (ADHD)//LNC
aggression	P80001//aggression//ICPC2P	10001488//Aggression//MDR	F-90940//Aggression//SNM	F-93032//Aggressive behavior//SNMI	MTHU003629//Aggression//OMIM	C117262//Aggression//NCI_NICHD	00052//Impaired social interaction//NANDA-I	61372001//Aggressive behavior//SNOMEDCT_US	D000374//Aggression//MSH	0000003725//aggression//AOD	2483-0139//aggression//CSP	GO:0002118//aggressive behavior//GO	0000000823//aggression//CHV	HP:0000718//Aggressive behavior//HPO	BASC-2//Emotional Symptoms Index//NCI
applied behavior analysis intervention is recommended	
oppositionality	C117261//Oppositionality//NCI_NICHD
specific medical problems are treated in the following ways:	
hydrocephalus as needed with ventriculo-peritoneal shunting	
aortic dilation with beta blocker therapy in some affected individuals	
strabismus in the usual manner	
recurrent otitis media in the usual manner	
poor feeding in infants	
human growth hormone replacement therapy	
club feet	MTHU004124//Club feet//OMIM	HP:0001762//Talipes equinovarus//HPO
casting	
educational program should be tailored to individual needs	
educational programs to address the specific needs identified	
speech therapy directed at improving communication skills	
therapeutic management of sleep disturbances if necessary	
early intervention with occupational therapy for feeding problems	
consideration of tube feeding for severe persisting feeding problems	
anticholinergics (e	
, trihexyphenidyl)	
if medications fail	
, prior to sufficient medication trials)	
acetazolamide	U000023//Acetazolamide//LCH	D000086//Acetazolamide//MSH	x02MU//Acetazolamide//RCD	E-8881//Acetazolamide//SNM	C-97910//Acetazolamide//SNMI	167//Acetazolamide//RXNORM	O3FX965V0I//Acetazolamide//MTHSPL	N0000007364//Acetazolamide [Chemical/Ingredient]//NDFRT	LP16018-1//Acetazolamide//LNC	MTHU005569//Acetazolamide//LNC	sh85000458//Acetazolamide//LCH_NW	DB00819//Acetazolamide//DRUGBANK	33664007//Acetazolamide//SNOMEDCT_US	372709008//Acetazolamide//SNOMEDCT_US	00420//Acetazolamide//PSY	C28809//Acetazolamide//NCI	MTHU000958//Acetazolamide//USPMG	NOCODE//Developmental arithmetic disorder//MTH	2840-2359//acetazolamide//CSP	4121//salicylic acid topical 20% topical liquid//MMSL	41316//acetazolamide//MEDCIN	0000000604//acetazolamide//CHV	002286//RUTIN 50 mg ORAL TABLET//NDDF	S01EC01//acetazolamide//ATC	N0000146250//ACETAZOLAMIDE//NDFRT	4017898//ACETAZOLAMIDE//VANDF	d00161//acetaZOLAMIDE//MMSL	814//albuterol with CFC 90 mcg/inh inhalation aerosol//MMSL
sulthiame 50-200 mg daily may reduce the attack rate	
this medication is generally well tolerated	
surgical intervention is required to correct pyloric atresia	
many children need medical treatment for gastroesophageal reflux disease	
primary layers may include any the following:	
ordinary band-aids®	
non-stick products (e	
, telfa® or n-terface®)	
, mepitel® or mepilex®)	
other nutritional deficiencies must also be addressed:	
calcium and vitamin d supplementation for osteopenia and osteoporosis	
selenium and carnitine replacement to help prevent dilated cardiomyopathy	
zinc replacement to enhance wound healing	
occupational therapy may be helpful in preventing progressive hand contractures	
psychosocial support including social services and psychological counseling is essential	
ordinaryband-aids®	
the most common secondary complication is infection	
both antibiotics and antiseptics need to be employed	
dressings usually involve three layers:	
some individuals with ebs can use ordinary bandages	
foam dressings and/or rolls of gauze (e	
, one-layer) dressing	
dystrophic nails	0000021365//nail dystrophy//CHV	MTHU036408//Dystrophic nails//OMIM	HP:0008404//Nail dystrophy//HPO
in many cases, wigs are helpful	
palmoplantar hyperkeratosis	MTHU013230//Palmoplantar hyperkeratosis//OMIM	HP:0000972//Palmoplantar hyperkeratosis//HPO
skin emollients may help relieve palmoplantar hyperkeratosis	
however, pain can be difficult to control	
career counseling is recommended	
deep stitches should be applied generously	
anti-inflammatory drugs may help with joint pain	
cardiovascular problems should be treated in a standard manner	
modalities must be tailored to the individual	
assistive devices	24-504//Assistive Devices//UMD	3136//Assistive Devices//MEDLINEPLUS	D012656//Self-Help Devices//MSH	0000011179//self-help devices//CHV
braces are useful to improve joint stability	
pain medication	40164//analgesics//MEDCIN
adjustments may be necessary for other populations	
nsaids (nonsteroidal anti-inflammatory drugs) (e	
cox-2 inhibitors (e	
they are also sometimes helpful in treating neuropathic pain	
all require gradual titration before reaching therapeutic levels	
topiramate and lamotrigine have also been used successfully	
nausea is the most common side effect	
routine use of benzodiazepines is not recommended	
medication precautions	
abrupt cessation of anti-seizure medications can precipitate a seizure	
when discontinuing, they should be tapered gradually	
severity can range from mild to life threatening	
surgery and other procedures	
anesthetic nerve blocks can provide temporary relief of neuropathic pain	
bone density	D015519//Bone Density//MSH	5935//Bone Density//MEDLINEPLUS	NOCODE//Developmental arithmetic disorder//MTH	2715-3972//bone density//CSP	0000002064//bone density//CHV	011302//Bone density//NOC	021102//Bone density//NOC	LP34385-2//Bone density//LNC	MTHU011986//Bone density//LNC	CDR0000407755//bone density//NCI_NCI-GLOSS
for severe bleeding (e	
other treatable causes, such as h	
pylori infection, should be investigated	
rarely, severe enlargement (>4	
5-5	
0 cm) requires surgical evaluation	
periodontal disease should be identified and treated	
temporomandibular joint laxity and dysfunction are difficult to treat	
there are no specific interventions of proven benefit	
intra-oral devices are sometimes helpful	
psychiatric	PSY//Psychiatric//HL7V2.5	C17026//Psychiatry//NCI	G-B112//Psychiatric//SNMI	LP7508-7//Psychiatric//LNC	MTHU002618//Psychiatric//LNC	27296002//Psychiatric//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000020622//psychiatric//CHV	0043166//PSYCHIATRIC//CCPSS	Psy//Psychiatric//HL7V2.5	PSYCH//Psychiatric//HL7V3.0
antidepressants are also of great benefit	
consumer support groups are available and can be very beneficial	
, the uterus in pregnancy)	
bracing may be required to support unstable joints	
swimming is recommended	
vascular surgery is fraught with danger	
antispastic medications	
muscle relaxants	LP31447-3//Muscle relaxants//LNC	sh85088683//Muscle relaxants//LCH_NW	NOCODE//Developmental arithmetic disorder//MTH	M03//MUSCLE RELAXANTS//ATC	0000031374//muscle relaxant//CHV	41041//muscle relaxants//MEDCIN	C05AE//Muscle relaxants FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE//ATC
contractures	D003286//Contracture//MSH	MTHU002170//Contractures//OMIM	02086//Contractures//NANDA-I	HP:0001371//Flexion contracture//HPO	0000003326//contracture//CHV
severe diarrhea	MTHU026059//Severe diarrhea//OMIM	409587002//Severe diarrhea//SNOMEDCT_US
maintain hydration & caloric intake	
tube feeding often necessary	
poor energy metabolism & oxidative stress	
, contractures)	
, feeding, grooming, dressing, writing)	
routine repair is appropriate	
pulmonary emphysema is treated symptomatically	
no definitive treatment is available	
based on experience in other related disorders (e	
aortic aneurysm replacement has been performed successfully	
joint hypermobility can be supported by muscle reinforcing physical therapy	
standard management of gastroesophageal reflux	
standard interventions for:	
cardiac defects	MTHU015745//Cardiac defects//OMIM	0000047328//cardiac defects//CHV
hip dysplasia and other skeletal complications	
cryptorchidism and/or micropenis	
refractive errors, strabismus, or other ophthalmologic issues	
seizures, if present	
then 1 mg 1x daily thereafter)	
prevnar-13® and h	
the incidence of post-splenectomy sepsis varies among studies	
cholecystectomy	47600//Cholecystectomy//CPT	965//Cholecystectomy//ICD10AM	30443-00//Cholecystectomy//ICD10AM	D52005//cholecystectomy//ICPC2P	U000984//Cholecystectomy//LCH	10008611//Cholecystectomy//MDR	7810.//Cholecystectomy//RCD	P-1100//Excision, NOS (-ectomy)//SNM	P1-5C330//Cholecystectomy//SNMI	C51676//Cholecystectomy//NCI	259//Gallbladder Diseases//MEDLINEPLUS	1014153//Cholecystectomy//CPT	sh85024639//Cholecystectomy//LCH_NW	LA14290-3//Cholecystectomy//LNC	38102005//Cholecystectomy//SNOMEDCT_US	51.2//Cholecystectomy//ICD9CM	51.22//Cholecystectomy//ICD9CM	D002763//Cholecystectomy//MSH	0060034//CHOLECYSTECTOMY//CCPSS	175//CHOLECYSTECTOMY//COSTAR	0000008311//cholecystectomy//AOD	BI00756//cholecystectomy//BI	0413-8805//cholecystectomy//CSP	0000002863//surgical removal of the gallbladder//CHV	41673//cholecystectomy//MEDCIN
valproic acid is the first drug of choice	
it diminishes myoclonus and the frequency of generalized seizures	
the phototoxic pain is not responsive to narcotic analgesics	
tanning products	
β-carotene	
hepatic complications may be accompanied by motor neuropathy	
the pain is not responsive to narcotic analgesics	
sun creams containing a physical reflecting agent (e	
reports on treatments in a series involve heterogeneous populations	
cooling the extremities reduces pain in a symptomatic person	
01) [mork et al 2004]	
experts have reported typically mild to moderate pain relief	
remissions (i	
carbamazepine	U000779//Carbamazepine//LCH	D002220//Carbamazepine//MSH	U000138//Toxic erythema//MTH	X7957//Carbamazepine - chemical//RCD	dn3..//Carbamazepine product//RCD	E-7761//Carbamazepine//SNM	C-61110//Carbamazepine//SNMI	2002//Carbamazepine//RXNORM	33CM23913M//Carbamazepine//MTHSPL	N0000007470//Carbamazepine [Chemical/Ingredient]//NDFRT	LP16061-1//Carbamazepine//LNC	MTHU003352//Carbamazepine//LNC	sh85020070//Carbamazepine//LCH_NW	DB00564//Carbamazepine//DRUGBANK	30461//Carbamazepine//CPM	387222003//Carbamazepine//SNOMEDCT_US	40820003//Carbamazepine//SNOMEDCT_US	07483//Carbamazepine//PSY	C341//Carbamazepine//NCI	MTHU000272//Carbamazepine//USPMG	U001779//Carbamazepine//MTH	0000020942//carbamazepine//AOD	0314-6873//carbamazepine//CSP	4350//hydrogen peroxide topical 3% topical solution//MMSL	41094//carbamazepine//MEDCIN	0000002381//carbamazepine//CHV	001634//carbamazepine//NDDF	N03AF01//carbamazepine//ATC	CDR0000042418//carbamazepine//PDQ	N0000146226//CARBAMAZEPINE//NDFRT	4017873//CARBAMAZEPINE//VANDF	d00058//carBAMazepine//MMSL	513//aminophylline 100 mg oral tablet//MMSL	1011157//Carbamazepine//CPT
oxcarbazepine use in treating em has not been reported	
topical application of 1	
0% amitriptyline hydrochloride and 0	
calcium antagonists	
magnesium	D008274//hořčík//MSHCZE	U002778//Magnesium//LCH	5535//acetaminophen 650 mg/25 mL oral liquid//MMSL	X80D2//Magnesium//RCD	F-10400//Magnesium//SNM	6574//Magnesium//RXNORM	N0000006335//Magnesium [Chemical/Ingredient]//NDFRT	LP14343-5//Magnesium//LNC	I38ZP9992A//Magnesium//MTHSPL	4298//Minerals//MEDLINEPLUS	MTHU002163//Magnesium//LNC	sh85079651//Magnesium//LCH_NW	03072//Magnesium//NCI_DCP	32031//Magnesium//CPM	DB01378//Magnesium//DRUGBANK	72717003//Magnesium//SNOMEDCT_US	29110//Magnesium//PSY	C29239//Magnesium//NCI	MTHU001746//Magnesium//USPMG	U002057//Magnesium//MTH	0000005765//magnesium//AOD	1852-6512//magnesium//CSP	5005//chlorhexidine topical 4% topical soap//MMSL	199598//magnesium//MEDCIN	0000007660//magnesium//CHV	004557//CARBAMAZEPINE 100 mg/5 mL ORAL SUSPENSION, ORAL (FINAL DOSE FORM)//NDDF	000784//POTASSIUM GUAIACOLSULFONATE/D-METHORPHAN/PROMETH/SOD CITRAT ORAL EXPECTORANT//NDDF	CDR0000373087//magnesium//NCI_NCI-GLOSS	004558//CARBAMAZEPINE 200 mg ORAL TABLET//NDDF	004560//CLONAZEPAM 0.5 mg ORAL TABLET//NDDF	004559//CARBAMAZEPINE 100 mg ORAL TABLET, CHEWABLE//NDDF	0046813//MAGNESIUM//CCPSS	N0000146038//MAGNESIUM//NDFRT	4017660//MAGNESIUM//VANDF	10025430//magnesium//MDRDUT	83735//Magnesium//CPT	U000302//White color//MTH	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC	C64840//Magnesium//NCI_CDISC	C68264//Dietary Magnesium//NCI_CRCH	A12CC//Magnesium supplements//ATC	N0000029441//[TN460] MAGNESIUM//NDFRT	4021888//MAGNESIUM//VANDF
cyclosporine was successful in one person with erythromelalgia	
sympathetic block, surgical sympathectomy, and epidural infusion	
the main problems to manage are:	
adaptation of education to the level of cognitive handicap	
epilepsy, which is amendable to standard treatments	
osteochondromas require no therapy in the absence of clinical problems	
leg-length inequalities greater than 2	
surgical resection is the treatment for sarcomatous degeneration	
3% (±5	
9%) [mehta et al 2017]	
mds/aml treatment remains challenging	
solid tumors	0000027308//solid tumor//CHV
acroparesthesia	X205S//Acroparesthesia//RCDAE	F-82580//Acroparesthesia//SNM	F-A2580//Acroparesthesia//SNMI	10062860//Acroparesthesia//MDR	HP:0031006//Acroparesthesia//HPO	79256006//Acroparesthesia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000023280//acroparesthesia//CHV	MTHU003020//acroparesthesia//ICPC2ICD10ENG	275694//acroparesthesia//MEDCIN
diphenylhydantoin	E-7812//Diphenylhydantoin//SNM	C-61640//Phenytoin//SNMI	C741//Phenytoin//NCI	N0000006023//Phenytoin [Chemical/Ingredient]//NDFRT	DB00252//Phenytoin//DRUGBANK	387220006//Phenytoin//SNOMEDCT_US	14320//Diphenylhydantoin//PSY	D010672//Phenytoin//MSH	0000009622//phenytoin//CHV	1548-7299//phenytoin//CSP
a potential side effect of diphenylhydantoin is gingival hypertrophy	
carbamazepine has similar effects	
chronic hemodialysis and/or renal transplantation have become lifesaving procedures	
therefore, successful renal transplantation corrects renal function	
thrombosis	U004672//Thrombosis//LCH	10043607//Thrombosis//MDR	D013927//Thrombosis//MSH	XC0fW//Thrombosis//RCD	M-35100//Thrombus//SNM	MTHU005312//Thrombosis//OMIM	439127006//Thrombosis//SNOMEDCT_US	N0000002936//Thrombosis [Disease/Finding]//NDFRT	LP31622-1//Thrombosis//LNC	sh85135077//Thrombosis//LCH_NW	C26891//Thrombosis//NCI_NICHD	2100//Thrombosis//NCI_FDA	264579008//Thrombosis//SNOMEDCT_US	453.9//Thrombosis//MTHICD9	NOCODE//Developmental arithmetic disorder//MTH	0019080//THROMBOSIS//CCPSS	THROM//THROMBOSIS//CST	U004006//THROMBOSIS//DXP	0481//THROMBOSIS//WHO	0000005938//thrombosis//AOD	0571-8378//thrombosis//CSP	0000058002//thrombosis//CHV	MTHU075597//thrombosis//ICPC2ICD10ENG	0000012227//thrombosis//CHV	C27083//THROMBUS//NCI_CDISC	CDR0000044231//thrombosis//NCI_NCI-GLOSS
5 (therapeutic range 2	
colonic polyps	D003111//Colonic Polyps//MSH	N0000000814//Colonic Polyps [Disease/Finding]//NDFRT	3134//Colonic Polyps//MEDLINEPLUS	NOCODE//Developmental arithmetic disorder//MTH	BI00227//colonic polyps//BI	0000003174//colon polyp//CHV	MTHU036752//Colonic polyps//OMIM	V18.51//Colonic polyps//MTHICD9
types of colectomy include the following:	
total colectomy with ileorectal anastomosis (ira)	
this is a single-stage procedure	
total proctocolectomy with permanent ileostomy	
the choice of procedure depends on the clinical circumstances	
small-bowel polyps	
osteomas may be removed for cosmetic reasons	
desmoid tumors	0000015129//desmoid//CHV	HP:0100245//Desmoid tumors//HPO
adrenal tumors	0000000767//adrenal tumor//CHV
chemoprevention	C15604//Chemoprevention//NCI	CDR0000045487//chemoprevention//NCI_NCI-GLOSS	D018890//Chemoprevention//MSH	sh92002504//Chemoprevention//LCH_NW	NOCODE//Developmental arithmetic disorder//MTH	0000027626//chemoprophylaxis//CHV	4001-0027//chemoprevention//CSP
nsaids	40457//nonsteroidal anti-inflammatory drugs//MEDCIN	CDR0000045807//NSAIDs//NCI_NCI-GLOSS	D000894//Anti-Inflammatory Agents, Non-Steroidal//MSH	0000001258//nonsteroidal anti-inflammatory drugs (NSAIDs)//CHV	4007-0090//nonsteroidal antiinflammatory agent//CSP
appropriate treatment for:	
inguinal hernias	D006552//Hernia, Inguinal//MSH	0000006085//inguinal hernia//CHV	MTHU036928//Inguinal hernias//OMIM	10022017//Inguinal hernias//MDR
routine repair	
cutis laxa	D003483//cutis laxa//MSHCZE	10011692//cutis laxa//MDRDUT	C84663//Cutis Laxa//NCI	N0000000884//Cutis Laxa [Disease/Finding]//NDFRT	NOCODE//Developmental arithmetic disorder//MTH	X50CO//Cutis laxa//RCD	M-56810//Cutis laxa//SNM	MTHU006920//Cutis laxa//OMIM	HP:0000973//Cutis laxa//HPO	58588007//Cutis laxa//SNOMEDCT_US	2716-6258//cutis laxa//CSP	0000003512//loose skin//CHV	31802//cutis laxa//MEDCIN
pulmonary emphysema	D011656//Pulmonary Emphysema//MSH	NOCODE//Developmental arithmetic disorder//MTH	C3348//Pulmonary Emphysema//NCI	N0000002542//Pulmonary Emphysema [Disease/Finding]//NDFRT	3623//Emphysema//MEDLINEPLUS	1832//Emphysema, Pulmonary//NCI_FDA	42290//Pulmonary Emphysema//PSY	U002201//Pulmonary Emphysema//MTH	X101n//Pulmonary emphysema//RCD	M-32800//Emphysema//SNM	HP:0002097//Emphysema//HPO	87433001//Pulmonary emphysema//SNOMEDCT_US	R0121746//PULMONARY EMPHYSEMA//QMR	0000010388//lung emphysema//CHV
no treatment available	
no definite treatment is available to date	
inadequate nutrition	01226//Inadequate nutrition//NANDA-I
standard treatment w/antiepileptic drugs	
immobility/wheelchair dependence	
, wheelchair	
cardiomyopathy and arrhythmia	
standard treatment per cardiology recommendations	
consider granulocyte colony stimulating factor 2	
significant acidosis	
consider bicarbonate therapy	
cataract and/or strabismus	
surgical treatment if indicated	
hearing aids	11-967//Hearing Aids//UMD	5216//Hearing Aids//MEDLINEPLUS	22430//Hearing Aids//PSY	D006310//Hearing Aids//MSH	U002102//Hearing aids//LCH	sh85059616//Hearing aids//LCH_NW	0000005855//hearing aids//CHV
there is no definite treatment for fcmd	
monitoring for orthopedic complications such as foot deformity and scoliosis	
prompt treatment of acute respiratory tract infections	
antiepileptic drugs (aeds) when indicated	
surgical treatment for gastroesophageal reflux when indicated	
gastrostomy when indicated to assure adequate caloric intake	
routine therapy of cardiomyopathy	
feeding problems	0000022945//feeding problems//CHV	1850//Feeding Problems//NCI_FDA	MTHU002106//Feeding problems//OMIM	HP:0011968//Feeding difficulties//HPO	0000044561//feeding problems//CHV
maintain adequate nutrition and avoid aspiration	
gastroesophageal reflux	N0000001319//Gastroesophageal Reflux [Disease/Finding]//NDFRT	512//GERD//MEDLINEPLUS	D005764//Gastroesophageal Reflux//MSH	GI DIS//GASTROINTESTINAL DISORDER//CST	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	1149//GASTROESOPHAGEAL REFLUX//WHO	109350//GASTROESOPHAGEAL REFLUX//OMIM	F-52440//Gastroesophageal reflux//SNMI	530.81//Gastroesophageal reflux//MTHICD9	MTHU002522//Gastroesophageal reflux//OMIM	BI00251//gastroesophageal reflux//BI	0000005382//gastroesophageal reflux disease (GERD)//CHV	C113396//Gastroesophageal Reflux//NCI_NICHD	U001928//Gastroesophageal reflux//LCH	sh85053480//Gastroesophageal reflux//LCH_NW	10017924//Gastroesophageal reflux//MDR	HP:0002020//Gastroesophageal reflux//HPO	C92560//Gastroesophageal Reflux//NCI	1018151//GASTROESOPHAGEAL REFLUX//CCPSS	1248-5846//reflux esophagitis//CSP	CDR0000257517//gastroesophageal reflux//NCI_NCI-GLOSS
orthostatic hypotension	537//ORTHOSTATIC HYPOTENSION//COSTAR	HYPOTENS POST//POSTURAL HYPOTENSION//CST	U002936//ORTHOSTATIC HYPOTENSION//DXP	I95.1//Orthostatic hypotension//ICD10	10031127//Orthostatic hypotension//MDR	PRB_11000.03//Orthostatic hypotension//PCDS	G870.//Orthostatic hypotension//RCD	D3-04100//Orthostatic hypotension//SNMI	060106//Orthostatic hypotension//NOC	040107//Orthostatic hypotension//NOC	MTHU001817//Orthostatic hypotension//OMIM	HP:0001278//Orthostatic hypotension//HPO	02986//Orthostatic hypotension//NANDA-I	458.0//Orthostatic hypotension//ICD9CM	28651003//Orthostatic hypotension//SNOMEDCT_US	BI00122//orthostatic hypotension//BI	0571-5870//postural hypotension//CSP	38311//orthostatic hypotension//MEDCIN	0000006494//orthostatic hypotension//CHV	K88005//orthostatic hypotension//ICPC2P	6059//orthostatic hypotension//MEDCIN	C84970//Orthostatic Hypotension//NCI	N0000001650//Hypotension, Orthostatic [Disease/Finding]//NDFRT	4242//Autonomic Nervous System Disorders//MEDLINEPLUS	1225//Low Blood Pressure//MEDLINEPLUS	D007024//Hypotension, Orthostatic//MSH
counter-maneuvers (e	
squatting had the greatest effect	
kidney and bladder	
bradyarrhythmia	NOCODE//Sepsis//COSTAR	10049765//Bradyarrhythmia//MDR	353825//Bradyarrhythmia//MEDCIN	421869004//Bradyarrhythmia//SNOMEDCT_US	0000005360//bradyarrhythmia//AOD	MTHU012485//bradyarrhythmia//ICPC2ICD10ENG	1393-3297//bradycardia//CSP	0000015098//bradyarrhythmia//CHV	0027788//BRADYARRHYTHMIA//CCPSS	N0000000600//Bradycardia [Disease/Finding]//NDFRT	D001919//Bradycardia//MSH
soft contact lenses can promote corneal healing	
corneal transplantation has had limited success	
spinal fusion may be necessary	
many adults use walkers or wheelchairs when outside the home	
sialorrhea is a common	
surgical treatment of gastrointestinal atresia when present	
follow up and treatment of possible cardiac and renal anomalies	
treatment for significant hearing loss	
developmental or educational intervention for children with learning difficulties	
retinal avascularity per se often requires no treatment	
individualized management of behavior problems	
neurologic management of seizures	
standard management of chronic constipation for individuals with fgs1	
communication rehabilitation with sign languages or alternative means of communication	
standard treatment for any of the following if identified:	
refractive errors and strabismus	
orthopedic complications	
investigation for celiac disease if indicated by clinical features	
cervical spine instability	N1489//Cervical spine instability//RCD	HP:0010646//Cervical spine instability//HPO	202821008//Cervical spine instability//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000032832//cervical spine instability//CHV	155013//cervical spine instability//MEDCIN
large joint dislocations	HP:0005008//Large joint dislocations//HPO
scoliosis is treated medically	
no effective surgical intervention has been described	
club feet are managed in a routine manner	
febrile and inflammatory episodes are usually treated with nsaids	
papillomatosis	10051278//papillomatosis//MDRDUT	Xa98C//Papillomatosis//RCD	M-8060/0//Papillomatosis//SNM	MTHU003001//Papillomatosis//OMIM	82049002//Squamous papillomatosis//SNOMEDCT_US	C3713//Papillomatosis//NCI	D010212//Papilloma//MSH	0000020739//papillomatosis//CHV
camptodactyly often improves with physical and occupational therapy	
consultation with:	
folate formulations	
leucovorin is available in oral and parenteral formulations	
neither drug is available for parenteral administration	
deplin® is available as a 15-mg tablet	
folate dosing	
with intramuscular injections of approximately 1	
speech and language deficits	
no single recommended treatment exists	
dysarthria [pennington et al 2009]	
language deficits [law et al 2003]	
literacy impairments [snowling & hulme 2012]	
cognitive deficits	0000043077//cognitive deficits//CHV	10075//Cognitive Deficits//PSY	MTHU004914//Cognitive deficits//OMIM	HP:0100543//Cognitive impairment//HPO
fine and gross motor deficits	
fragile x syndrome	D005600//Fragile X Syndrome//MSH	C84717//Fragile X Syndrome//NCI	N0000001290//Fragile X Syndrome [Disease/Finding]//NDFRT	3690//Fragile X Syndrome//MEDLINEPLUS	20295//Fragile X Syndrome//PSY	NOCODE//Developmental arithmetic disorder//MTH	U001873//Fragile X syndrome//LCH	10017324//Fragile X syndrome//MDR	X78FB//Fragile X syndrome//RCD	D4-00504//Fragile X syndrome//SNMI	Q99.2//Fragile X chromosome//ICD10CM	sh85051162//Fragile X syndrome//LCH_NW	759.83//Fragile X syndrome//ICD9CM	613003//Fragile X syndrome//SNOMEDCT_US	1254-8431//fragile X syndrome//CSP	38282//fragile X syndrome//MEDCIN	0000005246//fragile x syndrome//CHV	309550//FMR1 GENE//OMIM	300624//FRAGILE X SYNDROME//OMIM
therapy must be individualized and closely monitored	
fxtas	C564105//Fragile X Tremor Ataxia Syndrome//MSH	C126566//Fragile X Tremor/Ataxia Syndrome//NCI	300623//FRAGILE X TREMOR/ATAXIA SYNDROME//OMIM
poi	X90eP//Poi//RCD	262059009//Poi//SNOMEDCT_US	0000038635//personal orientation inventory (POI)//CHV	0000024359//POI//AOD
there is little objective evidence regarding management of frda	
speech therapy to maximize communication skills	
treatment of sleep apnea by continuous positive airway pressure	
measures include the following:	
in fryns syndrome, additional anomalies may dictate further consultations	
see also congenital diaphragmatic hernia overview	
physical therapy and rehabilitation	
consultation with a physical therapist is indicated	
exercise in fshd	
ophthalmologic disease	
orthopedic intervention	
there is no consensus treatment guideline for ftd3	
individuals with seizures are treated with antiepileptic drugs	
nutritional intervention (e	
wheelchairs can be useful for some individuals	
5x109/l can vary greatly among patients	
fevers and infections require prompt treatment with antibiotics	
treatment of arterial calcification	
bisphosphonate therapy	723950005//Bisphosphonate therapy//SNOMEDCT_US
026, log-rank test)	
the dose of pamidronate has varied from 0	
cardiovascular treatment	
anti-hypertensive therapy	
017-0	
068 μg/kg/min [ciana et al 1997]	
prevention of coronary thrombosis	
treatment of hearing loss	
generalized epimerase deficiency galactosemia	
, some fruits and vegetables, organ meats)	
, hepatic cirrhosis or mature cataracts)	
peripheral epimerase deficiency galactosemia	
intermediate epimerase deficiency galactosemia	
however, insufficient data exist to make firm recommendations	
appropriate ophthalmologic treatment (e	
individuals with gata1-related cytopenia are treated supportively	
transfusion of blood products for severe anemia and bleeding	
analgesics for bone pain	
, improved joint range of motion)	
supplemental treatment	
care is best provided by a physician (e	
clobazam (0	
topiramate [coppola et al 2002]	
ethosuximide	4199//charcoal-simethicone 250 mg-80 mg oral tablet//MMSL	D005013//Ethosuximide//MSH	dn5..//Ethosuximide//RCD	E-7813//Ethosuximide//SNM	C-61B10//Ethosuximide//SNMI	4135//Ethosuximide//RXNORM	C47523//Ethosuximide//NCI	5SEH9X1D1D//Ethosuximide//MTHSPL	N0000006713//Ethosuximide [Chemical/Ingredient]//NDFRT	LP16137-9//Ethosuximide//LNC	MTHU004937//Ethosuximide//LNC	DB00593//Ethosuximide//DRUGBANK	30592//Ethosuximide//CPM	387244008//Ethosuximide//SNOMEDCT_US	44790008//Ethosuximide//SNOMEDCT_US	MTHU000253//Ethosuximide//USPMG	U001910//Ethosuximide//MTH	2521-1649//pyrrolidinedione//CSP	4701//lactase 3000 units oral tablet//MMSL	41096//ethosuximide//MEDCIN	0000004709//ethosuximide//CHV	001631//FERROUS SULFATE 190 mg ORAL CAPSULE//NDDF	N03AD01//ethosuximide//ATC	d00227//ethosuximide//MMSL	N0000146944//ETHOSUXIMIDE//NDFRT	4018631//ETHOSUXIMIDE//VANDF	80168//Ethosuximide//CPT
can be effective for absence seizures	
levetiracetam (20-80 mg/kg/day)	
potassium bromide	34299//potassium bromide//RXNORM	005010//DEXTROAMPHETAMINE SULFATE 15 mg ORAL TABLET//NDDF	C039004//potassium bromide//MSH	E-7863//Sodium bromide//SNM	C-64015//Potassium bromide//SNMI	421196003//Potassium bromide//SNOMEDCT_US	35903003//Potassium bromide//SNOMEDCT_US	C76725//Potassium Bromide//NCI	NOCODE//administration devices//MMSL	OSD78555ZM//Potassium Bromide//MTHSPL
phenobarbital	2390//metOLazone 10 mg oral tablet//MMSL	D010634//Phenobarbital//MSH	dn7..//Phenobarbitone product//RCD	E-7886//Phenobarbital//SNM	C-61320//Phenobarbital//SNMI	8134//Phenobarbital//RXNORM	N0000005893//Phenobarbital [Chemical/Ingredient]//NDFRT	YQE403BP4D//Phenobarbital//MTHSPL	LP14729-5//Phenobarbital//LNC	MTHU003431//Phenobarbital//LNC	00018//Phenobarbital//NCI_DCP	MTHU002230//Phenobarbital//USPMG	DB01174//Phenobarbital//DRUGBANK	30763//Phenobarbital//CPM	373505007//Phenobarbital//SNOMEDCT_US	51073002//Phenobarbital//SNOMEDCT_US	38160//Phenobarbital//PSY	C739//Phenobarbital//NCI	U002158//Phenobarbital//MTH	0000020819//phenobarbital//AOD	2517-5803//phenobarbital//CSP	5272//hyoscyamine 0.125 mg/5 mL oral liquid//MMSL	41155//phenobarbital//MEDCIN	0000009598//phenobarbital//CHV	001406//MAGNESIUM OXIDE 250 mg ORAL TABLET//NDDF	CDR0000045470//phenobarbital//NCI_NCI-GLOSS	CDR0000042405//phenobarbital//PDQ	N03AA02//phenobarbital//ATC	1003639//PHENOBARBITAL//CCPSS	N0000145810//PHENOBARBITAL//NDFRT	4017422//PHENOBARBITAL//VANDF	d00340//PHENobarbital//MMSL	C75368//Phenobarbital//NCI_CDISC	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC	80184//Phenobarbital//CPT
sleep deprivation and illness can exacerbate scn1a-related seizures	
routine seizure and personal safety counseling is indicated	
seizures are not always responsive to conventional aeds	
ethosuximide and high-dose piracetam for myoclonic seizures	
placement of an indwelling venous access device	
creating a portable microenvironment	
having a written emergency department protocol	
establishing emergency routines for the family	
creating personal time to decrease parent stress	
finding respite care	
contacting an internet support group	
joint manifestations: regular physiotherapy to prevent joint limitation	
heart: valve replacement	
tracheal stenosis: tracheostomy when severe	
surgical treatment	0000024442//surgical treatment//AOD	0000038661//surgery//CHV
pcg is almost always managed surgically	
beta-blockers (e	
, timolol), parasympathomimetics (e	
, pilocarpine), sympathomimetics (e	
treatment of refractive errors	
affected individuals develop a mild compensated metabolic acidosis when ketotic	
phenobarbital and valproic acid can inhibit glut1 transport	
valproic acid may partially inhibit beta-oxidation of fatty acids	
these agents also can cause kidney stones	
response has been modest at best	
gm1 gangliosidosis	X40V7//GM1 gangliosidosis//RCD	E75.19//Other gangliosidosis//ICD10CM	315536//GM1 gangliosidosis//MEDCIN	238025006//GM1 gangliosidosis//SNOMEDCT_US	0000015452//gangliosidosis gm1//CHV	C84739//GM1 Gangliosidosis//NCI	N0000003432//Gangliosidosis, GM1 [Disease/Finding]//NDFRT	D016537//Gangliosidosis, GM1//MSH
maintenance of adequate hydration and adequate calories for growth	
aggressive seizure control	
medical management of cardiac involvement	
mps ivb	253010//MUCOPOLYSACCHARIDOSIS, TYPE IVB//OMIM	D009085//Mucopolysaccharidosis IV//MSH
the general concepts of care include the following	
sex assignment	
all individuals should receive a sex of rearing	
surgical intervention should focus on functionality	
removal of müllerian remnants may be considered	
management of gonads	
hormone therapy	C15445//Endocrine Therapy//NCI	23255//Hormone Therapy//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000008012//hormone therapy//AOD	1025-8739//hormone therapy//CSP	0000027219//hormone therapy//CHV	CDR0000045110//hormone therapy//NCI_NCI-GLOSS	CDR0000038712//hormone therapy//PDQ	5A87.//Hormone therapy//RCD	sh85061979//Hormone therapy//LCH_NW	10065646//Hormone therapy//MDR	169413002//Hormone therapy//SNOMEDCT_US
if an individual is given a male sex assignment:	
5 standard deviations below the mean for age)	
testosterone therapy is typically required to initiate and sustain puberty	
if an individual is given a female sex assignment:	
estrogen therapy is used to initiate breast development and puberty	
psychosocial aspects of care	
” [lee et al 2006]	
later, educational and behavioral therapy are often warranted	
oral-motor therapy to alleviate chewing and swallowing problems	
routine protocols to alleviate sleep apnea	
tympanostomy tube placement for recurrent ear infections	
surgical removal of ingrown toenails to prevent infection	
walkers or other assistive walking devices	
intravenous fluids to prevent dehydration in individuals with recurrent vomiting	
surgical bone lengthening may be an option for some	
adaptive aids for people with short stature are appropriate	
speech/language deficits	
metabolic specialist familiar with the multisystem nature of gsdi	
medical nutrition therapy goals	
maintain	C53297//Maintenance//NCI	8060//Maintain//MMSL
normal glucose levels and prevent hypoglycemia:	
frequent daytime feedings	
note: recommendations for uncooked cornstarch dosing are: 1	
provide	0000031415//provide//CHV	x00A9//Provide//RCD	C80514//Provide//NCI
optimal nutrition for growth and development:	
, protein low in fat)	
treatment of other manifestations	
sodium levels should also be monitored	
kidney transplantation can be performed for esrd	
liver transplantation can be considered when other interventions have failed	
g-csf should be administered subcutaneously starting at 1	
0 μg/kg given daily or every other day	
0 x 109/l is reached	
arteriopathy	XaBYF//Generalised atherosclerosis//RCD	D-7303//Arterial vascular disease//SNM	10003209//Arteriopathy//MDR	C35317//Arterial Disorder//NCI	39823006//Generalized atherosclerosis//SNOMEDCT_US	MTHU008057//arteriopathy//ICPC2ICD10ENG	0000005418//arteriopathy//CHV
conduction disturbances	
muscle weakness	0000009312//muscle weakness//CHV	02933//Muscle weakness//NANDA-I	D018908//Muscle Weakness//MSH	C50658//Muscle Weakness//NCI	N0000003878//Muscle Weakness [Disease/Finding]//NDFRT	1967//Muscle Weakness//NCI_FDA	NOCODE//Developmental arithmetic disorder//MTH	XM03n//Muscle weakness//RCD	F-80850//Paresis//SNM	F-A0850//Paresis, NOS//SNMI	MTHU004882//Muscle weakness//OMIM	HP:0001324//Muscle weakness//HPO	10028350//Muscle weakness//MDR	728.87//Muscle weakness//MTHICD9	26544005//Muscle weakness//SNOMEDCT_US	1016472//MUSCLE WEAKNESS//CCPSS	U000452//MUSCLE WEAKNESS//COSTAR	MYASTHENIA//MYASTHENIA//CST	1128//MUSCLE WEAKNESS//WHO	BI00549//muscle weakness//BI	0000017070//muscle weakness//CHV	L19012//muscle weakness//ICPC2P	281082//muscle weakness//MEDCIN
nutrition/feeding	
respiratory insufficiency	C51447//Pulmonary Insufficiency//NCI	D012131//Respiratory Insufficiency//MSH	N0000002599//Respiratory Insufficiency [Disease/Finding]//NDFRT	NOCODE//Developmental arithmetic disorder//MTH	RESPIRAT DIS//RESPIRATORY DISORDER//CST	0537//RESPIRATORY INSUFFICIENCY//WHO	U004096//Respiratory insufficiency//LCH	XM09V//Respiratory failure//RCD	MTHU000730//Respiratory insufficiency//OMIM	sh85113193//Respiratory insufficiency//LCH_NW	HP:0002093//Respiratory insufficiency//HPO	10038701//Respiratory insufficiency//MDR	MTHU054873//Respiratory insufficiency//LNC	LP230020-2//Respiratory insufficiency//LNC	786.09//Respiratory distress//MTHICD9	409623005//Respiratory insufficiency//SNOMEDCT_US	0000005457//respiratory insufficiency//AOD	2596-8662//respiratory insufficiency/failure//CSP	0000010761//respiratory insufficiency//CHV	0000055221//respiratory failure//CHV
respiratory support including cpap and bipap may be required	
special formulas are not required	
3 mmol/l)	
emergency protocol	
5 normal saline administered at 1	
hepatic manifestations	
selecting appropriate candidates for liver transplantation can be complex	
aerobic training (on a regular diet)	
95% confidence intervals 20	
3 to 2496	
7) after controlling for age	
7 metabolic equivalents (mets, with 1met equaling 3	
5 ml o2/kg/min) necessary for independent living	
5mets higher than in those who were not active	
avoid a totally sedentary life, which induces deconditioning	
pharmacologic and nutritional treatments	
the authors' conclusions:	
this treatment does not influence sustained or unexpected exercise	
a carbohydrate-rich diet was of benefit	
pharmacologic treatments	
nutritional treatments	
liver phk deficiency	
hypoglycemia	T87//Hypoglycemia//ICPC	U002328//Hypoglycemia//LCH	D007003//Hypoglycemia//MSH	U000269//Hypoglycemia//MTH	Xa9Ao//Hypoglycemia//RCDAE	F-11824//Glucose, decreased level//SNM	MTHU000371//Hypoglycemia//OMIM	N0000001635//Hypoglycemia [Disease/Finding]//NDFRT	10027566//Hypoglycaemia//ICNP	1264//Hypoglycemia//MEDLINEPLUS	44621000009101//Blood glucose level below normal//SNOMEDCT_VET	sh85063783//Hypoglycemia//LCH_NW	E12322//Hypoglycemia//NCI_CTCAE	LA16993-0//Hypoglycemia//LNC	C3126//Hypoglycemia//NCI_NICHD	1912//Hypoglycemia//NCI_FDA	HP:0001943//Hypoglycemia//HPO	10021005//Hypoglycemia//MDR	00908//Hypoglycemia//NANDA-I	10020993//Hypoglycaemia//MDR	302866003//Hypoglycemia//SNOMEDCT_US	23980//Hypoglycemia//PSY	NOCODE//Developmental arithmetic disorder//MTH	1003516//HYPOGLYCEMIA//CCPSS	401//HYPOGLYCEMIA//COSTAR	HYPOGLYCEM//HYPOGLYCEMIA//CST	U002048//HYPOGLYCEMIA//DXP	0000005725//hypoglycemia//AOD	BI00351//hypoglycemia//BI	0551-5561//hypoglycemia//CSP	35.09//hypoglycemia//OMS	0000006474//low blood sugar level//CHV	CDR0000044114//hypoglycemia//NCI_NCI-GLOSS	CDR0000041392//hypoglycemia//PDQ	MTHU036930//hypoglycemia//ICPC2ICD10ENG	T87005//hypoglycaemia//ICPC2P	30449//hypoglycemia//MEDCIN
the dose of cornstarch can range from 0	
6 to 2	
5 g/kg every six hours based on clinical symptoms	
for signs of	
muscle phk deficiency	
surgery may be required	
hypothalamic involvement	
central diabetes insipidus may require treatment with desmopressin	
temperature dysregulation can be managed by modifying the environment	
surgery of hand and foot defects can improve dexterity	
tethered cord may require surgical intervention	
some children may require a gastrostomy and/or tracheostomy	
acute attacks	
in an individual presenting with acute abdominal symptoms:	
discontinue all nonessential medications	
provide glucose-containing iv solution to reverse the fasting state	
treat seizures with a short-acting benzodiazepine (e	
not yet approved in the us)	
some individuals recover with a glucose infusion only	
200 mg once daily is appropriate for most individuals	
the following responses to hematin infusion can be expected:	
chronic (cutaneous) manifestations	
grey or smoke colored filters provide only partial protection	
pharmacologic agents may suppress abnormal movements	
tremor in one individual was suppressed with clonazepam	
no specific therapy is currently available for alsp	
other:	
treatment should be coordinated through a hemophilia treatment center	
(individuals in the usa see national hemophilia foundation	
immunizations should be administered preferably subcutaneously	
ddavp®	
(desmopressin acetate)	
immune tolerance therapy	
elsewhere worldwide: see world federation of hæmophilia)	
immunizations should be administered subcutaneously	
inhibitors	Q000037//antagonists & inhibitors//MSH
clinical	G-A304//Clinical//SNMI	TCGA//Enterovirus//NCI	58147004//Clinical//SNOMEDCT_US	C25398//Clinical//NCI	NOCODE//Developmental arithmetic disorder//MTH	CDR0000044168//clinical//NCI_NCI-GLOSS	0000020405//clinical//CHV	C96111//Clinical//NCI_FDA
biochemical	G-B017//Biochemical//SNMI	TCGA//Enterovirus//NCI	80534008//Biochemical//SNOMEDCT_US	C25434//Biochemical//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000020612//biochemical//CHV
non-expressing p	
cys282tyr homozygotes	
variceal bleeding	
transjugular intrahepatic portosystemic shunts (tips) are widely available	
hypersplenism	NOCODE//Sepsis//COSTAR	D73.1//Hypersplenism//ICD10	B99004//hypersplenism//ICPC2P	U002316//Hypersplenism//LCH	D414.//Hypersplenism//RCD	N0000001614//Hypersplenism [Disease/Finding]//NDFRT	MTHU037461//Hypersplenism//OMIM	sh85063721//Hypersplenism//LCH_NW	HP:0001971//Hypersplenism//HPO	10020769//Hypersplenism//MDR	58381000//Hypersplenism//SNOMEDCT_US	C34714//Hypersplenism//NCI	289.4//Hypersplenism//ICD9CM	D006971//Hypersplenism//MSH	0015073//HYPERSPLENISM//CCPSS	SPLENOMEGALY//SPLENOMEGALY//CST	U000883//HYPERSPLENISM//DXP	MTHU036476//hypersplenism//ICPC2ICD10ENG	30255//hypersplenism//MEDCIN
hypersplenism usually does not result in clinically significant sequelae	
abnormalities of the biliary tree	
cholangitis is best treated with rapid institution of appropriate antibiotics	
biliary stones	0343//CHOLELITHIASIS//WHO	10004674//Biliary stones//MDR	CHOLELITH//CHOLELITHIASIS//CST	0000026223//bile duct stone//CHV
cholangiocarcinoma and hepatocellular carcinoma	
these should be managed by a multidisciplinary team	
patient education	S//Patient Education//NIC	D010353//Patient Education as Topic//MSH	36952//Patient Education//PSY	C16959//Patient Education//NCI	U003505//Patient education//LCH	XaCv2//Patient education//RCD	sh85098703//Patient education//LCH_NW	311401005//Patient education//SNOMEDCT_US	0000009078//patient education//AOD	0986-9773//health education//CSP	0000009365//patient education//CHV	41871//patient education//MEDCIN	0044774//PATIENT EDUCATION//CCPSS
urologic referral is indicated	
gynecologic referral is indicated	
hymenectomy may be necessary for tight constriction ring	
however, no data on its use are available	
lymphedema management (manual lymphatic drainage, compression)	
muscle	U006531//Muscle//LCH	D009132//Muscles//MSH	X74sw//Skeletal muscle//RCD	T-13001//Muscle//SNM	30316//Muscle//UWDA	MTHU023760//Muscle//OMIM	LP32940-6//Muscle//LNC	LP20705-7//Muscle//LNC	LP33444-8//Muscle//LNC	91727004//Muscle//SNOMEDCT_VET	MTHU016812//Muscle//LNC	TCGA//Enterovirus//NCI	LP199993-9//Muscle//LNC	71616004//Muscle structure//SNOMEDCT_US	C13056//Muscle//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000002457//muscle//AOD	1979-3864//muscle//CSP	0000008358//muscle//CHV
physical therapy and exercise to promote mobility and prevent contractures	
lung	D008168//Lung//MSH	7N225//Lung//RCD	U000434//Lung//SNM	T-28000//Lung//SNM	7195//Lung//UWDA	MTHU000106//Lung//OMIM	MTHU016106//Lung//OMIM	LP7407-2//Lung//LNC	MTHU008683//Lung//LNC	TCGA//Enterovirus//NCI	LA4579-4//Lung//LNC	LP199934-3//Lung//LNC	39607008//Lung structure//SNOMEDCT_US	28960//Lung//PSY	C12468//Lung//NCI	LUNG//Lung//HL7V2.5	NOCODE//Developmental arithmetic disorder//MTH	0000002514//lung//AOD	2612-7088//lung//CSP	CDR0000270740//lung//NCI_NCI-GLOSS	0000007565//lung//CHV
noninvasive ventilation if needed	
pancreas	D010179//Pancreas//MSHDUT	U003452//Pancreas//LCH	MT030002//Pancreas//MTHMST	7N340//Pancreas//RCD	U000468//Pancreas//SNM	T-59000//Pancreas//SNM	7198//Pancreas//UWDA	MTHU000376//Pancreas//OMIM	LP30158-7//Pancreas//LNC	MTHU012054//Pancreas//LNC	sh85097370//Pancreas//LCH_NW	TCGA//Enterovirus//NCI	LP199937-6//Pancreas//LNC	15776009//Pancreatic structure//SNOMEDCT_US	36240//Pancreas//PSY	C12393//Pancreas//NCI	PANCR//Pancreas//HL7V2.5	U002139//Pancreas//MTH	0024179//PANCREAS//CCPSS	T-65000//Pancreas, NOS//SNMI	0000000017//pancreas//AOD	2201-8988//pancreas//CSP	CDR0000046254//pancreas//NCI_NCI-GLOSS	0000009212//pancreas//CHV	0000048754//pancreas//CHV	006702//HYDROCORTISONE MISCELL POWDER (GRAM)//NDDF	LA4654-5//Pancreas//LNC
treatment of pancreatic exocrine insufficiency with pancreatic enzyme supplementation	
treatment of cholestasis with ursodeoxycholic acid	
enteral feeding as needed	
surgical removal of visually significant cataracts	
the primary curative treatment of gastric cancer is surgical resection	
frequent small meals tend to maximize caloric intake	
stiffened peripheral vasculature may be less tolerant to dehydration	
therefore maintaining optimal hydration orally is recommended	
infections are generally handled as for unaffected children	
anesthetics should be used with particular caution	
nitroglycerin is frequently of benefit if angina develops	
statins are recommended for their putative effect on farnesylation inhibition	
injuries	Q000293//injuries//MSH	3858//Wounds and Injuries//MEDLINEPLUS	25450//Injuries//PSY	D014947//Wounds and Injuries//MSH	0000018167//injury from an external force//CHV
wound healing is normal	
fracture rate is equivalent to the general pediatric population	
hips	D006615//Hip//MSH	23020//Hips//PSY	T-D2500//Hip, NOS//SNMI	0000006140//hip//CHV
teeth	U006243//Teeth//LCH	NOCODE//Developmental arithmetic disorder//MTH	X758I//Dentition//RCD	MTHU000055//Teeth//OMIM	s3200//Teeth//ICF	LP40376-3//Teeth//LNC	3069//Tooth Disorders//MEDLINEPLUS	MTHU021292//Teeth//LNC	sh85133203//Teeth//LCH_NW	LP200436-6//Teeth//LNC	75150//Set of teeth//UWDA	314001//Set of teeth//FMA	245543004//Dentition//SNOMEDCT_US	C12506//Tooth//NCI	D014070//Tooth//MSH	0000017244//teeth//AOD	0000012363//tooth//CHV	C33794//Teeth//NCI_CDISC	6782//examination of teeth//MEDCIN
, finger) joints	
eye care	225363004//Eye care//SNOMEDCT_US	1650//Eye Care//NIC	Q50.0//Eye Care//CCC	10031275//Eye Care//ICNP	0000052236//eye care//CHV
hearing aids can be used, when clinically necessary	
treatment of acute hyperammonemic episodes	
, as part of nitrogen scavenging therapy)	
this approach also stops all protein intake	
infusion 1	
infants and children	
adolescents and adults	
10% arginine hcl	
210 mg/kg/day	
drug	x00xm//Drug//RCD	E-7000//Drug//SNM	C459//Medication//NCI	410942007//Drug or medicament//SNOMEDCT_US	0000004159//drug//CHV	0055234//DRUG//CCPSS	LP172750-4//Drug//LNC	C1909//Drug//NCI_BRIDG	CDR0000348921//drug//NCI_NCI-GLOSS
action	129264002//Action//SNOMEDCT_US	0000034833//action//CHV	ACTN//action//HL7V3.0	XC00r//Action//RCD	273248003//Action attribute//SNOMEDCT_US	C25404//Action//NCI	NOCODE//Developmental arithmetic disorder//MTH
glucose	U001989//Glucose//LCH	9763//Glucose//MMSL	D005947//Glucose//MSH	X80Hv//Glucose//RCD	F-11820//Glucose//SNM	4850//Glucose//RXNORM	111138002//Glucose preparation//SNOMEDCT_US	82743//Glucose//FMA	N0000006402//Glucose [Chemical/Ingredient]//NDFRT	LP32534-7//Glucose//LNC	LP14635-4//Glucose//LNC	MTHU001675//Glucose//LNC	sh85055360//Glucose//LCH_NW	NSC0406891//Glucose//NCI_DTP	C2831//Glucose//NCI_CRCH	DB09341//Glucose//DRUGBANK	31987//Glucose//CPM	DB01914//D-glucose//DRUGBANK	67079006//Glucose//SNOMEDCT_US	21160//Glucose//PSY	U001953//Glucose//MTH	0000001884//glucose//AOD	1439-4863//glucose//CSP	4787//Clorfed II//MMSL	0000005563//glucose//CHV	V04CA02//glucose//ATC	V06DC01//glucose//ATC	B05CX01//glucose//ATC	CDR0000044033//glucose//NCI_NCI-GLOSS	002597//BENZOCAINE/CAPSAICIN DENTAL POULTICE//NDDF	d00595//glucose//MMSL	N0000147647//GLUCOSE//NDFRT	4019541//GLUCOSE//VANDF	10018414//glucose//MDRDUT	U000144//Dissecting aortic aneurysm//MTH	U000264//Malva parviflora//MTH	U000375//Histamine measurement//MTH	6121//Blood Sugar//MEDLINEPLUS	1011445//Glucose//CPT	C105585//Glucose//NCI_CDISC	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC
arginine 1	
sodium benzoate 3	
sodium phenylacetate 3	
hemodialysis	7.16//Hemodialysis//CCS	58//Other nutritional; endocrine; and metabolic disorders//CCS	1059//Hemodialysis//ICD10AMAE	13100-00//Hemodialysis//ICD10AMAE	U002145//Hemodialysis//LCH	Xa8S7//Hemodialysis//RCDAE	P-6850//Hemodialysis//SNM	T59.1//Hemodialysis//CCC	3789//Dialysis//MEDLINEPLUS	sh85060189//Hemodialysis//LCH_NW	LA9975-9//Hemodialysis//LNC	10019480//Hemodialysis//MDR	10018875//Haemodialysis//MDR	302497006//Hemodialysis//SNOMEDCT_US	22690//Hemodialysis//PSY	C15248//Hemodialysis//NCI	D006435//Renal Dialysis//MSH	39.95//Hemodialysis//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	U001938//TUSSIVE SYNCOPE//DXP	0000007993//hemodialysis//AOD	0458-3279//hemodialysis//CSP	0000005977//hemodialysis//CHV	LP149600-1//hemodialysis//LNC	LP173518-4//hemodialysis//LNC	MTHU034006//hemodialysis//ICPC2ICD10ENG	U59008//haemodialysis//ICPC2P	41811//hemodialysis//MEDCIN	C38200//HEMODIALYSIS//NCI_FDA	140//HEMO//NCI_FDA
dialysis may be prolonged if the catabolic state persists	
note: non-essential amino acids (i	
nosebleeds	D004844//Epistaxis//MSH	168//nosebleeds//MEDCIN
oral drug therapy	
topical drug therapy	
, timolol 0	
gastrointestinal bleeding	MT160018//Gastrointestinal bleeding//MTHMST	PRB_18050.02//Gastrointestinal bleeding//PCDS	MTHU037874//Gastrointestinal bleeding//OMIM	HP:0002239//Gastrointestinal hemorrhage//HPO	10017936//Gastrointestinal bleeding//MDR	LP209002-7//Gastrointestinal bleeding//LNC	74474003//Gastrointestinal hemorrhage//SNOMEDCT_US	324//GASTROINTESTINAL BLEEDING//COSTAR	HEM GI//GASTROINTESTINAL HEMORRHAGE//CST	U001648//REACTIVE DEPRESSION//DXP	BI00254//gastrointestinal bleeding//BI	0000005385//gastrointestinal bleeding//CHV	D15001//gastrointestinal bleeding//ICPC2P	35863//gastrointestinal bleeding//MEDCIN	1308//Gastrointestinal Bleeding//MEDLINEPLUS
pulmonary avms	
hepatic avms	
cerebral avms	
cerebral avms greater than 1	
intestinal polyps	N0000001704//Intestinal Polyps [Disease/Finding]//NDFRT	D007417//Intestinal Polyps//MSH	U002483//Intestinal polyps//LCH	sh85067570//Intestinal polyps//LCH_NW	HP:0005266//Intestinal polyp//HPO	0000006861//intestinal polyps//CHV
most investigators recommend maintaining all glucose levels above 3	
somatostatin analogs (e	
glucagon, which increases hepatic gluconeogenesis, helps prevents hypoglycemia	
however, therapeutic success has not been confirmed	
dietary intervention:	
night-time continuous gastric drip containing glucose or glucose polymer	
in such individuals, surgery must be considered	
if structural damage to the lungs (e	
, pseudomonas) or fungi (e	
, aspergillus)	
adequate skin lubrication is needed with frequent bleach baths	
hlh-1994	
hlh-2004	
in general, treatment involves the following:	
after achievement of clinical remission in simplex cases (i	
, a single occurrence in a family)	
cutaneous lesions	
cutaneous leiomyomas should be examined by a dermatologist	
treatment of cutaneous leiomyomas is difficult:	
surgical excision may be performed for a solitary painful lesion	
lesions can be treated by cryoablation and/or lasers	
uterine fibroids should be evaluated by a gynecologist	
hysterectomy should be performed only when necessary	
renal tumors	0000007096//kidney tumor//CHV	C3150//Kidney Neoplasm//NCI	HP:0009726//Renal neoplasm//HPO
early detection of kidney tumor in hlrcc is important	
chelation therapy with disodium calcium edetate	
short term	0000035310//short-term//CHV
, >3 hours)	
long term	0000035277//long term//CHV	C25322//Long-Term//NCI
chelation therapy should be continued lifelong	
iron therapy	
iron is a competitive inhibitor of intestinal manganese uptake	
dystonia can result in physical deformities and pain	
at present no disease-modifying therapy exists	
pain management is the primary goal of therapy:	
cleft palate is best managed by a local craniofacial team	
management of colon cancer in a person with lynch syndrome	
complications should be managed appropriately (e	
multidisciplinary management at various ages may include:	
endocrinology to optimize bone homeostasis and avoid exacerbating treatments	
nephrology to monitor calcium homeostasis and examine for nephrocalcinosis	
neurology to prophylactically or prospectively treat seizures and manage myopathy	
neurosurgery or craniofacial team to manage pseudocraniosynostosis	
orthopedics to manage primary and secondary skeletal manifestations	
pain management	10056350//Pain management//MDR	Xa0iE//Pain management//RCD	LP89789-9//Pain management//LNC	MTHU031888//Pain management//LNC	278414003//Pain management//SNOMEDCT_US	A59007//pain management//ICPC2P	NOCODE//Developmental arithmetic disorder//MTH	1400//Pain Management//NIC	36165//Pain Management//PSY	C15180//Pain Therapy//NCI	D059408//Pain Management//MSH	0000009301//pain management//AOD	2682-4101//analgesia//CSP	0000001082//pain management//CHV	CDR0000039013//pain therapy//PDQ	76116//pain management//MEDCIN	0003339//PAIN MANAGEMENT//CCPSS
pediatric and adult dentistry to manage tooth loss	
enzyme replacement therapy	C16221//Protein Replacement Therapy//NCI	D056947//Enzyme Replacement Therapy//MSH	1042-1841//enzyme therapy//CSP	0000041885//enzyme replacement therapy//CHV
perinatal/infantile hpp study outcomes	
survival	sh85130882//Survival//LCH_NW	TCGA//Enterovirus//NCI	C17177//Survival//NCI	D013534//Survival//MSH	0000011937//survival//CHV	Q000401//mortality//MSH
bone findings	
juvenile-onset hpp study outcomes	
age at treatment onset was six to 12 years	
perinatal types	
infantile type	
in the absence of ert, supportive management remains	
calcium homeostasis	H05//CALCIUM HOMEOSTASIS//ATC
craniosynostosis in those with the infantile phenotype is variable	
childhood (juvenile) and adult hypophosphatasia	
osteoarthritis may respond to nsaids	
pseudofractures and stress fractures are difficult to manage	
early surgical repair may improve feeding	
the principles of treatment are summarized in table 7	
goal	D006040//Goals//MSH	410518001//Goal//SNOMEDCT_US	0000004063//goal//AOD	0000005636//goal//CHV	GOL//Goal//HL7V3.0
means	C47955//Means//NCI	NOCODE//Developmental arithmetic disorder//MTH
practical details	
to avoid triggering or aggravating factors for paralytic attacks	
avoid:	
strenuous effortprolonged immobilitycarbohydrate-rich diet	
treatment of paralytic attack:	
shorten/prevent aggravation of the weakness episodenormalize kalemia	
preventive treatment for paralytic attacks	
daily k+ supplementation	
slow-release forms of potassium may be used	
diamox (acetazolamide)	
k+-sparing diuretics	
preventive treatment for late-onset myopathy	
diamox (acetazolamide)?	
medical precautions	
other elements of management	
strenuous effort	
prolonged immobility	
carbohydrate-rich diet	
provide dietary review/counseling	
shorten/prevent aggravation of the weakness episode	
normalize kalemia	
avoid glucose intake	
do not use slow-release forms of potassium	
oral potassium: initially, 1 meq/kg	
3 meq/kg after 30 minutes if no improvement	
iv potassium: 0	
avoid corticosteroids if possible	
kinesitherapy in case of permanent pelvic deficit	
paralytic crisis	
mild to moderate paralytic episodes	
aqueous potassium contained in vials may act more rapidly	
, 4	
3 meq/kg can be administered (20 meq	
, 1	
severe paralytic episodes	
note the following critical points:	
3 meq/kg/h of potassium (i	
some individuals exhibit serious arrhythmias with only mild hypokalemia	
they are associated with a risk for cardiac arrest	
attempting to abort paralytic attacks when they begin	
correction of these refractive errors can improve visual acuity	
the surgery is not always successful	
humidifiers may reduce the frequency of nosebleeds	
oral contraceptives can limit the duration of menstrual periods	
the authors know of several additional successful lung transplantations	
primary hyperparathyroidism	E21.0//Primary hyperparathyroidism//ICD10	X40KJ//Primary hyperparathyroidism//RCD	DB-90110//Primary hyperparathyroidism//SNMI	HP:0008200//Primary hyperparathyroidism//HPO	10036693//Primary hyperparathyroidism//MDR	315330//Primary hyperparathyroidism//MEDCIN	MTHU056898//Primary hyperparathyroidism//OMIM	252.01//Primary hyperparathyroidism//ICD9CM	36348003//Primary hyperparathyroidism//SNOMEDCT_US	BI00349//hyperparathyroidism//BI	0000021253//primary hyperparathyroidism//CHV	C48280//Primary Hyperparathyroidism//NCI	N0000171687//Hyperparathyroidism, Primary [Disease/Finding]//NDFRT	D049950//Hyperparathyroidism, Primary//MSH
minimally invasive parathyroidectomy requires the use of:	
preoperative imaging (e	
jaw tumors	
uterine tumors	
a diabetic clinic is a good source of advice	
appropriate shoes and socks are recommended	
it is best to prevent callous formation in neuropathic skin	
hyperthermia or hypothermia	
hypothermia responds to warming by a blanket as necessary	
of note, longstanding infections require wide surgical debridement	
bone and joint deformities can be managed by corrective osteotomy	
joint dislocations are best treated conservatively	
the oral self-mutilation (i	
6-0	
see warren & nade [1999]	
charcot joints may require arthrodesis	
opiates are contraindicated as hsn1a is a chronic disorder	
current recommendations:	
commonly required interventions include the following:	
shunting for hydrocephalus	
tonsillectomy and adenoidectomy	75306//Tonsillectomy and adenoidectomy//RCD	P-1100//Excision, NOS (-ectomy)//SNM	42821//Tonsillectomy and adenoidectomy; age 12 or over//CPT	42820//Tonsillectomy and adenoidectomy; younger than age 12//CPT	1007178//Tonsillectomy and adenoidectomy//CPT	28913000//Tonsillectomy and adenoidectomy//SNOMEDCT_US
positive pressure ventilation (cpap or tracheostomy)	
carpal tunnel release	10007696//carpal tunnel release//MDRDUT	L59002//carpal tunnel release//ICPC2P	70560//Decompression of median nerve at wrist//RCD	47534009//Decompression of median nerve//SNOMEDCT_US	0038740//CARPAL TUNNEL RELEASE//CCPSS	0000019647//carpal tunnel release//CHV
cardiac valve replacement	
inguinal hernia repair	0038692//INGUINAL HERNIA REPAIR//CCPSS	419//INGUINAL HERNIA REPAIR//COSTAR	10022020//Inguinal hernia repair//MDR	D54010//inguinal hernia repair//ICPC2P	0000006727//inguinal hernia repair//CHV
hip replacement	XaBFE//Prosthetic arthroplasty of the hip//RCD	304890//Hip replacement//MEDCIN	10020102//Hip replacement//MDR	397956004//Prosthetic arthroplasty of the hip//SNOMEDCT_US	3922//Hip Replacement//MEDLINEPLUS	0000032174//hip replacement//CHV
developmental, occupational, and physical therapy are often necessary	
for further information about eculizumab, click here	
typically, plasma exchange is undertaken daily initially	
cfb	CDR0000042108//clofibrate//PDQ	C378//Clofibrate//NCI	HGNC:1037//complement factor B//HGNC	138470//COMPLEMENT FACTOR B//OMIM
cfh autoantibodies	
cfi	C010073//chemotactic factor inactivator//MSH	173320002//Chemotaxis factor inhibitor//SNOMEDCT_US	F-C0B30//Inactivator chemotaxis//SNMI	GO:0034029//2-oxoglutarate carboxylase activity//GO	HGNC:5394//complement factor I//HGNC	217030//COMPLEMENT FACTOR I//OMIM
, persistent severe thrombocytopenia and hemolytic anemia)	
molecular genetic testing can help to define graft prognosis	
c3, cfb, and cfi	
four individuals with isolated	
importantly, there were no ahus recurrences after transplantation	
beta blockers	0000000779//beta blocker//CHV	05827//Beta Blockers//PSY	LP18062-7//Beta blockers//LNC	MTHU003324//Beta blockers//LNC
l-type calcium channel blockers	
note: direct vasodilators (e	
dose is based on response to therapy	
gout typically responds well to prednisone or colchicine	
prednisone is the preferable alternative	
fludrocortisone treatment (0	
mineralocorticoid replacement	
kidney transplantation cures adtkd-ren	
treatment for hyperpp is symptomatic and not curative	
, 2 g glucose per kg body weight)	
1 mg salbutamol	
calcium gluconate (0	
adults with fh	
risk factors (e	
4 mmol/l])	
risk factors:	
clinically evident cad or other atherosclerotic cardiovascular disease	
8 mmol/l)	
diabetes mellitus or metabolic syndrome	
women age <55 years)	
current smoking	
3 mmol/l] using an isoform insensitive assay)	
class	Xa0I6//Class//RCD	31911000009103//Class//SNOMEDCT_VET	277046005//Class//SNOMEDCT_US	C25346//Class//NCI	U002889//Class//MTH	0032297//CLASS//CCPSS	0000036592//class//CHV	LP6795-1//Class//LNC	MTHU001366//Class//LNC	CLAS//Class//HL7V2.5	C45280//Class//NCI
ldl-lowering response	
statins	4909//Statins//MEDLINEPLUS	372912004//HMG-CoA reductase inhibitor//SNOMEDCT_US	96302009//HMG-CoA reductase inhibitor//SNOMEDCT_US	D019161//Hydroxymethylglutaryl-CoA Reductase Inhibitors//MSH
↑ ldlr activity (1o)	
>35% 1, 2	
cholesterol absorption inhibitors (ezetimibe)	
mipomersen (apob antisense) 4	
blocks apob production in the liver	
mtp inhibitor(lomitapide) 4	
pcsk9 inhibitors(alirocumab, evolocumab)	
↓ ldl-receptor degradation	
50% 6	
bile acid sequestrants(cholestyramine, colesevelam)	
stanol esters	
10% 1, 3	
children with fh	
9 mmol/l)	
consultation or referral to a lipid specialist is recommended	
statins are the preferred initial pharmacologic treatment in children	
4 mmol/l)	
children and adults with homozygous fh (hofh)	
nla guidelines for homozygous fh (full text):	
referral to a lipid specialist is indicated	
early initiation of therapy and monitoring are recommended	
multiple drug therapy is usually needed	
many states do not have an apheresis center	
in adults the initial dose is 0	
5 mg twice a day	
the dose can be increased up to 2	
0 mg three times a day	
antiepileptic drugs if epileptic seizures are present	
the usual neurosurgical approach to spinal stenosis is laminectomy	
the l2-3 level most commonly required decompression	
seizure disorders should be treated in the standard manner	
management of blisters in a standard manner (i	
, not opening them, avoiding trauma)	
topical treatment (e	
, medications, oatmeal baths) to relieve discomfort	
significant skin involvement may benefit from dermatology management	
treatment of infections as for any other cellulitis	
standard treatment for retinal detachment	
physical and occupational therapy to promote mobility and independence	
aids for mobility and limb function	
treatment is symptomatic only:	
management should be tailored to the individual	
paget disease of bone	N0000002242//Osteitis Deformans [Disease/Finding]//NDFRT	D010001//Osteitis Deformans//MSH	CDR0000350239//Paget disease of bone//NCI_NCI-GLOSS	MTHU048958//Paget disease of bone//OMIM
actonel®/risedronate	
fosamax®/alendronate	
aredia®/pamidronate	
tnfα antagonists have also been used	
growth hormone (gh) therapy	
treatment by a psychiatrist for neuropsychiatric symptoms is indicated	
dopamine agonist therapy has been tried in some cases	
monitor fluid intake to assure adequate intravascular volume	
appropriate medications for management of seizures and spasticity	
chest physiotherapy to prevent respiratory complications	
sleep studies to assess nocturnal hypoventilation and institute appropriate interventions	
assessment for scoliosis	
dietary	C15222//Diet//NCI	C78373//DIETARY//NCI_CDISC
medical	MED//MedImmune, Inc.//HL7V3.0	G-B101//Medical//SNMI	TCGA//Enterovirus//NCI	74188005//Medical//SNOMEDCT_US	C25261//Medical//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000020613//medical//CHV	0022842//MEDICAL//CCPSS	M//Maiden Name//HL7V2.5	Med//Medical//HL7V2.5
management focuses on rehabilitation to optimize mobility and communication	
treatment of seizures follows standard management principles	
treatment of iron overload	
it is simple, safe, and effective	
the hematocrit should be monitored prior to phlebotomy	
usually four to six phlebotomies annually are sufficient	
treatment of secondary complications	
transdermal preparations (i	
arthropathy is not modified by treatment	
cirrhosis is thought to be irreversible despite iron removal	
diabetes mellitus may require insulin administration	
cardiac issues	
even with additional therapies (e	
qtc interval >550 msec	
syncope before age five years	
left cardiac sympathetic denervation has been effective for some individuals	
iron deficiency anemia	4.1.3.1//Iron deficiency anemia//CCS	D50//Iron deficiency anemia//ICD10AE	B80//Iron deficiency anemia//ICPC	XE13c//Iron deficiency anemia//RCDAE	D-4072//Iron deficiency anemia//SNM	MTHU036458//Iron deficiency anemia//OMIM	sh85068186//Iron deficiency anemia//LCH_NW	HP:0001891//Iron deficiency anemia//HPO	10022974//Iron deficiency anemia//MDR	10022972//Iron deficiency anaemia//MDR	87522002//Iron deficiency anemia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	428//IRON DEFICIENCY ANEMIA//COSTAR	R0121654//IRON DEFICIENCY ANEMIA//QMR	ANEMIA IRON DEFIC//IRON DEFICIENCY ANEMIA//CST	0000005902//iron deficiency anemia//AOD	BI00294//iron deficiency anemia//BI	0427-2389//microcytic/hypochromic anemia//CSP	0000017791//iron deficiency anemia//CHV	MTHU037482//iron deficiency anemia//MTHICPC2ICD10AE	B80002//iron deficiency anaemia//ICPC2P	30322//iron deficiency anemia//MEDCIN	D018798//Anemia, Iron-Deficiency//MSH	139//Anemia//MEDLINEPLUS
hypotonia and therapeutic interventions	
periodic neuropsychologic and developmental testing at appropriate ages	
other cns malformations	
posterior fossa cysts and fluid collections rarely require intervention	
encephalocele may require primary surgical closure	
corrective lenses for refractive errors	
consultation with a nephrologist is indicated	
hepatic fibrosis	K74.0//Hepatic fibrosis//ICD10	10019668//Hepatic fibrosis//MDR	X307W//Fibrosis of liver//RCD	190//Cirrhosis//MEDLINEPLUS	MTHU037221//Hepatic fibrosis//OMIM	HP:0001395//Hepatic fibrosis//HPO	62484002//Hepatic fibrosis//SNOMEDCT_US	U001952//URETER, INJURY//DXP	0000024309//liver fibrosis//CHV	30245//hepatic fibrosis//MEDCIN
consultation with a gastroenterologist is indicated	
some individuals have needed orthotopic liver transplantation	
surgical treatment for polydactyly	
appropriate medical management by an orthopedic specialist for scoliosis	
orofacial clefting is treated by standard surgical interventions	
no specific guidelines are currently available	
jps	174900//JUVENILE POLYPOSIS SYNDROME//OMIM
jps/hht	175050//JUVENILE POLYPOSIS/HEREDITARY HEMORRHAGIC TELANGIECTASIA SYNDROME//OMIM
treat manifestations of hht as needed	
see hereditary hemorrhagic telangiectasia	
monitoring for nocturnal lagophthalmos by parents or caregivers is recommended	
if present, evaluation by an ophthalmologist is indicated	
skeletal features	
early referral to physical therapy to help increase joint mobility	
orchiopexy in males with undescended testes	
anal anomalies	
referral to an urologist or nephrologist as indicated	
facial features	0000051509//facial features//CHV	18993//Facial Features//PSY
hearing aids as needed for hearing loss	
no specific management guidelines have been developed	
management is mostly supportive	
lacrimal duct obstruction	D007767//Lacrimal Duct Obstruction//MSH	N0000001775//Lacrimal Duct Obstruction [Disease/Finding]//NDFRT	C34757//Lacrimal Duct Obstruction//NCI	NOCODE//Developmental arithmetic disorder//MTH	0047415//LACRIMAL DUCT OBSTRUCTION//CCPSS	LACRIMATION DIS//LACRIMATION DISORDER//CST	1137//LACRIMAL DUCT OBSTRUCTION//WHO	0000007175//blocked tear duct//CHV	MTHU019212//Lacrimal duct obstruction//OMIM	10023622//Lacrimal duct obstruction//MDR	HP:0000579//Nasolacrimal duct obstruction//HPO
tear duct massage	
consider lacrimal duct stent placement	
cleft palate, bifid uvula, or velopharyngeal insufficiency	
management by a cleft/craniofacial team	
cpap or bipap	
ent evaluation for tonsillectomy/adenoidectomy	
pulmonary consultation	
feeding difficulties or signs of aspiration	
use of a special nipple or bottle with cleft palate	
short-term nasogastric feeding tube	
consideration of gastrostomy tube	
gastroesophageal reflux disease	D5-30140//Gastroesophageal reflux disease//SNMI	235595009//Gastroesophageal reflux disease//SNOMEDCT_US	MTHU001906//Gastroesophageal reflux disease//OMIM	LP100601-6//Gastroesophageal reflux disease//LNC	512//GERD//MEDLINEPLUS	E10739//Gastroesophageal reflux disease//NCI_CTCAE	HP:0002020//Gastroesophageal reflux//HPO	10066874//Gastroesophageal reflux disease//MDR	01172//Gastroesophageal reflux disease//NANDA-I	NOCODE//Developmental arithmetic disorder//MTH	1001976//GASTROESOPHAGEAL REFLUX DISEASE//CCPSS	109350//GASTROESOPHAGEAL REFLUX//OMIM	N0000001319//Gastroesophageal Reflux [Disease/Finding]//NDFRT	TCGA//Enterovirus//NCI	C26781//Gastroesophageal Reflux Disease//NCI_NICHD	D005764//Gastroesophageal Reflux//MSH	0000005382//gastroesophageal reflux disease (GERD)//CHV
standard positioning & pharmacologic treatment	
musculoskeletal findings (i	
, contractures, scoliosis)	
ankle-foot orthoses or other assistive devices	
physical therapy and/or occupational therapy evaluation	
consultation w/an orthopedist	
seizure disorder	N0000001126//Epilepsy [Disease/Finding]//NDFRT	C3020//Seizure Disorder//NCI	D004827//Epilepsy//MSH	0037587//SEIZURE DISORDER//CCPSS	673//SEIZURE DISORDER//COSTAR	BI00559//seizure disorder//BI	0000004556//epilepsy//CHV	31974//seizure disorder//MEDCIN	MTHU018883//Seizure disorder//OMIM	MTHU020809//Seizure disorder//LNC	03188//Seizure disorder//NANDA-I	128613002//Seizure disorder//SNOMEDCT_US
evaluation of blood sugar & electrolytes	
standard treatment for seizures	
consider eeg and referral to a neurologist	
unexplained hypoglycemia or suspected hyperinsulinism	
consideration of diazoxide therapy	
consider referral to an endocrinologist	
consider referral to a neurodevelopmental specialist and/or neuropsychiatric testing	
benign familial neonatal epilepsy (bfne)	
all but three had family histories of neonatal seizures	
pathogenic variants in kcnq3 were present in two	
earlier initiation of cbz was associated with shorter hospitalization	
no side effects of cbz were reported	
8 years)	
benign familial infantile epilepsy (bfie)	
no established treatment for kindler syndrome exists	
standard blister care in childhood	
antibiotics may be used to treat an infected blister	
use of moisturizers for dry, pruritic skin	
mucosal involvement	
mouth and periodontium	
gastrointestinal tract	C34082//GASTROINTESTINAL TRACT//NCI_CDISC	TCGA//Enterovirus//NCI	D041981//Gastrointestinal Tract//MSH	Xa1Fl//Gastrointestinal tract//RCD	T-50100//Gastrointestinal tract//SNM	71132//Gastrointestinal tract//FMA	MTHU030134//Gastrointestinal tract//LNC	LP208558-9//Gastrointestinal tract//LNC	122865005//Gastrointestinal tract structure//SNOMEDCT_US	0000017264//gastrointestinal tract//AOD	1250-0402//gastrointestinal system//CSP	0000005391//gastrointestinal (GI) tract//CHV	CDR0000046189//gastrointestinal tract//NCI_NCI-GLOSS
esophageal dilatation may be indicated for those with dysphagia	
anal stenosis and bleeding requires regular laxatives	
severe colitis may require surgical bowel resection in some cases	
urethra	D014521//Urethra//MSHDUT	U004858//Urethra//LCH	Xa8SR//Urethra//RCD	U000478//Urethra//SNM	T-75000//Urethra//SNM	19667//Urethra//UWDA	s6103//Urethra//ICF	LP30364-1//Urethra//LNC	MTHU001321//Urethra//LNC	sh85141386//Urethra//LCH_NW	TCGA//Enterovirus//NCI	LP206638-1//Urethra//LNC	13648007//Urethral structure//SNOMEDCT_US	C12417//Urethra//NCI	URTH//Urethra//HL7V2.5	U002338//Urethra//MTH	0000017385//urethra//AOD	3045-5916//urethra//CSP	CDR0000046640//urethra//NCI_NCI-GLOSS	0000012765//urethra//CHV
meatal stenosis may require dilatation	
strictures may require stenting and/ or surgical intervention	
phimosis	D010688//Phimosis//MSHDUT	U003625//Phimosis//LCH	M-34170//Phimosis//SNM	D7-57164//Phimosis//SNMI	MTHU007766//Phimosis//OMIM	N47.1//Phimosis//ICD10CM	N0000002392//Phimosis [Disease/Finding]//NDFRT	449826002//Phimosis//SNOMEDCT_US	sh85101006//Phimosis//LCH_NW	C26852//Phimosis//NCI	605//Paraphimosis//MTHICD9	NOCODE//Developmental arithmetic disorder//MTH	1015200//PHIMOSIS//CCPSS	U000529//PHIMOSIS//COSTAR	U001490//PHIMOSIS//DXP	U003141//PHIMOSIS//DXP	1142//PENIS DISORDER//WHO	11171//phimosis//MEDCIN	0000009631//phimosis//CHV	MTHU059394//phimosis//ICPC2ICD10ENG	35833//phimosis//MEDCIN	Y81//phimosis//ICPCHUN	10034878//phimosis//MDRDUT	X785L//Congenital phimosis//RCD	HP:0001741//Phimosis//HPO	0000030999//phimosis//CHV	0000032568//phimosis//CHV	XE0e9//Acquired phimosis//RCD
no well-controlled treatment trials have been reported	
specialized neurologic care for individuals with epilepsy	
males with igd age ≥18 years	
hormone replacement therapy for males not desiring fertility	
doses do vary with newer testosterone preparations	
if testosterone levels fall, therapy should be reinitiated	
human chorionic gonadotropin (hcg)	0000005655//human chorionic gonadotropin (HCG)//CHV	F-27120//Human chorionic gonadotropin (HCG)//SNM
male infants/adolescents with suspicion of igd	
if igd is clinically suspected (e	
fsh is added at doses ranging from 37	
5 to 75 iu as either hmg or recombinant formulation	
pulsatile gnrh stimulation vs	
females with igd	
hormone replacement therapy for females not desiring fertility	
many formulations of estrogens are available	
a suggested oral regimen is using premarin 0	
25 mg daily	
in vitro fertilization	8E0ZXY1//In Vitro Fertilization//ICD10PCS	C16580//In Vitro Fertilization//NCI	6242//Assisted Reproductive Technology//MEDLINEPLUS	24655//In Vitro Fertilization//PSY	D005307//Fertilization in Vitro//MSH	1138-3732//in vitro fertilization//CSP	0000004981//fertilization in vitro//CHV	CDR0000440108//in vitro fertilization//NCI_NCI-GLOSS	W59004//in vitro fertilisation//ICPC2P	42825//in vitro fertilization//MEDCIN	P2-87522//Test tube ovum fertilization//SNMI	10021572//In vitro fertilization//MDR	LP207984-8//In vitro fertilization//LNC	10056204//In vitro fertilisation//MDR	52637005//In vitro fertilization//SNOMEDCT_US	Z31.2//In vitro fertilization//ICD10AMAE
the following treatment recommendations are appropriate:	
educational intervention and speech therapy beginning in infancy	
cataract and ptosis surgery if indicated	
hearing aids or cochlear implant if needed	
cardiac function assessment and treatment if needed	
orchidopexy in males with undescended testes	
treatment of vesicoureteral reflux if indicated	
other facial	
cleft palate repair if present	
placement of eyelid slings for severe ptosis	
cochlear implants and hearing aids for neurosensory hearing loss	
hormone replacement for endocrinopathies	
dilation of the upper esophageal sphincter to alleviate cricopharyngeal achalasia	
replacement of pancreatic enzymes in pearson syndrome	
treatment of depression	
ventilatory support for respiratory abnormalities in leigh syndrome	
surgical treatment should be performed as needed	
developmental progress should be monitored and stimulated	
adducted thumbs	MTHU005933//Adducted thumbs//OMIM	HP:0001181//Adducted thumb//HPO
surgical intervention is not generally indicated	
a splint may help reduce the degree of adduction	
neurologic features should be monitored	
follow up and treatment is nonspecific	
autonomic dysfunction	MTHU008082//Autonomic dysfunction//OMIM	10049559//Autonomic dysfunction//MDR	HP:0002459//Dysautonomia//HPO	0000047249//autonomic dysfunction//CHV	0017784//AUTONOMIC DYSFUNCTION//CCPSS
neurogenic bladder:	
urinary urgency may require spasmolytics (e	
, solifenacine succinate)	
, docusate) or a laxative is needed	
sexual dysfunction can be alleviated with sildenafil	
anhidrosis is managed by avoiding overheating	
cognitive dysfunction can affect social interactions and financial management	
valproic acid is the traditional antiepileptic treatment for ld	
wolman disease	D015223//Wolman Disease//MSH	C61271//Wolman Disease//NCI	N0000003209//Wolman Disease [Disease/Finding]//NDFRT	NOCODE//Developmental arithmetic disorder//MTH	X40VX//Acid esterase deficiency//RCD	33570//Wolman disease//MEDCIN	82500001//Wolman's disease//SNOMEDCT_US	0000013179//wolman disease//CHV	278000//LYSOSOMAL ACID LIPASE DEFICIENCY//OMIM	613497//LIPASE A, LYSOSOMAL ACID//OMIM	HGNC:6617//lipase A, lysosomal acid type//HGNC
malabsorption and malnutrition	
hepatomegaly and liver disease	
adrenal cortical insufficiency	10001344//Adrenal cortical insufficiency//MDR	ADREN INSUFFIC//ADRENAL CORTEX INSUFFIENCY//CST	0410//ADRENAL INSUFFICIENCY//WHO	0000006014//adrenal cortical insufficiency//AOD	0000032628//adrenal insufficiency//CHV	C26691//Adrenocortical Insufficiency//NCI
consider discussion of comfort care options	
cesd	278000//LYSOSOMAL ACID LIPASE DEFICIENCY//OMIM	HGNC:6617//lipase A, lysosomal acid type//HGNC
lipophilic vitamin supplementation may also be beneficial	
the following as needed:	
recurrence is possible even with more definitive treatment	
surgery for ptosis if clinically indicated (e	
, obscured vision, cosmetic appearance)	
individualized education plans for learning disorders and school performance issues	
biotin-thiamine-responsive basal ganglia disease	703522009//Biotin-thiamine-responsive basal ganglia disease//SNOMEDCT_US
biotinidase deficiency	C84598//Biotinidase Deficiency//NCI	N0000010998//Biotinidase Deficiency [Disease/Finding]//NDFRT	D028921//Biotinidase Deficiency//MSH	NOCODE//Developmental arithmetic disorder//MTH	X40TG//Biotinidase deficiency//RCD	D6-B2230//Biotinidase deficiency//SNMI	MTHU011117//Biotinidase deficiency//OMIM	D81.810//Biotinidase deficiency//ICD10CM	LP56771-6//Biotinidase deficiency//LNC	10071434//Biotinidase deficiency//MDR	MTHU021599//Biotinidase deficiency//LNC	LA12532-0//Biotinidase deficiency//LNC	8808004//Biotinidase deficiency//SNOMEDCT_US	609019//BIOTINIDASE//OMIM	253260//BIOTINIDASE DEFICIENCY//OMIM	0000021183//biotinidase deficiency//CHV	213071//biotinidase deficiency//MEDCIN
(btd)	
coenzyme q10 biosynthesis deficiency	
(pdss2)	
early intervention with special education maximizes cognitive development	
referral to services for the visually impaired is recommended	
treatment of hearing loss may include the following:	
extrapyramidal manifestations	
dystonia and dyskinesias may cause significant disability	
pharmacologic treatment may result in significant functional improvement	
cognitive developmental delay/encephalopathy	
augmentative communication may be used to address speech deficits	
referral to a cardiologist for standard supportive treatment of cardiomyopathy	
clinical genetics consultation	
avoidance of prolonged immobility is recommended	
there is no curative therapy for lp	
treatments of unproven efficacy	
click here (pdf) for further details	
specific treatment for lms does not currently exist	
lateral spinal meningoceles	
symptomatic treatment of neurologic sequelae (e	
physiotherapy to reduce risk for joint subluxation and dislocation	
routine management of the following:	
congenital cardiac defects	
hyperuricemia	A91023//hyperuricemia//ICPC2P	U000355//Calcitonin measurement//MTH	X40PQ//Hyperuricemia//RCDAE	F-11473//Uric acid, increased level//SNM	MTHU004766//Hyperuricemia//OMIM	N0000010234//Hyperuricemia [Disease/Finding]//NDFRT	264//Gout//MEDLINEPLUS	sh85063735//Hyperuricemia//LCH_NW	E12305//Hyperuricemia//NCI_CTCAE	C3961//Hyperuricemia//NCI_NICHD	HP:0002149//Hyperuricemia//HPO	10020907//Hyperuricemia//MDR	MTHU050770//Hyperuricemia//LNC	LP200321-0//Hyperuricemia//LNC	363338//Hyperuricemia//MEDCIN	10020903//Hyperuricaemia//MDR	35885006//Hyperuricemia//SNOMEDCT_US	D033461//Hyperuricemia//MSH	0048739//HYPERURICEMIA//CCPSS	400//HYPERURICEMIA//COSTAR	HYPERURICEM//HYPERURICEMIA//CST	U002038//ZINC DEFICIENCY//DXP	NOCODE//Developmental arithmetic disorder//MTH	BI00350//hyperuricemia//BI	1849-8097//hyperuricemia//CSP	0000047106//hyperuricemia//CHV	CDR0000045466//hyperuricemia//NCI_NCI-GLOSS	MTHU036773//hyperuricemia//ICPC2ICD10ENG	CDR0000042380//hyperuricemia//PDQ
allopurinol therapy results in the accumulation of hypoxanthine and xanthine	
xanthine may also form stones	
hypoxanthine is soluble	
neurologic dysfunction	D009461//Neurologic Manifestations//MSH	0000048419//neurologic dysfunction//CHV
two important considerations when managing cardiovascular features of lds:	
vascular disease is not limited to the aortic root	
0 cm	
0 cm and the excellent response to prophylactic surgery	
clubfeet require surgical correction by an orthopedic surgeon	
surgical intervention for protusio acetabulae is rarely indicated	
treatment focuses on pain control	
orthotics are only indicated for severe pes planus	
some individuals prefer use of arch supports	
others find them irritating	
surgical intervention is rarely indicated or successful	
cataract surgeons and glaucoma specialists may also be needed	
others require surgery	
most seizure disorders can be controlled with anticonvulsant therapy	
early childhood and preschool intervention programs, e	
kidney	D007668//Kidney//MSH	U000107//Kidney//PCDS	7N500//Kidney//RCD	U000476//Kidney//SNM	T-71000//Kidney//SNM	269//Kidney//ULT	7203//Kidney//UWDA	s6100//Kidney//ICF	LP7380-1//Kidney//LNC	MTHU002935//Kidney//LNC	TCGA//Enterovirus//NCI	LA4591-9//Kidney//LNC	LP200461-4//Kidney//LNC	64033007//Kidney structure//SNOMEDCT_US	C12415//Kidney//NCI	KIDN//Kidney//HL7V2.5	NOCODE//Developmental arithmetic disorder//MTH	0000002574//kidney//AOD	1679-5191//kidney//CSP	CDR0000046325//kidney//NCI_NCI-GLOSS	0000007085//kidney//CHV	0041470//KIDNEY//CCPSS	0000022156//kidney//CHV
, with surgical procedures	
most undescended testes descend with time into the scrotum	
some require hormone therapy and/or surgical correction	
treatment of acute hyperammonemic crises	
pharmacologic management	C21090//Pharmacologic Management//NCI
therapy with ondansetron can be started to decrease vomiting	
dietary protein restriction and citrulline supplementation	
current treatment consists of dietary protein restriction (0	
8-1	
5 g/kg/day in children and 0	
lysine supplementation	
carnitine supplemetation	
additional therapies	
treatment of late complications	
however, relapses may require serial lavage	
medical nutrition therapy	D044623//Nutrition Therapy//MSH	NOCODE//Developmental arithmetic disorder//MTH	1013548//Medical nutrition therapy//CPT	0000056271//medical nutrition therapy//CHV	CDR0000482428//medical nutrition therapy//NCI_NCI-GLOSS	194806//medical nutrition therapy//MEDCIN
recurrent or persistent eruptive xanthomas indicate inadequate therapy	
treatment is largely symptomatic	
oxygen supplementation if necessary	
education on complete bladder emptying when voiding	
medical treatment of pulmonary hypertension (e	
, by sildenafil)	
surgical treatment of congenital diaphragmatic hernia or severe hiatal hernia	
physical therapy for muscle strength and joint stability	
psychosocial support	122763//psychosocial support//MEDCIN	10037246//Psychosocial support//MDR	C126880//Psychosocial Care//NCI	CDR0000040661//psychosocial assessment/care//PDQ
painful bilateral madelung deformity (uncommon)	
audiologist	C51804//Audiologist//NCI	XaBqv//Audiologist//RCD	2.16.840.1.113883.1.11.13637//Audiologist//HL7V3.0	D000072018//Audiologists//MSH	309418004//Audiologist//SNOMEDCT_US	231HA2500N//Speech, Language and Hearing Service; Audiologist; Assistive Technology Supplier//HL7V3.0	NOCODE//Developmental arithmetic disorder//MTH	0000018221//audiologist//CHV
dietitian	03K1.//Dietitian//RCD	D064686//Nutritionists//MSH	159033005//Dietitian//SNOMEDCT_US	C28248//Dietitian//NCI	NOCODE//Developmental arithmetic disorder//MTH	CDR0000044661//dietitian//NCI_NCI-GLOSS	0000032505//dietitian//CHV
clinical geneticist and genetic counselor	
nurse coordinator	
ophthalmologist	CDR0000631048//ophthalmologist//NCI_NCI-GLOSS	0000025289//ophthalmologist//CHV	J-06137//Ophthalmologist//SNMI	D000072163//Ophthalmologists//MSH	C17822//Ophthalmologist//NCI	422234006//Ophthalmologist//SNOMEDCT_US
oral and maxillofacial surgeon	J-06340//Oral surgeon//SNMI	49993003//Oral surgeon//SNOMEDCT_US	C93048//Oral and Maxillofacial Surgeon//NCI	CDR0000389465//oral and maxillofacial surgeon//NCI_NCI-GLOSS
orthodontist	XaBsJ//Orthodontist//RCD	J-06321//Orthodontist//SNMI	C63737//Orthodontist//NCI	D000066792//Orthodontists//MSH	37504001//Orthodontist//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000025292//orthodontist//CHV
orthopedist	D000072161//Orthopedic Surgeons//MSH
otolaryngologist	D000072220//Otolaryngologists//MSH	C17823//Otolaryngologist//NCI	NOCODE//Developmental arithmetic disorder//MTH	CDR0000046252//otolaryngologist//NCI_NCI-GLOSS	0000025293//otolaryngologist//CHV
pediatric dentist	0000040860//pediatric dentist//CHV	XaBsH//Pediatric dentist//RCDAE	90201008//Pedodontist//SNOMEDCT_US	D003815//Dentists//MSH
pediatrician	Ub1jN//Pediatrician//RCDAE	J-06152//Pediatrician//SNMI	C83190//Pediatrician//NCI	D000072143//Pediatricians//MSH	82296001//Pediatrician//SNOMEDCT_US	0634-6596//child health care personnel//CSP	1385-7843//physician//CSP	0000023816//pediatrician//CHV
plastic and reconstructive surgeon	
psychosocial professionals (psychologist, social worker)	
speech pathologist	C19177//Speech Therapist//NCI	CDR0000043973//speech pathologist//NCI_NCI-GLOSS
referral to a craniofacial center or otolaryngologist is recommended	
face	U001723//Face//LCH	D005145//Face//MSH	NOCODE//Developmental arithmetic disorder//MTH	Xa8T3//Face//RCD	T-Y0200//Face//SNM	24728//Face//UWDA	MTHU000089//Face//OMIM	LP7223-3//Face//LNC	MTHU003030//Face//LNC	sh85046785//Face//LCH_NW	TCGA//Enterovirus//NCI	LP199970-7//Face//LNC	89545001//Face structure//SNOMEDCT_US	C13071//Face//NCI	FACE//Face//HL7V2.5	0000013914//face//AOD	0468-5015//face//CSP	0000004839//face//CHV	1004843//FACE//CCPSS	611546//ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 6//OMIM	C86552//FANCE wt Allele//NCI	600901//FANCONI ANEMIA, COMPLEMENTATION GROUP E//OMIM	GTEx-BPV//Brevital//NCI	C126364//Face//NCI
jaw and teeth	
good oral hygiene is especially important for children with cfm	
children should have consistent primary preventative dental care	
early referral to an otolaryngologist is recommended	
this surgery typically occurs after age five years	
speech	U004410//Speech//LCH	D013060//Speech//MSH	U000235//Speech//SNM	F-94700//Speech//SNM	091317//Speech//NOC	LP121781-1//Speech//LNC	MTHU039958//Speech//LNC	sh85126434//Speech//LCH_NW	LP251050-3//Speech//LNC	49050//Speech//PSY	C38025//Speech//NCI	NOCODE//Developmental arithmetic disorder//MTH	1579-2767//speech//CSP	0000011573//speech//CHV	8263//assessment of speech//MEDCIN	130084//ENT surgical result speech//MEDCIN
ears	D004423//Ear//MSH	U000515//Ears//SNM	MTHU000052//Ears//OMIM	0000004225//ear//CHV	T-AB000//Ear, NOS//SNMI	HGNC:3418//glutamyl-prolyl-tRNA synthetase//HGNC
options for management of microtia include the following:	
no action	
prosthetic management, either adhesive or implant-retained	
family and social support	
crmo is treated as follows:	
thus, their efficacy in this disorder is unknown	
physical therapy to avoid disuse atrophy of muscles or contractures	
colon polyps and colon cancer	
colonoscopy is effective surveillance for colon cancer	
duodenal polyps	0000031090//duodenal polyp//CHV
management of polyps is similar to individuals with fap	
protusio acetabulae can be associated with pain or functional limitations	
surgical intervention is rarely indicated	
orthotics are indicated only in severe cases	
surgical intervention is rarely indicated or fully successful	
pneumothorax can be a recurrent problem	
school-age children benefit from an individualized educational program	
no information is available on response to specific aeds	
fibrous dysplasia	C34609//Fibrous Dysplasia//NCI	NOCODE//Developmental arithmetic disorder//MTH	1005113//FIBROUS DYSPLASIA//CCPSS	U000292//FINANCES//COSTAR	0000025230//fibrous dysplasia//CHV	M27.8//Other specified diseases of jaws//ICD10CM	733.29//Monostotic dysplasia//MTHICD9	254145001//Fibrous dysplasia//SNOMEDCT_US
the primary elements of management include the following	
see fibrous dysplasia management (pdf):	
see precocious puberty management in girls (pdf)	
see gonadal involvement management in boys (pdf)	
, letrozole) [boyce et al 2012]	
thyroid disease	0056633//THYROID DISEASE//CCPSS	U000674//THYROID DISEASE//COSTAR	D013959//Thyroid Diseases//MSH	LA15157-3//Thyroid Disease//LNC	XE100//Disorder of thyroid gland//RCD	MTHU018343//Thyroid disease//OMIM	HP:0000820//Abnormality of the thyroid gland//HPO	14304000//Disorder of thyroid gland//SNOMEDCT_US	0000012259//thyroid disease//CHV	3726//reported prior thyroid disease//MEDCIN
see hyperthyroidism management (pdf)	
methimazole is effective for management of hyperthyroidism	
the risk may potentially be enhanced by radiation exposure	
growth hormone (gh) excess	
see gh excess: management (pdf)	
medical therapy is the preferred first-line treatment	
fgf23-mediated phosphate wasting	
hypercortisolism	DB-70100//Hypercortisolism//SNMI	10020611//Hypercortisolism//MDR	47270006//Hypercortisolism//SNOMEDCT_US	4006-0047//hypercortisolism//CSP	0000000765//hypercortisolism//CHV	0029459//HYPERCORTISOLISM//CCPSS	N0000000883//Cushing Syndrome [Disease/Finding]//NDFRT	4318//Cushing's Syndrome//MEDLINEPLUS	C2969//Cushing Syndrome//NCI_NICHD	D003480//Cushing Syndrome//MSH	HP:0003118//Increased circulating cortisol level//HPO
see hypercortisolism management (pdf)	
definitive treatment includes surgical removal of the diseased adrenal glands	
care by a nephrologist is recommended	
gout prevention with allopurinol or probenecid should be considered	
kidney disease	X30Hc//Disorder of kidney//RCD	D-6502//Kidney disease//SNM	OMFAQ//Anemia//NCI	HP:0000077//Abnormality of the kidney//HPO	90708001//Kidney disease//SNOMEDCT_US	U002249//KIDNEY DISEASE//DXP	D007674//Kidney Diseases//MSH	C3149//Kidney Disease//NCI_NICHD	LA10528-0//Kidney Disease//LNC	0000007090//kidney disease//CHV
kidney transplantation cures adtkd-umod	
treatment of psychiatric problems according to the clinical presentation	
antiepileptic drugs (aeds) for treatment of seizures	
early-onset	MTHU006340//Early-onset//OMIM
nutrition/weight	
weight needs to increase annually by small increments	
gastroesophageal reflux is treated as needed	
respiratory function testing	
assistance with coughing	
noninvasive ventilation support is indicated in the setting of:	
daytime hypercapnea and/or nocturnal hypoventilation	
toddlers often fight the masks	
non-ambulant children require standing frames for postural support	
late-onset	
antiepileptic drugs should be used to treat seizures	
additional management in healthy adults who have the 15q13	
, schizophrenia)	
routine treatment of ophthalmologic, cardiac, neurologic findings	
speech, occupational, and physical therapies	
because manifestations of 16p12	
early diagnosis and treatment facilitate the best outcome	
developmental and cognitive delays	
initiate developmental therapies promptly when indicated	
individuals with 16p12	
psychiatric and/or behavior problems	
standard treatment should be provided for hearing loss	
other malformations	
mody5	137920//RENAL CYSTS AND DIABETES SYNDROME//OMIM	HGNC:11630//HNF1 homeobox B//HGNC	C70998//HNF1B wt Allele//NCI
neurodevelopmental/neuropsychiatric disorders	
routine medical care by a pediatrician or other primary physician	
speech therapy directed at improving verbal and nonverbal communication skills	
the seizures usually are easy to control with medication	
treatment for cryptorchidism if indicated	
routine treatment of ophthalmologic, cardiac, and neurologic findings	
speech, occupational, and physical therapies, as appropriate	
early speech and language therapy to address speech delays	
individualized education program (iep) for school-age children	
applied behavioral analysis or other treatment for manifestations of asd	
ataxia may require assistive devices or eventually wheelchair	
consultation with a speech pathologist may be helpful	
cognitive impairment	PRB_03000.00//Cognitive impairment//PCDS	X00RS//Mild cognitive disorder//RCD	F-90402//Disturbance in cognition//SNMI	MTHU003329//Cognitive impairment//OMIM	LP128695-6//Cognitive impairment//LNC	MTHU040636//Cognitive impairment//LNC	LA15213-4//Cognitive impairment//LNC	HP:0100543//Cognitive impairment//HPO	10009846//Cognitive impairment//MDR	386806002//Impaired cognition//SNOMEDCT_US	C116921//Cognitive Impairment//NCI_NICHD	D060825//Cognitive Dysfunction//MSH	10113//Cognitive Impairment//PSY	P28006//cognitive impairment//ICPC2P	0000030482//cognitive impairment//CHV
developmental stimulation including speech therapy is appropriate	
treatment is nonspecific	
predisposition to infections	HP:0002719//Recurrent infections//HPO
all vaccines should be given	
gastrointestinal dysfunction	MTHU044591//Gastrointestinal dysfunction//OMIM	0000005569//gastrointestinal dysfunction//AOD
for (progressive) spasticity	
for excessive drooling	
patients experienced great improvement (e	
for failure to thrive	
no therapy is available for peo or retinopathy	
physical therapy should be implemented in individuals after strokes	
seizures respond to traditional anticonvulsant therapy	
standard analgesics can be used for migraine headaches	
cardiac manifestations can benefit from standard pharmacologic therapy	
phpt	
subtotal parathyroidectomy (i	
removal of ≤3	
pituitary tumors	N0000002408//Pituitary Neoplasms [Disease/Finding]//NDFRT	5328//Pituitary Tumors//MEDLINEPLUS	D010911//Pituitary Neoplasms//MSH	0000009767//pituitary tumor//CHV
prl-secreting tumors (prolactinomas)	
growth hormone-secreting tumors	
acth-secreting tumors	
non-secreting pituitary adenomas	
gastrinoma	D015408//Eilandceltumor, ulcerogene//MSHDUT	10017852//Gastrinoma//MDR	Xa98O//Gastrinoma//RCD	M-8153/1//Gastrinoma//SNM	MTHU018342//Gastrinoma//OMIM	N0000003228//Gastrinoma [Disease/Finding]//NDFRT	16189002//Gastrinoma//SNOMEDCT_US	302824004//Gastrinoma//SNOMEDCT_US	C3050//Gastrin-Producing Neuroendocrine Tumor//NCI	0000005374//gastrinoma//CHV	CDR0000044239//gastrinoma//NCI_NCI-GLOSS	CDR0000038718//gastrinoma//PDQ	352610//gastrinoma//MEDCIN	D015043//Syndroom, Zollinger-Ellison-//MSHDUT
pancreatic tumors	0000009225//pancreatic tumor//CHV
the optimal therapy of gastrinoma is controversial	
occult metastatic disease (i	
carcinoid tumors	D002276//Carcinoid Tumor//MSH	1277//Carcinoid Tumors//MEDLINEPLUS	BB5R.//Carcinoid tumors//RCDSA	MTHU018346//Carcinoid tumors//OMIM	10007283//Carcinoid tumours//MDR	HP:0100570//Carcinoid tumor//HPO	0000002415//carcinoid tumor//CHV
adrenocortical tumors	
medullary thyroid carcinoma (mtc)	
menkes disease	422//Menkes syndrome//JABL	D6-32110//Menkes kinky-hair syndrome//SNMI	59178007//Menkes kinky-hair syndrome//SNOMEDCT_US	0000007116//menkes disease//CHV	300011//ATPase, Cu(2+)-TRANSPORTING, ALPHA POLYPEPTIDE//OMIM	309400//MENKES DISEASE//OMIM	C75486//Menkes Disease//NCI	N0000001757//Menkes Kinky Hair Syndrome [Disease/Finding]//NDFRT	D007706//Menkes Kinky Hair Syndrome//MSH
surgery for bladder diverticula that occur in classic menkes disease	
developmental intervention	
atp7a-related dmn	
physical therapy (strength and stretching exercises)	
occupational therapy	522//Rehabilitation//MEDLINEPLUS	C121351//Occupational Therapy//NCI	35100//Occupational Therapy//PSY	D009788//Occupational Therapy//MSH	U003320//Occupational therapy//LCH	8F3..//Occupational therapy//RCD	P7-90300//Occupational therapy//SNMI	10066401//Occupational therapy//MDR	LP98453-1//Occupational therapy//LNC	LP6426-3//Occupational therapy//LNC	MTHU035233//Occupational therapy//LNC	sh85093850//Occupational therapy//LCH_NW	93.83//Occupational therapy//ICD9CM	84478008//Occupational therapy//SNOMEDCT_US	0000007922//occupational therapy//AOD	1385-4139//occupational therapy//CSP	0000058121//occupational therapy//CHV	0000008884//occupational therapy//CHV	MTHU010682//occupational therapy//ICPC2ICD10ENG	191321//occupational therapy//MEDCIN	OT//Occupational Therapy//HL7V2.5
ankle foot orthotics	
the seizure disorder can be treated with conventional anticonvulsant therapy	
clonazepam can also reduce myoclonus	
physical therapy is helpful for any impaired motor abilities	
standard pharmacologic therapy is used to treat cardiac symptoms	
mandibulofacial dysostosis	D008342//Mandibulofacial Dysostosis//MSH	C75018//Treacher Collins Syndrome//NCI	N0000001939//Mandibulofacial Dysostosis [Disease/Finding]//NDFRT	NOCODE//Developmental arithmetic disorder//MTH	154500//TREACHER COLLINS SYNDROME 1//OMIM	Q75.4//Mandibulofacial dysostosis//ICD10	10051456//Mandibulofacial dysostosis//MDR	XE2ud//Treacher Collins syndrome//RCD	D-5113//Mandibulofacial dysostosis//SNM	D4-00722//Treacher Collins syndrome//SNMI	HP:0005321//Mandibulofacial dysostosis//HPO	82203000//Treacher Collins syndrome//SNOMEDCT_US	414//mandibulofacial dysostosis//JABL	0000024804//treacher collins syndrome//CHV	312443//mandibulofacial dysostosis//MEDCIN
see esophageal atresia/tracheoesophageal fistula overview	
thumb anomalies	MTHU056591//Thumb anomalies//OMIM
other thumb anomalies are not generally functionally significant	
short stature is managed expectantly	
treatment of scoliosis by spinal fusion is appropriate	
orthoses are indicated for treatment of foot drop	
discontinue use of potent inhalation agents and succinylcholine	
increase minute ventilation to lower end-tidal co2	
get help	
prepare and administer dantrolene: 2	
5 mg/kg initial dose	
tachycardia, hypercarbia, and muscle rigidity respond rapidly	
multiple doses of dantrolene may be needed	
the suggested upper limit is 10 mg/kg	
however, more may be given as needed	
continue dantrolene at 1	
dantrolene may aggravate previously existing muscle weakness	
begin cooling measures	
stop cooling measures at core body temperature of 38	
5° c	
treat cardiac arrhythmias as needed	
do not use calcium channel blockers	
check values every six to 12 hours	
the earliest sign of rhabdomyolysis is myoglobinuria/myoglobinemia	
serum ck levels may not rise for several hours	
ensure urine output of 2	
evaluate need for invasive monitoring and continued mechanical ventilation	
myoglobinuria	NOCODE//Sepsis//COSTAR	R82.1//Myoglobinuria//ICD10	U003099//Myoglobinuria//LCH	10028629//Myoglobinuria//MDR	D009212//Myoglobinuria//MSH	X709S//Myoglobinuria//RCD	F-13166//Myoglobin, abnormal presence//SNM	F-73650//Myoglobinuria//SNMI	N0000002090//Myoglobinuria [Disease/Finding]//NDFRT	MTHU036870//Myoglobinuria//OMIM	sh85089259//Myoglobinuria//LCH_NW	C114705//Myoglobinuria//NCI	HP:0002913//Myoglobinuria//HPO	48165008//Myoglobinuria//SNOMEDCT_US	791.3//Myoglobinuria//ICD9CM	0043968//MYOGLOBINURIA//CCPSS	MYOPATHY//MYOPATHY//CST	U002702//MYOGLOBINURIA//DXP	1002//MYOGLOBINURIA//WHO	0000008433//myoglobinuria//CHV	MTHU051125//myoglobinuria//ICPC2ICD10ENG	30670//myoglobinuria//MEDCIN
physical habilitation	
standard care for other medical issues (e	
therapy is supportive and involves the following:	
special education programs tailored to the needs of the individual	
speech and language therapy	8E21.//Speech and language therapy//RCD	5154007//Speech therapy//SNOMEDCT_US	0000011578//speech and language therapy//CHV
behavioral therapy as needed	
occupational therapy as needed	
community services that provide support for families	
ritalin® may be helpful to treat marked hyperkinesia	
objective efficiency of gh therapy has not been evaluated	
use of a prosthesis in severe microphthalmia and anophthalmia	
, fitting stockings, massage) is important	
adaptation of the school environment (e	
no definitive treatments exist for the limb-girdle muscular dystrophies	
standard treatment is indicated for the following:	
polydactyly and syndactyly	
anal anomalies and hirschsprung disease (surgical treatment)	
joint	D007596//Joints//MSH	T-12000//Joint//SNM	7490//Joint//UWDA	LP30640-4//Joint//LNC	C13044//JOINT//NCI_CDISC	TCGA//Enterovirus//NCI	MTHU048551//Joint//LNC	LP199931-9//Joint//LNC	39352004//Joint structure//SNOMEDCT_US	0000004691//joint//AOD	2715-4746//joint//CSP	CDR0000458080//joint//NCI_NCI-GLOSS	0000007022//joint//CHV	0000032186//joint//CHV	Xa8Sp//Joint//RCD	854//LIQ ER//NCI_FDA	C50013//Joint Device Component//NCI
intellectual impairment in ml ii is rarely severe	
severe gingival thickening can compromise routine dental cleaning	
otic	T-AB000//Ear, NOS//SNMI	LA9445-3//Otic//LNC	NOCODE//Developmental arithmetic disorder//MTH	0000037950//otic//CHV	C69040//Otic//NCI_NCPDP	OT//Occupational Therapy//HL7V2.5	C38192//Auricular Route of Administration//NCI	013//OTIC//NCI_FDA
the recommended dose is 1 mg/kg monthly	
bone density needs to be monitored closely	
the long-term effect(s) are unknown	
sillence, personal communication]	
not all affected individuals benefit from bisphosphonate treatment	
the prevalence decreases with age	
psychosocial support of patients and families is recommended	
management of pain in the hips is required	
surgical correction of strabismus	
speech therapy as needed	
pulmonary function and vision may also need attention	
stabilization of critically ill individuals	
volume replacement with isotonic solutions	
adequate kcals must be delivered	
once symptoms appear, treatment is primarily supportive	
management of gi dysfunction can include the following:	
trial of dromperidone for nausea and vomiting	
celiac plexus block with bupivicaine	
physical therapy and occupational therapy to help preserve mobility	
activity as tolerated should be encouraged	
osteopenia and osteolysis	
at present no specific therapy can alleviate the progressive osteopenia	
nonsteroidal anti-inflammatory drugs may not provide sufficient relief	
provide medical or surgical interventions as appropriate	
monosomy 7 in children with de	
novo aml (i	
eye anomalies	
notched or bifid nose	
rhinoplasty may be performed for cosmetic purposes	
anal stenosis is generally managed by serial dilatations	
the cardiomyopathy may respond to ace inhibitors or other medication	
cardiac consultation is recommended	
kyphoscoliosis may be treated with surgical stabilization of the spine	
there is no treatment for spinal rigidity	
these agents are not widely used in children	
renal allografts	
001)	
005)	
allograft survival appears to be age-dependent in ddd	
neurosurgical complications (hydrocephalus and cerebellar tonsillar ectopia)	
epilepsy may require long-term antiepileptic treatment	
developmental delays	
joint replacement and atlanto-occipital stabilization may be necessary	
repeated surgery may be required	
cardiac valve replacement should be considered early	
hearing aids should also be considered	
ent (otolaryngologic)	
gastrointestinal system	U001931//Gastrointestinal system//LCH	Xa0sJ//Digestive system//RCD	LP7256-3//Gastrointestinal system//LNC	MTHU001048//Gastrointestinal system//LNC	sh85053487//Gastrointestinal system//LCH_NW	71132//Gastrointestinal system//UWDA	NOCODE//Developmental arithmetic disorder//MTH	C12378//GASTROINTESTINAL SYSTEM//NCI_CDISC	20640//Gastrointestinal System//PSY	0000027754//gastrointestinal system//AOD	1250-0402//gastrointestinal system//CSP	0000005390//gastrointestinal system//CHV	C36279//GASTROINTESTINAL SYSTEM//NCI_CDISC
hydrocephaly	N85003//hydrocephaly//ICPC2P	M-33320//Hydrocephalus//SNM	N0000001566//Hydrocephalus [Disease/Finding]//NDFRT	MTHU037109//Hydrocephaly//OMIM	230745008//Hydrocephalus//SNOMEDCT_US	HP:0000238//Hydrocephalus//HPO	10020513//Hydrocephaly//MDR	23630//Hydrocephaly//PSY	D006849//Hydrocephalus//MSH	0000006343//hydrocephalus//CHV	236600//HYDROCEPHALUS, NONSYNDROMIC, AUTOSOMAL RECESSIVE 1//OMIM
early surgical intervention may prevent severe complications	
physical therapist to optimize mobility	
occupational therapist to optimize autonomy	
psychological support to optimize coping skills and quality of life	
educational professions to optimize learning in a medically fragile individual	
home care for affected individuals with multiple medical equipment needs	
hospice for end-of-life care	
enzyme replacement therapy (ert)	
the recommendation dose is 2 mg/kg/week intravenous	
upper extremities	D034941//Upper Extremity//MSH	T-D8000//Upper extremity, NOS//SNMI	0000055073//upper limb//CHV
knee and ankle valgus	
however, no absolute indications for intervention exist	
hip dysplasia	HP:0001385//Hip dysplasia//HPO	52781008//Hip dysplasia//SNOMEDCT_VET	D006617//Hip Dislocation//MSH	NOCODE//Developmental arithmetic disorder//MTH	MTHU011174//Hip dysplasia//OMIM	10063175//Hip dysplasia//MDR
affected individuals undergoing surgical fusion typically do well	
lumbar spine malalignment	
when kyphosis exceeds 45 degrees, progression is likely	
progressive thoracolumbar kyphosis greater than 70 degrees	
uncontrolled back pain	
neurologic changes related to spinal stenosis	
thus tachycardia treatment with beta blockers should be avoided	
restrictive lung disease is managed by supportive treatment	
learning environment	27991//Learning Environment//PSY
cataract surgery may benefit those with cataracts	
orthodontic management to correct malocclusion may be necessary	
prevention of hypoglycemia requires frequent feeds and avoidance of fasting	
hepatocellular carcinoma	1017965//HEPATOCELLULAR CARCINOMA//CCPSS	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	R0121630//HEPATOCELLULAR CARCINOMA//QMR	114550//HEPATOCELLULAR CARCINOMA//OMIM	B1503//Hepatocellular carcinoma//RCD	M-8170/3//Hepatocellular carcinoma//SNM	MTHU008946//Hepatocellular carcinoma//OMIM	C22.0//Liver cell carcinoma//ICD10CM	309//Liver Cancer//MEDLINEPLUS	10073071//Hepatocellular carcinoma//MDR	10049010//Hepatocellular carcinoma//NCI_CTEP-SDC	HP:0001402//Hepatocellular carcinoma//HPO	109841003//Liver cell carcinoma//SNOMEDCT_US	155.0//Hepatoblastoma//MTHICD9	25370001//Hepatocellular carcinoma//SNOMEDCT_US	0000004597//hepatocellular carcinoma//AOD	2003-4684//hepatocellular carcinoma//CSP	0000006061//liver cell cancer//CHV	CDR0000046363//hepatocellular carcinoma//NCI_NCI-GLOSS	N0000001511//Carcinoma, Hepatocellular [Disease/Finding]//NDFRT	TCGA//Enterovirus//NCI	C3099//Hepatocellular Carcinoma//NCI	D006528//Carcinoma, Hepatocellular//MSH
treatment of muscular manifestations is symptomatic	
cataracts are removed surgically during the first decade of life	
hypergonadotropic hypogonadism (i	
home therapy	0000050955//home therapy//CHV	U006457//Home therapy//LCH
acute decompensation	
indication for hospitalization	
number	XC03Y//Number//RCD	G-A603//Quantity//SNMI	260299005//Number//SNOMEDCT_US	LP18011-4//Number//LNC	MTHU024869//Number//LNC	NHIS//Adult//NCI	TCGA//Enterovirus//NCI	SNS//Ability//NCI	C25337//Number//NCI	410680006//Number//SNOMEDCT_US	410681005//Number//SNOMEDCT_US	0000035871//number//CHV	NBR//Number//HL7V3.0
vomiting and viral gastroenteritis	
viral bronchiolitis	0000002188//viral bronchiolitis//CHV	D001990//Bronchiolitis, Viral//MSH
sinusitis	D012852//Sinusitis//MSHDUT	10040753//sinusitis//MDRDUT	R75007//sinusitis//ICPC2P	U004327//Sinusitis//LCH	M-40000//Inflammation//SNM	MTHU006260//Sinusitis//OMIM	N0000002756//Sinusitis [Disease/Finding]//NDFRT	404//Sinusitis//MEDLINEPLUS	sh85122938//Sinusitis//LCH_NW	E11563//Sinusitis//NCI_CTCAE	C35024//Sinusitis//NCI_NICHD	HP:0000246//Sinusitis//HPO	36971009//Sinusitis//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	1014656//SINUSITIS//CCPSS	680//SINUSITIS//COSTAR	SINUSITIS//SINUSITIS//CST	U003573//SINUSITIS//DXP	0540//SINUSITIS//WHO	0000005440//sinusitis//AOD	BI00664//sinusitis//BI	1997-2491//sinusitis//CSP	0000011371//sinus infection//CHV	MTHU067997//sinusitis//ICPC2ICD10ENG	31349//sinusitis//MEDCIN
neonatal encephalopathy	Xa09H//Neonatal encephalopathy//RCD	D8-78106//Neonatal encephalopathy//SNMI	P91.81//Neonatal encephalopathy//ICD10CM	95628005//Neonatal encephalopathy//SNOMEDCT_US	0000023609//neonatal encephalopathy//CHV	C119758//Neonatal Encephalopathy//NCI_NICHD
urinary tract infection	U71008//urinary tract infection//ICPC2P	020410//Urinary tract infection//NOC	PRB_07010.09//Urinary tract infection//PCDS	D-6501//Urinary tract infectious disease//SNM	MTHU037523//Urinary tract infection//OMIM	E11614//Urinary tract infection//NCI_CTCAE	LA6437-3//Urinary tract infection//LNC	10046571//Urinary tract infection//MDR	03351//Urinary tract infection//NANDA-I	68566005//Urinary tract infectious disease//SNOMEDCT_US	U002658//Urinary tract infection//MTH	1018076//URINARY TRACT INFECTION//CCPSS	766//URINARY TRACT INFECTION//COSTAR	INFECT URIN TRACT//URINARY TRACT INFECTION//CST	U004246//URINARY TRACT INFECTION//DXP	0628//URINARY TRACT INFECTION//WHO	D014552//Urinary Tract Infections//MSH	C50791//Urinary Tract Infection//NCI	2120//Infection, Urinary Tract//NCI_FDA	10029915//Urinary Tract Infection//ICNP	BI00430//urinary tract infection//BI	3045-9850//urinary tract infection//CSP	0000012789//urinary tract infection//CHV	31394//urinary tract infection//MEDCIN	HP:0000010//Recurrent urinary tract infections//HPO
cellulitis	L03//Cellulitis//ICD10DUT	D002481//Cellulitis//MSHDUT	10007882//cellulitis//MDRDUT	S76005//cellulitis//ICPC2P	U000875//Cellulitis//LCH	M-40200//Inflammation, diffuse//SNM	N0000000707//Cellulitis [Disease/Finding]//NDFRT	MTHU034281//Cellulitis//OMIM	1227//Cellulitis//MEDLINEPLUS	sh85021701//Cellulitis//LCH_NW	C26715//Cellulitis//NCI_NICHD	1768//Cellulitis//NCI_FDA	HP:0100658//Cellulitis//HPO	128045006//Cellulitis//SNOMEDCT_US	385627004//Cellulitis//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	1017421//CELLULITIS//CCPSS	163//CELLULITIS//COSTAR	CELLULITIS//CELLULITIS//CST	U000311//CELLULITIS//DXP	U000578//EPIGLOTTITIS, ACUTE//DXP	1372//CELLULITIS//WHO	0000023000//cellulitis//AOD	0000002607//cellulitis//CHV	CDR0000044789//cellulitis//NCI_NCI-GLOSS	MTHU015337//cellulitis//ICPC2ICD10ENG	0729-7208//connective tissue disorder//CSP	0944-6244//inflammation//CSP	30907//cellulitis//MEDCIN	D000071697//Cellulitis//MSHGER	164014//cellulitis on exam//MEDCIN
influenza	R80//Influenza//ICPC2EDUT	8.1.2//Influenza//CCS	123//Influenza//CCS	R80002//influenza//ICPC2P	U002431//Influenza//LCH	10022000//Influenza//MDR	H27..//Influenza//RCD	D-0411//Influenza//SNM	C53482//Influenza//NCI	N0000171628//Influenza, Human [Disease/Finding]//NDFRT	299//Flu//MEDLINEPLUS	sh85066127//Influenza//LCH_NW	D007251//Influenza, Human//MSH	6142004//Influenza//SNOMEDCT_US	25260//Influenza//PSY	487//Influenza//ICD9CM	U002008//Influenza//MTH	0052277//INFLUENZA//CCPSS	417//INFLUENZA//COSTAR	U002094//INFLUENZA//DXP	R0121650//INFLUENZA//QMR	U000934//INFLUENZA//DXP	BI00709//influenza//BI	3100-0019//influenza//CSP	0000006710//flu//CHV	MTHU032867//influenza//ICPC2ICD10ENG	30986//influenza//MEDCIN	10016790//Influenza//MDRHUN	N0000020118//INFLUENZA//NDFRT	4022112//INFLUENZA//VANDF
viral meningitis	A87//Viral meningitis//ICD10	Xa9B5//Viral meningitis//RCD	D-0500//Viral meningitis//SNM	10047469//Viral meningitis//MDR	58170007//Viral meningitis//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	N0000001987//Meningitis, Viral [Disease/Finding]//NDFRT	C118298//Viral Meningitis//NCI_NICHD	D008587//Meningitis, Viral//MSH	BI00545//viral meningitis//BI	2042-5450//viral meningitis//CSP	0000007938//viral meningitis//CHV	35668//viral meningitis//MEDCIN
bacterial pharyngitis	0000055097//pharyngitis bacterial//CHV
esophageal candidiasis	1004502//ESOPHAGEAL CANDIDIASIS//CCPSS	R0121602//ESOPHAGEAL CANDIDIASIS//QMR	U001164//MENINGOCOCCEMIA//DXP	MT060082//Esophageal candidiasis//MTHMST	AB201//Esophageal candidiasis//RCDAE	10015365//Esophageal candidiasis//MDR	10030154//Oesophageal candidiasis//MDR	BI00214//candida esophagitis//BI	0000024182//candida esophagitis//CHV	D84013//oesophageal candidiasis//ICPC2P	31011//esophageal candidiasis//MEDCIN	C27027//Esophageal Candidiasis//NCI_NICHD
appendicitis	D88//Appendicitis//ICPCDUT	D001064//Appendicitis//MSHDUT	10003011//appendicitis//MDRDUT	U000335//Appendicitis//LCH	Xa9C4//Appendicitis//RCD	M-40000//Inflammation//SNM	N0000000456//Appendicitis [Disease/Finding]//NDFRT	1223//Appendicitis//MEDLINEPLUS	sh85006090//Appendicitis//LCH_NW	C35145//Appendicitis//NCI_NICHD	E11292//Appendicitis//NCI_CTCAE	74400008//Appendicitis//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0041146//APPENDICITIS//CCPSS	068//APPENDICITIS//COSTAR	1755//APPENDICITIS//WHO	540-543.99//APPENDICITIS//ICD9CM	0000005627//appendicitis//AOD	0000001390//appendicitis//CHV	MTHU007602//appendicitis//ICPC2ICD10ENG	30034//appendicitis//MEDCIN
the primary goals of in-hospital therapy	
25 mosm/l per hour	
minimize exposure to hypotonic fluid sources	
the most commonly encountered are hypokalemia and hypophosphatemia	
methods of achieving these goals	
identify and treat precipitating conditions (e	
, infection, inflammation, and fever)	
administer antiemetics (e	
, odansetron 0	
15 mg/kg/dose) to control nausea and vomiting	
provide at least 1	
10 units/kg/hour and titrated to maintain euglycemia	
5 g/kg/day	
provide specific amino acid supplements during metabolic crisis:	
isoleucine and valine	
20-120 mg/kg/day each	
glutamine and alanine	
tyrosine	U004833//Tyrosine//LCH	D014443//Tyrosine//MSH	X807a//Tyrosine//RCD	F-14710//Tyrosine//SNM	F-64510//Tyrosine//SNMI	10962//Tyrosine//RXNORM	42HK56048U//Tyrosine//MTHSPL	C915//L-Tyrosine//NCI	82768//Tyrosine//FMA	N0000006152//Tyrosine [Chemical/Ingredient]//NDFRT	LP15793-0//Tyrosine//LNC	LP32175-9//Tyrosine//LNC	MTHU004109//Tyrosine//LNC	sh85139195//Tyrosine//LCH_NW	49029//Tyrosine//CPM	DB00135//L-Tyrosine//DRUGBANK	27378009//Tyrosine//SNOMEDCT_US	54590//Tyrosine//PSY	418246001//Tyrosine//SNOMEDCT_US	NOCODE//administration devices//MMSL	U002331//Tyrosine//MTH	0000018392//tyrosine//AOD	0777-8387//tyrosine//CSP	199264//tyrosine//MEDCIN	0000012692//tyrosine (Tyr)//CHV	003449//BENZOCAINE/MENTHOL MUCOUS MEM LOZENGE//NDDF	15487//colistimethate compounding powder//MMSL	d07831//tyrosine//MMSL	N0000146989//TYROSINE//NDFRT	4018678//TYROSINE//VANDF	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC	C122159//Tyrosine//NCI_CDISC	84510//Tyrosine//CPT
strauss & morton, unpublished observation]	
nutrient	D005502//Food//MSH	C1814//Nutrient//NCI	CDR0000044697//nutrient//NCI_NCI-GLOSS	0000042889//nutrient//CHV	C68603//Nutrient//NCI_CRCH
age in months (# of persons)	
0-2 (31)	
3-5 (18)	
6-8 (21)	
9-12 (18)	
13-18 (21)	
19-24 (18)	
25-36 (32)	
leucine (mg)	
72(64-84)	
58(47-68)	
44(37-51)	
35(30-41)	
33(26-39)	
27(22-28)	
21(20-25)	
energy (kcal)	
111(103-119)	
99(94-107)	
89(82-99)	
78(71-87)	
67(55-77)	
57(49-71)	
38(39-51)	
total protein (g)	
1-2	C15693//PHASE I/II TRIAL//NCI_CDISC	LA14352-1//1-2//LNC	NOCODE//Developmental arithmetic disorder//MTH
5(1	
isoleucine supplement (mg)	
4(0-7)	
3(0-3	
7(0-3	
6(0-3	
8(2	
1-5	
7(1	
5(3	
valine supplement (mg)	
5(9	
8-14	
4(9	
0-13	
0(9	
5-12	
1(6	
8(5	
4-10	
2(2	
8(4	
9-8	
alanine intake (mg)	
233(200-262)	
209(197-234)	
206(193-225)	
189(168-218)	
178(159-199)	
159(140-192)	
117(114-149)	
glutamine intake (mg)	
416(361-471)	
363(337-405)	
358(332-400)	
320(288-371)	
294(252-337)	
256(221-318)	
184(181-235)	
iron (mg)	
1(2	
6-2	
8(1	
zinc (mg)	
6(3	
1-4	
4-4	
9-4	
6(2	
6-3	
selenium (µg)	
0(5	
7-6	
7(4	
8-6	
7(5	
3-6	
3(4	
4-6	
0(4	
0-4	
378(307-401)	
330(307-378)	
330(307-354)	
307(260-354)	
307(283-330)	
283(236-330)	
212(212-260)	
leucine / energy ratio (mg/kcal)	
65(0	
57-0	
72)	
58(0	
48-0	
66)	
56)	
46(0	
37-0	
53)	
48(0	
38-0	
54(0	
44-0	
55)	
control of brain edema	
measure head circumference and fontanel size in neonates	
papilledema	NOCODE//Sepsis//COSTAR	D010211//Papilledema//MSH	F4H0.//Papilledema//RCDAE	M-36510//Edema, localized//SNM	MTHU007182//Papilledema//OMIM	423341008//Optic disc edema//SNOMEDCT_US	H47.1//Papilledema//ICD10CM	N0000002294//Papilledema [Disease/Finding]//NDFRT	E10411//Papilledema//NCI_CTCAE	C3307//Papilledema//NCI_NICHD	HP:0001085//Papilledema//HPO	10033703//Papilledema//MDR	10033712//Papilloedema//MDR	377.0//Papilledema//ICD9CM	1016680//PAPILLEDEMA//CCPSS	PAPILLEDEMA//PAPILLEDEMA//CST	U003007//PAPILLEDEMA//DXP	BI00848//papilledema//BI	1114-9268//papilledema//CSP	6630//papilledema//MEDCIN	0000009246//papilledema//CHV	CDR0000046241//papilledema//NCI_NCI-GLOSS	MTHU057352//papilledema//ICPC2ICD10ENG	F99038//papilloedema//ICPC2P	99181//papilledema//MEDCIN
disorientation, combativeness	
depressed level of consciousness	C78253//DEPRESSED//NCI_CDISC	D003244//Consciousness Disorders//MSH	NOCODE//Developmental arithmetic disorder//MTH	U000950//INTESTINE, SMALL, VOLVULUS//DXP	E12625//Depressed level of consciousness//NCI_CTCAE	10012373//Depressed level of consciousness//MDR	299088//depressed level of consciousness//MEDCIN
refractory vomiting	
extremity hyperreflexia	
bradycardic hypertension	
hyperactive gag	
pupillary asymmetry	13045009//Pupillary asymmetry//SNOMEDCT_VET
ophthalmoplegia	D009886//oftalmoplegie//MSHCZE	NOCODE//Sepsis//COSTAR	F99040//ophthalmoplegia//ICPC2P	MTHU008498//Ophthalmoplegia//OMIM	C79697//Ophthalmoplegia//NCI	N0000002223//Ophthalmoplegia [Disease/Finding]//NDFRT	HP:0000602//Ophthalmoplegia//HPO	10030875//Ophthalmoplegia//MDR	16110005//Ophthalmoplegia//SNOMEDCT_US	0024336//OPHTHALMOPLEGIA//CCPSS	OPHTHALMOPLEGIA//OPHTHALMOPLEGIA//CST	1429//EYE MUSCLE PARALYSIS//WHO	0000008967//ophthalmoplegia//CHV	MTHU054228//ophthalmoplegia//ICPC2ICD10ENG	30732//ophthalmoplegia//MEDCIN
decorticate posturing	LA18264-4//Decorticate posturing//LNC	MTHU001068//Decorticate posturing//OMIM
methods to minimize the possibility of brain swelling:	
elevate the individual's head	
note: give furosemide (0	
methods to manage brain swelling:	
furosemide: 0	
0 mg/kg, followed by	
mannitol: 0	
0 g/kg over 60 minutes, followed by	
hypertonic (3%-5%) saline: 2	
5 meq/kg over 60 minutes	
neuroimaging	33698//Neuroimaging//PSY	D059906//Neuroimaging//MSH	0000007606//neuroimaging//AOD	5001-0015//neuroimaging//CSP	0000043091//neuroimaging//CHV
hemodialysis/hemofiltration	
other potential complications in hospitalized persons with msud:	
monitor for and promptly treat hospital-acquired infections	
superficial and invasive candida infections are common	
the management of enlarged parietal foramina is generally conservative	
associated headaches or seizures should be treated symptomatically	
appropriate rehabilitation, e	
enrollment in educational programs appropriate for the hearing impaired	
for mild keratoderma, use of lotions and emollients	
for severe keratoderma, dermatologic evaluation	
treatment by a psychiatrist for those with significant neuropsychiatric symptoms	
tracheostomy as indicated for difficulty managing secretions	
prevention strategies under investigation	
other disciplines are involved as needed	
this procedure is usually transcranial (i	
severe initial clinical presentation requiring a staged repair	
postoperative increased icp	
recurrent deformity requiring a second transcranial repair:	
seven (24	
1%) of 29 individuals with the p	
3%) of 47 without the pathogenic variant	
048) [thomas et al 2005]	
15 were expected to undergo extracranial contouring	
note that none had increased icp	
hearing loss is often sensorineural	
strabismus surgery/correction is indicated to prevent amblyopia	
evaluation for hscr and ultrashort hscr	
referral to a urologist or nephrologist as indicated	
bleeding tendency	0000001990//bleeding tendency//CHV	F-D0730//Bleeding diathesis//SNMI	MTHU016228//Bleeding tendency//OMIM	HP:0001892//Abnormal bleeding//HPO	10005134//Bleeding tendency//MDR	64779008//Blood coagulation disorder//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	HEM//HEMORRHAGE//CST	C115221//Bleeding Diathesis//NCI	MTHU011894//bleeding tendency//ICPC2ICD10ENG
suturing for treatment of accidental or surgical wounds	
mouthwash with tranexamic acid may control gingival bleeding	
eltrombopag	CDR0000491973//eltrombopag//PDQ	C520809//eltrombopag//MSH	711942//eltrombopag//RXNORM	d07357//eltrombopag//MMSL	N0000179799//eltrombopag [Chemical/Ingredient]//NDFRT	012912//eltrombopag//NDDF	B02BX05//eltrombopag//ATC	CDR0000628808//eltrombopag//NCI_NCI-GLOSS	304548//eltrombopag//MEDCIN	NOCODE//Developmental arithmetic disorder//MTH	C71634//Eltrombopag//NCI	441995009//Eltrombopag//SNOMEDCT_US	DB06210//Eltrombopag//DRUGBANK	432005001//Eltrombopag//SNOMEDCT_US	4028105//ELTROMBOPAG//VANDF	N0000177933//ELTROMBOPAG//NDFRT	S56D65XJ9G//ELTROMBOPAG//NCI_FDA
antifibrinolytic agents	D000933//Antifibrinolytic Agents//MSH	NOCODE//Developmental arithmetic disorder//MTH	U000291//Antifibrinolytic agents//LCH	sh85005671//Antifibrinolytic agents//LCH_NW	0000001285//antifibrinolytics//CHV	40934//antifibrinolytic agents//MEDCIN
ten of them benefited from cochlear implants	
glomerular nephropathy	
dialysis or kidney transplantation is required in individuals with esrd	
cataract surgery remedies clouding of the lens	
elevation of liver enzymes does not require any specific treatment	
treatment is largely symptomatic and may include the following	
elective tracheal surgery/intubation should be avoided	
symptomatic treatment of restrictive lung disease	
oxygen supplementation as necessary	
noninvasive 3d imaging may be preferred	
neuropsychiatric	
global developmental disability/intellectual disability educational issues	
persistent middle ear effusions	
myringotomy tubes as needed	
ophthalmology	U003358//Ophthalmology//LCH	LP32911-7//Ophthalmology//LNC	247//Eye Diseases//MEDLINEPLUS	sh85095071//Ophthalmology//LCH_NW	C16939//OPHTHALMOLOGY//NCI_CDISC	394594003//Ophthalmology//SNOMEDCT_US	35420//Ophthalmology//PSY	D009885//Ophthalmology//MSH	0000008966//ophthalmology//CHV	0024335//OPHTHALMOLOGY//CCPSS
routine treatment of strabismus and refractive errors	
all experienced substantial improvement of both myoclonus (61	
5%) and dystonia (48	
2%)	
no adverse effects on cognition or affect were noted	
the results of case studies are summarized below:	
no specific therapy currently exists for this disorder	
special education evaluation is indicated for children with dm1	
statins)	
pain management can be an important part of dm1 treatment	
treatment guidelines for dm2 have been published	
no one medication has been consistently effective	
treatment as in the general population for:	
glaucoma	6.7.3//Glaucoma//CCS	88//Glaucoma//CCS	H40//Glaucoma//ICD10	H40-H42.9//Glaucoma//ICD10	F93//Glaucoma//ICPC	F93001//glaucoma//ICPC2P	U001972//Glaucoma//LCH	D005901//Glaucoma//MSH	F45..//Glaucoma//RCD	D-X300//Glaucoma//SNM	MTHU004639//Glaucoma//OMIM	N0000001345//Glaucoma [Disease/Finding]//NDFRT	42//Glaucoma//MEDLINEPLUS	MTHU020819//Glaucoma//LNC	sh85055227//Glaucoma//LCH_NW	E10392//Glaucoma//NCI_CTCAE	C26782//Glaucoma//NCI_NICHD	OMFAQ//Anemia//NCI	LA16302-4//Glaucoma//LNC	1875//Glaucoma//NCI_FDA	HP:0000501//Glaucoma//HPO	10018304//Glaucoma//MDR	23986001//Glaucoma//SNOMEDCT_US	21090//Glaucoma//PSY	365//Glaucoma//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	0043103//GLAUCOMA//CCPSS	331//GLAUCOMA//COSTAR	GLAUCOMA//GLAUCOMA//CST	U001708//SCHISTOSOMIASIS, CUTANEOUS//DXP	0227//GLAUCOMA//WHO	0000006031//glaucoma//AOD	BI00013//glaucoma//BI	1114-9010//glaucoma//CSP	0000005514//glaucoma//CHV	CDR0000534224//glaucoma//NCI_NCI-GLOSS	MTHU032085//glaucoma//ICPC2ICD10ENG	30746//glaucoma//MEDCIN	5882//Glaucoma//NCBI	C55842//Glaucoma//NCI_CTCAE
supportive management includes treatment of the following:	
treatments for nbia are palliative	
botulinum toxin for those with focal dystonia	
l-dopa treatment, which is beneficial in rare cases	
some will develop prominent dyskinesias early in the treatment	
spectacles as needed to correct refractive errors	
orchiopexy as needed	
trihexyphenydil improves dystonia and sialorrhea	
general management	
thiazide diuretics (i	
emergency treatment for dehydration	
5% dextrose in water is the preferred solution	
if administration of iv fluids is required, 2	
special situations	
hydronephrosis, hydroureter, and megacystis	
aggressive treatment of lower respiratory tract infections	
standard treatment of gastroesophageal reflux, if present	
physical therapy for maintenance/improvement of function and joint mobility	
speech therapy if dysarthria and/or hypernasal speech is present	
currently no cure for nephronophthisis exists	
treatment of anemia, hypertension, and proteinuria if present	
dialysis or renal transplantation when patients reach esrd	
botulinum toxin is helpful for painful focal dystonia	
further studies are in progress	
vestibular schwannoma	B7F10//Vestibular schwannoma//RCD	MTHU013711//Vestibular schwannoma//OMIM	1624//Acoustic Neuroma//MEDLINEPLUS	126949007//Acoustic neuroma//SNOMEDCT_US	0000008646//acoustic neuroma//CHV	N0000002175//Neuroma, Acoustic [Disease/Finding]//NDFRT	MTHU043236//Vestibular Schwannoma//OMIM	HP:0009588//Vestibular Schwannoma//HPO	C3276//Acoustic Schwannoma//NCI	D009464//Neuroma, Acoustic//MSH
therapy remains primarily surgical	
small vestibular tumors (<1	
lip-reading skills may be enhanced by instruction	
ocular involvement	
infections	L70//Infections//ICPC	54536-8//Infections:-:Pt:^Patient:-//LNC	D007239//Infection//MSH	12//Infections//MEDLINEPLUS	25150//Infections//PSY	MTHU021171//Infections//LNC	0000006691//infection//CHV
the spectrum of recurrent infections in nbs is not opportunistic	
puberty and fertility	
females are infertile	
similarly, no male paternity has been reported	
no effective treatment for severe glycine encephalopathy exists	
flusser et al 2005	
van hove et al, unpublished]	
it increases alertness	
nmda receptor site antagonists	
use of each has resulted in improved seizure control	
this may be different in mildly affected children	
blood concentration can be monitored	
seizure control is important for symptomatic benefit	
various antiepileptic drugs have been used with variable success	
most affected individuals need physical therapy	
scoliosis is managed with standard techniques	
chorea	D002819//chorea//MSHCZE	10008748//Chorea//MDRCZE	N08011//chorea//ICPC2P	U000998//Chorea//LCH	XM045//Chorea//RCD	F-84510//Chorea//SNM	F-A4510//Chorea//SNMI	MTHU003622//Chorea//OMIM	C84633//Chorea//NCI	N0000000772//Chorea [Disease/Finding]//NDFRT	520//Movement Disorders//MEDLINEPLUS	sh85024740//Chorea//LCH_NW	HP:0002072//Chorea//HPO	271700006//Chorea//SNOMEDCT_US	09120//Chorea//PSY	NOCODE//Developmental arithmetic disorder//MTH	0060001//CHOREA//CCPSS	CHOREOATHETOSIS//CHOREOATHETOSIS//CST	U000745//GONADAL DYSGENESIS//DXP	0090//CHOREOATHETOSIS//WHO	0000006200//chorea//AOD	2057-3278//chorea//CSP	0000002907//chorea//CHV	337502//chorea//MEDCIN	MTHU016370//chorea//ICPC2ICD10ENG	8995//chorea//MEDCIN
children: 0	
adults: 37	
5 mg/day starting dose divided in 2-3 doses	
of note:	
other neurologic manifestations	
pulmonary dysfunction	2019//Pulmonary Dysfunction//NCI_FDA	C50712//Pulmonary Dysfunction//NCI
treat asthma and interstitial lung disease as needed	
thyroid hormone replacement therapy is recommended	
there is substantial early mortality associated with hypertrophic cardiomyopathy	
significant short stature compared with normal peers	
documented response to gh treatment in studies	
no standard dose has been established	
the increase in height sd varies from 0	
6 to 1	
ophthalmologic evaluation is warranted	
at 23 months of life	
5 months) [walsh et al 2010]	
severe neurodegenerative form (npd-a)	
progressive neurologic disease	
regular consultation with a dietician should be provided	
sleep disorder	0000011416//sleep disorder//CHV	F-85830//Sleep disorder//SNM	MTHU037343//Sleep disorder//OMIM	10040984//Sleep disorder//MDR	03225//Sleep disorder//NANDA-I	39898005//Sleep disorder//SNOMEDCT_US	1012197//SLEEP DISORDER//CCPSS	689//SLEEP DISORDER//COSTAR	SLEEP DIS//SLEEP DISORDER//CST	0195//SLEEP DISORDER//WHO	C3376//Sleep Disorder//NCI_NICHD	D012893//Sleep Wake Disorders//MSH	0000006771//sleep disorder//AOD	BI00561//sleep disorder//BI	2056-7094//sleep disorder//CSP	CDR0000454814//sleep disorder//NCI_NCI-GLOSS	MTHU068090//sleep disorder//ICPC2ICD10ENG	P06011//sleep disorder//ICPC2P	338074//sleep disorder//MEDCIN
npd-b	
most affected individuals have thrombocytopenia	
individuals with symptomatic pulmonary disease may require supplemental oxygen	
no curative therapy for npc exists	
child syndrome	D4-00912//Child syndrome//SNMI	17608003//Child syndrome//SNOMEDCT_US	0000025874//child syndrome//CHV	C562515//Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects//MSH	308050//CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS//OMIM	300275//NAD(P)H STEROID DEHYDROGENASE-LIKE PROTEIN//OMIM
oral aromatic retinoids (etretinate) to ameliorate cutaneous symptoms	
topical statins	
dermatologic surgery	418018006//Dermatologic surgery//SNOMEDCT_US	D062109//Dermatologic Surgical Procedures//MSH
orthopedic abnormalities	
other medical care as appropriate based on clinical findings	
ck syndrome	300275//NAD(P)H STEROID DEHYDROGENASE-LIKE PROTEIN//OMIM	300831//CK SYNDROME//OMIM
antiepileptic drugs (aed) to control seizures	
ophthalmologic management of ocular abnormalities	
ophthalmologic care	
surgery may improve peripheral binocularity or appearance	
nystagmus surgery remains highly controversial	
additional classroom aids may include:	
high contrast reading materials (black on white)	
large font texts or xerographically enlarged worksheets	
computers and tablets with zoom-magnification text software	
skin cancer is treated as for the general population	
a hat with a brim (e	
removal of accessory teeth	
orthodontia for malocclusion	
surgery to repair syndactyly, if present	
routine management of seizures	
physical medicine treatment	
avoid sudden acceleration/deceleration movements	
and avoid throwing a child in the air	
older children should not ride on amusement park rides	
physical activity serves a number of purposes	
analgesics can be used to control pain from fractures	
casts should be small and lightweight	
these studies are still ongoing	
a study comparing pamidronate to zoledronic acid was completed	
to date, the results have not been published	
basilar impression	N0000002419//Platybasia [Disease/Finding]//NDFRT	D010985//Platybasia//MSH	Xa0Yu//Basilar impression//RCD	M-20130//Platybasia//SNM	D4-11212//Platybasia//SNMI	MTHU037817//Basilar impression//OMIM	HP:0005758//Basilar impression//HPO	86587003//Platybasia//SNOMEDCT_US	0000009841//basilar invagination//CHV
criteria for surgical intervention are not well defined	
plastic polymers are sometimes used to coat teeth	
outcome data are limited	
management of lethal oi	
other therapies	16.42.4//Other therapies//CCS
, pulse oximeter) and ventilation (i	
ongoing studies have not confirmed this report	
hirschsprung disease	D006627//Hirschsprung Disease//MSH	N0000001542//Hirschsprung Disease [Disease/Finding]//NDFRT	C34700//Hirschsprung Disease//NCI_NICHD	NOCODE//Developmental arithmetic disorder//MTH	0054860//HIRSCHSPRUNG DISEASE//CCPSS	U000845//HIRSCHSPRUNG DISEASE//DXP	0000006151//hirschsprung's disease//CHV	MTHU003463//Hirschsprung disease//OMIM	HP:0002251//Aganglionic megacolon//HPO	204739008//Hirschsprung's disease//SNOMEDCT_US	142623//HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1//OMIM
tumors of neural crest origin	
no treatment for opa1 is of proven efficacy	
for treatment of ataxia, see ataxia overview	
hand and foot malformations may also require surgery	
surgical correction of limb bowing has not been reported	
apnea prevention	
treatment as needed by an ophthalmologist	
surgical intervention as needed for hypospadias	
surgical treatment of medically significant laryngotracheoesophageal (lte) abnormalities	
surgical management for cleft lip/palate and other craniofacial anomalies	
neuropsychological support	
surgical intervention for imperforate anus	
surgical repair as needed for heart defects	
ptosis	XM050//Ptosis of eyelid//RCD	MTHU000509//Ptosis//OMIM	5404//Eyelid Disorders//MEDLINEPLUS	2620//Ptosis//NCI_FDA	C27298//Ptosis//NCI_NICHD	HP:0000508//Ptosis//HPO	11934000//Ptosis of eyelid//SNOMEDCT_US	PTOSIS//PTOSIS//CST	2042//drooping eyelid//MEDCIN	0000001973//drooping eyelid//CHV	CDR0000044081//ptosis//NCI_NCI-GLOSS	6436//ptosis//MEDCIN	10015995//Ptosis//MDRFRE	D001763//Blépharoptose//MSHFRE	M-31050//Displacement, inferior//SNM	10037272//Ptosis//MDR	29696001//Prolapse//SNOMEDCT_US	U000308//Ptosis//MTH	1015620//PTOSIS//CCPSS	627//PTOSIS//COSTAR	U003258//PTOSIS//DXP	0142//PTOSIS//WHO	BI00840//ptosis//BI	MTHU062684//ptosis//ICPC2ICD10ENG	0000010175//ptosis//CHV
however, the procedure requires general anesthesia	
food should be cut into small pieces	
care of hyperammonemic coma	
rapid lowering of the plasma ammonia	
ammonia scavenger therapy	
citrulline is supplemented at 170 mg/kg/day or 3	
8g/m2/day (enterally)	
table 2	
patient weight	
components of infusion solution	
loading 1 and maintenance dose 2, 3	
sodium phenylacetate & sodium benzoate 4	
arginine hcl injection, 10%	
arginine hcl 5	
<25 kg	
undiluted: 2	
0 ml at 100 mg/ml	
200 mg/kg	
≥25 kg	
40 ml at 100 mg/ml	
4,000 mg/m2	
protein intake	0000037285//protein intake//CHV	100902//Protein intake//NOC	MTHU024647//Protein intake//LNC
recommendations for ammonia scavenger therapy:	
9-13	
0 g/m2/day of sodium phenylbutyrate and 3	
it is typically performed by age six months	
attention deficit/hyperactivity disorder (adhd)	
seizure disorders	0000004556//epilepsy//CHV	D004827//Epilepsy//MSH
learning disability/intellectual disability	
also see urea cycle disorders overview	
bleeding disorder	0000001990//bleeding tendency//CHV	D30..//Coagulation disorder//RCD	F-D0730//Bleeding diathesis//SNMI	64779008//Blood coagulation disorder//SNOMEDCT_US	U000080//ACROMIO CLAVICULAR JOINT DISLOCATION//COSTAR	C115221//Bleeding Disorder//NCI_NICHD	B28001//bleeding disorder//ICPC2P
cardiac fibrosis	MTHU034875//Cardiac fibrosis//OMIM
pancreatectomy	978//Pancreatectomy//ICD10AM	30593-00//Pancreatectomy//ICD10AM	U003453//Pancreatectomy//LCH	10033596//Pancreatectomy//MDR	D010180//Pancreatectomy//MSH	X20aH//Pancreatectomy//RCD	P-1100//Excision, NOS (-ectomy)//SNM	sh85097382//Pancreatectomy//LCH_NW	33149006//Pancreatectomy//SNOMEDCT_US	C15294//Pancreatectomy//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000008306//pancreatectomy//AOD	2202-3670//pancreatectomy//CSP	0000009214//pancreatectomy//CHV	CDR0000046237//pancreatectomy//NCI_NCI-GLOSS	44120//pancreatectomy//MEDCIN	0054493//PANCREATECTOMY//CCPSS
issues to consider prior to referral for tpiat:	
the operation is irreversible	
pain relief is not universal	
chronic pancreatitis	9.9.2//Chronic pancreatitis//CCS	J671.//Chronic pancreatitis//RCD	MTHU038873//Chronic pancreatitis//OMIM	HP:0006280//Chronic pancreatitis//HPO	10009093//Chronic pancreatitis//MDR	577.1//Chronic pancreatitis//ICD9CM	235494005//Chronic pancreatitis//SNOMEDCT_US	0000005656//chronic pancreatitis//AOD	BI00282//chronic pancreatitis//BI	0000016603//chronic pancreatitis//CHV	D99058//chronic pancreatitis//ICPC2P	30030//chronic pancreatitis//MEDCIN	NOCODE//Sepsis//COSTAR	C84637//Chronic Pancreatitis//NCI	N0000171626//Pancreatitis, Chronic [Disease/Finding]//NDFRT	5876//Pancreatitis//MEDLINEPLUS	D050500//Pancreatitis, Chronic//MSH
cholecystokinin (cck) and its analogs (e	
, mineral oil, olestra), or	
, orlistat), or	
routine screening of patients with chronic pancreatitis for glucose intolerance	
esrd is treated with renal replacement therapy (i	
, dialysis and/or renal transplantation)	
registration or institutional access required)	
most are benign and can be completely excised	
preoperative	X90ed//Preoperative//RCD	C54732//Preoperative//NCI	TCGA//Enterovirus//NCI	LP91296-1//Preoperative//LNC	262068006//Preoperative//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	LP207806-3//preoperative//LNC	0000035526//preoperative//CHV
a liberal sodium diet	
, 3 days prior to surgery)	
postoperative	X90eS//Postoperative period//RCD	TCGA//Enterovirus//NCI	LP207124-1//Postoperative//LNC	C28006//Postoperative//NCI	262061000//Postoperative period//SNOMEDCT_US	0000009996//after surgery period//CHV	0000035522//postoperative (post-op)//CHV	LP207954-1//postoperative//LNC	CDR0000043980//postoperative//NCI_NCI-GLOSS
occupational, physical, and speech therapy are often helpful	
treatment focuses on symptomatic therapy	
feeding and nutrition	
no specific metabolic diet is recommended	
neurologic function	200613//Neurologic function//NOC	0000008608//neurological function//CHV	0017498//NEUROLOGIC FUNCTION//CCPSS
early intervention services should be provided	
seizures are present in approximately one third of affected individuals	
standard antiepileptic drugs (aeds) may be used	
no type of aed is contraindicated	
pch2	277470//PONTOCEREBELLAR HYPOPLASIA, TYPE 2A//OMIM	C124057//Pontocerebellar Hypoplasia Type 2//NCI	C118329//TRIP13 wt Allele//NCI
919g>t (p	
ala307ser)	
all other subtypes are very rare	
the main problems to manage:	
central visual impairment	MTHU045688//Central visual impairment//OMIM	432141000124105//Central visual impairment//SNOMEDCT_US	C118710//Cerebral Visual Impairment//NCI_NICHD
epilepsy, which is amenable to standard treatments	
physiotherapy can be helpful	
pch4 and pch5	
respiratory support is usually given for a limited time	
palmoplantar keratoderma	0000007067//palmoplantar keratoderma//CHV	MTHU000701//Palmoplantar keratoderma//OMIM	10033554//Palmoplantar keratoderma//MDR	HP:0000982//Palmoplantar keratoderma//HPO	706885006//Palmoplantar keratoderma//SNOMEDCT_US	N0000001743//Keratoderma, Palmoplantar [Disease/Finding]//NDFRT	C34748//Palmoplantar Keratoderma//NCI_NICHD	D007645//Keratoderma, Palmoplantar//MSH
however, trimming too aggressively can greatly increase pain	
topical therapies to remove the hyperkeratosis:	
occlusive ointments are often poorly tolerated	
nail dystrophy	L60.3//Nail dystrophy//ICD10	10028698//Nail dystrophy//MDR	M23y0//Nail dystrophy//RCD	M-56500//Nail dystrophy//SNM	MTHU036684//Nail dystrophy//OMIM	HP:0008404//Nail dystrophy//HPO	87065009//Dystrophia unguium//SNOMEDCT_US	U002716//NAIL DYSTROPHY//DXP	0020//NAIL DISORDER//WHO	0000021365//nail dystrophy//CHV	6349//nail dystrophy//MEDCIN
particularly troublesome nails can be successfully removed surgically	
oral leukokeratosis	MTHU023979//Oral leukokeratosis//OMIM	HP:0002745//Oral leukoplakia//HPO	D007972//Leukoplakia, Oral//MSH
follicular hyperkeratosis	M-72610//Follicular hyperkeratosis//SNMI	MTHU023980//Follicular hyperkeratosis//OMIM	HP:0007502//Follicular hyperkeratosis//HPO	81845009//Follicular hyperkeratosis//SNOMEDCT_US	402341008//Follicular hyperkeratosis//SNOMEDCT_US	0000029880//follicular hyperkeratosis//CHV	6313//follicular hyperkeratosis//MEDCIN
leukokeratosis with laryngeal involvement	
cysts	U001247//Cysts//LCH	471//Neoplasms//MTH	U000301//Cysts//SNM	N0000000896//Cysts [Disease/Finding]//NDFRT	D003560//Cysts//MSH	M-33400//Cyst, NOS//SNMI	0000003564//cyst//CHV
intralesional injection of steroid (e	
if necessary, cysts can be excised	
at present, no specific therapies can correct ciliary dysfunction	
, vigorous exercise)	
routine immunizations to protect against respiratory pathogens:	
pertussis	11//Non-covered service submitted for FI review (condition code 20 from header information on claim)//HL7V2.5	461//Whooping Cough//MEDLINEPLUS	LA10493-7//Pertussis//LNC	D014917//Pertussis//MSHDUT	10034738//pertussis//MDRDUT	NOCODE//Sepsis//COSTAR	R71001//pertussis//ICPC2P	XE0Qw//Whooping cough//RCD	D-0160//Pertussis//SNM	DE-13210//Pertussis//SNMI	C85231//Whooping Cough//NCI	N0000003163//Whooping Cough [Disease/Finding]//NDFRT	27836007//Pertussis//SNOMEDCT_US	U001470//PERTUSSIS//DXP	0000016258//pertussis//AOD	0368-3326//pertussis//CSP	CDR0000508686//pertussis//NCI_NCI-GLOSS	MTHU059327//pertussis//ICPC2ICD10ENG	0000013163//pertussis//CHV	31438//pertussis//MEDCIN
haemophilus influenzae type b	D019741//Hemophilis influenzae type b//MSHDUT	50937//Haemophilus influenzae type b//RXNORM	103442008//Haemophilus influenzae type b//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	L-1F722//Haemophilus influenzae type B//SNMI	0000016305//haemophilus influenzae type b (Hib) bacteria//CHV	F2TW0N64FI//HAEMOPHILUS INFLUENZAE TYPE B//MTHSPL
pneumococcal vaccine	n4b..//Pneumococcal vaccine//RCD	MTHU021223//Pneumococcal vaccine//LNC	sh85103620//Pneumococcal vaccine//LCH_NW	333598008//Pneumococcal vaccine//SNOMEDCT_US	398730001//Pneumococcal vaccine//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	3055-9857//Streptococcus pneumoniae vaccine//CSP	305948//pneumococcal vaccine//MEDCIN	0000031372//pneumococcal vaccine//CHV	0000044197//pneumococcal vaccine//CHV	007326//PROPIONIC ACID/CHLOROPHYLLIN COPPER COMPLEX TOPICAL OINTMENT (GRAM)//NDDF	N0000020131//PNEUMOCOCCAL VACCINE//NDFRT	4022125//PNEUMOCOCCAL VACCINE//VANDF	55021-0//Pneumococcal vaccine:-:Pt:^Patient:-//LNC
annual influenza virus vaccine	
this approach, however, is controversial	
nasal congestion and sinus infections	
chronic/recurrent ear infection	
male infertility	N46//Male infertility//ICD10	K26..//Male infertility//RCD	MTHU037362//Male infertility//OMIM	HP:0003251//Male infertility//HPO	2904007//Male infertility//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	D007248//Infertility, Male//MSH	5656//Male Infertility//MEDLINEPLUS	0000006701//male infertility//CHV	Y10001//male infertility//ICPC2P	30445//male infertility//MEDCIN	1086//inability to impregnate//MEDCIN
situs abnormalities	
special education programs should be offered	
, carbamazepine, phenytoin, valproate)	
hearing habilitation (hearing aids as early as possible)	
educational programs designed for individuals with hearing impairment	
provision should be made for any special educational needs	
estrogen can be administered orally or topically	
before considering pregnancy, uterine size should be assessed	
depression	DEPRS//Depression//AIR	P76001//depression//ICPC2P	10012378//Depression//MDR	NOCODE//Developmental arithmetic disorder//MTH	X00SO//Depressive disorder//RCD	F-90820//Depression//SNM	210620//Depression//NOC	130609//Depression//NOC	250508//Depression//NOC	251128//Depression//NOC	000612//Depression//NOC	210510//Depression//NOC	120420//Depression//NOC	121221//Depression//NOC	120327//Depression//NOC	250201//Depression//NOC	120614//Depression//NOC	020513//Depression//NOC	200302//Depression//NOC	MTHU000940//Depression//OMIM	113//Depression//MEDLINEPLUS	MTHU013514//Depression//LNC	E12909//Depression//NCI_CTCAE	2361//Depression//NCI_FDA	MPN-SAF//Problem//NCI	00362//Depression//NANDA-I	C2982//Depression//NCI	D003863//Depression//MSH	1017889//DEPRESSION//CCPSS	224//DEPRESSION//COSTAR	NERDEPRESS//DEPRESSION//CST	DEPRESSION//DEPRESSION//CST	U000951//INTUSSUSCEPTION//DXP	R0121579//DEPRESSION//QMR	0172//DEPRESSION//WHO	BI00003//depression//BI	2483-2785//depression//CSP	0000003777//mental depression//CHV	MTHU022371//depression//ICPC2ICD10ENG	CDR0000430479//depression//NCI_NCI-GLOSS	HP:0000716//Depression//HPO	LA10576-9//Depression//LNC	35489007//Depressive disorder//SNOMEDCT_US	0000003782//depressive disorder//CHV	36309//depression//MEDCIN	0000030931//sadness//CHV	X78x6//Depression - motion//RCD	255339005//Depression - motion//SNOMEDCT_US	CDR0000043272//depression and suicide//PDQ	CDR0000042480//depression//PDQ	1204//depression//MEDCIN	C55447//Depression//NCI_CTCAE	BASC-2//Emotional Symptoms Index//NCI	PROMIS//In General How Would You Rate Your Mental Health Including Your Mood And Ability To Think//NCI	C124639//Depression//NCI
weight loss	N0000010968//Weight Loss [Disease/Finding]//NDFRT	MPN-SAF//Problem//NCI	C3445//Weight Loss//NCI_NICHD	D015431//Weight Loss//MSH	1017158//WEIGHT LOSS//CCPSS	799//WEIGHT LOSS//COSTAR	WEIGHT DEC//WEIGHT LOSS//CST	U004458//WEIGHT LOSS//DXP	T08//Weight loss//ICPC	X76CA//Weight loss//RCD	F-01804//Decreased body weight//SNMI	070206//Weight loss//NOC	060223//Weight loss//NOC	210608//Weight loss//NOC	120831//Weight loss//NOC	210713//Weight loss//NOC	121308//Weight loss//NOC	MTHU004026//Weight loss//OMIM	262285001//Weight loss//SNOMEDCT_VET	MTHU020881//Weight loss//LNC	sh85112135//Weight loss//LCH_NW	E12228//Weight loss//NCI_CTCAE	HP:0001824//Weight loss//HPO	10047900//Weight loss//MDR	89362005//Weight loss//SNOMEDCT_US	BI00017//weight loss//BI	4001-0142//weight loss//CSP	0000013130//weight loss//CHV	C55339//Weight loss//NCI_CTCAE	MSAS-SF//Almost Constantly//NCI	MSAS//Dry mouth//NCI
additional management is symptomatic and expectant	
thoracic society 2000, american thoracic	
society & european respiratory society 2002]	
transplantation are good candidates	
five-year survival rates post transplant in	
non-pharmologic treatments:	
oxygen therapy may improve exercise tolerance in patients with	
hypoxemia	U000129//Stramonium extract//MTH	U000186//Toxic effect of trichloroethylene//MTH	XM09U//Hypoxemia//RCDAE	F-10474//Oxygen decrease//SNM	F-60294//Decreased oxygen supply//SNMI	R09.02//Hypoxemia//ICD10CM	C93047//Hypoxemia//NCI	MTHU038721//Hypoxemia//OMIM	338144//Hypoxemia//MEDCIN	356601000009102//Hypoxemia (finding)//SNOMEDCT_VET	HP:0012418//Hypoxemia//HPO	10021142//Hypoxemia//MDR	00910//Hypoxemia//NANDA-I	D000860//Hypoxia//MSH	389087006//Hypoxemia//SNOMEDCT_US	799.02//Hypoxemia//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	1015172//HYPOXEMIA//CCPSS	HYPOXIA//HYPOXIA//CST	0000004395//hypoxemia//AOD	CDR0000597155//hypoxemia//NCI_NCI-GLOSS	0000044721//hypoxemia//CHV
pulmonary rehabilitation is a recommended option for patients who would	
benefit	0000049261//benefit//CHV	C25387//Benefits//NCI
ipf	378//Pulmonary Fibrosis//MEDLINEPLUS	4008-0052//idiopathic pulmonary fibrosis//CSP	C35716//Idiopathic Pulmonary Fibrosis//NCI	178500//PULMONARY FIBROSIS, IDIOPATHIC//OMIM
immunosuppressive/cytotoxic agents, and antifibrotic agents	
however, at least	
two antifibrotic pharmacologic interventions recently approved may be an option	
see therapies under	
investigation	U006481//Investigation//LCH	26550//Investigation//PSY	LP36377-7//Investigation//LNC	10062026//Investigation//MDR	C41198//Investigation//NCI	INVSTG//investigation//HL7V3.0
no management guidelines have been published	
the majority of individuals with pfcp require no regular treatment	
when symptoms of the hyperviscosity syndrome are evident	
hyperviscosity symptoms (see	
evaluations following initial diagnosis)	
grade 1	0000012721//grade 1//AOD	0000044111//grade 1//CHV	X7A8o//Grade 1//RCD	TCGA//Enterovirus//NCI	LA9629-2//Grade 1//LNC	C28077//Grade 1//NCI	C41338//1//NCI_CDISC	C62394//WHO Central Nervous System Grade I//NCI	C117825//GRADE 1//NCI_CDISC	Bayer-VA//Grade 1//NCI	C128617//Simpson Grade 1//NCI	Bayer-CM//Grade 1//NCI
grade 2	X7A8p//Grade 2//RCD	LA9630-0//Grade 2//LNC	0000012722//grade 2//AOD	0000044112//grade 2//CHV	C41339//2//NCI_CDISC	C84264//2//NCI_CDISC	TCGA//Enterovirus//NCI	C28078//Grade 2//NCI	C62395//WHO Central Nervous System Grade II//NCI	C117826//GRADE 2//NCI_CDISC	C128618//Simpson Grade 2//NCI	Bayer-VA//Grade 1//NCI	Bayer-CM//Grade 1//NCI
in the presence of persistent symptoms perform phlebotomy	
grade 3	X7A8q//Grade 3//RCD	TCGA//Enterovirus//NCI	LA9631-8//Grade 3//LNC	C28079//Grade 3//NCI	0000012723//grade 3//AOD	0000044113//grade 3//CHV	C41340//3//NCI_CDISC	C62396//WHO Central Nervous System Grade III//NCI	C117827//GRADE 3//NCI_CDISC	C128619//Simpson Grade 3//NCI	Bayer-CM//Grade 1//NCI	Bayer-VA//Grade 1//NCI
consider additional aspirin treatment	
thromboembolic events	MTHU010071//Thromboembolic events//OMIM	HP:0001907//Thromboembolism//HPO
provide acute treatment according to established practice for the event	
evaluate for other thrombophilic risk factors	
consider additional aspirin treatment in all patients	
consider life-long anticoagulation (e	
pharmacologic therapy	Q000188//drug therapy//MSH
nutritional therapy and supplementation	
nasogastric tube feeding has been useful in some infants	
other approaches	
interruption of the enterohepatic circulation of bile acids	
the internal biliary bypass approach of cholecystojejunocolic anastomosis	
liver transplantation (ltx)	
steatohepatitis can be progressive and lead to cirrhosis	
extrahepatic manifestations	
the general therapies for nephrolithiasis benefit all individuals with ph1	
patients should be advised to seek early medical attention	
alkalinzation of urine (ph 6	
2-6	
15 mg/kg or 0	
3-0	
treatment of kidney stones	
swl	
ureteroscopy	36803-00//Ureteroscopy//ICD10AM	U40004//ureteroscopy//ICPC2P	10046413//Ureteroscopy//MDR	D018666//Ureteroscopy//MSH	X30Dp//Ureteroscopic operation//RCD	P-1300//Endoscopy, NOS (-scopy)//SNM	387717002//Ureteroscopy//SNOMEDCT_US	56.31//Ureteroscopy//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	0000019540//ureteroscopy//CHV	CDR0000354470//ureteroscopy//NCI_NCI-GLOSS	0000032479//ureteroscopy//CHV	C94308//Ureteroscopy//NCI
percutaneous nephrolithotomy and ureteroscopy	
reduction of oxalate biosynthesis	
agt is a pyridoxal phosphate (plp)-dependent enzyme	
7 mmol/1	
phe152ile pathogenic allele	
73 m2/day)	
transplantation (tx) options:	
simultaneous liver - kidney	
sequential liver - kidney	
isolated kidney	
isolated liver	
hemodialysis (hd) strategy:	
perioperative ± postoperative based on pox & gfr	
preoperative & perioperative	
sometimes perioperative	
ckd category / residual gfr	
ckd category 3 (30<gfr<59)	
option in carefully selected patients	
ckd category 4 (15<gfr<29)	
option	C25374//Options//NCI	OPT//option//HL7V3.0
ckd category 5 (gfr <15)	
infantile form (esrd <2 yrs)	
use of deceased vs	
living donors for either or both organs	
, gfr >60 ml/min/1	
adequate fluid intake (>2	
5 l/m2 surface area/day)	
urinary inhibitors of calcium oxalate crystallization:	
potassium citrate (0	
maintainance of high oral fluid intake (>2	
5 l/m2 bsa)	
oral administration of an inhibitor of calcium oxalate crystallization	
avoidance of supersaturation of calcium oxalate in the blood	
avoidance of marked dietary oxalate excess	
simple avoidance of marked dietary oxalate excess is recommended	
metabolic abnormalities and hypertension generally improve within one week	
different thiazide diuretics exist, with different dosing regimens	
anal atresia or stenosis should be treated in standard fashion	
seizures are treated symptomatically	
repair of polydactyly should be undertaken on an elective basis	
if asymptomatic, observation alone is prudent	
when symptomatic, topical agents (e	
leg-length discrepancy secondary to segmental somatic overgrowth	
cardiac abnormalities (i	
, structural cardiovascular disease and arrhythmias)	
renal abnormalities	MTHU047527//Renal abnormalities//OMIM
speech, swallowing, and feeding difficulties	
neurologic and neurosurgical manifestations	
mcap syndrome	
hmeg	
somatic overgrowth, vascular, lymphatic and musculoskeletal manifestations	
infant feeding assessment to address early hypotonia as needed	
behavioral modification for self-injurious behavior or anxiety	
eyeglasses or surgery as needed for amblyopia	
orthopedic treatment of scoliosis as indicated	
standard care for other medical issues	
polyps	0000009937//polyp//CHV	NOCODE//Developmental arithmetic disorder//MTH	MT170012//Polyps//MTHMST	U000384//Polyps//SNM	N0000002458//Polyps [Disease/Finding]//NDFRT	MTHU015582//Polyps//LNC	10036137//Polyps//MDR	D011127//Polyps//MSH	NEOPL//NEOPLASM//CST	M-76800//Polyp, NOS//SNMI	POL//Polyps//HL7V2.5
this strategy has two goals:	
from st	
intussusception should be treated in a standard manner	
malignancies should be treated in a standard manner	
intramuscular botulinum toxin	
intrathecal and intraventricular baclofen	
ablative pallidotomy or thalmotomy	
referral for adaptive aids as needed (e	
, a walker or wheelchair for gait abnormalities)	
other manifestations	
treatment and interventions for retinopathy as per ophthalmology	
flank pain	N0000004242//Flank Pain [Disease/Finding]//NDFRT	D021501//Flank Pain//MSH	C34615//Flank Pain//NCI	NOCODE//Developmental arithmetic disorder//MTH	1017337//FLANK PAIN//CCPSS	306//FLANK PAIN//COSTAR	PAIN BACK//BACK PAIN//CST	PAIN FLANK//FLANK PAIN//CST	U001533//PNEUMONIA, PNEUMOCYSTIS CARINII//DXP	0717//BACK PAIN//WHO	10016750//Flank pain//MDR	X75rg//Flank pain//RCD	E12414//Flank pain//NCI_CTCAE	HP:0030157//Flank pain//HPO	MTHU048535//Flank pain//OMIM	247355005//Flank pain//SNOMEDCT_US	L05001//flank pain//ICPC2P	0000005079//flank pain//CHV
cyst hemorrhage and gross hematuria	
nephrolithiasis	95570007//Kidney stone//SNOMEDCT_US	10029148//Nephrolithiasis//MDR	XE0dk//Calculus of kidney//RCD	M-30010//Lithiasis//SNM	D053040//Nephrolithiasis//MSH	MTHU007103//Nephrolithiasis//OMIM	N0000181137//Nephrolithiasis [Disease/Finding]//NDFRT	1224//Kidney Stones//MEDLINEPLUS	C114667//Kidney Stone//NCI_NICHD	HP:0000787//Nephrolithiasis//HPO	NOCODE//Developmental arithmetic disorder//MTH	0054202//NEPHROLITHIASIS//CCPSS	513//NEPHROLITHIASIS//COSTAR	KIDNEY CALCULUS//KIDNEY CALCULUS//CST	R0121692//NEPHROLITHIASIS//QMR	0617//RENAL CALCULUS//WHO	0000005854//nephrolithiasis//AOD	BI00446//nephrolithiasis//BI	1682-0486//nephrolithiasis//CSP	0000032106//nephrolithiasis//CHV	MTHU052263//nephrolithiasis//ICPC2ICD10ENG	30661//nephrolithiasis//MEDCIN
5), and administration of allopurinol	
cyst infection	
cyst infection is often difficult to treat	
therapeutic agents of choice include trimethoprim-sulfamethoxazole and fluoroquinolones	
chloramphenicol has shown therapeutic efficacy in otherwise refractory disease	
end-stage renal disease (esrd)	
females appear to do better than males	
complications directly related to adpkd are rare	
polycystic liver disease	10048834//Polycystic liver disease//MDR	PB620//Polycystic liver disease//RCD	MTHU014343//Polycystic liver disease//OMIM	C536330//Polycystic liver disease//MSH	HP:0006557//Polycystic liver disease//HPO	72925005//Congenital cystic disease of liver//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	R0121807//POLYCYSTIC LIVER DISEASE//QMR	C82833//Polycystic Liver Disease//NCI	0000017661//polycystic liver disease//CHV
and the results are often short-lived	
ruptured or symptomatic intracranial aneurysm	
asymptomatic aneurysms	
those aneurysms measuring 5	
if the size increases, surgery is indicated	
the management of aneurysms 6	
0-9	
0 mm in size remains controversial	
surgical intervention is usually indicated for aneurysms larger than 10	
aortic dissection	C50461//Aortic Dissection//NCI	4931//Aortic Aneurysm//MEDLINEPLUS	2491//Aortic Dissection//NCI_FDA	D000784//Aneurysm, Dissecting//MSH	Q0300332//AORTIC DISSECTION//QMR	U000211//BILE DUCT, EXTRAHEPATIC, CARCINOMA//DXP	MTHU017249//Aortic dissection//OMIM	10002895//Aortic dissection//MDR	HP:0002647//Aortic dissection//HPO	0000030605//aortic dissection//CHV	36017//dissection of aorta//MEDCIN
early recognition and treatment of dehydration is critical	
and (2) the risk for ascending cholangitis	
administration of synthetic bile acids	
portosystemic shunting may be necessary to treat progressive portal hypertension	
dual-organ transplantation	
see table 2 (pdf) and figure 1	
feeding and growth	
see acmg management guidelines for pku	
treatment of classic pku	
restriction of dietary phenylalanine	
maintain blood tyr in the normal range	
sapropterin (kuvan®)	
reviewed in ho & christodoulou [2014]	
large neutral amino acids (lnaa) transporters	
treatment for non-classic hyperphenylalaninemia	
neuropsychiatric testing may be considered to identify learning differences	
bone health assessment	
only symptomatic treatment is available	
epileptic seizures may worsen the individual's condition	
those with severe dysphagia may require feeding by gastrostomy	
response to pharmacologic treatment is poor	
however, clonazepam or diazepam can be effective	
no disease-modifying drug treatment exists for pnpla6-related disorders	
speech therapy [sapir et al 2003]	
swallowing therapy	311677003//Swallowing promotion therapy//SNOMEDCT_US	1860//Swallowing Therapy//NIC
assistive walking devices and ankle-foot orthotics	
, baclofen [oral or intrathecal], tolperison	
botox® injections) and urinary urgency (e	
hypothyroidism is treated with thyroid hormone replacement (e	
, levothyroxine) at the time of diagnosis	
dysphagia management is therefore important	
hypersalivation is managed with the multidisciplinary team and an otolaryngologist	
treatment must be individualized	
therapies to consider include rehabilitation (e	
, oromotor therapy, behavioral therapy)	
medical therapy (e	
, anticholinergic medications, botulinum toxin injections)	
and, in severe cases, surgery (e	
learning difficulties are likely to progress slowly	
patients should be followed regularly by an endocrinologist	
patients need to be followed regularly by an ophthalmologist	
the following treatment is recommended:	
speech therapy for those with language impairment	
occupational therapy for those with language impairment	
severe obesity	0000056322//severe obesity//CHV	361444//severe obesity//MEDCIN	278.01//Severe obesity//MTHICD9	83911000119104//Severe obesity//SNOMEDCT_US	D009767//Obesity, Morbid//MSH
therefore, lifestyle measures should be instigated	
fair skin	HP:0007513//Generalized hypopigmentation//HPO	C115220//Fair Skin//NCI	NOCODE//Developmental arithmetic disorder//MTH	NMDP/CIBMTR//Tetraploidy//NCI	MTHU004843//Fair skin//OMIM
growth hormone (gh) deficiency	
treatment is highly effective	
iron reduction	
iron chelation therapy (e	
serum ferritin concentration should be measured before starting phlebotomy treatment	
for persons with the hfe genotypes p	
cys282tyr or p	
low-dose anti-malarial agents	
combining both treatment modalities (i	
pct may also improve after treatment of coexisting hepatitis c	
pct should be treated first in most individuals:	
neurovisceral symptoms	
most acute neurovisceral attacks require hospital admission	
harmful medications should be discontinued	
cutaneous symptoms	
patients should wear protective clothing and avoid exposure to sunlight	
topical steroids are of little or no benefit	
strabismus and/or refractive errors	
standard treatment as recommended by ophthalmologist	
dental crowding / malocclusion	
evidence of sleep apnea	
standard treatment as indicated	
diet diary & calorie counts may be requested	
hypoglycemia, short stature, evidence of growth hormone deficiency	
standard treatment(s) as recommended by endocrinologist	
standard treatment as recommended by cardiologist	
renal anomaly and/or vesicoureteral reflux	
standard treatment as recommended by nephrologist/urologist	
enrollment in dda (developmental disabilities administration) is recommended	
, scoliosis)	
consider:	
evaluation for alternative means of communication (e	
pleuropulmonary blastoma (ppb)	
individuals receiving neoadjuvant chemotherapy may have marked tumor reduction	
chemotherapy alone is insufficient to eradicate solid ppb	
pleural effusions	U003723//Pleural effusions//LCH	sh85103499//Pleural effusions//LCH_NW	MTHU012482//Pleural effusions//OMIM	D010996//Pleural Effusion//MSH	BI00187//pleural effusions//BI	0000009851//pleural effusion//CHV
drainage of pleural effusions should be approached with caution	
surgery for metastases	
therapeutic resection of bone and liver metastases is rarely indicated	
type i ppb	
types ii and iii ppb	
aggressive chemotherapy is necessary	
ppbregistry	
radiation therapy	Q000532//radiotherapy//MSH	2724//Radiation Therapy//MEDLINEPLUS	TCGA//Enterovirus//NCI	42690//Radiation Therapy//PSY	C15313//Radiation Therapy//NCI	D011878//Radiotherapy//MSH	0000024409//radiation therapy//AOD	2537-3531//radiation therapy//CSP	0000010554//radiation therapy//CHV	CDR0000044971//radiation therapy//NCI_NCI-GLOSS	CDR0000038085//radiation therapy//PDQ	41544//radiation therapy//MEDCIN	1009620//RADIATION THERAPY//CCPSS	U003310//RADIATION THERAPY//DXP	Xa8SI//Radiotherapy//RCD	03133//Radiation therapy//NANDA-I	211//Other connective tissue disease//CCS_10	10037770//Radiation therapy//MDR	RT//Route of medicine//HL7V2.5
treatment failure	0000009320//treatment failure//AOD	0000017922//treatment failure//CHV	NOCODE//Developmental arithmetic disorder//MTH	D017211//Treatment Failure//MSH	10066901//Treatment failure//MDR	SDTM-RSSTRESC//NE//NCI_CDISC	SDTM-REASTINT//TREATMENT FAILURE//NCI_CDISC	102471002//Absence of therapeutic response//SNOMEDCT_US	03//Discharged/transferred to skilled nursing facility (SNF)//HL7V2.5
ovarian sex cord-stromal tumors	
sertoli-leydig cell tumor	D018310//Sertoli-Leydig Cell Tumor//MSH	N0000003774//Sertoli-Leydig Cell Tumor [Disease/Finding]//NDFRT	NOCODE//Developmental arithmetic disorder//MTH	BBC7.//Sertoli-Leydig cell tumor//RCDAE	M-8631/0//Sertoli-Leydig cell tumor//SNM	M-86310//Sertoli-Leydig cell tumor//SNMI	M8631/0//Sertoli-Leydig cell tumor//ICD10AMAE	0000021047//sertoli-leydig cell tumor//CHV	128905000//Sertoli-Leydig cell tumor of intermediate differentiation//SNOMEDCT_US
juvenile granulosa cell tumor (jgct)	
hyperthermic chemotherapy has been used by some investigators	
gynandroblastoma	D018312//Kiemstrengstromatumor//MSHDUT	M8632/1//Gynandroblastoma//ICD10AM	BBC8.//Gynandroblastoma//RCD	M-8632/1//Gynandroblastoma//SNM	M-86321//Gynandroblastoma//SNMI	26735007//Gynandroblastoma//SNOMEDCT_US	C3072//Ovarian Gynandroblastoma//NCI	D018309//Nowotwory gonad//MSHPOL
the malignant potential of gynandroblastoma is not yet clear	
cystic nephroma	MTHU033179//Cystic nephroma//OMIM	C7504//Cystic Nephroma//NCI
multinodular goiter (mng) and thyroid cancer	
observation with or without biopsy	
ciliary body medulloepithelioma (cbme)	
the four management options include:	
observation	D019370//Observation//MSH	0000012675//observation//AOD	0000027966//observation in research//CHV	MTHU053563//observation//ICPC2ICD10ENG	0000044735//watchful waiting//CHV	CDR0000045981//observation//NCI_NCI-GLOSS	CDR0000467903//observation//PDQ	C15722//Patient Observation//NCI	MT250010//Observation//MTHMSTFRE	OBS//Observation//HL7V2.5	C25598//Observation//NCI_NICHD
local resection	86743009//Local excision//SNOMEDCT_US
however, many of these tumors will progress	
enucleation	P-1102//Enucleation//SNM	P1-03056//Enucleation//SNMI	C48601//Enucleation//NCI	39250009//Enucleation//SNOMEDCT_US	0000008397//enucleation//AOD	CDR0000335065//enucleation//NCI_NCI-GLOSS	0000004512//enucleation//CHV	GO:0090601//enucleation//GO
long-term survival is common after this definitive therapy	
orbital exenteration	72000//Orbital exenteration//RCD	P-1125//Exenteration//SNM
nasal chondromesenchymal hamartoma (ncmh)	
however, complete extirpation is preferred	
pituitary blastoma	
pineoblastoma	D010871//ПИНЕАЛОМА//MSHRUS	35000//pineoblastoma of pineal body//MEDCIN	0000020745//pineoblastoma//CHV	CDR0000046227//pineoblastoma//NCI_NCI-GLOSS	MTHU059670//pineoblastoma//ICPC2ICD10ENG	NOCODE//Developmental arithmetic disorder//MTH	M9362/3//Pineoblastoma//ICD10AM	BBa3.//Pineoblastoma//RCD	M-9362/3//Pineoblastoma//SNM	M-93623//Pineoblastoma//SNMI	TCGA//Enterovirus//NCI	10035058//Pineoblastoma//MDR	HP:0030408//Pineoblastoma//HPO	31671006//Pineoblastoma//SNOMEDCT_US	C9344//Pineoblastoma//NCI
immediate management issues may include interventions for obstructive hydrocephalus	
an aggressive surgical approach is associated with prolonged survival	
medications in use for pah include the following:	
endothelin blockers (oral)bosentanambrisenanmacitentan	
phosphodiesterase inhibitors (oral)sildenafiltadalafil	
guanylate cyclase stimulator (oral)riociguat	
calcium channel blockers	D002121//Calcium Channel Blockers//MSH	07250//Calcium Channel Blockers//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000019255//calcium channel blockers//AOD	0000002294//calcium channel blocker//CHV	40586//calcium channel blockers//MEDCIN	4021566//CALCIUM CHANNEL BLOCKERS//VANDF	N0000029119//[CV200] CALCIUM CHANNEL BLOCKERS//NDFRT	C08//CALCIUM CHANNEL BLOCKERS//ATC	LP31438-2//Calcium channel blockers//LNC	N0000000069//Calcium Channel Antagonists [MoA]//NDFRT
adjunctive agents	
mean survival after lung transplantation is about five years	
no specific therapy for ppd is available	
pain due to secondary osteoarthritis may respond to nsaids	
physical therapy may help preserve joint mobility	
immobilization (e	
, casting) should be avoided	
angular deformities of lower limbs	
progressive joint stiffness	
, hip and knee replacement)	
progressive stiffness and deformities of the spine	
scoliosis and mild kyphosis can be managed with bracing	
therapy is aimed at controlling symptoms that may cause discomfort	
myoclonus can sometimes be mitigated by clonazepam	
issues related to dysphagia are often difficult to resolve	
no curative treatment is available	
care is preferably provided by a multidisciplinary team	
growth hormone	D013006//Growth Hormone//MSH	N0000006637//Growth Hormone [Chemical/Ingredient]//NDFRT	21917//Growth Hormone//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000028412//growth hormone//AOD	CDR0000538639//growth hormone//NCI_NCI-GLOSS	0000011526//growth hormone//CHV	X80Fk//Growth hormone//RCD	DB00052//Somatotropin//DRUGBANK	10018747//Growth hormone//MDR	C80360//Somatotrophin//NCI_CDISC	GO:0005131//growth hormone receptor binding//GO	C2288//Somatotropin//NCI	2334-5503//somatotropin//CSP
, recombinant) gh	
tsh	D013972//thyreotropin//MSHCZE	2334-5627//thyrotropin//CSP	E-8608//Thyrotropic hormone, injectable//SNM	F-B1540//Thyroid stimulating hormone//SNMI	0000012272//thyroid stimulating hormone (TSH)//CHV	CDR0000537425//TSH//NCI_NCI-GLOSS	DB00024//Thyrotropin Alfa//DRUGBANK	C2280//Thyroid-Stimulating Hormone//NCI	65428006//Thyroid stimulating hormone//SNOMEDCT_US	10044712//TSH//MDRCZE	SDTM-LBTESTCD//PCP//NCI_CDISC
lh and fsh	
usually sex steroids are used to maintain secondary sex characteristics	
acth	D000324//adrenokortikotropní hormon//MSHCZE	0000028400//ACTH//AOD	2334-2251//adrenocorticotropic hormone//CSP	NOCODE//Developmental arithmetic disorder//MTH	F-B1500//Adrenocorticotropic hormone//SNMI	40957//adrenocorticotropic hormone//MEDCIN	74639//Adrenocorticotropin//FMA	N0000006478//Adrenocorticotropic Hormone [Chemical/Ingredient]//NDFRT	0000000781//adrenocorticotropic hormone (ACTH)//CHV	sh85000684//ACTH//LCH_NW	DB01285//Corticotropin//DRUGBANK	40789008//Adrenocorticotropic hormone//SNOMEDCT_US	CDR0000039133//corticotropin//PDQ	10000607//ACTH//MDRCZE	SDTM-LBTESTCD//PCP//NCI_CDISC	HGNC:9201//proopiomelanocortin//HGNC	NSC0025934//Acthar//NCI_DTP	C52424//POMC wt Allele//NCI	H01AA//ACTH and synthetic analog preparations//ATC	CDR0000549437//ACTH//NCI_NCI-GLOSS	C2282//Corticotropin//NCI
neonatal/acute decompensation	
in-patient management	
assess and manage ventilation and circulation as necessary	
determine the need for sepsis workup and antibiotics	
reverse catabolism by giving intravenous glucose and lipids	
dextrose solutions exceeding the concentration of 12	
5% require a central line placement	
additional calories can be provided using parenteral lipid emulsion	
manage protein intake to reduce propiogenic precursors	
remove toxic compounds	
pharmacologic detoxification:	
oral n-carbamoylglutamate (carglumic acid	
manage pancreatitis using standard practices	
home management of metabolic status	
at-home detection and monitoring of urine ketones	
diet modification under the direction of the metabolic team	
management of arrhythmias is similar to that from other causes	
dermatologic manifestations (e	
evaluation for dvts	
evaluation of pe	
bullous pulmonary disease	
psychosocial issues	C15891//Social Aspects of Cancer//NCI
0 mg/dl (360 μmol/l)	
febuxostat, a newer urate-lowering xanthine oxidase inhibitor	
note: excretion of >1	
high daily fluid intake (i	
, ≥2 l/day in the adult)	
xanthinuria does not respond to urinary alkalinization	
several expert groups (e	
giessen, germany)	
burtonsville, md)	
cholecystokinin (cck) and its analogues (e	
13c-mixed triglyceride breath test	
72-hour fecal fat	
sudan stain	314900004//Sudan stain//SNOMEDCT_US	0000057156//sudan stain//CHV
, mineral oil, olestra)	
, orlistat)	
chronic pancreatitis is associated with a gradual loss of function	
surgical methods are standard	
a target inr of 2	
5 (therapeutic range: 2	
anticoagulation is recommended:	
indefinitely for those with recurrent idiopathic vte	
cognitive/developmental delay	
see global developmental disability/ intellectual disability educational issues	
management by a neurologist	
, dystonia, dyskinesia, dysconjugate eye movements)	
vision deficits	
correction of refractive errors	
vision support	
standard treatment for strabismus & exophoria	
supplementary oxygen (at night) & rarely tracheostomy	
ambulatory peripheral saturation monitoring may be required	
congenital heart defect	N0000001431//Heart Defects, Congenital [Disease/Finding]//NDFRT	D006330//Heart Defects, Congenital//MSH	MTHU008662//Congenital heart defect//OMIM	HP:0001627//Abnormal heart morphology//HPO	0000005874//congenital heart defect//CHV	33162//congenital heart defect//MEDCIN
frequent aspiration (or high risk of aspiration)	
a percutaneous endoscopic gastrostomy tube may be considered	
medical management	
referral to a gastroenterologist may be required in severe cases	
congenital urogenital defect	
management as per current practice for the specific urogenital defect	
progressive neuropathic scoliosis may require spinal fusion	
osteoporosis/osteopenia	
instability in standing position	
neuropathic hip dysplasia, progressive subluxation, & dislocation	
consideration of hip reconstructions w/varus derotational proximal femoral osteotomies	
vitamin d deficiency	NOCODE//Sepsis//COSTAR	D014808//Vitamin D Deficiency//MSH	N0000003134//Vitamin D Deficiency [Disease/Finding]//NDFRT	C114830//Vitamin D Deficiency//NCI_NICHD	AVITAMINOSIS//AVITAMINOSIS//CST	U004413//VITAMIN D DEFICIENCY//DXP	0839//VITAMIN D DEFICIENCY//WHO	E55//Vitamin D deficiency//ICD10	U004979//Vitamin D deficiency//LCH	10047626//Vitamin D deficiency//MDR	XE112//Vitamin D deficiency//RCD	MTHU037303//Vitamin D deficiency//OMIM	sh85143983//Vitamin D deficiency//LCH_NW	HP:0100512//Vitamin D deficiency//HPO	268//Vitamin D deficiency//ICD9CM	34713006//Vitamin D deficiency//SNOMEDCT_US	0000004772//vitamin D deficiency//AOD	2116-7610//vitamin D deficiency//CSP	99877//vitamin D deficiency//MEDCIN	0000013055//vitamin d deficiency//CHV
vitamin d supplementation	
anterior pituitary hormone deficiencies	
standard treatment as directed by an endocrinologist	
global developmental disability/ intellectual disability educational issues	
, scoliosis, hip dislocation)	
, feeding, grooming, dressing)	
feeding, hyperphagia, and obesity	
therapies, education and behavior management	
initiate appropriate educational programming in children:	
social skills training groups have been beneficial	
however, preservation of fertility is not an issue	
standard treatment is appropriate	
angulo & miller, unpublished data]	
schulze et al 2001	
vats & cassidy, unpublished data]	
sleep issues	
skin picking	
management of strabismus is as for any infant	
adulthood	U005131//Adulthood//LCH	Xa1y5//Adulthood//RCD	F-08200//Adulthood//SNM	sh85001056//Adulthood//LCH_NW	41847000//Adulthood//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000010052//adulthood//AOD	0000044836//adulthood//CHV
affected individuals generally require a sheltered employment environment	
no specific treatment for pxe exists	
for all phenotypes	
occupational therapy to maximize motor function	
speech therapy for dysarthria	
rdp	179780//DIPEPTIDASE 1//OMIM	HGNC:13974//negative elongation factor complex member E//HGNC	128235//DYSTONIA 12//OMIM
standard therapies for the following are appropriate:	
ahc	C35261//Adrenal Hypoplasia Congenita//NCI_NICHD	300200//ADRENAL HYPOPLASIA, CONGENITAL//OMIM	C75865//NR0B1 wt Allele//NCI
episode prophylaxis (avoiding triggers	
prophylactic medications	
flunarizine	4459//Flunarizine//RXNORM	C83718//Flunarizine//NCI	N0000167125//Flunarizine [Chemical/Ingredient]//NDFRT	DB04841//Flunarizine//DRUGBANK	418221001//Flunarizine//SNOMEDCT_US	D005444//Flunarizine//MSH	0570-4361//vasodilator//CSP	2059-0377//anticonvulsant//CSP	2332-0723//piperazine//CSP	0000005110//flunarizine//CHV	003847//PROCHLORPERAZINE MALEATE 25 mg ORAL TABLET//NDDF	N07CA03//flunarizine//ATC	R7PLA2DM0J//FLUNARIZINE//NCI_FDA
chloral hydrate	3870//bicalutamide 50 mg oral tablet//MMSL	D002697//Chloral Hydrate//MSH	2344//Chloral Hydrate//RXNORM	N0000006140//Chloral Hydrate [Chemical/Ingredient]//NDFRT	08910//Chloral Hydrate//PSY	C28922//Chloral Hydrate//NCI	NOCODE//Developmental arithmetic disorder//MTH	XM0lA//Chloral hydrate//RCD	E-7866//Chloral hydrate//SNM	C-64220//Chloral hydrate//SNMI	LP16316-9//Chloral hydrate//LNC	MTHU007756//Chloral hydrate//LNC	DB01563//Chloral hydrate//DRUGBANK	28748001//Chloral hydrate//SNOMEDCT_US	273948005//Chloral hydrate//SNOMEDCT_US	0000019716//chloral hydrate//AOD	1371-6594//chloral hydrate//CSP	4404//sulfur topical 10% topical soap//MMSL	41179//chloral hydrate//MEDCIN	0000002810//chloral hydrate//CHV	001427//RINGER'S SOLUTION INTRAVEN INTRAVENOUS SOLUTION//NDDF	N05CC01//chloral hydrate//ATC	d00147//chloral hydrate//MMSL	N0000146094//CHLORAL HYDRATE//NDFRT	418M5916WG//CHLORAL HYDRATE//NCI_FDA	4017726//CHLORAL HYDRATE//VANDF
other sleep inducers	
epilepsy management utilizes existing anticonvulsants	
capos syndrome	C535351//CAPOS syndrome//MSH
symptomatic treatment includes hearing and visual aids	
capillary malformations (cms)	
avms/avfs	
, embolization vs	
surgery)	
cardiac overload	0000023326//cardiac overload//AOD
hemihyperplasia and/or leg length discrepancy	
lymphangiography to evaluate for lymphatic malformations may be considered	
prostheses	D019736//Prostheses and Implants//MSH	41150//Prostheses//PSY	C17598//Prosthesis//NCI	13-131//Prostheses//UMD	A-04000//Prosthesis, NOS//SNMI	0000018158//prosthesis//CHV
intervention and/or special education if developmental delays are detected	
cataract extraction may preserve some vision	
orthopedic procedures have improved function in some individuals	
dietary restriction of phytanic acid intake	
avoidance of sudden weight loss	
lifelong treatment with hydrating creams	
treatment of acute presentation	
treatment options for the eye include enucleation	
cryotherapy	0000003488//cryotherapy//CHV	S52014//cryotherapy//ICPC2P	X79uZ//Cryotherapy - action//RCD	10011483//Cryotherapy//MDR	26782000//Cryotherapy//SNOMEDCT_US	257786008//Cryotherapy - action//SNOMEDCT_US	C40030//Cryotherapy//NCI	D017679//Cryotherapy//MSH	2871-4676//cryotherapy//CSP	0000003489//cold temperature therapy//CHV	CDR0000045985//cryotherapy//NCI_NCI-GLOSS	CDR0000041882//cryosurgery//PDQ	41748//dermatological cryotherapy//MEDCIN
radiation therapy using episcleral plaques	
legal use of telescopic lenses may vary by locale	
retinoschisis affects primarily the inner retinal layers	
psychosocial support for families is an integral part of management	
they are tolerated better than milk of magnesia	
high dose supplementation	
supportive care	10068369//Supportive care//MDR	243114000//Support//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000030913//supportive care//CHV	CDR0000046609//supportive care//NCI_NCI-GLOSS	133455//supportive care//MEDCIN	C15747//Supportive Care//NCI
respiratory support	
physiotherapy to avoid contractures	
occupational therapy for support in activities of daily living	
orthotics for limb and trunk bracing	
speech and language therapy to avoid choking and respiratory problems	
wheel chair as needed	
low vision aids for those with decreased visual acuity	
routine management of scoliosis to avoid long term respiratory problems	
routine management of depression	
pharmacologic treatment focuses on improving pain and correcting bone deformation	
low dose	X90ph//Low dose//RCD	LP30872-3//Low dose//LNC	262459003//Low dose//SNOMEDCT_US	0000035571//low dose//CHV
high dose	X90YT//High dose//RCD	LP30871-5//High dose//LNC	261829003//High dose//SNOMEDCT_US	0000035494//high dose//CHV
50 to 0	
75 µg daily	
in these individuals, surgical treatment is frequently pursued	
the literature consists of case series	
craniofacial treatment	
sensorineural hearing loss has been reported in persons with xlh	
see hereditary hearing loss and deafness overview, management	
corrective surgeries may be required for repair of:	
abnormal penile insertion/penoscrotal position	
hormone therapy may be helpful for males with micropenis	
orthodontic treatment is typically required	
corrective surgeries may be required for the following:	
syndactyly repair	
severe scoliosis secondary to hemivertebrae and rib abnormalities	
cleft lip and cleft palate repair	
hormone therapy should be monitored by a pediatric endocrinologist	
orthodontic treatment is usually required	
no treatment is required	
cystoid macular edema (cme)	
optical aids	35565//Optical Aids//PSY
however, its current cost limits widespread use	
retinal prostheses	D057488//Visual Prosthesis//MSH
agencies for the visually impaired	
general management guidelines for those with systemic involvement:	
nutritional support (e	
management may include consideration of tracheostomy and artificial ventilation	
referral to a pediatric neurologist for seizure management	
of note, seizures may be refractory to treatment	
aggressive management of fever and infection	
5 epimutations possibly because children with 11p15	
initial treatment is use of a shoe lift	
neurodevelopment	2047-3428//neurogenesis//CSP	2053-6900//developmental neurobiology//CSP	1016-7347//neural plate/tube//CSP	0000042100//neurodevelopment//CHV
gastrointestinal disorders should be aggressively managed	
craniofacial anomalies	LA12675-7//Craniofacial anomalies//LNC
orthognathic surgery is rarely required	
referral of males with cryptorchidism to a urologist	
referral of males with micropenis to an endocrinologist	
androgenic hormone therapy as indicated	
neoplasia	A79002//neoplasia//ICPC2P	XE1vN//Tumour//RCD	N0000002128//Neoplasms [Disease/Finding]//NDFRT	HP:0002664//Neoplasm//HPO	C3262//Neoplasm//NCI	D009369//Neoplasms//MSH	0000004514//neoplasia//AOD	0000008566//tumor//CHV	CDR0000045801//neoplasia//NCI_NCI-GLOSS	MTHU000126//NEOPLASIA//OMIM	10028980//Neoplasia//MDRHUN	108369006//neoplasia//SCTSPA	55342001//Neoplastic disease//SNOMEDCT_US
standard treatment for hearing loss if identified	
standard treatment for cardiac defects if identified	
aggressive management of gastroesophageal reflux and constipation	
standard treatment for cryptorchidism if identified	
surgical repair of significantly angulated thumbs or duplicated halluces	
appropriate treatment for sleep apnea if identified	
visually significant cataracts require surgical removal	
complete cessation of symptoms is the goal	
it is therefore important that:	
adequate posture should be maintained when lying prone and sitting	
hematologic manifestations	
treatment is symptomatic:	
sensory axonal neuropathy	MTHU002517//Sensory axonal neuropathy//OMIM	HP:0003390//Sensory axonal neuropathy//HPO
physiotherapy and orthoses to prevent foot and spine deformity	
supportive shoes, splints, and braces	
foot care to treat calluses and ulcerations	
a walker, wheelchair, physiotherapy, occupational therapy	
some patients have benefited from lamotrigine or levetiracetam	
psychiatric symptoms	0000023100//psychiatric symptoms//CHV	41475//Psychiatric Symptoms//PSY	MTHU008320//Psychiatric symptoms//LNC
canes and walkers help prevent falling	
occupational therapy, including home adaptations	
physiotherapy and assessment for cane and wheelchair	
ankle-foot orthotics (afos) for those with neuropathy	
modest success has been observed in some affected individuals	
supplements of antioxidants, which may have some beneficial effects	
treatment of psychiatric syndromes as needed	
technical assistance with writing and other fine-motor tasks	
epileptic seizures can be improved by treatment with anticonvulsive medications	
treatment of seizures with antiepileptic drugs (aeds)	
treatment of dystonia with local injections of botulinum toxin	
at present, only symptomatic treatments are available	
these include the following:	
crutches (less often canes) and walkers	
speech/language therapy for dysarthria and swallowing difficulties	
surgical intervention as needed for severe ptosis	
symptoms of restless legs syndrome may respond to these agents	
non-pharmacologic therapy is important in sca3:	
specific treatment for sca36 is currently not available	
walking aids to facilitate ambulation and mobility	
the use of a wheelchair is rare	
speech therapy and communication devices for those with dysarthria	
the utility of cochlear implants in sca36 is unknown	
vestibular suppressants may reduce vertigo and/or osscilopsia	
canes, walking sticks, and walkers help prevent falling	
note: rbd is rare in individuals with sca6	
continuous positive airway pressure may be used for sleep apnea	
cerebellar ataxia	NOCODE//Sepsis//COSTAR	D002524//Cerebellar Ataxia//MSH	N0000000711//Cerebellar Ataxia [Disease/Finding]//NDFRT	1001650//CEREBELLAR ATAXIA//CCPSS	ATAXIA CEREBELL//CEREBELLAR ATAXIA//CST	U000582//EPILEPSY, PETIT MAL, MYOCLONIC ASTATIC//DXP	N99001//cerebellar ataxia//ICPC2P	10008025//Cerebellar ataxia//MDR	XM0qi//Cerebellar ataxia//RCD	F-84580//Ataxia//SNM	MTHU000926//Cerebellar ataxia//OMIM	sh92003930//Cerebellar ataxia//LCH_NW	HP:0001251//Ataxia//HPO	85102008//Cerebellar ataxia//SNOMEDCT_US	0000006221//cerebellar ataxia//AOD	0485-1497//cerebellar ataxia/dyskinesia//CSP	0000002646//cerebellar ataxia//CHV	36381//cerebellar ataxia//MEDCIN
retinal degeneration	N0000002607//Retinal Degeneration [Disease/Finding]//NDFRT	C34979//Retinal Degeneration//NCI	D012162//Retinal Degeneration//MSH	649//RETINAL DEGENERATION//COSTAR	RETINAL DEGENERAT//RETINAL DEGENERATION//CST	U004106//Retinal degeneration//LCH	10038845//Retinal degeneration//MDR	MTHU004856//Retinal degeneration//OMIM	350337//Retinal degeneration//MEDCIN	sh85113332//Retinal degeneration//LCH_NW	HP:0000546//Retinal degeneration//HPO	95695004//Degeneration of retina//SNOMEDCT_US	0000010794//retinal degeneration//CHV
use of canes and walkers helps prevent falls	
compound heterozygous for pathogenic variant and a susceptibility variant	
free carnitine levels were normal in all individuals	
no published treatment guidelines exist	
, dravet syndrome	
see scn1a-related seizure disorders and differential diagnosis)	
sodium channel blockers	D026941//Sodium Channel Blockers//MSH	NOCODE//Developmental arithmetic disorder//MTH	0000051565//sodium channel blockers//CHV	N0000181004//Sodium Channel Antagonists [MoA]//NDFRT
other aeds	
vagus nerve stimulator	447033006//Vagal nerve stimulator//SNOMEDCT_US
cannabinoids	U000770//Cannabinoids//LCH	D002186//Cannabinoids//MSH	N0000008010//Cannabinoids [Chemical/Ingredient]//NDFRT	LP16058-7//Cannabinoids//LNC	C105578//Cannabinoid//NCI	MTHU006737//Cannabinoids//LNC	sh85019609//Cannabinoids//LCH_NW	07436//Cannabinoids//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000000713//cannabinoids//AOD	0000002349//cannabinoids//CHV	10051623//Cannabinoids//MDR	N02BG10//cannabinoids//ATC	C74689//Cannabinoids//NCI_CDISC	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC
sleep hygiene	D000070263//Sleep Hygiene//MSH
it prevents the following:	
in most cases, cranioplasty precedes palatal repair	
ophthalmologic abnormalities are treated in a standard fashion	
routine monitoring (see surveillance) is recommended	
hematologic abnormalities	
prompt treatment of hypoglycemia if present	
ophthalmologist for management of vision problems	
neurologist if seizures are present	
oncologist if a tumor is identified	
surgical intervention for aneurysms may be indicated	
surgical repair of abdominal hernias may be indicated	
cleft palate and craniosynostosis require management by a craniofacial team	
surgical fixation of cervical spine instability may be necessary	
clubfoot deformity may require surgical correction	
pectus excavatum may be severe	
rarely, surgical correction is indicated for medical reasons	
physiotherapy	722138006//Physiotherapy//SNOMEDCT_US	L57005//physiotherapy//ICPC2P	10034998//Physiotherapy//MDR	Xa9EJ//Physiotherapy//RCD	LP94822-1//Physiotherapy//LNC	C15302//Physical Therapy//NCI_NICHD	38730//Physiotherapy//PSY	91251008//Physical therapy procedure//SNOMEDCT_US	0000024398//physiotherapy//AOD	0000053447//physical therapy//CHV	CDR0000041731//physiotherapy//PDQ
physiotherapy may help increase mobility in individuals with joint contractures	
axenfeld-rieger anomaly or related anterior chamber ocular anomalies	
dental anomalies	MTHU019019//Dental anomalies//OMIM	HP:0000164//Abnormality of the dentition//HPO
insulin resistance/diabetes mellitus	
a systematic approach to pain management should be reviewed regularly	
vaso-occlusive pain episodes (including dactylitis)	
, cold, dehydration)	
nsaids (e	
fever/suspected infection	
individuals with temperature greater than 38	
rapid triage and physical assessment	
urgent cbc and reticulocyte count	
acute chest syndrome (acs)	
perform chest x-ray examination	
incentive spirometry should be encouraged	
aplastic crisis	F-53920//Aplastic crisis//SNM	F-D0540//Aplastic crisis//SNMI	69075005//Aplastic crisis//SNOMEDCT_US	0000027912//aplastic crisis//CHV	0042612//APLASTIC CRISIS//CCPSS
blood transfusion may be necessary	
splenic sequestration	289.52//Splenic sequestration//ICD9CM	10063715//Splenic sequestration//MDR	0000056325//splenic sequestration//CHV	272874//splenic sequestration//MEDCIN
pulmonary hypertension	N0000001619//Hypertension, Pulmonary [Disease/Finding]//NDFRT	3634//Pulmonary Hypertension//MEDLINEPLUS	C3120//Pulmonary Hypertension//NCI_NICHD	D006976//Hypertension, Pulmonary//MSH	NOCODE//Developmental arithmetic disorder//MTH	0003536//PULMONARY HYPERTENSION//CCPSS	U000570//SUPERFICIAL VEIN PHLEBITIS//COSTAR	HYPERTENS PULM//PULMONARY HYPERTENSION//CST	U003273//PULMONARY HYPERTENSION//DXP	U003947//Pulmonary hypertension//LCH	X2033//Pulmonary hypertension//RCD	MTHU002225//Pulmonary hypertension//OMIM	LP128702-0//Pulmonary hypertension//LNC	MTHU040643//Pulmonary hypertension//LNC	sh85109008//Pulmonary hypertension//LCH_NW	E13539//Pulmonary hypertension//NCI_CTCAE	10037400//Pulmonary hypertension//MDR	416.0//Idiopathic pulmonary arteriosclerosis//MTHICD9	70995007//Pulmonary hypertension//SNOMEDCT_US	0000005282//pulmonary hypertension//AOD	2595-6954//pulmonary hypertension//CSP	0000006446//hypertension caused by lung disease//CHV	33363//pulmonary hypertension//MEDCIN	C55068//Pulmonary hypertension//NCI_CTCAE
the following general approach is reasonable:	
, thrombotic disease, obstructive sleep apnea)	
optimization of scd-related therapy to stop progression (e	
stroke	K90017//stroke//ICPC2P	NOCODE//Developmental arithmetic disorder//MTH	X00D1//Stroke//RCD	MTHU009877//Stroke//OMIM	N0000004160//Stroke [Disease/Finding]//NDFRT	8//Stroke//MEDLINEPLUS	E12826//Stroke//NCI_CTCAE	OMFAQ//Anemia//NCI	C3390//Cerebrovascular Accident//NCI_NICHD	1770//Cerebrovascular Accident//NCI_FDA	HP:0001297//Stroke//HPO	10042244//Stroke//MDR	LA22099-8//Stroke//LNC	230690007//Cerebrovascular accident//SNOMEDCT_US	D020521//Stroke//MSH	706//STROKE//COSTAR	CEREBROVASC ACCID//CEREBROVASCULAR ACCIDENT//CST	U003839//STROKE//DXP	0445//CEREBROVASCULAR DISORDER//WHO	0000006137//stroke//AOD	BI00086//stroke//BI	0617-5539//stroke//CSP	CDR0000439425//stroke//NCI_NCI-GLOSS	MTHU010383//stroke//ICPC2ICD10ENG	0000011781//stroke//CHV
cerebral hemorrhage requires immediate neurosurgical consultation	
chronic transfusion has been shown to reduce silent infarcts	
priapism	NOCODE//Sepsis//COSTAR	N48.3//Priapism//ICD10	Y08004//priapism//ICPC2P	U003825//Priapism//LCH	10036661//Priapism//MDR	XE0eE//Priapism//RCD	F-99010//Priapism//SNM	D7-57150//Priapism//SNMI	C85022//Priapism//NCI	N0000002492//Priapism [Disease/Finding]//NDFRT	sh85106605//Priapism//LCH_NW	HP:0200023//Priapism//HPO	MTHU054345//Priapism//OMIM	6273006//Priapism//SNOMEDCT_US	607.3//Priapism//ICD9CM	D011317//Priapism//MSH	1009964//PRIAPISM//CCPSS	PRIAPISM//PRIAPISM//CST	U001583//PRIAPISM//DXP	U003220//PRIAPISM//DXP	0890//PRIAPISM//WHO	0000010106//priapism//CHV	MTHU061617//priapism//ICPC2ICD10ENG	34200//priapism//MEDCIN
there is no effective treatment for xlsa/a	
weighted eating utensils may help promote independent skills in childhood	
speech therapy may improve intelligibility problems resulting from dysarthria	
hepatic and systemic iron overload does not occur	
orthopedic manifestations	
treatment of scoliosis and/or kyphosis is standard	
immunologic manifestations	
individuals with autoimmune problems have had variable responses to treatment	
infectious disease manifestations	
hypothyroidism can be treated with levothyroxine supplementation	
chelation therapy	D015913//Chelation Therapy//MSH	1630-1188//chelation therapy//CSP	0000002732//chelation therapy//CHV	sh85022868//Chelation therapy//LCH_NW	10052922//Chelation therapy//MDR
monitoring includes the following:	
complete blood count	D001772//Blood Cell Count//MSH	C28133//Blood Cell Count//NCI	6351//Blood Count Tests//MEDLINEPLUS	NOCODE//Developmental arithmetic disorder//MTH	0455-2482//blood cell count//CSP	U000007//complete blood count//MTH	0000003246//complete blood count test (CBC)//CHV	CDR0000045107//complete blood count//NCI_NCI-GLOSS	10010135//Complete blood count//MDR	26604007//Complete blood count//SNOMEDCT_US
assessment of liver function	
assessment of iron status	
treatment may need to be discontinued if:	
white blood count is <3	
5x109/l	
neutrophil count is <2	
0x109/l	
platelet count is <150x109/l	
although the role of atypical tranquilizers (e	
treatment of status dystonicus	
standard protocols are used in an intensive care setting	
cholesterol supplementation	
dental management can be challenging	
recurrent otitis media may require tympanostomy tube placement	
see spinal muscular atrophy	
feeding/growth	
manage gastroesophageal reflux disorder in the standard manner	
use oral suctioning as needed	
in some cases artificial ventilation and tracheostomy may be employed	
manage accordingly	
health issues specific to sma	
scoliosis occurs frequently in individuals with sma ii	
no surgical complications were identified	
hip dislocation is another orthopedic concern in sma	
ongoing pediatric care with regular immunizations	
[hildenbrand & smith 2012]	
no well-controlled treatment trials have been reported:	
thus, dosages may not be exact	
enclosed bed system for containment during sleep	
treatment with diet or medication as indicated	
treatment with corrective lenses as indicated for ophthalmologic abnormalities	
treatment of recurrent otitis media with tympanostomy tubes as needed	
the bones in sclerosteosis are thick and dense	
surgical intervention may be difficult and prolonged	
standard neurosurgical instruments may not be sufficient (i	
tooth extraction may be difficult	
management by an orthodontic or craniofacial team is recommended	
when clinical problems (e	
care includes:	
early referral to an experienced multidisciplinary team	
referral to special educational services for visually impaired infants	
referral to endocrinologist for growth or hypogonadism concerns	
referral to physiotherapist if any evidence of motor impairment exists	
referral to special educational services for neurodevelopmental problems as needed	
parent/caregiver training in seizure management	
no specific drug treatment or cures exist for spg11	
physiotherapy for stretching of the spastic muscles to prevent contractures	
anti-spastic drugs such as baclofen and tizanidine	
anticholinergic drugs are indicated for urinary urgency	
psychiatric manifestations should be treated in accordance with standard practice	
physiotherapy is appropriate	
foot deformities are corrected by surgical treatment	
improve muscle strength (through resistance exercise)	
improve cardiovascular fitness	
oxybutynin is helpful in reducing urinary urgency	
see also hereditary spastic paraplegia overview	
spasticity can be treated with:	
oral baclofen or tizanidine	
chemodenervation with botulinum a or b toxins	
intrathecal baclofen pump	342651//intrathecal baclofen pump//MEDCIN
see also prevention of secondary complications	
referral to orthotic services may be helpful	
urinary urgency can be treated with anticholinergic antispasmodic drugs	
symptomatic treatment includes use of the following:	
antispastic drugs for leg spasticity	
anticholinergic antispasmodic drugs for urinary urgency	
regular physiotherapy for stretching of spastic muscles	
no specific drug treatments or cures exist for spg7	
antispasmodic drugs (e	
no significant toxicity limits their use	
routine treatment of inguinal herniae	
surgical intervention as needed if scoliosis is significant	
l-dopa (0	
optimal therapeutic level is determined by clinical response	
tetrahydrobiopterin (bh4	
monoamine oxidase inhibitors (selegeline)	
serotonin reuptake inhibitors (sertraline)	
melatonin	D008550//melatonin//MSHCZE	U002892//Melatonin//LCH	5609//cefoTEtan 1 g/100 mL intravenous solution//MMSL	F-27820//Melatonin//SNM	F-B7080//Melatonin//SNMI	6711//Melatonin//RXNORM	116523008//Melatonin preparation//SNOMEDCT_US	74644//Melatonin//FMA	N0000010145//Melatonin [Chemical/Ingredient]//NDFRT	LP15036-4//Melatonin//LNC	JL5DK93RCL//Melatonin//MTHSPL	MTHU002350//Melatonin//LNC	sh85083394//Melatonin//LCH_NW	DB01065//Melatonin//DRUGBANK	41199001//Melatonin//SNOMEDCT_US	30540//Melatonin//PSY	C2267//Melatonin//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000018731//melatonin//AOD	2334-4121//melatonin//CSP	5037//coal tar topical 1% topical shampoo//MMSL	0000007900//melatonin//CHV	005039//ALBUTEROL SULFATE 2.5 mg/3 mL (0.083 %) INHALATION VIAL, NEBULIZER (ML)//NDDF	N05CH01//melatonin//ATC	CDR0000440118//melatonin//NCI_NCI-GLOSS	CDR0000042346//melatonin//PDQ	d04058//melatonin//MMSL	N0000148757//MELATONIN//NDFRT	4021324//MELATONIN//VANDF	C74867//Melatonin//NCI_CDISC	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC	199505//melatonin//MEDCIN	00552//Melatonin//NCI_DCP	C632//Therapeutic Melatonin//NCI
dopamine agonists (bromocriptine, pramipexole)	
anticholinergics	MTHU002579//Anticholinergics//USPMG	D018680//Cholinergic Antagonists//MSH	0000028631//anticholinergics//AOD	0000025026//anticholinergic drug//CHV	41065//anticholinergics//MEDCIN	R03BB//Anticholinergics inhalants for obstructive airway diseases//ATC	S01FA//Anticholinergic mydriatics and cycloplegics//ATC
methylphenidate	D008774//Methylphenidate//MSH	dw1..//Methylphenidate//RCD	E-7731//Methylphenidate//SNM	C-65520//Methylphenidate//SNMI	6901//Methylphenidate//RXNORM	C62045//Methylphenidate//NCI	N0000005717//Methylphenidate [Chemical/Ingredient]//NDFRT	LP16202-1//Methylphenidate//LNC	MTHU008754//Methylphenidate//LNC	sh91001552//Methylphenidate//LCH_NW	207ZZ9QZ49//Methylphenidate//MTHSPL	DB00422//Methylphenidate//DRUGBANK	18548003//Methylphenidate//SNOMEDCT_US	373337007//Methylphenidate//SNOMEDCT_US	31210//Methylphenidate//PSY	MTHU001089//Methylphenidate//USPMG	NOCODE//Developmental arithmetic disorder//MTH	0000019942//methylphenidate//AOD	2332-4330//methylphenidate//CSP	d00900//methylphenidate//MMSL	0000008064//methylphenidate//CHV	N06BA04//methylphenidate//ATC	004619//DEXTROMETHORPHAN HBR/PHENOL ORAL LOZENGE//NDDF	340443//methylphenidate//MEDCIN	32827//methylphenidate//MMSL	N0000147920//METHYLPHENIDATE//NDFRT	4019832//METHYLPHENIDATE//VANDF	80360//Methylphenidate//CPT
5 years [escalera et al 2010]	
and speech therapy [gropman 2003]	
refractive errors should be corrected with spectacles	
myringotomy tubes are often required	
some of these treatments have only been partially effective	
current treatment therapies focus on the following:	
treatments should begin at the time of diagnosis	
often existing xanthomas regress	
partial ileal bypass surgery (i	
sitosterolemia does not respond to standard statin treatment	
global developmental delay, cognitive dysfunction and intellectual disability	
seizure management is symptomatic	
other neurologic findings	
bracing for scoliosis and kyphosis	
blepharoplasty for significant ptosis	
hearing aids and/or cochlear implantation for sensorineural hearing loss	
agents such as gabapentin should be considered	
gentle handling may reduce pain that is worsened with movement	
splinting of affected joints may provide comfort	
consultation with a pain management specialist may be helpful	
palliative care may be an option in severe cases	
a nutritionist should follow affected individuals	
protein-losing enteropathy	N0000002505//Protein-Losing Enteropathies [Disease/Finding]//NDFRT	D011504//Protein-Losing Enteropathies//MSH	J69y1//Protein-losing enteropathy//RCD	D5-47170//Protein-losing enteropathy//SNMI	MTHU005035//Protein-losing enteropathy//OMIM	HP:0002243//Protein-losing enteropathy//HPO	66972006//Protein-losing enteropathy//SNOMEDCT_US	0000005579//protein-losing enteropathy//AOD	0000010248//protein losing enteropathy//CHV	30214//protein losing enteropathy//MEDCIN	R0121735//PROTEIN-LOSING ENTEROPATHY//QMR
an effective long-term treatment is lacking	
dermatitis	D003872//Dermatitis//MSHDUT	10012431//dermatitis//MDRDUT	S88005//dermatitis//ICPC2P	X505K//Eczema//RCD	M-40000//Inflammation//SNM	MTHU001691//Dermatitis//OMIM	N0000000939//Dermatitis [Disease/Finding]//NDFRT	208//Rashes//MEDLINEPLUS	1215//Eczema//MEDLINEPLUS	703938007//Inflammatory dermatosis//SNOMEDCT_US	HP:0011123//Inflammatory abnormality of the skin//HPO	13710//Dermatitis//PSY	C2983//Dermatitis//NCI	NOCODE//Developmental arithmetic disorder//MTH	0050959//DERMATITIS//CCPSS	226//DERMATITIS//COSTAR	RASH//RASH//CST	0007//DERMATITIS//WHO	BI00582//dermatitis//BI	4008-0032//dermatitis//CSP	0000003790//skin inflammation//CHV	CDR0000045667//dermatitis//NCI_NCI-GLOSS	MTHU022506//dermatitis//ICPC2ICD10ENG	3393//dermatitis//MEDCIN
perianal masses may be excised, but may recur	
contractures are typically progressive	
immune system/infections	
the treatment for thrombocytopenia is platelet transfusion as needed	
but the clinical response is unpredictable and generally poor	
the management of epilepsy in many genetic epilepsies is complex	
refer to an urologist or nephrologist as indicated	
manage according to the anomalies detected	
imperforate anus	PB26.//Imperforate anus//RCD	M-26900//Imperforation, congenital//SNM	D4-56912//Congenital atresia of anus//SNMI	MTHU001447//Imperforate anus//OMIM	Q42.3//Congenital absence, atresia and stenosis of anus without fistula//ICD10CM	HP:0002023//Anal atresia//HPO	10021528//Imperforate anus//MDR	751.2//Congenital absence of anus//MTHICD9	204731006//Imperforate anus//SNOMEDCT_US	ANUS IMPERFOR//IMPERFORATE ANUS//CST	C84784//IMPERFORATE ANUS//NCI_CDISC	0000001341//imperforate anus//CHV	362043//imperforate anus//MEDCIN	263358//imperforate anus//MEDCIN	D001006//Anus, Imperforate//MSH
immediate surgical intervention is required	
thumb malformations	
, removal of additional thumbs)	
birth to 2 years: airway and feeding difficulties	
13 years to 18 years: orthognathic surgery	
generally, bone reconstruction precedes soft tissue corrections	
reconstruction can prevent the progression of facial asymmetry	
maxillomandibular reconstruction	
orthognathic procedures are typically indicated before age 16 years	
misaligned teeth often require orthodonture	
nasal reconstruction, if needed, should follow orthognathic surgeries	
other measures:	
medication to control seizures, as in the general population	
shunt placement, when hydrocephaly is identified	
suboccipital decompression for relief of craniocervical junction constriction	
hearing aids, when hearing loss is identified	
supplemental oxygen should be administered as needed	
other individualized ambulatory devices may be indicated	
carpal tunnel release surgery for carpal tunnel syndrome	
vitrectomy for vitreous involvement	
therapeutic phlebotomy	99195//Phlebotomy, therapeutic (separate procedure)//CPT	127606004//Therapeutic phlebotomy//SNOMEDCT_US	0000002029//venesection//CHV	40090//therapeutic phlebotomy//MEDCIN
periodic phlebotomy (i	
the usual therapy is weekly phlebotomy	
camaschella & roetto, unpublished observation]	
treatment of clinical complications	
in some cases, joint replacement has been performed	
diabetes mellitus may require lifelong insulin treatment	
glycopyrolate or scopolamine to improve drooling	
standard anticonvulsant medication to control seizures, if present	
placement of permanent feeding tube to avert malnutrition	
see also therapies under investigation	
, 0	
mild form (th-deficient drd)	
individuals demonstrate complete responsiveness of symptoms to levodopa treatment	
individuals show a marked response to levodopa	
very severe form (th-deficient progressive infantile encephalopathy)	
individuals are extremely sensitive to levodopa	
2 to 1	
long qt interval	
beta-blockers	C29576//Beta-Adrenergic Antagonist//NCI
pacemaker	CDR0000476118//pacemaker//NCI_NCI-GLOSS	1396-2279//electronic pacemaker//CSP	A89003//pacemaker//ICPC2P	0000009174//pacemaker//CHV	1008565//PACEMAKER//CCPSS	546//PACEMAKER//COSTAR	D010138//Pacemaker//MSHFRE	PACEM//Pacemaker//HL7V2.5	C99998//PACEMAKER//NCI_CDISC	C111285//Pacemaker//NCI_CDISC	SDTM-HETEST//Comparison to a Prior ECG//NCI_CDISC	SDTM-EGTEST//Comparison to a Prior ECG//NCI_CDISC
implants	U000275//Implants//SNM	NOCODE//Developmental arithmetic disorder//MTH	0000006623//implant//CHV	59771-6//Procedure implants:Find:Pt:^Patient:Nar//LNC
respiratory infections	0000010770//respiratory tract infection (RTI)//CHV	MTHU008079//Respiratory infections//OMIM	8.1//Respiratory infections//CCS	sh91002859//Respiratory infections//LCH_NW	HP:0011947//Respiratory tract infection//HPO	N0000002603//Respiratory Tract Infections [Disease/Finding]//NDFRT	D012141//Respiratory Tract Infections//MSH
the possibility of reduced immune response should be considered	
surgical release of syndactyly	
currently there is no definitive treatment	
management should involve a multidisciplinary team	
management of trps is principally supportive	
ectodermal features	
hair	U002065//Hair//LCH	D006197//Hair//MSH	U000413//Hair//SNM	T-01400//Hair//SNM	53667//Hair//UWDA	MTHU000252//Hair//OMIM	LP7280-3//Hair//LNC	MTHU001341//Hair//LNC	sh85058305//Hair//LCH_NW	C32705//HAIR//NCI_CDISC	386045008//Hair structure//SNOMEDCT_US	22100//Hair//PSY	HAR//Hair//HL7V2.5	NOCODE//Developmental arithmetic disorder//MTH	0000000630//hair//AOD	2716-0900//hair//CSP	0000005762//hair//CHV
however, reported results vary	
hands	D006225//Hand//MSH	MTHU000072//Hands//OMIM	0000005789//hand//CHV
regular simple analgesia (e	
physiotherapy may aid mobility	
for trps ii only	
exostoses	0000004775//ear blockage caused by overgrown bone//CHV	D005096//Exostoses//MSH	N0000001174//Exostoses [Disease/Finding]//NDFRT	MTHU027312//Exostoses//OMIM	HP:0100777//Exostoses//HPO	NOCODE//Developmental arithmetic disorder//MTH
restriction of dietary trimethylamine and its precursors	
choline	U000991//Choline//LCH	4875//Choline//MMSL	D002794//Choline//MSH	Ub08Y//Choline//RCD	F-11620//Choline//SNM	F-61620//Choline//SNMI	2449//Choline//RXNORM	C61674//Choline//NCI	N0000007087//Choline [Chemical/Ingredient]//NDFRT	N91BDP6H0X//Choline//MTHSPL	sh85024656//Choline//LCH_NW	00994//Choline//NCI_DCP	DB00122//Choline//DRUGBANK	65123005//Choline//SNOMEDCT_US	09030//Choline//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000018517//choline//AOD	0663-0420//choline//CSP	d03159//choline//MMSL	4436//Xylocaine Viscous//MMSL	0000002888//choline//CHV	CDR0000556410//choline//NCI_NCI-GLOSS	002058//LYSINE HCL/VITAMIN B COMPLEX ORAL LIQUID (ML)//NDDF	N0000146071//CHOLINE//NDFRT	4017699//CHOLINE//VANDF
dietary choline is absorbed through the small intestine	
trimethylamine n-oxide	C005855//trimethyloxamine//MSH
intake of such vegetables should be restricted	
use of acid soaps and body lotions	
trimethylamine is a strong base (pka 9	
thus, at ph 6	
0, less than 0	
02% of trimethylamine exists as the volatile free base	
sequestering of trimethylamine produced in the gut	
suppression of intestinal production of trimethylamine	
enhancement of residual fmo3 enzyme activity	
counseling	U001183//Counseling//LCH	D003376//Counseling//MSH	X71Ec//Counseling//RCDAE	5240//Counseling//NIC	C61547//Counseling//NCI	sh85033421//Counseling//LCH_NW	1014980//Counseling//CPT	409063005//Counseling//SNOMEDCT_US	12080//Counseling//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000009662//counseling//AOD	4000-0156//counseling//CSP	0000003409//counseling//CHV	0000019730//counseling therapy//CHV	CDR0000450098//counseling//NCI_NCI-GLOSS	309567//counseling//MEDCIN	MTHU081707//counseling//ICPC2ICD10ENG	133355//duration of counseling//MEDCIN
affected individuals and their families benefit from counseling	
see table 3	
dental crowding /	
malocclusion	NOCODE//Sepsis//COSTAR	U002796//Malocclusion//LCH	D008310//Malocclusion//MSH	Xa0ll//Malocclusion//RCD	F-60430//Malocclusion//SNM	MTHU001511//Malocclusion//OMIM	C85055//Malocclusion//NCI	N0000001930//Malocclusion [Disease/Finding]//NDFRT	sh85080183//Malocclusion//LCH_NW	707598004//Malocclusion//SNOMEDCT_US	HP:0000689//Dental malocclusion//HPO	10061274//Malocclusion//MDR	01301//Malocclusion//NANDA-I	47944004//Malocclusion of teeth//SNOMEDCT_US	U002497//MALOCCLUSION//DXP	0000005487//malocclusion//AOD	0828-3880//malocclusion//CSP	45.05//malocclusion//OMS	0000007703//malocclusion//CHV	MTHU047342//malocclusion//ICPC2ICD10ENG	95987//malocclusion//MEDCIN
dietary diary & calorie counts may be requested	
gerd and/or constipation	
standard treatment(s)	
standard treatment(s) as recommended by neurologist	
scoliosis / kyphosis	
standard treatment as recommended by orthopedist	
effectiveness should be evaluated on an individual basis	
high-dose thiamine supplementation:	
invariably improves the hematologic picture	
additional treatment	
red blood cell transfusion for severe anemia is indicated	
treatment has included cochlear implant [hagr 2014]	
in some instances intrathecal baclofen pumps can be considered	
dystonia can be managed with:	
baclofen or intramuscular botulinum toxin when associated with spasticity	
trihexyphenidyl or tetrabenazine	
dysarthria may warrant augmentative communication tools	
anticonvulsant medications should be used when seizures are present	
subependymal giant cell astrocytomas (segas)	
additional trials are underway to confirm these preliminary findings	
renal angiomyolipoma	MTHU020005//Renal angiomyolipoma//OMIM	HP:0006772//Renal angiomyolipoma//HPO	C3888//Kidney Angiomyolipoma//NCI	31540//angiomyolipoma of kidney//MEDCIN
facial angiofibromas	MTHU018351//Facial angiofibromas//OMIM	HP:0009720//Adenoma sebaceum//HPO
cardiac rhabdomyomas	
, outflow tract obstruction) was surgery	
however, response to treatment is highly individual	
oxygen therapy is necessary with impaired lung function	
persons with severe disease require lung transplantation	
management guidelines have been published	
acute management of liver failure	
nitisinone (orfadin®)	
nitisinone is generally prescribed at 1	
0 mg/kg/day	
individual requirements may vary	
nitisinone is typically given in two divided doses	
low-tyrosine diet	
3 mg/dl)	
transplant recipients require long-term immunosuppression	
transplant recipients may also benefit from low-dose (0	
ocular abnormalities (nystagmus/strabismus)	
ophthalmologic management	
oral feeding difficulties	
g-tube feeding	
braces and/or corrective surgery	
self-injurious behavior	D016728//Self-Injurious Behavior//MSH	NOCODE//Developmental arithmetic disorder//MTH	250210//Self-injurious behavior//NOC	MTHU005697//Self-injurious behavior//OMIM	X766K//Self-injurious behavior//RCDAE	sh91001773//Self-injurious behavior//LCH_NW	HP:0100716//Self-injurious behavior//HPO	03191//Self-injurious behavior//NANDA-I	248062006//Self-injurious behavior//SNOMEDCT_US	0000022682//self-injurious behavior//AOD	0000015530//deliberate self harm//CHV
behavior modification therapy	41849//behavior modification therapy//MEDCIN
hypo/hypertonia, gross motor delays, sensory processing difficulties	
physical therapy, occupational therapy	
absent speech	MTHU012538//Absent speech//OMIM	HP:0001344//Absent speech//HPO
sign language instruction	
consider alternate forms of communication	
urinary tract	X755v//Urinary tract//RCD	T-70100//Urinary tract//SNM	LP7687-9//Urinary tract//LNC	MTHU001416//Urinary tract//LNC	NOCODE//Developmental arithmetic disorder//MTH	D014551//Urinary Tract//MSH	0018688//URINARY TRACT//CCPSS	T-70000//Urinary tract, NOS//SNMI	3045-4980//urinary tract//CSP	0000012788//urinary tract//CHV	326482//Urinary tract//FMA	CDR0000046095//urinary tract//NCI_NCI-GLOSS
urinary tract infections warrant rapid and complete treatment	
antibiotic prophylaxis may also be considered	
bowel	T-50500//Intestine//SNM	7199//Intestine//UWDA	LP7078-1//Bowel//LNC	MTHU002653//Bowel//LNC	C12736//Intestine//NCI	BOWEL//Bowel//HL7V2.5	113276009//Intestinal structure//SNOMEDCT_US	CDR0000046500//bowel//NCI_NCI-GLOSS	0000006866//bowel//CHV	SDS//Bowel//NCI
constipation is managed as for the general population	
balance	NOCODE//Developmental arithmetic disorder//MTH	X76o9//Balance//RCD	249982003//Balance//SNOMEDCT_US	4000-0124//balance//CSP	0000004587//balance//CHV	705235004//Balance//SNOMEDCT_US	G-A636//Balanced//SNMI	78933003//Balanced//SNOMEDCT_US	091101//Balance//NOC	0202//Balance//NOC	020801//Balance//NOC	LP21354-3//Balance//LNC	C73497//Balance//NCI	164806//examination of balance//MEDCIN	DB12938//Isoxaflutole//DRUGBANK
hearing aids are helpful	
environmental trauma (e	
, noise) or a genetic susceptibility (e	
in such individuals, cochlear implantation may be warranted	
no guidelines exist for the management of vhl lesions	
cns hemangioblastoma	C7007//Central Nervous System Hemangioblastoma//NCI
two patients required additional surgery	
retinal hemangioblastoma	HP:0009711//Retinal capillary hemangioma//HPO	C39783//Retinal Hemangioblastoma//NCI
renal cell carcinoma	N0000000678//Carcinoma, Renal Cell [Disease/Finding]//NDFRT	TCGA//Enterovirus//NCI	C9385//Renal Cell Carcinoma//NCI_NICHD	D002292//Carcinoma, Renal Cell//MSH	NOCODE//Developmental arithmetic disorder//MTH	M8312/3//Renal cell carcinoma//ICD10AM	X78Yx//Clear cell carcinoma of kidney//RCD	M-8312/3//Renal cell carcinoma//SNM	M-83123//Renal cell carcinoma//SNMI	10067946//Renal cell carcinoma//MDR	sh93001433//Renal cell carcinoma//LCH_NW	702391001//Renal cell carcinoma//SNOMEDCT_US	HP:0005584//Renal cell carcinoma//HPO	41607009//Renal cell carcinoma//SNOMEDCT_US	1007858//RENAL CELL CARCINOMA//CCPSS	R0121764//RENAL CELL CARCINOMA//QMR	U001659//RENAL CELL CARCINOMA//DXP	4003-0049//renal cell carcinoma//CSP	0000002435//renal cell carcinoma//CHV	CDR0000661352//renal cell carcinoma//NCI_NCI-GLOSS	CDR0000038140//renal cell cancer//PDQ	31535//renal cell carcinoma//MEDCIN	C91501//Renal cell carcinoma//NCI_KEGG	C103084//Renal Cell Carcinoma//NCI_CTEP-SDC
3% and 4	
3%, respectively [young et al 2012]	
pheochromocytomas	D010673//Pheochromocytoma//MSH	0000009623//pheochromocytoma//CHV
pheochromocytomas should be surgically removed	
laparoscopic approaches have been shown to be effective	
partial adrenalectomy could be considered	
one long-term follow-up study (9	
partial adrenalectomy is also therapy of choice in children	
in 10 vhl patients 18 successful operations were performed	
after follow up (median 7	
pancreatic cysts and neuroendocrine tumors	
a tumor of ≥3 cm	
a pathogenic variant in exon 3	
a tumor with a doubling rate <500 days	
endolymphatic sac tumors (elst)	
twenty-nine patients were symptomatic	
epididymal or broad ligament papillary cyst adenomas	
physical therapy to promote ambulation	
treatment is required for any symptomatic vmcm lesion	
an appropriate dose is 0	
625 ml/kg) or 150 mg/m2 (3	
75 ml/m2)	
desmopressin	d00583//desmopressin//MMSL	3251//desmopressin//RXNORM	0000003812//desmopressin//CHV	H01BA02//desmopressin//ATC	004784//PHENOBARBITAL/HYOSCYAMINE SULF/ATROPINE SULF/SCOPOLAMINE HB 48.6 mg ORAL TABLET, EXTENDED RELEASE//NDDF	ENR1LLB0FP//desmopressin//MTHSPL	NOCODE//Developmental arithmetic disorder//MTH	fl1..//Desmopressin product//RCD	C61701//Desmopressin//NCI	N0000170340//Deamino Arginine Vasopressin [Chemical/Ingredient]//NDFRT	sh93001848//Desmopressin//LCH_NW	DB00035//Desmopressin//DRUGBANK	126189002//Desmopressin//SNOMEDCT_US	MTHU001341//Desmopressin//USPMG	D003894//Deamino Arginine Vasopressin//MSH	N0000147801//DESMOPRESSIN//NDFRT	4019709//DESMOPRESSIN//VANDF
intranasal preparations are also available	
intravenous infusion of vwf/fviii clotting factor concentrates	
in those who are non-responsive to desmopressin (i	
virus inactivation procedures eliminate potential pathogens	
indirect treatments	
fibrinolytic inhibitors (i	
hormonal treatments (i	
treatment by vwd type	
type 1 vwd	
treatments that directly increase vwf levels (e	
indirect treatment with fibrinolytic inhibitors or hormones is often effective	
type 2a vwd	
indirect treatments can be beneficial	
type 2b vwd	
[federici et al 2009]	
indirect treatments (i	
, fibrinolytic inhibitors) can be useful	
type 2m vwd	
type 2n vwd	
type 3 vwd	N0000181201//von Willebrand Disease, Type 3 [Disease/Finding]//NDFRT	D056729//von Willebrand Disease, Type 3//MSH
desmopressin is not effective in type 3 vwd	
indirect treatments may also be beneficial	
vwf levels are higher in the neonatal period	
pharmacotherapy	C15986//Pharmacotherapy//NCI	TCGA//Enterovirus//NCI	D004358//Drug Therapy//MSH	38080//Pharmacotherapy//PSY	U001875//Pharmacotherapy//MTH	0000024417//pharmacotherapy//AOD	0000004154//drug therapy//CHV	0962-5748//chemotherapy//CSP	Q000188//drug therapy//MSH
to reduce or delay side effects (e	
patients treated with ergot-derived dopamine agonists require periodic echocardiograms	
droxidopa may be used to treat orthostasis	
click here for full text	
management is supportive/symptomatic	
cleft lip	NOCODE//Sepsis//COSTAR	C87175//Cleft Lip//NCI	N0000000792//Cleft Lip [Disease/Finding]//NDFRT	D002971//Cleft Lip//MSH	CLEFT LIP//CLEFT LIP//CST	U000772//HEART BLOCK, CONGENITAL//DXP	0680//CLEFT PALATE//WHO	Q36//Cleft lip//ICD10	10009259//Cleft lip//MDR	P91..//Cleft lip//RCD	MTHU036343//Cleft lip//OMIM	sh85058909//Cleft lip//LCH_NW	LA14411-5//Cleft lip//LNC	02032//Cleft lip//NANDA-I	749.1//Cleft lip//ICD9CM	80281008//Cleft lip//SNOMEDCT_US	0000023218//cleft lip//AOD	0725-8436//cleft lip//CSP	6759//cleft lip//MEDCIN	0000003026//cleft lip//CHV	30402//cleft lip//MEDCIN	HP:0410030//Cleft lip//HPO
management is surgical, dental, and orthodontic	
lip pits	28041003//Congenital lip pits//SNOMEDCT_US	X20TO//Lip pits//RCD	MTHU019216//Lip pits//OMIM	0000030647//lip pits//CHV
popliteal pterygium	MTHU041204//Popliteal pterygium//OMIM	HP:0009756//Popliteal pterygium//HPO
syndactyly may require surgery	
the genital anomalies may result in infertility	
refractive error is corrected by spectacles or contact lenses	
visually disabling cataract is treated by cataract surgery	
wiskott-aldrich syndrome	D014923//Wiskott-Aldrich Syndrome//MSH	N0000003164//Wiskott-Aldrich Syndrome [Disease/Finding]//NDFRT	C3448//Wiskott-Aldrich Syndrome//NCI_NICHD	NOCODE//Developmental arithmetic disorder//MTH	U002027//WISKOTT-ALDRICH SYNDROME//DXP	277970//WISKOTT-ALDRICH SYNDROME//OMIM	300392//WAS GENE//OMIM	301000//WISKOTT-ALDRICH SYNDROME//OMIM	D82.0//Wiskott-Aldrich syndrome//ICD10	10047992//Wiskott-Aldrich syndrome//MDR	C3912//Wiskott-Aldrich syndrome//RCD	D-4612//Immunodeficiency with thrombocytopenia and eczema//SNM	DC-51210//Wiskott-Aldrich syndrome//SNMI	31865//Wiskott-Aldrich syndrome//MEDCIN	CDR0000539110//Wiskott-Aldrich syndrome//NCI_NCI-GLOSS	36070007//Wiskott-Aldrich syndrome//SNOMEDCT_US	279.12//Wiskott-aldrich syndrome//ICD9CM	0000013173//wiskott-aldrich syndrome//CHV	HGNC:12731//Wiskott-Aldrich syndrome//HGNC
[buchbinder et al 2014]	
hematopoietic cell transplantation (hct)	
eczema	S88006//eczema//ICPC2P	U001503//Eczema//LCH	10014184//Eczema//MDR	D004485//Eczema//MSH	X505K//Eczema//RCD	M-48000//Dermatitis, eczematous//SNM	MTHU003535//Eczema//OMIM	N0000001056//Eczema [Disease/Finding]//NDFRT	1215//Eczema//MEDLINEPLUS	sh85040936//Eczema//LCH_NW	TCGA//Enterovirus//NCI	C3001//Eczema//NCI_NICHD	HP:0000964//Eczema//HPO	00500//Eczema//NANDA-I	43116000//Eczema//SNOMEDCT_US	15950//Eczema//PSY	NOCODE//Developmental arithmetic disorder//MTH	0043411//ECZEMA//CCPSS	272//ECZEMA//COSTAR	ECZEMA//ECZEMA//CST	U000509//ECZEMA//DXP	0012//ECZEMA//WHO	0000005208//eczema//AOD	BI00585//eczema//BI	2716-6344//eczema//CSP	0000004268//eczema//CHV	CDR0000462675//eczema//NCI_NCI-GLOSS	MTHU024808//eczema//ICPC2ICD10ENG	310699//eczema//MEDCIN
topical steroids are the mainstay of therapy	
autoimmune disease	Xa2b1//Autoimmune disease//RCD	D-4700//Autoimmune disease//SNM	MTHU027840//Autoimmune disease//OMIM	LP128504-0//Autoimmune disease//LNC	MTHU040494//Autoimmune disease//LNC	HP:0002960//Autoimmunity//HPO	01925//Autoimmune disease//NANDA-I	85828009//Autoimmune disease//SNOMEDCT_US	N0000000514//Autoimmune Diseases [Disease/Finding]//NDFRT	C2889//Autoimmune Disease//NCI_NICHD	1732//Autoimmune Disease//NCI_FDA	D001327//Autoimmune Diseases//MSH	0000023560//autoimmune disease//AOD	0000001603//autoimmune disease//CHV	CDR0000045604//autoimmune disease//NCI_NCI-GLOSS	MTHU009485//autoimmune disease//ICPC2ICD10ENG	98338//autoimmune disease//MEDCIN	0022871//AUTOIMMUNE DISEASE//CCPSS	109100//AUTOIMMUNE DISEASE//OMIM
x-linked thrombocytopenia (xlt)	
, risk of secondary malignancy, infertility)	
x-linked neutropenia (xln)	
camptodactyly	M-31030//Displacement, anterior//SNM	D1-80411//Camptodactyly//SNMI	298005//Camptodactyly//MEDCIN	U000535//ENCEPHALITIS, JAPANESE B//DXP	0000021409//acquired camptodactyly//CHV	PF5r2//Camptodactyly//RCD	MTHU000189//Camptodactyly//OMIM	HP:0012385//Camptodactyly//HPO	29271008//Camptodactyly//SNOMEDCT_US	0000044014//congenital camptodactyly//CHV
occasionally toe camptodactyly may require surgical intervention	
physiotherapy may also be beneficial	
ligamentous laxity	HP:0001388//Joint laxity//HPO	MTHU010839//Ligamentous laxity//OMIM
control of type 2 diabetes mellitus	
use of cholesterol-lowering drugs if lipid profile is abnormal	
muscle atrophy is a potential complication	
surgical treatment of ocular cataracts	
treatment of malignancies in a standard fashion	
treatment follows routine practices for insulin-dependent diabetes mellitus	
wfs	222300//WOLFRAM SYNDROME 1//OMIM	HGNC:12762//wolframin ER transmembrane glycoprotein//HGNC
low-frequency sensorineural hearing loss (lfsnhl)	
psychiatric difficulties	
neurogenic bladder	NOCODE//Sepsis//COSTAR	C79696//Neurogenic Bladder//NCI	N0000000565//Urinary Bladder, Neurogenic [Disease/Finding]//NDFRT	164//Bladder Diseases//MEDLINEPLUS	D001750//Urinary Bladder, Neurogenic//MSH	N99029//neurogenic bladder//ICPC2P	U003189//Neurogenic bladder//LCH	10029279//Neurogenic bladder//MDR	X30Nj//Neuropathic bladder//RCD	F-65890//Neurogenic dysfunction of the urinary bladder//SNM	F-72150//Neurogenic dysfunction of the urinary bladder//SNMI	MTHU037120//Neurogenic bladder//OMIM	sh85091123//Neurogenic bladder//LCH_NW	HP:0000011//Neurogenic bladder//HPO	398064005//Neurogenic bladder//SNOMEDCT_US	BI00421//neurogenic bladder//BI	0000001957//neurogenic bladder//CHV	30650//neurogenic bladder//MEDCIN
treatment of central diabetes insipidus follows routine practices	
treatment of gastroparesis and celiac disease follows routine practices	
(see celiac disease	
sleeping problems	
if no medical factors (e	
hepatic adenomas	
other structural anomalies (e	
cognitive/behavioral	
self-calming techniques can help manage anxiety	
hypertension is usually treated medically	
hypercalcemia	U002302//Hypercalcemia//LCH	U000232//Blood group antigen Hr//MTH	X40Qa//Hypercalcemia//RCDAE	F-10123//Calcium, increased level//SNM	D6-34700//Hypercalcemia//SNMI	E83.52//Hypercalcemia//ICD10CM	N0000001577//Hypercalcemia [Disease/Finding]//NDFRT	MTHU036717//Hypercalcemia//OMIM	166702002//Hypercalcemia//SNOMEDCT_VET	sh85063679//Hypercalcemia//LCH_NW	E12270//Hypercalcemia//NCI_CTCAE	C3112//Hypercalcemia//NCI_NICHD	HP:0003072//Hypercalcemia//HPO	10020587//Hypercalcemia//MDR	2780//Calcium//MEDLINEPLUS	02487//Hypercalcemia//NANDA-I	10020583//Hypercalcaemia//MDR	66931009//Hypercalcemia//SNOMEDCT_US	275.42//Hypercalcemia//ICD9CM	D006934//Hypercalcemia//MSH	0048935//HYPERCALCEMIA//CCPSS	392//HYPERCALCEMIA//COSTAR	HYPERCALCEM//HYPERCALCEMIA//CST	U002015//VULVA, HERPES//DXP	NOCODE//Developmental arithmetic disorder//MTH	0000005779//hypercalcemia//AOD	BI00346//hypercalcemia//BI	0531-7446//hypercalcemia//CSP	0000006403//hypercalcemia//CHV	CDR0000045363//hypercalcemia//NCI_NCI-GLOSS	CDR0000041391//hypercalcemia//PDQ	A91025//hypercalcaemia//ICPC2P	33645//hypercalcemia//MEDCIN
management of hypercalcemia involves the following:	
hydration status should be assessed	
increase water intake as indicated	
but the serum concentration of calcium must be monitored	
vitamin supplements containing vitamin d should be avoided	
refractory hypercalcemia may be treated with oral steroids	
eye, ear, nose, and throat	
hyperopia is treated with corrective lenses	
dacrostenosis is treated as in the general population	
recurrent otitis media may be treated with tympanotomy tubes	
dental care may require assistance with daily brushing and flossing	
orthodontic referral should be considered for treatment of malocclusion	
infants often benefit from feeding therapy	
urinary tract abnormalities	HP:0000079//Abnormality of the urinary system//HPO
hypothyroidism is treated with oral thyroxine therapy	
treatment is life long, including during pregnancy	
d-penicillamine (chelator)	
pyridoxine must be given along with d-penicillamine	
zinc (metallothionein inducer)	
antioxidants	U000301//Antioxidants//LCH	D000975//Antioxidants//MSH	LP94260-4//Antioxidants//LNC	1590//Antioxidants//MEDLINEPLUS	MTHU032426//Antioxidants//LNC	sh85005727//Antioxidants//LCH_NW	58079//Antioxidants//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000018926//antioxidants//AOD	0000001314//antioxidants//CHV	306409//antioxidants//MEDCIN
, vegetarians) consult with a trained dietitian	
no specific treatment exists for wss	
all treatment is symptomatic	
note: standard replacement hormonal treatment will not promote fertility	
low igf-1	
standard treatment	
l-thyroxine replacement therapy	
ectodermal	C12703//Ectoderm//NCI	T-F6100//Ectoderm, NOS//SNMI	NOCODE//Developmental arithmetic disorder//MTH	0000037965//ectodermal//CHV
treatment is symptomatic and cosmetic only	
movement disorders	D009069//Movement Disorders//MSH	N0000002039//Movement Disorders [Disease/Finding]//NDFRT	520//Movement Disorders//MEDLINEPLUS	C116757//Movement Disorders//NCI_NICHD	32375//Movement Disorders//PSY	NOCODE//Developmental arithmetic disorder//MTH	U003043//Movement disorders//LCH	sh85088017//Movement disorders//LCH_NW	MTHU006688//Movement disorders//OMIM	0000008293//movement disorders//CHV	NERMOVE//MOVEMENT DISORDERS//CST
benzodiazepines, especially clonazepam	
its use in wss has not been documented	
dysarthria	D004401//Dysartrie//MSHDUT	N19006//dysarthria//ICPC2P	10013887//Dysarthria//MDR	Ub1TM//Dysarthria//RCD	F-86480//Dysarthria//SNM	F-A6660//Dysarthria//SNMI	MTHU000283//Dysarthria//OMIM	C79549//Dysarthria//NCI	784.51//Dysarthria//ICD9CM	N0000001014//Dysarthria [Disease/Finding]//NDFRT	LP145911-6//Dysarthria//LNC	MTHU043324//Dysarthria//LNC	E12635//Dysarthria//NCI_CTCAE	HP:0001260//Dysarthria//HPO	8011004//Dysarthria//SNOMEDCT_US	15580//Dysarthria//PSY	NOCODE//Developmental arithmetic disorder//MTH	1014723//DYSARTHRIA//CCPSS	U000211//DYSARTHRIA//COSTAR	DYSARTHRIA//DYSARTHRIA//CST	U001005//LARYNGEAL NERVE, RECURRENT, BILATERAL PARALYSIS//DXP	0150//SPEECH DISORDER//WHO	0000006291//dysarthria//AOD	1579-3337//dysarthria//CSP	0000004198//dysarthria//CHV	MTHU024292//dysarthria//ICPC2ICD10ENG	8282//dysarthria//MEDCIN
consultation with a speech therapist may be helpful	
nutritional management by a knowledgeable nutritionist is helpful	
treatment is symptomatic and should be tailored to each patient	
orthopedic management of leg length discrepancy	
surgical correction of polydactyly	
cataract extraction and correction of vision	
dermatologic management of skin lesions	
hypohidrosis	NOCODE//Sepsis//COSTAR	D007007//Hypohidrosis//MSH	X50AS//Hypohidrosis//RCD	D0-52020//Hypohidrosis//SNMI	296587//Hypohidrosis//MEDCIN	L74.4//Anhidrosis//ICD10CM	N0000001637//Hypohidrosis [Disease/Finding]//NDFRT	MTHU036385//Hypohidrosis//OMIM	E13652//Hypohidrosis//NCI_CTCAE	C34718//Hypohidrosis//NCI_NICHD	HP:0000966//Hypohidrosis//HPO	10021013//Hypohidrosis//MDR	45004005//Hypohidrosis//SNOMEDCT_US	705.0//Hypohidrosis//MTHICD9	S92015//hypohidrosis//ICPC2P	1298//SWEATING DECREASED//WHO	MTHU036964//hypohidrosis//ICPC2ICD10ENG	0000006478//hypohidrosis//CHV
some individuals may benefit from "cooling vests	
hypodontia	10055001//Hypodontia//MDR	J0004//Hypodontia//RCD	D4-51014//Partial congenital absence of teeth//SNMI	MTHU002570//Hypodontia//OMIM	K00.0//Anodontia//ICD10CM	sh2010013988//Hypodontia//LCH_NW	HP:0000668//Hypodontia//HPO	358301000009106//Hypodontia//SNOMEDCT_VET	64969001//Partial congenital absence of teeth//SNOMEDCT_US	D000848//Anodontia//MSH	520.0//Hypodontia//MTHICD9	NOCODE//Developmental arithmetic disorder//MTH	MTHU036839//hypodontia//ICPC2ICD10ENG	0000006471//hypodontia//CHV
orthodontics may be necessary	
dental implants in adults can support aesthetic and functional dentition	
lubrication eye drops can be helpful for dry eyes	
no formal management guidelines exist	
the following are general considerations	
hypogammaglobulinemia is treated with ivig	
treatment with antiepileptic agents	
many individuals with periventricular nodular heterotopia have dyslexia	
pharmacologic treatment of dystonia	
anticholinergic agents and benzodiazepines	
the benzodiazepine associated with the best response is clonazepam	
zolpidem	D011725//pyridiny//MSHCZE	d00910//zolpidem//MMSL	39993//zolpidem//RXNORM	7K383OQI23//zolpidem//MTHSPL	N0000007347//zolpidem [Chemical/Ingredient]//NDFRT	0000015070//zolpidem//CHV	N05CF02//zolpidem//ATC	CDR0000386236//zolpidem//NCI_NCI-GLOSS	340500//zolpidem//MEDCIN	004146//ASPIRIN/CODEINE PHOSPHATE 325 mg-30 mg ORAL TABLET//NDDF	C049109//zolpidem//MSH	d1f..//Zolpidem//RCD	C-64330//Zolpidem//SNMI	C62000//Zolpidem//NCI	LP17255-8//Zolpidem//LNC	MTHU012369//Zolpidem//LNC	DB00425//Zolpidem//DRUGBANK	96231005//Zolpidem//SNOMEDCT_US	MTHU001693//Zolpidem//USPMG	387569009//Zolpidem//SNOMEDCT_US	4023596//ZOLPIDEM//VANDF	N0000021601//ZOLPIDEM//NDFRT
risperidone seems less effective than haloperidol in controlling dystonia	
pharmacologic treatment of parkinsonism	
surgical treatment of dystonia and parkinsonism	
optical devices	D055096//Optical Devices//MSH
pharmacologic	C16974//Pharmacology//NCI	G-B005//Pharmacologic//SNMI	56183000//Pharmacologic//SNOMEDCT_US
total parenteral nutrition may be required	
institute appropriate antimicrobial therapy for infections	
treat lymphomas and gi cancer	
the following treatments are recommended:	
early intervention programs and special education for developmental delays	
premalignant lesions (e	
this involves electrodesiccation/curettage or surgical excision	
calcification of ligaments and tendons	
however, no controlled studies have been reported	
recurrent bacterial infections are treated with standard antibiotics	
standard management is recommended for the following:	
behavioral and psychiatric problems	
kyphoscoliosis	0000031003//kyphoscoliosis//CHV	X789E//Congenital kyphoscoliosis//RCD	L85006//kyphoscoliosis//ICPC2P	10023506//Kyphoscoliosis//MDR	Xa6vR//Kyphoscoliosis deformity of spine//RCD	M-31550//Kyphoscoliosis//SNM	D1-81415//Kyphoscoliosis//SNMI	MTHU002160//Kyphoscoliosis//OMIM	HP:0002751//Kyphoscoliosis//HPO	U002295//KYPHOSCOLIOSIS//DXP	BI00512//scoliosis//BI	M41//Scoliosis//ICD10CM	0000040242//kyphoscoliosis//CHV	297808//kyphoscoliosis//MEDCIN	MTHU042260//kyphoscoliosis//ICPC2ICD10ENG	32586//kyphoscoliosis//MEDCIN	0000042149//kyphoscoliosis//CHV	Xa1jg//Acquired kyphoscoliosis//RCD
eye problems	0000025411//eye problem//CHV
testosterone-replacement therapy	
gynecomastia	D006177//Gynecomastia//MSH	XE0eN//Gynecomastia//RCDAE	M-71000//Hypertrophy//SNM	D7-90420//Gynecomastia//SNMI	MTHU006965//Gynecomastia//OMIM	N0000001396//Gynecomastia [Disease/Finding]//NDFRT	N62//Hypertrophy of breast//ICD10CM	283172//Gynecomastia//MEDCIN	332421//Gynecomastia//MEDCIN	474//Breast Diseases//MEDLINEPLUS	311361000009109//Gynecomastia of non-human mammary gland//SNOMEDCT_VET	E13115//Gynecomastia//NCI_CTCAE	C3073//Gynecomastia//NCI_NICHD	HP:0000771//Gynecomastia//HPO	10018801//Gynecomastia//MDR	10018800//Gynaecomastia//MDR	4754008//Gynecomastia//SNOMEDCT_US	611.1//Gynecomastia//MTHICD9	NOCODE//Developmental arithmetic disorder//MTH	1005810//GYNECOMASTIA//CCPSS	340//GYNECOMASTIA//COSTAR	GYNECOMASTIA//GYNECOMASTIA//CST	U001755//SNAKE BITE, VENOMOUS//DXP	0000004462//gynecomastia//AOD	BI00342//gynecomastia//BI	2587-5894//gynecomastia//CSP	0000005746//male breast enlargement//CHV	Y16005//gynaecomastia//ICPC2P	MTHU033080//gynecomastia//ICPC2ICD10ENG	C55619//Gynecomastia//NCI_CTCAE
regression of gynecomastia may occur with testosterone replacement therapy	
